CA2387013C - 6-position substituted indolinones, the preparation thereof and their use as pharmaceutical compositions - Google Patents

6-position substituted indolinones, the preparation thereof and their use as pharmaceutical compositions Download PDF

Info

Publication number
CA2387013C
CA2387013C CA002387013A CA2387013A CA2387013C CA 2387013 C CA2387013 C CA 2387013C CA 002387013 A CA002387013 A CA 002387013A CA 2387013 A CA2387013 A CA 2387013A CA 2387013 C CA2387013 C CA 2387013C
Authority
CA
Canada
Prior art keywords
group
alkyl
amino
phenyl
denotes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002387013A
Other languages
French (fr)
Other versions
CA2387013A1 (en
Inventor
Armin Heckel
Gerald Jurgen Roth
Rainer Walter
Jacobus Van Meel
Norbert Redemann
Ulrike Tontsch-Grunt
Walter Spevak
Frank Hilberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26006858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2387013(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19949208A external-priority patent/DE19949208A1/en
Priority claimed from DE2000142696 external-priority patent/DE10042696A1/en
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of CA2387013A1 publication Critical patent/CA2387013A1/en
Application granted granted Critical
Publication of CA2387013C publication Critical patent/CA2387013C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to indolinones of general formula (see formula I) substituted in the 6 position, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof which have valuable pharmacological properties, especially an inhibitory effect on receptor tyrosine kinases and cyclin/CDK complexes, as well as on the proliferation of endothelial cells and various tumour cells, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

Description

DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE I)E CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.
CECI EST LE TOME DE _2 NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.

NOTE: For additional volumes please contact the Canadian Patent Office.

6-position substituted indolinones, the preparation thereof and their use as pharmaceutical compositions The present invention relates to new indolinones of general formula N

)0!7>==

substituted in the 6 position, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof which have valuable properties.

The above compounds of general formula I wherein Rl denotes a hydrogen atom or a prodrug group have valuable pharmacological properties, in particular an inhibiting effect on various kinases, especially receptor tyrosine kinases such as VEGFR2, PDGFRa, PDGFRP, FGFR1, FGFR3, EGFR, HER2, IGF1R and HGFR, as well as complexes of CDK's (Cyclin Dependent Kinases) such as CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9 with their specific cyclins (A, Bl, 22, C, Dl, D2, D3, E, F, G1, G2, H, I and K) and to viral cyclin (cf. L. Mengtao in J.
Virology 71(3), 1984-1991 (1997)), and on the proliferation of cultivated human cells, in particular endothelial cells, e.g.
in angiogenesis, but also on the proliferation of other cells, in particular tumour cells.
The other compounds of the above general formula I
wherein Rl does not denote a hydrogen atom or a prodrug group are valuable intermediate products for preparing the abovementioned compounds.

The present invention thus relates to the above compounds of general formula I, whereby those compounds wherein R1 denotes a hydrogen atom or a prodrug group have valuable pharmacological properties, pharmaceutical compositions containing the pharmacologically active compounds, the use thereof and processes for preparing them.
According to one aspect of the present invention, there is provided a compound of the formula I

N

Rs X (I), N

wherein: X denotes an oxygen or sulphur atom, R1 denotes a hydrogen atom or a C1_4-alkoxycarbonyl or C2_4-alkanoyl group, R2 denotes a carboxy group, a straight-chain or branched C1_6-alkoxy-carbonyl group, a C4_7-cycloalkoxy-carbonyl or an aryloxycarbonyl group; a straight-chain or branched C1_6-alkoxy-carbonyl group, which is terminally substituted in the alkyl moiety by a phenyl, heteroaryl, carboxy, C1_3-alkoxy-carbonyl, aminocarbonyl, C,._3-alkylamino-carbonyl or di-(C1_3-alkyl)-aminocarbonyl group; a straight-chain or branched C2_6-alkoxy-carbonyl group, which is terminally substituted in the alkyl moiety by a chlorine atom or a - 2a -hydroxy, C1_3-alkoxy, amino, C1_3-alkylamino or di-(C1_3-alkyl)-amino group; or an aminocarbonyl or methylaminocarbonyl group or an ethylaminocarbonyl group optionally substituted in the 2 position of the ethyl group by a hydroxy or C1_3-alkoxy group; R3 denotes a hydrogen atom, a C1_6-alkyl, C3_7-cycloalkyl, trifluoromethyl or heteroaryl group, a phenyl or naphthyl group or a phenyl or naphthyl group mono- or disubstituted by a fluorine, chlorine, bromine or iodine atom, by a trifluoromethyl, C1_3-alkyl or C1_3-alkoxy group, wherein, in the event of disubstitution, the substituents are identical or different and wherein the abovementioned unsubstituted as well as the mono- and disubstituted phenyl and naphthyl groups are optionally further substituted by a hydroxy, hydroxy-C1_3-alkyl or C1_3-alkoxy-C1_3-alkyl group; by a cyano, carboxy, carboxy-C1_3-alkyl, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylamino-carbonyl or di- (C1_3-alkyl) -aminocarbonyl group; by a nitro group; by an amino, C1_3-alkylamino, di-(C1_3-alkyl) -amino or amino-C1_3-alkyl group; by a C1_3-alkylcarbonylamino, N- (C1_3-alkyl) -C1_3-alkyl-carbonylamino, C1_3-alkylcarbonylamino-C1_3-alkyl, N- (C7_3-alkyl) -C1_3-alkylcarbonylamino-Cl_3-alkyl, Cl_3-alkyl-sulphonylamino, C1_3-alkylsulphonylamino-C1_3-alkyl, N- (C1_3-alkyl) -C1_3-alkylsulphonylamino-C1_3-alkyl or aryl-C1_3-alkylsulphonylamino group; by a cycloalkylamino, cycloalkyleneimino, cycloalkyleneiminocarbonyl, cycloalkyleneimino-C1_3-alkyl, cycloalkyleneiminocarbonyl-C1_3-alkyl or cycloalkyleneiminosulphonyl-C1_3-alkyl group having 4 to 7 ring members in each case, wherein in each case the methylene group in position 4 of a 6- or 7-membered cycloalkyleneimino group is optionally replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, -NH or -N(C1_3-alkyl) group; or by a heteroaryl or heteroaryl-C1_3-alkyl group; R4 denotes a C3_-,-cycloalkyl - 2b -group, wherein the methylene group in the 4 position of a 6-or 7-membered cycloalkyl group is optionally substituted by an amino, C1_3-alkylamino or di- (C1_3-alkyl) -amino group or is optionally replaced by an -NH or -N(C1_3-alkyl) group; or a phenyl group substituted by the group R6, which is optionally further mono- or disubstituted by fluorine, chlorine, bromine or iodine atoms or by C1_5-alkyl, trifluoromethyl, hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, amino, acetylamino, C1_3-alkyl-sulphonylamino, aminocarbonyl, Cl_3-alkyl-aminocarbonyl, di- (C1_3-alkyl) -aminocarbonyl, aminosulphonyl, C1_3-alkyl-aminosulphonyl, di-(C1_3-alkyl)-aminosulphonyl, nitro or cyano groups, wherein the substituents are identical or different; R6 denotes a hydrogen, fluorine, chlorine, bromine or iodine atom; a cyano, nitro, amino, C1_5-alkyl, C3_7-cycloalkyl, trifluoromethyl, phenyl, tetrazolyl or heteroaryl group; a group of formula O

NH
CH
N O
H

wherein the hydrogen atoms bound to a nitrogen atom are optionally in each case replaced independently of one another by a C1_3-alkyl group; a C1_3-alkoxy group, a C1_3-alkoxy-C1_3-alkoxy, phenyl-C1_3-alkoxy, amino-C2_3-alkoxy, C1_3-alkylamino-C2_3-alkoxy, di- (C1_3-alkyl) -amino-C2_3-alkoxy, phenyl-C1_3-alkylamino-C2_3-alkoxy, N- (C1_3-alkyl) -phenyl-C1_3-alkylamino-C2_3-alkoxy, CS_7-cycloalkyleneimino-C2_3-alkoxy or C1_3-alkylmercapto group; a carboxy, C1_4-alkoxycarbonyl, aminocarbonyl, C1_3-alkylamino-carbonyl, N- (C1_5-alkyl) -C1_3-alkylaminocarbonyl, phenyl-C1_3-alkylamino-carbonyl, N-(C1_3-alkyl)-phenyl-C1_3-alkylamino-carbonyl, piperazinocarbonyl or - 2c -N- (C1_3-alkyl) -piperazinocarbonyl group; a C1_3-alkylaminocarbonyl or N- (C1_5-alkyl) -C1_3-alkylaminocarbonyl group wherein an alkyl moiety is substituted by a carboxy or C1_3-alkoxycarbonyl group or in the 2 or 3 position by a di-(C1_3-alkyl) -amino, piperazino, N- (C1_3-alkyl) -piperazino or a 4- to 7-membered cycloalkyleneimino group; a C3_7-cycloalkyl-carbonyl group; wherein the methylene group in the 4 position of the 6- or 7-membered cycloalkyl moiety is optionally substituted by an amino, C1_3-alkylamino or di-(C1_3-alkyl)-amino group or replaced by an -NH or -N(C1_3-alkyl) group; a 4- to 7-membered cycloalkyleneimino group wherein a methylene group linked to the imino group is optionally replaced by a carbonyl or sulphonyl group or the cycloalkylene moiety is optionally fused to a phenyl ring or one or two hydrogen atoms are optionally each replaced by a C1_3-alkyl group and/or in each case the methylene group in the 4 position of a 6- or 7-membered cycloalkyleneimino group is optionally substituted by a carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylaminocarbonyl, di- (C1_3-alkyl) -aminocarbonyl, phenyl-C1_3-alkylamino or N-(C1_3-alkyl) -phenyl-Cl_3-alkylamino group or is optionally replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, -NH, -N(C1_3-alkyl) , -N(phenyl), -N(Cl_3-alkyl-carbonyl) or -N(benzoyl) group; a Cl_4-alkyl group substituted by the group R7, wherein R7 denotes a C3_7-cycloalkyl group, wherein the methylene group in the 4 position of the 6- or 7-membered cycloalkyl group is optionally substituted by an amino, C1_3-alkylamino or di-(C1_3-alkyl)-amino group or is optionally replaced by an -NH or -N(C1_3-alkyl) group or in a 5- to 7-membered cycloalkyl group a-(CH2)z group is optionally replaced by a -CO-NH group, a-(CH2)3 group is optionally replaced by a -NH-CO-NH or -CO-NH-CO group or a-(CH2)4 group is optionally replaced by a -NH-CO-NH-CO group, wherein in each case a - 2d -hydrogen atom bound to a nitrogen atom is optionally replaced by a C1_3-alkyl group; an aryl or heteroaryl group;
wherein, when the heteroaryl is a pyrrolyl, pyrazolyl or imidazolyl group bound via a nitrogen atom, the heteroaryl is optionally substituted by a C1_3-alkyl group, and wherein the heteroaryl is a pyrrolidine, piperidino, morpholino, thiomorpholino or piperazino group, the heteroaryl is optionally substituted in the 4 position by a C1_3-alkyl, phenyl-C1_3-alkyl, C1_3alkylcarbonyl or C1_4-alkoxycarbonyl group or a hydrogen atom; a hydroxy or C1_3-alkoxy group; an amino, C1_7-alkylamino, di- (C1_,-alkyl) -amino, phenylamino, N-phenyl-C1_3-alkyl-amino, phenyl-C1_3-alkylamino, N- (C1_3-alkyl) -phenyl-C1_3-alkylamino or di- (phenyl-C1_3-alkyl) -amino group; an w-hydroxy-Cz_3-alkyl-amino, N- (C1_3-alkyl) -co-hydroxy-C2_3-alkyl-amino, di- (co-hydroxy-C2_3-alkyl) -amino, di- (m- (C1_3-alkoxy) -C2_3-alkyl) -amino or N- (dioxo-lan-2-yl) -C1_3-alkyl-amino group; a C1_3-alkoxy-C1_3-alkylamino, N- (C1_3-alkyl) -C1_3-alkoxy-C1_3-alkylamino or di-(2-methoxy-ethyl)-amino group; a C1_3-alkylcarbonylamino-C2_3-alkyl-amino or C1_3-alkylcarbonylamino-C2_3-alkyl-N- (C1_3-alkyl) -amino group; a C1_3-alkylsulphonylamino, N- (C1_3-alkyl) -C1_3-alkylsulphonylamino, C1_3-alkylsulphonylamino-C2_3-alkyl-amino or C1_3-alkylsulphonylamino-C2_3-alkyl-N- (C1_3-alkyl) -amino group; a hydroxycarbonyl-C1_3-alkylamino or N- (C1_3-alkyl) -hydroxycarbonyl-C1_3-alkyl-amino group; a guanidino group wherein one or two hydrogen atoms are each optionally replaced by a C1_3-alkyl group; a group of formula -N(Re) -CO- (CH2)n-R9 (II), wherein R8 denotes a hydrogen atom or a C1_3-alkyl group, n denotes 0, 1, 2 or 3 and R9 denotes an amino, C,._4-alkylamino, di- (C1_4-alkyl) -amino, phenylamino, N- (C1_4-alkyl) -2e -phenylamino, benzylamino, N- (C1-4-alkyl) -benzylamino or C1_4-alkoxy group, or a 4- to 7-membered cycloalkyleneimino group, wherein in each case the methylene group in the 4 position of a 6- or 7-membered cycloalkyleneimino group is optionally replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, -NH, -N(C1_3-alkyl), -N(phenyl), -N(Cl-3-alkyl-carbonyl) or -N(benzoyl) group, or, if n denotes 1, 2 or 3, R9 is as defined herein or is a hydrogen atom; a group of formula -N(Rlo) - (CH2)m- (CO) o-Rll (III), wherein Rlo denotes a hydrogen atom, a C1-3-alkyl group, a C1_3-alkylcarbonyl, arylcarboriyl, phenyl-C1_3-alkyl-carbonyl, C1_3-alkylsulphonyl, arylsulphonyl or phenyl-C1_3-alkylsulphonyl group; m denotes 1, 2, 3 or 4; o denotes 1 or, if m denotes 2, 3 or 4, o denotes 0 or 1; and R11 denotes an amino, C1._4-alkylamino, di-(C1-4-alkyl)-amino, phenylamino, N- (C1-4-alkyl) -phenylamino, benzylamino, N- (C1-4-alkyl) -benzylamino, C1-4-alkoxy or C1..3-alkoxy-Cl-3-alkoxy group, a di- (C1_4-alkyl) -amino-C1_3-alkylamino group optionally substituted in the 1 position by a C1_3-alkyl group or a 4-to 7-membered cycloalkyleneimino group, wherein the cycloalkylene moiety is optionally fused to a phenyl ring or in each case the methylene group in the 4 position of the 6-or 7-membered cycloalkyleneimino group is optionally replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, -NH, -N(C,.-3-alkyl), -N(phenyl), -N(C1-3-alkyl-carbonyl) or -N(benzoyl) group; a C4-7-cycloalkylamino, C4-7-cycloalkyl-C1_3-alkylamino or C4_7-cycloalkenylamino group wherein position 1 of the ring is not involved in the double bond and wherein the abovementioned groups are each optionally further substituted at the amino-nitrogen atom by a C5-7-cycloalkyl, C2_4-alkenyl or C1-4-alkyl group; or a 4- to 7-membered cycloalkyleneimino group, wherein the - 2f -cycloalkylene moiety is optionally fused to a phenyl group or to an oxazolo, imidazolo, thiazolo, pyridino, pyrazino or pyrimidino group optionally substituted by a fluorine, chlorine, bromine or iodine atom or by a nitro, C1_3-alkyl, C1_3-alkoxy or amino group, and/or one or two hydrogen atoms are each optionally replaced by a C1_3-alkyl, C5_7-cycloalkyl or phenyl group; and/or the methylene group in the 3 position of a 5-membered cycloalkyleneimino group is optionally substituted by a hydroxy, hydroxy-C1_3-alkyl, C1_3-alkoxy or C1_3-alkoxy-C1_3-alkyl group; the methylene group in the 3 or 4 position of a 6- or 7-membered cycloalkyleneimino group is optionally in each case substituted by a hydroxy, hydroxy-C1_3-alkyl, C1_3-alkoxy, C1_3-alkoxy-C1_3-alkyl, carboxy, C1_.4-alkoxycarbonyl, aminocarbonyl, Cl_3-alkylaminocarbonyl, di-(C1_3-alkyl)-aminocarbonyl, phenyl-C1-3-alkylamino or N- (C1_3-alkyl) -phenyl-C1_3-alkyl-amino group or is optionally replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, -NH, -N(C1_3-alkyl-), -N(phenyl), -N(phenyl-C1_3-alkyl-) , -N(C1_3-alkyl-carbonyl-) , -N(C1_4-hydroxy-carbonyl-), -N(C1_4-alkoxy-carbonyl-), -N(benzoyl-) or -N(phenyl-C1-3-alkyl-carbonyl-) group, wherein a methylene group linked to an imino-nitrogen atom of the cycloalkyleneimino group is optionally replaced by a carbonyl or sulphonyl group or in a 5- to 7-membered monocyclic cycloalkyleneimino group or a cycloalkyleneimino group fused to a phenyl group, the two methylene groups linked to the imino-nitrogen atom are each optionally replaced by a carbonyl group, or R6 denotes a C1_4-alkyl group which is substituted by a carboxy, Cl_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylaminocarbonyl or di- (C1_3-alkyl) -aminocarbonyl group or by a 4- to 7-membered cycloalkyleneiminocarbonyl group, an N- (C1_3-alkyl) -C2_4-alkanoylamino group which is additionally substituted in the - 2g -alkyl moiety by a carboxy or C1_3-alkoxycarbonyl group, a group of formula -N(R12) -CO- (CH2)p-R13 (IV) , wherein R12 denotes a hydrogen atom, a C1_6-alkyl or C3_7-cycloalkyl group or a C1_3-alkyl group terminally substituted by a phenyl, heteroaryl, trifluoromethyl, hydroxy, C1_3-alkoxy, aminocarbonyl, C1_4-alkylamino-carbonyl, di-(Cl_4-alkyl)-amino-carbonyl, C1_3-alkyl-carbonyl, C1_3-alkyl-sulphonylamino, N- (Cl_3-alkyl) -C1_3-alkyl-sulphonylamino, C1_3-alkyl-aminosulphonyl or di-(C1_3-alkyl)-aminosulphonyl group and p denotes 0, 1, 2 or 3 and R13 assumes the meanings of the abovementioned group R7, or, if p denotes 1, 2 or 3, R13 is as defined herein or R13 is a hydrogen atom; a group of formula -N (R14) - (CH2) q- (CO) r-R1s (V) ~

wherein R14 denotes a hydrogen atom, a C1_4-alkyl group or a Cl_3-alkylcarbonyl, arylcarbonyl, phenyl-Cl_3-alkylcarbonyl, heteroarylcarbonyl, heteroaryl-C1_3-alkylcarbonyl, C1_4-alkylsulphonyl, arylsulphonyl, phenyl-C1_3-alkylsulphonyl, heteroarylsulphonyl or heteroaryl-C1_3-alkyl-sulphonyl group, q denotes 1, 2, 3 or 4, r denotes the number 1 or, if q is 2, 3 and 4, r is 0 or 1, and R15 assumes the meanings of the abovementioned group R7; or a group of formula -N (R16) -SOz-R17 (VI) , wherein R16 denotes a hydrogen atom or a C1_4-alkyl group optionally terminally substituted by a cyano, trifluoromethyl-carbonylamino or N-(C1_3-alkyl)-trifluoromethyl-carbonyl-amino group and R17 denotes a C1_3-alkyl group; an amino group substituted by a di-(C1_3-alkyl)-amino-Cl_3-alkyl-carbonyl or di- (C1_3-alkyl) -amino-C1_3-alkyl-- 2h -sulphonyl group and a di-(C1_3-alkyl)-aminocarbonyl-C1_3-alkyl group, or an N- (C1_3-alkyl) -C1_5-alkylsulphonylamino or N-(C1_3-alkyl)-phenylsulphonylamino group wherein the alkyl moiety is additionally substituted by a cyano or carboxy group; wherein all the single-bonded or fused phenyl groups contained in the groups mentioned under R6 are optionally mono- or disubstituted by fluorine, chlorine, bromine or iodine atoms or by C1_5-alkyl, trifluoromethyl, hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_4-alkylamino-carbonyl, di-(C1_4-alkyl)-amino-carbonyl, aminosulphonyl, C1_3-alkyl-aminosulphonyl, di- (C1_3-alkyl) -aminosulphonyl, C1_3-alkyl-sulphonylamino, nitro or cyano groups, wherein the substituents are identical or different, or two adjacent hydrogen atoms of the phenyl groups are optionally replaced by a methylenedioxy group; and R5 denotes a hydrogen atom or a C1_3-alkyl group, wherein by an aryl group is meant a phenyl or naphthyl group optionally mono-or disubstituted by a fluorine, chlorine, bromine or iodine atom, by a cyano, trifluoromethyl, nitro, carboxy, aminocarbonyl, C1_3-alkyl or C1_3-alkoxy group and by a heteroaryl group is meant a monocyclic 5- or 6-membered heteroaryl group optionally substituted by a C1_3-alkyl group in the carbon skeleton, wherein the 6-membered heteroaryl group contains one, two or three nitrogen atoms and the 5-membered heteroaryl group contains an imino group optionally substituted by a C1_3-alkyl or phenyl-C1_3-alkyl group, an oxygen or sulphur atom or an imino group optionally substituted by a C1_3-alkyl or phenyl-C1_3-alkyl group or an oxygen or sulphur atom and additionally a nitrogen atom or an imino group optionally substituted by a C1_3-alkyl or phenyl-C1_3-alkyl group and two nitrogen atoms, and moreover a phenyl ring may be fused to the abovementioned monocyclic heterocyclic groups via two adjacent carbon atoms and the bonding takes place via a nitrogen atom or via a carbon atom - 2i -of the heterocyclic moiety or a fused phenyl ring; some or all of the hydrogen atoms in the abovementioned alkyl and alkoxy groups or in the alkyl moieties contained in the above-defined groups of formula I are optionally replaced by fluorine atoms; and wherein any carboxy group contained in the abovementioned groups are optionally replaced by a tert.butoxycarbonyl group; and wherein a hydrogen atom bound to a nitrogen atom is optionally each replaced by hydroxyl, benzoyl, pyridinoyl, formyl, acetyl, propionyl, butanoyl, pentanoyl, hexanoyl, allyloxycarbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert.butoxycarbonyl, pentoxycarbonyl, hexyloxycarbonyl, octyloxycarbonyl, nonyloxycarbonyl, decyloxycarbonyl, undecyloxycarbonyl, dodecyloxycarbonyl, hexadecyloxycarbonyl, benzyloxycarbonyl, phenylethoxycarbonyl, phenylpropoxycarbonyl, C1_3-alkylsulphonyl-C2_4-alkoxycarbonyl, C1_3-alkoxy-C2_4-alkoxy-C2_4-alkoxycarbonyl or an ReCO-O- (RfCRg) -0-CO group wherein Re denotes a C1_8-alkyl, C5_7-cycloalkyl, phenyl or phenyl-C1_3-alkyl group; Rf denotes a hydrogen atom, a C1_3-alkyl, C5_7-cycloalkyl or phenyl group and R. denotes a hydrogen atom or a C1_3-alkyl group; or wherein an amino nitrogen optionally forms part of a phthalimido group, or a tautomer or pharmaceutically acceptable salt thereof.

According to another aspect of the present invention, there is provided a compound, tautomer or salt as described herein, wherein: R1 and R3 are as described herein;
X denotes an oxygen atom; R2 denotes a carboxy group, a straight-chain or branched C1_6-alkoxy-carbonyl group, a C5_-7-cycloalkoxycarbonyl or a phenoxycarbonyl group; a straight-chain or branched C1_3-alkoxy-carbonyl group, which is terminally substituted in the alkyl moiety by a phenyl, heteroaryl, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-- 2j -alkylaminocarbonyl or di-(C1_3-alkyl)-aminocarbonyl group; a straight-chain or branched C2_3-alkoxy-carbonyl group, which is terminally substituted in the alkyl moiety by a chlorine atom or by a hydroxy, C1_3-alkoxy, amino, C1_3-alkylamino or di-(C1_3-alkyl)-amino group; an aminocarbonyl or methylaminocarbonyl group or an ethylaminocarbonyl group optionally substituted in the 2 position of the ethyl group by a hydroxy or C1_3-alkoxy group; R4 denotes a C3_7-cycloalkyl group, wherein the methylene group in the 4 position of the 6- or 7-membered cycloalkyl group is optionally substituted by an amino, C1_3-alkylamino or di- (C1_3-alkyl) -amino group or is optionally replaced by an -NH or -N(C1_3-alkyl) group; or a phenyl group substituted by the group R6 which is optionally mono- or disubstituted by fluorine, chlorine or bromine atoms or by C1_3-alkyl, trifluoromethyl, hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, amino, acetylamino, aminocarbonyl, C1_3-alkyl-aminocarbonyl, di- (C1_3-alkyl) -aminocarbonyl, nitro or cyano groups, wherein the substituents are identical or different; R6 denotes a hydrogen, fluorine, chlorine, bromine or iodine atom, or a cyano, nitro, amino, C1_5-alkyl, C3_-,-cycloalkyl, trifluoromethyl, phenyl, tetrazolyl or heteroaryl group; a group of formula O
CH NH

O
H

wherein a hydrogen atom bound to a nitrogen atom is optionally replaced by a C1_3-alkyl group, a C1_3-alkoxy group, an amino-C2_3-alkoxy, C1_3-alkylamino-C2_3-alkoxy, di-(C1_3-alkyl) -amino-C2_3-alkoxy, phenyl-C1_3-alkylamino-C2_3-alkoxy, N- (C1_3-alkyl) -phenyl-C1_3-alkylamino-C2_3-alkoxy, - 2k -pyrrolidino-C2_3-alkoxy, piperidino-C2_3-alkoxy or C1_3-alkylmercapto group; a carboxy, C1_4-alkoxycarbonyl, aminocarbonyl, C1_3-alkylamino-carbonyl, phenyl-C1_3-alkylamino-carbonyl or N-(C1_3-alkyl)-phenyl-C1_3-alkylamino-carbonyl group; a C3_7-cycloalkyl-carbonyl group, wherein the methylene group in the 4 position of the 6- or 7-membered cycloalkyl moiety is optionally replaced by an -NH or -N(C1_3-alkyl) group; a 4- to 7-membered cycloalkyleneimino group, wherein a methylene group linked to the imino group is optionally replaced by a carbonyl or sulphonyl group or one or two hydrogen atoms are each optionally replaced by a C1_3-alkyl group and/or in each case the methylene group in the 4 position of a 6- or 7-membered cycloalkyleneimino group is optionally substituted by a carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylaminocarbonyl, di-(C1_3-alkyl) -aminocarbonyl, phenyl-C1_3-alkylamino or N- (C1_3-alkyl)-phenyl-C1_3-alkylamino group or is optionally replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, -NH or -N(C1_3-alkyl) group; a C1_4-alkyl group terminally substituted by the group R7, wherein R7 denotes a C5_7-cycloalkyl group, wherein the methylene group in the 4 position of a 6- or 7-membered cycloalkyl group is optionally replaced by an -NH or -N(C1_3-alkyl) group or in a 5- to 7-membered cycloalkyl group a - (CHz)Z group is optionally replaced by a -CO-NH group, a-(CHZ)3 group is optionally replaced by a -NH-CO-NH- or a-(CHz)4 group is optionally replaced by a-NH-CO-NH-CO group, wherein in each case a hydrogen atom bound to a nitrogen atom is optionally replaced by a C1_3-alkyl group; a phenyl or heteroaryl group;

a hydroxy or C1_3-alkoxy group; an amino, C1_6-alkylamino, di-(C1_6-alkyl)-amino, phenylamino, N-phenyl-C1_3-alkyl-amino, phenyl-C1_3-alkylamino, N- (Cl_3-alkyl) -phenyl-C1_3-alkylamino or di- (phenyl-C1_3-alkyl) -amino group; a (o-hydroxy-C2_3-alkyl-amino, N- (C1_3-alkyl) -c)-hydroxy-C2_3-alkyl-amino, di- (co-hydroxy-C2_3-alkyl) -amino, di- ((0- (C1_3-alkoxy) -C2_3-alkyl) -amino or N-(dioxolan-2-yl)-C1_3-alkyl-amino group; a C1_3-alkylcarbonylamino-C2_3-alkyl-amino or C1_3-alkylcarbonylamino-C2_3-alkyl-N- (C1_3-alkyl) -amino group;
a C1_3-alkylsulphonylamino, N- (C1_3-alkyl) -C1_3-alkylsulphonylamino, C1_3-alkylsulphonylamino--C2_3-alkyl-amino or C1_3-alkylsulphonylamino-C2_3-alkyl--N- (C1_3-alk.yl) -amino group; a hydroxycarbonyl-Cl_3-alkylamino or N- (C1_3-alkyl) -hydroxycarbonyl-C1_3-alkyl-amino group; a guanidino group wherein a hydrogen atom is optionally replaced by a C1_3-alkyl group; a group of formula -N(R8) -CO- (CHz)n-Ry (II) , wherein R8 denotes a hydrogen atom or a C1_3-alkyl group; n denotes 0, 1, 2 or 3 and Ry denotes an amino, C1_3-alkylamino, di-(Cl_3-alkyl)-amino, phenylamino, benzylamino or C1_4-alkoxy group, or a 5- to 7-membered cycloalkyleneimino group, wherein the methylene group in position 4 of the cycloalkyleneimino group is optionally replaced by an oxygen or sulphur atom or by an -NH, -N(C1_3-alkyl),-N(phenyl) , -N(C1_.3-alkyl-carbonyl) or -N(benzoyl) group, or, if n denotes 1, 2 and 3, R9 is as defined herein or denotes a hydrogen atom; a group of formula -N(R10) - (CH2)m- (CO)o-Rll (III), wherein Rlo denotes a hydrogen. atom or a C1_3-alkyl, C1_3-alkylcarbonyl or C1_3-alkylsulphonyl group, m denotes 1, 2 or 3, o is 1 or, if m is 2 and 3, o is 0 or 1 and Rll denotes an amino, C1_3-alkylamino, di- (C1_3-alkyl) -amino, C1_4-alkoxy or C1_3-alkoxy-C1_3-alkoxy group or a 5- to 7-membered cycloalkyleneimino group, wherein the methylene group in position 4 of the cycloalkyleneimino group is - 2m -optionally replaced by an oxygen or sulphur atom or by an -NH, -N(C1_3-alkyl) , -N(phenyl), -N(C1_3-alkyl-carbonyl) or -N(benzoyl) group; a C4_7-cycloalkylamino or C4_7-cycloalkenylamino group wherein position 1 of the ring is not involved in the double bond; a 4- to 7-membered cycloalkyleneimino group, wherein the cycloalkylene moiety is optionally fused to a phenyl group or one or two hydrogen atoms is each optionally replaced by a C1_3-alkyl group and/or the methylene group in position 3 of the cycloalkyleneimino group is optionally substituted by a hydroxy or C1_3-alkoxy group, in each case the methylene group in the 4 position of a 6- or 7-membered cycloalkyleneimino group is optionally substituted by a hydroxy, hydroxy-C1_3-alkyl, C1_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylaminocarbonyl, di- (C1_3-alkyl) -aminocarbonyl, phenyl-C1_3-alkylamino or N- (C1_3-alkyl) -phenyl-C1_3-alkylamino group or is optionally replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, -NH, -N(C1_3-alkyl), -N(phenyl), -N(phenyl-C1_3-alkyl) , -N(C1_3-alkyl-carbonyl) , -N(C1_4-alkoxy-carbonyl) , -N(benzoyl) or -N(phenyl-C1_3-alkyl-carbonyl) group, wherein a methylene group linked to an imino-nitrogen atom of the cycloalkyleneimino group is optionally replaced by a carbonyl or sulphonyl group or in a 5- to 6-membered monocyclic cycloalkyleneimino group or a cycloalkyleneimino group fused to a phenyl group, the two methylene groups linked to the imino-nitrogen atom are each optionally replaced by a carbonyl group; or R6 denotes a C1_4-alkyl group which is terminally substituted by a carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylaminocarbonyl or di-(C1_3-alkyl)-aminocarbonyl group or by a 4- to 7-membered cycloalkyleneiminocarbonyl group;

- 2n -a group of formula -N (R12) -CO- (CHZ) p-R13 ( IV) wherein R12 denotes a hydrogen atom or a C1_3-alkyl, C5_-,-cycloalkyl, phenyl-C1_3-alkyl or heteroaryl-C1_3-alkyl group and p denotes 0, 1, 2 or 3 and R13 assumes the meanings of the abovementioned group R7, or, if p denotes one of the numbers 1, 2 and 3, R13 is as defined herein or denotes a hydrogen atom; a group of formula -N (R14) - (CHz) q- (CO) r-R15 (V) wherein R14 denotes a hydrogen atom, a C1_4-alkyl group or a C1_3-alkylcarbonyl, phenylcarbonyl, phenyl-C1_3-alkylcarbonyl, heteroarylcarbonyl, heteroaryl-C1_3-alkylcarbonyl, C1_4-alkylsulphonyl, phenylsulphonyl, phenyl-C1_3-alkylsulphonyl, heteroarylsulphonyl or heteroaryl-C1_3-alkyl-sulphonyl group, q denotes 1, 2, 3 or 4, r is 1 or, if q is 2, 3 or 4, r is 0 or 1 and R15 assumes the meanings of the abovementioned group R7; a group of formula -N(R16) -SO2-R17 (VI) , wherein R16 denotes a hydrogen atom or a C1_4-alkyl group optionally terminally substituted by a cyano, trifluoromethyl-carbonylamino or N-(C1_3-alkyl)-trifluoromethyl-carbonyl-amino group and R17 denotes a C1_3-alkyl group; or an amino group substituted by a di- (C1_3-alkyl) -amino-C1_3-alkyl-carbonyl or di- (C1_3-alkyl) -amino-C1_3-alkyl-sulphonyl group and a di- (C1_3-alkyl) -aminocarbonyl-C1_3-alkyl group, wherein all the single-bonded or fused phenyl groups contained in the groups mentioned under R6 are optionally mono- or disubstituted by fluorine, chlorine or bromine atoms or by C1_3-alkyl, trifluoromethyl, hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, - 2o -aminocarbonyl, C1_3-alkyl-aminocarbonyl, aminosulphonyl, Cl_3-alkyl-aminosulphonyl, nitro or cyano groups, wherein the substituents are identical or different, or two adjacent hydrogen atoms of the phenyl groups are optionally replaced by a methylenedioxy group; and R5 denotes a hydrogen atom or a C1_3-alkyl group; wherein, by a heteroaryl group as mentioned above is meant a pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, furyl, thienyl, oxazolyl, thiazolyl, pyrazolyl, imidazolyl or triazolyl group optionally substituted in the carbon skeleton by a C1_3-alkyl group wherein a hydrogen atom bound to a nitrogen atom is optionally replaced by a C1_3-alkyl or phenyl-C1_3-alkyl group and wherein the 5-membered heteroaryl groups containing at least one imino group are bound via a carbon or nitrogen atom; wherein a hydrogen atom bound to a nitrogen atom in the abovementioned groups is optionally replaced by hydroxyl, benzoyl, pyridinoyl, formyl, acetyl, propionyl, butanoyl, pentanoyl, hexanoyl, allyloxycarbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert.butoxycarbonyl, pentoxycarbonyl, hexyloxycarbonyl, octyloxycarbonyl, nonyloxycarbonyl, decyloxycarbonyl, undecyloxycarbonyl, dodecyloxycarbonyl, hexadecyloxycarbonyl, benzyloxycarbonyl, phenylethoxycarbonyl, phenylpropoxycarbonyl, C1_3-alkylsulphonyl-C2_4-alkoxycarbonyl, C1_3-alkoxy-C2_4-alkoxy-C2_4-alkoxycarbonyl or an ReCO-O- (RfCRg) -0-CO group wherein Re denotes a C1_$-alkyl, C5_-,-cycloalkyl, phenyl or phenyl-C1_3-alkyl group, Rf denotes a hydrogen atom or a C1_3-alkyl, C5_7-cycloalkyl or phenyl group and Rg denotes a hydrogen atom or a C1_3-alkyl, or wherein an amino nitrogen optionally forms part of a phthalimido group; and wherein any carboxy group contained in the abovementioned groups is optionally replaced by a tert.butoxycarbonyl group, and wherein some or all of the hydrogen atoms in the - 2p -abovementioned alkyl and alkoxy groups or in the alkyl moieties contained in the above-defined groups of formula I
optionally replaced by fluorine atoms.

According to still another aspect of the present invention, there is provided a compound, tautomer or salt as described herein, wherein: X denotes an oxygen atom; R1 denotes a hydrogen atom; R2 denotes a carboxy group, a straight-chain or branched C1_4-alkoxycarbonyl group or a phenoxycarbonyl group; a straight-chain or branched C1_3-alkoxy-carbonyl group, which is terminally substituted in the alkyl moiety by a phenyl, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylaminocarbonyl or di-(C1_3-alkyl)-aminocarbonyl group; a straight-chain or branched C2_3-alkoxy-carbonyl group which is terminally substituted in the alkyl moiety by a hydroxy, C1_3-alkoxy, amino, C1_3-alkylamino or di- (C1_3-alkyl) -amino group; or an aminocarbonyl or methylaminocarbonyl group, or an ethylaminocarbonyl group optionally substituted in the 2 position of the ethyl group by a hydroxy or C1_3-alkoxy group or, if R4 denotes something other than an aminosulphonyl-phenyl or N- (C1_5-alkyl) -C1_3-alkylaminocarbonyl-phenyl group, the optional substituent further optionally denotes a di- (C1_2-alkyl) -aminocarbonyl group; R3 denotes a C1_4-alkyl group or a phenyl group which is optionally substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C1_3-alkyl, hydroxy or C1_3-alkoxy group; R4 denotes a C5_6-cycloalkyl group, wherein the methylene group in position 4 of the C5-C6 cycloalkyl group when the C5-C6 cycloalkyl group is a cyclohexyl group is optionally substituted by an amino, C1_3-alkylamino or di- (C1_3-alkyl) -amino group or is optionally replaced by an -NH or -N(C1_3-alkyl) group; a phenyl group, a phenyl group disubstituted by C1_3-alkyl, C1_3-alkoxy or nitro groups, wherein the substituents are - 2q -identical or different; or a phenyl group substituted by the group R6, which is optionally further substituted by a fluorine, chlorine or bromine atom or by an amino or nitro group, wherein R6 denotes a fluorine, chlorine or bromine atom; a C1_3-alkyl, C1_3-alkoxy, nitro, amino or C5_6-cycloalkyl group; a pyrrolyl, pyrazolyl, imidazolyl, triazolyl or tetrazolyl group bound via a carbon atom, wherein the abovementioned heteroaromatic groups in the carbon skeleton are optionally substituted by a C1_3-alkyl group or a hydrogen atom bound to a nitrogen atom is optionally replaced by a C1_3-alkyl or phenyl-C,._3-alkyl group; a group of formula O
CH NH
--~' H O
~
a carboxy, C1_4-alkoxycarbonyl, phenyl-C1_3-alkylamino-carbonyl or C5_7-cycloalkyl-carbonyl group; a 5 or 6-membered cycloalkyleneimino group, wherein the methylene group in position 4 of the cycloalkyleneimino group is optionally replaced by an oxygen or sulphur atom or by an -NH or -N (C1_3-alkyl ) group; an unbranched C1_3-alkyl group terminally substituted by the group R7, wherein R7 denotes a C5_7-cycloalkyl group; wherein in a 5 or 6-membered cycloalkyl group a - (CHz)Z group is optionally replaced by a -CO-NH group, a-(CHz)3 group is optionally replaced by an -NH-CO-NH- or a-(CH2)4 group is optionally replaced by an -NH-CO-NH-CO group, wherein in each case a hydrogen atom bound to a nitrogen atom is optionally replaced by a C1_3-alkyl group; a phenyl or pyridinyl group or a pyrrolyl, pyrazolyl, imidazolyl or triazolyl group bound via a carbon or nitrogen atom, wherein the pyridinyl, pyrrolyl, - 2r -pyrazolyl, imidazolyl and triazolyl groups in the carbon skeleton are optionally substituted by a C1_3-alkyl group or a hydrogen atom bound to a nitrogen atom is optionally replaced by a C1_3-alkyl group; a hydroxy or C1_3-alkoxy group; an amino, C1_6-alkylamino, di- (C1_6-alkyl) -amino, phenylamino, N-phenyl-C1_3-alkylamino, phenyl-C1_3-alkylamino or N- (C1_3-alkyl) -phenyl-C1_3-alkylamino group; a m-hydroxy-C2_3-alkyl-amino, N- (C1_3-alkyl) -co-hydroxy-C2_3-alkylamino, di- (c.o-hydroxy-C2_3-alkyl) -amino or di- ((o- (C1_3-alkoxy) -C2_3-alkyl) -amino group; a C1_3-alkylcarbonylamino-C2_3-alkyl-amino or C1_3-alkylcarbonylamino-C2_3-alkyl-N- (C1_3-alkyl) -amino group;
a C1_3-alkylsulphonylamino, N- (C1_3-alkyl) -C1_3-alkylsulphonylamino, C1_3-alkylsulphonylamino-C2_3-alkylamino or C1_3-alkylsulphonylamino-C2_3-alkyl-N-(C1_3-alkyl)-amino group; a hydroxycarbonyl-C1_3-alkylamino or N- (C1_3-alkyl) -hydroxycarbonyl-C1_3-alkyl-amino group; a guanidino group wherein a hydrogen atom is optionally replaced by a C1_3-alkyl group; a group of formula -N(R8) -CO- (CH2)n-R9 (II) , wherein R8 denotes a hydrogen atom or a C1_3-alkyl group, n denotes 0, 1, 2 or 3 and R9 denotes an amino, C1_3-alkylamino, di- (C1_3-alkyl) -amino or C1_4-alkoxy group, a 5- or 6-membered cycloalkyleneimino group, wherein the methylene group in position 4 of the cycloalkyleneimino group is optionally replaced by an -NH, -N(Cl_3-alkyl) or -N(C1_3-alkyl-carbonyl) group, or, if n denotes 1, 2 or 3, R9 is as defined herein or R9 denotes a hydrogen atom; a group of formula -N(Rlo) - (CH2)m- (CO)o-Rli (III), wherein Rlo denotes a hydrogen atom or a C1_3-alkyl group, m denotes 1, 2 or 3, o denotes 1 or, if m is 2 or 3, o denotes - 2s -0 or 1 and Rll denotes an amino, C1_3-alkylamino, di- (C1_3-alkyl)-amino, C1_4-alkoxy or methoxy-C1_3-alkoxy group or a 5-or 6-membered cycloalkyleneimino group, wherein the methylene group in position 4 of the cycloalkyleneimino group is optionally replaced by an -NH, -N(C1_3-alkyl) or -N(C1_3-alkyl-carbonyl) group; or an azetidino, pyrrolidino, piperidino, 2,6-dimethyl-piperidino, 3,5-dimethyl-piperidino or azepino group, wherein the methylene group in position 3 of the pyrrolidino group is optionally substituted by a hydroxy group, the methylene group in position 4 of the piperidino group is optionally substituted by a hydroxy, hydroxy-C1_3-alkyl or C1_3-alkoxy group or is optionally replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, -NH, -N(C1_3-alkyl) , -N(C1_3-alkyl-carbonyl) , -N(benzoyl) or -N(phenyl-C1_3-alkyl-carbonyl) group, wherein a methylene group linked to an imino-nitrogen atom of the pyrrolidino, piperidino or azepino group is optionally replaced by a carbonyl group; or R6 denotes a straight-chain C1_3-alkyl group which is terminally substituted by a carboxy or C1_3-alkoxy-carbonyl group; a group of formula -N(R12) -CO- (CHz)p-R13 (IV) , wherein R12 denotes a hydrogen atom, a C1_3-alkyl or phenyl-C1_3-alkyl group, p denotes 0, 1 or 2 and R13 denotes an amino, C1_4-alkylamino, di- (C1_4-alkyl) -amino, benzylamino, N- (C1_3-alkyl) -benzylamino, C1_3-alkoxy-C1_3-alkylamino, N- (C1_3-alkyl) -C1_3-alkoxy-C1_3-alkylamino, di-(2-methoxy-ethyl)-amino, di-(w-hydroxy-C2_3-alkyl)-amino or aminocarbonyl-methyl-N-(methyl)-amino group, a pyrrolyl, pyrazolyl or imidazolyl group bound via a nitrogen atom and optionally substituted by a C1_3-alkyl group, or a pyrrolidino, piperidino, morpholino, thiomorpholino or a piperazino group optionally substituted in the 4 position by - 2t -a C1_3-alkyl, phenyl-C1_3-alkyl, C1_3-alkylcarbonyl or C1_4-alkoxycarbonyl group or, if p denotes 1 or 2, R13 is as defined herein or denotes a hydrogen atom; a group of formula -N (R14) - (CH2) q- (CO) r-R15 (V) wherein R14 denotes a hydrogen atom or a C1_4-alkyl, C1_3-alkyl-carbonyl, phenylcarbonyl, phenyl-C1_3-alkylcarbonyl, furyl-carbonyl, pyridinyl-carbonyl, furyl-C1_3-alkylcarbonyl, pyridinyl-C1_3-alkylcarbonyl, C1_4-alkylsulphonyl, phenylsulphonyl or phenyl-C1_3-alkylsulphonyl group, q denotes 1, 2 or 3, r denotes 1 or, if q is 2 or 3, r denotes 0 or 1 and R15 denotes an amino, C1_4-alkylamino, di- (C1_4-alkyl) -amino, phenylamino, N-(C1_4-alkyl)-phenylamino, benzylamino or N-(C1_4-alkyl)-benzylamino group; or a group of formula -N(R16) -S02-R17 (VI) , wherein R16 denotes a hydrogen atom or a C1_3-alkyl group optionally terminally substituted by a cyano, trifluoromethyl-carbonylamino or N-(C1_3-alkyl)-trifluoromethyl-carbonyl-amino group and R17 denotes a C1_3-alkyl group, and RS denotes a hydrogen atom, wherein a hydrogen atom bound to a nitrogen atom in the abovementioned groups is optionally replaced by an acetyl or tert.butoxycarbonyl group, and the carboxy groups contained in the abovementioned groups are optionally replaced with a tert.butoxycarbonyl group.

According to yet another aspect of the present invention, there is provided a pharmaceutical composition comprising a compound or salt as described herein and a pharmaceutically acceptable carrier or diluent.

- 2u -According to a further aspect of the present invention, there is provided a pharmaceutical composition as described herein for treating excessive or anomalous cell proliferation.

According to yet a further aspect of the present invention, there is provided process for preparing a pharmaceutical composition as described herein, wherein a compound or salt as described herein is admixed with a pharmaceutically acceptable carrier or diluent.

According to still a further aspect of the present invention, there is provided use of a compound or salt as described herein in manufacture of a medicament for treatment of excessive or anomalous cell proliferation.

According to another aspect of the present invention, there is provided use of a compound or salt as described herein for treatment of excessive or anomalous cell proliferation.

According to yet another aspect of the present invention, there is provided a compound or salt as described herein for treatment of excessive or anomalous cell proliferation.

In the above general formula I
X denotes an oxygen or sulphur atom, R1 denotes a hydrogen atom or a prodrug group such as a C1_4-alkoxycarbonyl or C2_4-alkanoyl group, R2 denotes a carboxy group, a straight-chain or branched C1_6-alkoxy-carbonyl group, a C4_,-cycloalkoxy-carbonyl or an aryloxycarbonyl group, - 2v -a straight-chain or branched C1_6-alkoxy-carbonyl group, which is terminally substituted in the alkyl moiety by a phenyl, heteroaryl, carboxy, C1_3-alkoxy-carbonyl, aminocarbonyl, C1_3-alkylamino-carbonyl or di- (C1_3-alkyl) -aminocarbonyl group, a straight-chain or branched C2_6-alkoxy-carbonyl group, which is terminally substituted in the alkyl moiety by a chlorine atom or a hydroxy, C1_3-alkoxy, amino, C1_3-alkylamino or di-(C1_3-alkyl)-amino group, an aminocarbonyl or methylaminocarbonyl group, an ethylaminocarbonyl group optionally substituted in the 2 position of the ethyl group by a hydroxy or C1_3-alkoxy group or, if R4 does not denote an aminosulphonyl-phenyl or N-(C1_5-alkyl)-C1_3-alkylaminocarbonyl-phenyl group, it may also denote a di- (Cl_2-alkyl) -aminocarbonyl group, R3 denotes a hydrogen atom, a C1_6-alkyl, C3_,-cycloalkyl, trifluoromethyl or heteroaryl group, a phenyl or naphthyl group, a phenyl or naphthyl group mono-or disubstituted by a fluorine, chlorine, bromine or iodine atom, by a trifluoromethyl, Cl_3-alkyl or Cl_3-alkoxy group, whilst in the event of disubstitution the substituents may be identical or different and wherein the abovementioned unsubstituted as well as the mono- and disubstituted phenyl and naphthyl groups may additionally be substituted by a hydroxy, hydroxy-Cl_3-alkyl or Cl_3-alkoxy-Cl_3-alkyl group, by a cyano, carboxy, carboxy-C1_3-alkyl, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylamino-carbonyl or di-(C1_3-alkyl)-arninocarbonyl group, by a nitro group, by an amino, Cl_j-alkylamino, di- (C1_3-alkyl) -amino or amino-Cl_3-alkyl group, by a C1_3-alkylcarbonylamino, N- (Cl_3-alkyl) -Cl_3-alkyl-carbonylamino, C1_3-alkylcarbonylamino-C1_3-alkyl, N- (Cl_3-alkyl) -C1_3-alkylcarbonylamino-C1_3-alkyl, C1_3-alkyl-sulphonylamino, C1_3-alkylsulphonylamino-C1_3-alkyl, N- (Cl_3-alkyl) -Cl_3-alkylsulphonylamino-C,_3-alkyl or aryl-C1_3-alkylsulphonylamino group, by a cycloalkylamino, cycloalkyleneimino, cyclo-alkyleneiminocarbonyl, cycloalkyleneimino-C1_3-alkyl, cycloalkyleneiminocarbonyl-C1_3-alkyl or cycloalkyleneiminosulphonyl-C1_3-alkyl group having 4 to 7 ring members in each case, whilst in each case the methylene group in position 4 of a 6- or 7-membered cycloalkyleneimino group may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, -NH or -N(C1_3-alkyl) group, or by a heteroaryl or heteroaryl-C1_,-alkyl group, R4 denotes a C3_,-cycloalkyl group, whilst the methylene group in the 4 position of a 6- or 7-membered cycloalkyl group may be substituted by an amino, Cl_3-alkylamino or di- (Cl_3-alkyl) -amino group or replaced by an -NH or -N(C1_3-alkyl) group, or a phenyl group substituted by the group R6, which may additionally be mono- or disubstituted by fluorine, chlorine, bromine or iodine atoms, by C1_5-alkyl, trifluoromethyl, hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, amino, acetylamino, C1_3-alkyl-sulphonylamino, aminocarbonyl, Cl_3-alkyl-aminocarbonyl, di- (Cl_3-alkyl) -aminocarbonyl, aminosulphonyl, C1_3-alkyl-aminosulphonyl, di-(C1_3-alkyl)-aminosulphonyl, nitro or cyano groups, wherein the substituents may be identical or different and wherein R6 denotes a hydrogen, fluorine, chlorine, bromine or iodine atom, a cyano, nitro, amino, Cl_5-alkyl, C3_,-cycloalkyl, trifluoromethyl, phenyl, tetrazolyl or heteroaryl group, the group of formula O

CH
N O
H

wherein the hydrogen atoms bound to a nitrogen atom may in each case be replaced independently of one another by a Cl_3-alkyl group, a C1_3-alkoxy group, a C1_3-alkoxy-C1_3-alkoxy, phenyl-C1_3-alkoxy, amino-C2_3-alkoxy, Cl_3-alkylamino-C2_3-alkoxy, di- (Cl_3-alkyl) -amino-C2_3-alkoxy, phenyl-Cl_3-alkylamino-CZ_3-alkoxy, N- (C1_3-alkyl) -phenyl-C1_3-alkylamino-C2_3-alkoxy, CS_,-cycloalkyleneimino-C2_3-alkoxy or Cl_3-alkylmercapto group, a carboxy, Cl_4-alkoxycarbonyl, aminocarbonyl, C1_3-alkyl-amino-carbonyl, N- (Cl_5-alkyl) -Cl_3-alkylaminocarbonyl, phenyl-C1_3-alkylamino-carbonyl, N- (C1_3-alkyl) -phenyl-Cl_3-alkylamino-carbonyl, piperazinocarbonyl or N-(C,_3-alkyl)-piperazinocarbonyl group, a C1_3-alkylaminocarbonyl or N- (C1_5-alkyl) -C1_3-alkylaminocarbonyl group wherein an alkyl moiety is substituted by a carboxy or C1_3-alkoxycarbonyl group or in the 2 or 3 position by a di-(C1_3-alkyl)-amino, piperazino, N- (Cl_3-alkyl) -piperazino or a 4- to 7-membered cycloalkyleneimino group, a C3_,-cycloalkyl-carbonyl group, wherein the methylene group in the 4 position of the 6- or 7-membered cycloalkyl moiety may be substituted by an amino, C1_3-alkylamino or di- (C1_3-alkyl) -amino group or replaced by an -NH or -N(Cl_3-alkyl) group, a 4- to 7-membered cycloalkyleneimino group wherein a methylene group linked to the imino group may be replaced by a carbonyl or sulphonyl group or the cycloalkylene moiety may be fused to a phenyl ring or one or two hydrogen atoms may each be replaced by a C1_3-alkyl group and/or in each case the methylene group in the 4 position of a 6-or 7-membered cycloalkyleneimino group may be substituted by a carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylaminocarbonyl, di-(C1_3-alkyl)-aminocarbonyl, phenyl-Cl_3-alkylamino or N- (C1_3-alkyl) -phenyl-C1_3-alkylamino group or may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, -NH, -N(C1_3-alkyl) , -N(phenyl) , -N(C1_3-alkyl-carbonyl) or -N(benzoyl) group, a C1_4-alkyl group substituted by the group Rõ wherein R7 denotes a C3_,-cycloalkyl group, whilst the methylene group in the 4 position of a 6- or 7-membered cycloalkyl group may be substituted by an amino, Cl_3-alkylamino or di- (Cl_3-alkyl) -amino group or replaced by an -NH or -N(C1_3-alkyl) group or in a 5- to 7-membered cycloalkyl group a-(CH2)2 group may be replaced by a -CO-NH group, a-(CH2)3 group may be replaced by a -NH-CO-NH or -CO-NH-CO group or a -(CH2)4 group may be replaced by a -NH-CO-NH-CO group, whilst in each case a hydrogen atom bound to a nitrogen atom may be replaced by a C1_3-alkyl group, an aryl or heteroaryl group, a hydroxy or Cl_3-alkoxy group, an amino, Cl_,-alkylamino, di- (Cl_,-alkyl) -amino, phenylamino, N-phenyl-C1_3-alkyl-amino, phenyl-C1_3-alkyl-amino, N- (C1_3-alkyl) -phenyl-C1_3-alkylamino or di-(phenyl-Cl_3-alkyl) -amino group, an w-hydroxy-C2_3-alkyl-amino, N- (Cl_3-alkyl) -w-hydroxy-C2_3-alkyl-amino, di- (co-hydroxy-C2_3-alkyl) -amino, di- ((o- (C1_3-alkoxy) -C2_3-alkyl) -amino or N- (dioxolan-2-yl) -Cl_3-alkyl-amino group, a Cl_3-alkylcarbonylamino-C2_3-alkyl-amino or Cl_3-alkylcarbonylamino-C2_3-alkyl-N- (Cl_3-alkyl) -amino group, a C1_3-alkylsulphonylamino, N- (Cl_3-alkyl) -C1_3-alkyl-sulphonylamino, C1_3-alkylsulphonylamino-C2_3-alkyl-amino or Cl_3-alkylsulphonylamino-CZ_3-alkyl-N- (Cl_3-alkyl) -amino group, a hydroxycarbonyl-Cl_3-alkylamino or N- (Cl_3-alkyl) -hydroxycarbonyl-C1_3-alkyl-amino group, a guanidino group wherein one or two hydrogen atoms may each be replaced by a C1_3-alkyl group, a group of formula -N(R8)-CO-(CH2)n-Rg (II), wherein R. denotes a hydrogen atom or a C1_3-alkyl group, n denates one of the numbers 0, 1, 2 or 3 and R9 denotes an amino, Cl_4-alkylamino, di- (Cl_4-alkyl) -amino, phenylamino, N-(C1_4-alkyl)-phenylamino, benzylamino, N- (Cl_4-alkyl) -benzylamino or Cl_4-alkoxy group, a 4- to 7-membered cycloalkyleneimino group, whilst in each case the methylene group in the 4 position of a 6- or 7-membered cycloalkyleneimino group may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, -NH, -N(Cl_3-alkyl) , -N(phenyl), -N(C1_3-alkyl-carbonyl) or -N(benzoyl) group, or, if n denotes one of the numbers 1, 2 or 3, it may also denote a hydrogen atom, a group of formula -N(R10) - (CH2)m- (CO)o-R11 (III), wherein Rla denotes a hydrogen atom, a Cl_3-alkyl group, a C1_3-alkylcarbonyl, arylcarbonyl, phenyl-C1_3-alkyl-carbonyl, C1_3-alkylsulphonyl, arylsulphonyl or phenyl-Cl_3-alkylsulphonyl group, m denotes one of the numbers 1, 2, 3 or 4, o denotes the number 1 or, if m denotes one of the numbers 2, 3 or 4, o may also denote the number 0 and Rll denotes an amino, Cl_,,-alkylamino, di- (Cl_4-alkyl) -amino, phenylamino, N-(C1_4-alkyl)-phenylamino, benzylamino, N- (Cl_4-alkyl) -benzylamino, C1_4-alkoxy or Cl_3-alkoxy-Cl_,-alkoxy group, a di- (Cl_4-alkyl) -amino-Cl_3-alkylamino group optionally substituted in the 1 position by a C1_3-alkyl group or a 4- to 7-membered cycloalkyleneimino group, wherein the cycloalkylene moiety may be fused to a phenyl ring or in each case the methylene group in the 4 position of a 6- or 7-membered cycloalkyleneimino group may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, -NH, -N(Cl_3-alkyl) , -N(phenyl), -N(Cl_3-alkyl-carbonyl) or -N(benzoyl) group, a C4_,-cycloalkylamino, C4_,-cycloalkyl-C1_3-alkylamino or C4_,-cycloalkenylamino group wherein position 1 of the ring is not involved in the double bond and wherein the abovementioned groups may each additionally be substituted at the amino-nitrogen atom by a CS_,-cycloalkyl, C2_4-alkenyl or Cl_4-alkyl group, a 4- to 7-membered cycloalkyleneimino group, wherein the cycloalkylene moiety may be fused to a phenyl group or to an oxazolo, imidazolo, thiazolo, pyridino, pyrazino or pyrimidino group optionally substituted by a fluorine, chlorine, bromine or iodine atom, by a nitro, Cl_3-alkyl, C1_3-alkoxy or amino group, and/or one or two hydrogen atoms may each be replaced by a Cl_3-alkyl, C5_,-cycloalkyl or phenyl group and/or the methylene group in the 3 position of a 5-membered cycloalkyleneimino group may be substituted by a hydroxy, hydroxy-Cl_3-alkyl, Cl_3-alkoxy or C,._3-alkoxy-C1_3-alkyl group, the methylene group in the 3 or 4 position of a 6- or 7-membered cycloalkyleneimino group may in each case be substituted by a hydroxy, hydroxy-C1_3-alkyl, C1_3-alkoxy, Cl_3-alkoxy-Cl_3-alkyl, carboxy, C1_4-alkoxycarbonyl, aminocarbonyl, C1_3-alkylaminocarbonyl, di-(C1_3-alkyl)-aminocarbonyl, phenyl-C1_3-alkylamino or N- (C1_3-alkyl) -phenyl-Cl_3-alkyl-amino group or may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, -NH, -N(C1_3-alkyl-), -N(phenyl), -N(phenyl-Cl_3-alkyl-) , -N(Cl_3-alkyl-carbonyl-) , -N(Cl_4-hydroxy-carbonyl-) , -N(Cl_4-alkoxy-carbonyl-) , -N(benzoyl-) or -N(phenyl-Cl_3-alkyl-carbonyl-) group, wherein a methylene group linked to an imino-nitrogen atom of the cycloalkyleneimino group may be replaced by a carbonyl or sulphonyl group or in a 5-to 7-membered monocyclic cycloalkyleneimino group or a cycloalkyleneimino group fused to a phenyl group the two methylene groups linked to the imino-nitrogen atom may each be replaced by a carbonyl group, or R. denotes a Cl_4-alkyl group which is substituted by a carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylaminocarbonyl or di- (Cl_3-alkyl) -aminocarbonyl group or by a 4- to 7-membered cycloalkyleneiminocarbonyl group, an N- (C1_3-alkyl) -CZ_4-alkanoylamino group which is additionally substituted in the alkyl moiety by a carboxy or C1_3-alkoxycarbonyl group, a group of formula -N(R12)-CO-(CH2)p-R13 (IV), wherein R12 denotes a hydrogen atom, a C1_6-alkyl or C3_,-cycloalkyl group or a C1_3-alkyl group terminally substituted by a phenyl, heteroaryl, trifluoromethyl, hydroxy, C1_3-alkoxy, aminocarbonyl, C1_4-alkylamino-carbonyl, di-(C1_4-alkyl)-amino-carbonyl, C1_3-alkyl-carbonyl, C1_3-alkyl-sulphonyl-amino, N- (Cl_3-alkyl) -C1_3-alkyl-sulphonylamino, C1_3-alkyl-aminosulphonyl or di-(C1_3-alkyl)-aminosulphonyl group and p denotes one of the numbers 0, 1, 2 or 3 and R13 assumes the meanings of the abovementioned group R7, or, if p denotes one of the numbers 1, 2 or 3, it may also denote a hydrogen atom, a group of formula -N(R14)-(CH2)q-(CO)r-R15 (V), wherein R14 denotes a hydrogen atom, a C1_4-alkyl group, a C1_3-alkylcarbonyl, arylcarbonyl, phenyl-C1_3-alkylcarbonyl, heteroarylcarbonyl, heteroaryl-C1_3-alkylcarbonyl, C1_4-alkylsulphonyl, arylsulphonyl, phenyl-C1_3-alkylsulphonyl, heteroarylsulphonyl or heteroaryl-C1_3-alkyl-sulphonyl group, q denotes one of the numbers 1, 2, 3 or 4, r denotes the number 1 or, if q is one of the numbers 2, 3 or 4, it may also denote the number 0 and R15 assumes the meanings of the abovementioned group R7, a group of formula -N(R16)-SO2-Rl7 (VI), wherein R16 denotes a hydrogen atom or a C1_4-alkyl group optionally terminally substituted by a cyano, trifluoromethyl-carbonylamino or N-(C1_3-alkyl)-trifluoromethyl-carbonyl-amino group and R17 denotes a Cl_3-alkyl group, an amino group substituted by a di-(C1_3-alkyl)-amino-C1_3-alkyl-carbonyl or di- (C1_3-alkyl) -amino-Cl_3-alkyl-sulphonyl group and a di- (Cl_3-alkyl) -aminocarbonyl-C1_3-alkyl group, or an N- (C1_3-alkyl) -Cl_5-alkylsulphonylamino or N-(C1_3-alkyl)-phenylsulphonylamino group wherein the alkyl moiety is additionally substituted by a cyano or carboxy group, wherein all the single-bonded or fused phenyl groups contained in the groups mentioned under R. may be mono- or disubstituted by fluorine, chlorine, bromine or iodine atoms, by Cl_5-alkyl, trifluoromethyl, hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_4-alkylamino-carbonyl, di-(C1_4-alkyl)-amino-carbonyl, aminosulphonyl, C1_3-alkyl-aminosulphonyl, di-(C1_3-alkyl)-aminosulphonyl, C1_3-alkyl-sulphonylamino, nitro or cyano groups, wherein the substituents may be identical or different, or two adjacent hydrogen atoms of the phenyl groups may be replaced by a methylenedioxy group, and R5 denotes a hydrogen atom or a C1_3-alkyl group, wherein by an aryl group is meant a phenyl or naphthyl group optionally mono- or disubstituted by a fluorine, chlorine, bromine or iodine atom, by a cyano, trifluoromethyl, nitro, carboxy, aminocarbonyl, Cl_3-alkyl or Cl_3-alkoxy group and by a heteroaryl group is meant a monocyclic 5- or 6-membered heteroaryl group optionally substituted by a C1_3-alkyl group in the carbon skeleton, wherein the 6-membered heteroaryl group contains one, two or three nitrogen atoms and the 5-membered heteroaryl group contains an imino group optionally substituted by a C1_3-alkyl or phenyl-Cl_3-alkyl group, an oxygen or sulphur atom or an imino group optionally substituted by a C1_3-alkyl or phenyl-C1_3-alkyl group or an oxygen or sulphur atom and additionally a nitrogen atom or an imino group optionally substituted by a C1_3-alkyl or phenyl-C1_3-alkyl group and two nitrogen atoms, and moreover a phenyl ring may be fused to the abovementioned monocyclic heterocyclic groups via two adjacent carbon atoms and the bonding takes place via a nitrogen atom or via a carbon atom of the heterocyclic moiety or a fused phenyl ring, some or all of the hydrogen atoms in the abovementioned alkyl and alkoxy groups or in the alkyl moieties contained in the above-defined groups of formula I optionally being replaced by fluorine atoms, the saturated alkyl and alkoxy moieties with more than 2 carbon atoms which are present in the groups defined hereinbefore also include the branched isomers thereof, such as for example the isopropyl, tert.butyl, isobutyl group, unless otherwise stated, and additionally the hydrogen atom of any carboxy group present or a hydrogen atom bound to a nitrogen atom, e.g. a hydrogen atom of an amino, alkylamino or imino group or a saturated N-heterocycle such as the piperidinyl group, may each be replaced by a group which can be cleaved in vivo.

By a group which can be cleaved in vivo from an imino or amino group is meant, for example, a hydroxy group, an acyl group such as the benzoyl or pyridinoyl group or a C1_16-alkanoyl group such as the formyl, acetyl, propionyl, butanoyl, pentanoyl or hexanoyl group, an allyloxycarbonyl group, a C1_16-alkoxycarbonyl group such as the methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert.butoxycarbonyl, pentoxycarbonyl, hexyloxycarbonyl, octyloxycarbonyl, nonyloxycarbonyl, decyloxycarbonyl, undecyloxycarbonyl, dodecyloxycarbonyl or hexadecyloxycarbonyl group, a phenyl-C1_6-alkoxycarbonyl group such as the benzyloxycarbonyl, phenylethoxycarbonyl or phenylpropoxycarbonyl group, a C1_3-alkylsulphonyl-C2_4-alkoxycarbonyl, C1_3-alkoxy-C2_4-alkoxy-C2_4-alkoxycarbonyl or ReCO-O- (RfCRg) -0-CO group wherein R. denotes a C1_e-alkyl, CS_,-cycloalkyl, phenyl or phenyl-C1_3-alkyl group, Rf denotes a hydrogen atom, a Cl_3-alkyl, CS_,-cycloalkyl or phenyl group and R. denotes a hydrogen atom, a Cl_3-alkyl or ReCO-O- (RfCRg) -O
group wherein R. to R. are as hereinbefore defined, wherein additionally the amino group may be a phthalimido group, whilst the abovementioned ester groups may also be used as a group which can be converted in vivo into a carboxy group.

One sub-group of compounds of general formula I which deserves special mention comprises those wherein X, R. and R3 to RS are as hereinbefore defined and R. denotes a straight-chain or branched C1_6-alkoxy-carbonyl group, a C4_7-cycloalkoxycarbonyl or a aryloxycarbonyl group, a straight-chain or branched C1_6-alkoxy-carbonyl group, which is terminally substituted in the alkyl moiety by a phenyl, heteroaryl, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, Cl_3-alkylaminocarbonyl or di- (Cl_3-alkyl) -aminocarbonyl group, a straight-chain or branched CZ_6-alkoxy-carbonyl group, which is terminally substituted in the alkyl moiety by a chlorine atom or a hydroxy, C1_3-alkoxy, amino, Cl_3-alkylamino or di- (Cl_3-alkyl) -amino group, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof.

A second sub-group of compounds of general formula I which deserves special mention comprises those wherein X, R. and R3 to RS are as hereinbefore defined and R2 denotes an aminocarbonyl or methylaminocarbonyl group, an ethylaminocarbonyl group optionally substituted in the 2 position of the ethyl group by a hydroxy or C1_3-alkoxy group or, if R4 does not denote an aminosulphonyl-phenyl or N- (C1_5-alkyl) -Cl_3-alkylaminocarbonyl-phenyl group, R2 may also denote a di-(C1_2-alkyl)-aminocarbonyl group, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof.

A third sub-group of compounds of general formula I which deserves special mention comprises those wherein X, R. to R3 and RS are as hereinbefore defined and R4 denotes an R,- (Cl_,4-alkyl) -phenyl group, wherein R, denotes an amino, C1_7-alkylamino, di- (Cl_7-alkyl) -amino, phenylamino, N-phenyl-C1_3-alkyl-amino, phenyl-C1_3-alkyl-amino, N- (Cl_3-alkyl) -phenyl-Cl_3-alkylamino or di- (phenyl-Cl_3-alkyl) -amino group, or a phenyl group substituted by the group of formula -N(R12)-CO-(CH2)p-R13 (IV), wherein R12, p and R13 are as hereinbefore defined, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof.

Preferred compounds of general formula I are those wherein R1 and R3 are as hereinbefore defined and X denotes an oxygen atom, R2 denotes a carboxy group, a straight-chain or branched C1_6-alkoxy-carbonyl group, a CS_,-cycloalkoxycarbonyl or a phenoxycarbonyl group, a straight-chain or branched C1_3-alkoxy-carbonyl group, which is terminally substituted in the alkyl moiety by a phenyl, heteroaryl, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, Cl_3-alkylaminocarbonyl or di- (Cl_3-alkyl) -aminocarbonyl group, a straight-chain or branched CZ_3-alkoxy-carbonyl group, which is terminally substituted in the alkyl moiety by a chlorine atom, by a hydroxy, C1_3-alkoxy, amino, C1_3-alkylamino or di- (C1_3-alkyl) -amino group, an aminocarbonyl or methylaminocarbonyl group, an ethylaminocarbonyl group optionally substituted in the 2 position of the ethyl group by a hydroxy or C1_3-alkoxy group or, if R4 does not denote an aminosulphonyl-phenyl or N- (Cl_5-alkyl) -C1_3-alkylaminocarbonyl-phenyl group, it may also denote a di- (C1_2-alkyl) -aminocarbonyl group, R4 denotes a C3_7-cycloalkyl group, whilst the methylene group in the 4 position of a 6- or 7-membered cycloalkyl group may be substituted by an amino, C1_3-alkylamino or di- (Cl_3-alkyl) -amino group or replaced by an -NH or -N(Cl_3-alkyl) group, or a phenyl group substituted by the group R6, which may additionally be mono- or disubstituted by fluorine, chlorine or bromine atoms, by C1_3-alkyl, trifluoromethyl, hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, amino, acetylamino, aminocarbonyl, C1_3-alkyl-aminocarbonyl, di-(C1_3-alkyl)-aminocarbonyl, nitro or cyano groups, wherein the substituents may be identical or different and wherein R. denotes a hydrogen, fluorine, chlorine, bromine or iodine atom, a cyano, nitro, amino, C,_5-alkyl, C3_7-cycloalkyl, trifluoromethyl, phenyl, tetrazolyl or heteroaryl group, the group of formula O
CH NH
--t~~O
H
wherein a hydrogen atom bound to the'nitrogen atom may be replaced by a C1_3-alkyl group, a Cl_3-alkoxy group, an amino-C2_3-alkoxy, Cl_3-alkylamino-C2_3-alkoxy, di- (Cl_3-alkyl) -amino-C2_3-alkoxy, phenyl-C1_3-alkylamino-C2_3-alkoxy, N- (Cl_3-alkyl) -phenyl-Cl_3-alkylamino-C2_3-alkoxy, pyrrolidino-C2_3-alkoxy, piperidino-C2_3-alkoxy or C1_3-alkylmercapto group, a carboxy, C1_4-alkoxycarbonyl, aminocarbonyl, Cl_3-alkyl-amino-carbonyl, phenyl-C1_3-alkylamino-carbonyl or N- (C1_3-alkyl) -phenyl-C1_3-alkylamino-carbonyl group, a C3_7-cycloalkyl-carbonyl group, wherein the methylene group in the 4 position of the 6- or 7-membered cycloalkyl moiety may be replaced by an -NH or -N ( C1_3-alkyl ) group, a 4- to 7-membered cycloalkyleneimino group, wherein a methylene group linked to the imino group may be replaced by a carbonyl or sulphonyl group or one or two hydrogen atoms may each be replaced by a C1_3-alkyl group and/or in each case the methylene group in the 4 position of a 6-or 7-membered cycloalkyleneimino group may be substituted by a carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylaminocarbonyl, di-(C1_3-alkyl)-aminocarbonyl, phenyl-Cl_3-alkylamino or N- (C1_3-alkyl) -phenyl-C1_3-alkylamino group or may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, -NH or -N(Cl_3-alkyl) group, a C,._4-alkyl group terminally substituted by the group Rõ
wherein R7 denotes a C5_,-cycloalkyl group, whilst the methylene group in the 4 position of a 6- or 7-membered cycloalkyl group may be replaced by an -NH
or -N(C1_3-alkyl) group or in a 5- to 7-membered cycloalkyl group a-(CHZ)2 group may be replaced by a -CO-NH group, a-(CH2)3 group may be replaced by a -NH-CO-NH- or a-(CH2)4 group may be replaced by a -NH-CO-NH-CO group, whilst in each case a hydrogen atom bound to a nitrogen atom may be replaced by a Cl_3-alkyl group, a phenyl or heteroaryl group, a hydroxy or C1_3-alkoxy group, an amino, Cl_6-alkylamino, di- (Cl_6-alkyl) -amino, phenylamino, N-phenyl-C1_3-alkyl-amino, phenyl-Cl_,-alkylamino, N- (Cl_3-alkyl) -phenyl-Cl_3-alkylamino or di- (phenyl-Cl_3-alkyl) -amino group, a w-hydroxy-CZ_3-alkyl-amino, N- (Cl_3-alkyl) -W-hydroxy--C2_3-alkyl-amino, di- ((o-hydroxy-C2_3-alkyl) -amino, di- (w- (Cl_3-alkoxy) -C2_3-alkyl) -amino or N-(dioxolan-2-yl)-C1_3-alkyl-amino group, a C1_3-alkylcarbonylamino-C2_3-alkyl-amino or C1_3-alkylcarbonylamino-C2_3-alkyl-N- (Cl_3-alkyl) -amino group, a Cl_3-alkylsulphonylamino, N- (Cl_3-alkyl) -C1_3-alkylsulphonylamino, C1_3=alkylsulphonylamino--C2_3-alkyl-amino or C1_3-alkylsulphonylamino-Cz_3-alkyl--N- (Cl_3-alkyl) -amino group, a hydroxycarbonyl-C1_3-alkylamino or N- (C1_3-alkyl) -hydroxycarbonyl-Cl_3-alkyl-amino group a guanidino group wherein a hydrogen atom may be replaced by a Cl_3-alkyl group, a group of formula -N (Rg ) -CO- (CH2 ) n-Rg ( I I ) , wherein R8 denotes a hydrogen atom or a C1_3-alkyl group, n denotes one of the numbers 0, 1, 2 or 3 and R9 denotes an amino, Cl_3-alkylamino, di- (C1_3-alkyl) -amino, phenylamino, benzylamino or C1_4-alkoxy group, a 5- to 7-membered cycloalkyleneimino group, wherein the methylene group in position 4 of the piperidino group may be replaced by an oxygen or sulphur atom, by an -NH, -N (Cl_3-alkyl) , -N (phenyl) , -N (Cl_3-alkyl-carbonyl) or -N(benzoyl) group, or, if n denotes one of the numbers 1, 2 or 3, it may also denote a hydrogen atom, a group of formula -N(R10)-(CH2)m-(CO)o-R11 (III), wherein Rlo denotes a hydrogen atom, a Cl_3-alkyl group, a Cl_3-alkylcarbonyl or Cl_3-alkylsulphonyl group, m denotes one of the numbers 1, 2 or 3, o denotes the number 1 or, if m is one of the numbers 2 or 3, o may also denote the number 0 and Rll denotes an amino, C1_3-alkylamino, di- (C1_,-alkyl) -amino, C1_4-alkoxy or C1_3-alkoxy-Cl_3-alkoxy group or a 5- to 7-membered cycloalkyleneimino group, wherein the methylene group in position 4 of the piperidino group may be replaced by an oxygen or sulphur atom, by an -NH, -N(C1_3-alkyl), -N(phenyl), -N(C1_3-alkyl-carbonyl) or -N(benzoyl) group, a C,4_7-cycloalkylamino or C4_,-cycloalkenylamino group wherein position 1 of the ring is not involved in the double bond, a 4- to 7-membered cycloalkyleneimino group, wherein the cycloalkylene moiety may be fused to a phenyl group or one or two hydrogen atoms may each be replaced by a C1_3-alkyl group and/or the methylene group in position 3 of the pyrrolidino group may be substituted by a hydroxy or C1_3-alkoxy group, in each case the methylene group in the 4 position of a 6- or 7-membered cycloalkyleneimino group may be substituted by a hydroxy, hydroxy-C1_3-alkyl, C1_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, Cl_3-alkylaminocarbonyl, di- (Cl_3-alkyl) -aminocarbonyl, phenyl-Cl_3-alkylamino or N- (C,_3-alkyl) -phenyl-Cl_3-alkyl-amino group or may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, -NH, -N(C1_3-alkyl), -N(phenyl), -N(phenyl-C1_3-alkyl) , -N(Cl_3-alkyl-carbonyl) , -N(Cl_4-alkoxy-carbonyl) , -N(benzoyl) or -N(phenyl-C1_3-alkyl-carbonyl) group, wherein a methylene group linked to an imino-nitrogen atom of the cycloalkyleneimino group may be replaced by a carbonyl or sulphonyl group or in a 5-to 6-membered monocyclic cycloalkyleneimino group or a cycloalkyleneimino group fused to a phenyl group the two methylene groups linked to the imino-nitrogen atom may each be replaced by a carbonyl group, or R6 denotes a C1_4-alkyl group which is terminally substituted by a carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, Cl_3-alkylaminocarbonyl or di- (Cl_3-alkyl) -aminocarbonyl group or by a 4- to 7-membered cycloalkyleneiminocarbonyl group, a group of formula -N(R12)-CO-(CH2)p-R13 (IV), wherein R12 denotes a hydrogen atom, a C1_3-alkyl, CS_,-cycloalkyl, phenyl-Cl_3-alkyl or heteroaryl-Cl_3-alkyl group and p denotes one of the numbers 0, 1, 2 or 3 and R13 assumes the meanings of the abovementioned group R,, or, if p denotes one of the numbers 1, 2 or 3, it may also denote a hydrogen atom, a group of formula -N(R14)-(CH2)q-(CO)r-R15 (V), wherein R14 denotes a hydrogen atom, a Cl_q-alkyl group, a C1_3-alkylcarbonyl, phenylcarbonyl, phenyl-C1_3-alkyl-carbonyl, heteroarylcarbonyl, heteroaryl-C1_3-alkylcarbonyl, C1_4-alkylsulphonyl, phenylsulphonyl, phenyl-C1_3-alkylsulphonyl-heteroarylsulphonyl or heteroaryl-C1_3-alkyl-sulphonyl group, q denotes one of the numbers 1, 2, 3 or 4, r denotes the number 1 or, if q is one of the numbers 2, 3 or 4, it may also denote the number 0 and R15 assumes the meanings of the abovementioned group Rõ
a group of formula -N(R16)-S02-R17 (VI), wherein R16 denotes a hydrogen atom or a C1_4-alkyl group optionally terminally substituted by a cyano, trifluoromethyl-carbonylamino or N- (C1_3-alkyl) -trifluoromethyl--carbonyl-amino group and Rl, denotes a Cl_3-alkyl group, an amino group substituted by a di- (Cl_3-alkyl) -amino-C1_3-alkyl-carbonyl or di- (C1_3-alkyl) -amino-Cl_3-alkyl-sulphonyl group and a di- (C1_3-alkyl) -aminocarbonyl-C1_3-alkyl group, wherein all the single-bonded or fused phenyl groups contained in the groups mentioned under R6 may be mono-or disubstituted by fluorine, chlorine or bromine atoms, by C1_3-alkyl, trifluoromethyl, hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkyl-aminocarbonyl, aminosulphonyl, C1_3-alkyl-aminosulphonyl, nitro or cyano groups, wherein the substituents may be identical or different, or two adjacent hydrogen atoms of the phenyl groups may be replaced by a methylenedioxy group, and R. denotes a hydrogen atom or a C1_3-alkyl group, whilst by a heteroaryl group as mentioned above is meant a pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, furyl, thienyl, oxazolyl, thiazolyl, pyrazolyl, imidazolyl or triazolyl group optionally substituted in the carbon skeleton by a C1_3-alkyl group wherein a hydrogen atom bound to a nitrogen atom may be replaced by a C1_3-alkyl or phenyl-C1_3-alkyl group and wherein the 5-membered heteroaryl groups containing at least one imino group are bound via a carbon or nitrogen atom, a hydrogen atom bound to a nitrogen atom in the abovementioned groups may be replaced by a group which can be cleaved in vivo, particularly by an acetyl or tert.butoxycarbonyl group, the carboxy groups contained in the abovementioned groups may each be substituted by a group which can be cleaved in vivo and may occur, for example, in the form of the tert.butoxycarbonyl group, some or all of the hydrogen atoms in the abovementioned alkyl and alkoxy groups or in the alkyl moieties contained in the above-defined groups of formula I optionally being replaced by fluorine atoms and the saturated alkyl and alkoxy moieties contained in the abovementioned groups, which contain more than 2 carbon atoms, may be straight-chain or branched, unless otherwise stated, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof.

One subgroup of preferred compounds of general formula I
deserving special mention comprises those wherein X, R. and R3 to R. are as hereinbefore defined and R2 denotes a straight-chain or branched Cl_6-alkoxy-carbonyl group, a C5_7-cycloalkoxycarbonyl or a phenoxycarbonyl group, a straight-chain or branched C1_3-alkoxy-carbonyl group, which is terminally substituted in the alkyl moiety by a phenyl-carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylaminocarbonyl or di-(C1_3-alkyl)-aminocarbonyl group, a straight-chain or branched CZ_3-alkoxy-carbonyl group, which is terminally substituted in the alkyl moiety by a hydroxy, Cl_3-alkoxy, amino, Cl_3-alkylamino or di- (Cl_3-alkyl) -amino group, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof.

A second sub-group of preferred compounds of general formula I
deserving special mention comprises those wherein X, Rl and R3 to R. are as hereinbefore defined and R2 denotes an aminocarbonyl or methylaminocarbonyl group, an ethylaminocarbonyl group optionally substituted in the 2 position of the ethyl group by a hydroxy or C1_3-alkoxy group or, if R4 does not denote an aminosulphonyl-phenyl or N- (Cl_5-alkyl) -Cl_3-alkylaminocarbonyl-phenyl group, R2 may also denote a di- (Cl_2-alkyl) -aminocarbonyl group, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof.

A third sub-group of preferred compounds of general formula I
deserving special mention comprises those wherein X, Rl to R3 and RS are as hereinbefore defined and R4 denotes an R,- (n-Cl_4-alkyl) -phenyl group, wherein R7 denotes an amino, Cl_6-alkylamino, di- (C1_6-alkyl) -amino, phenylamino, N-phenyl-C1_3-alkyl-amino, phenyl-C1_3-alkyl-amino, N- (C1_3-alkyl) -phenyl-Cl_3-alkylamino or di- (phenyl-C1_3-alkyl) -amino group, or a phenyl group substituted by the group of formula -N(R12)-CO-(CH2)p-R13 (IV), wherein R12, p and R13 are as hereinbefore defined, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof.

Particularly preferred compounds of general formula I are those wherein X denotes an oxygen atom, R. denotes a hydrogen atom, R2 denotes a carboxy group, a straight-chain or branched C1_4-alkoxycarbonyl group or a phenoxycarbonyl group, a straight-chain or branched C1_3-alkoxy-carbonyl group, which is terminally substituted in the alkyl moiety by a phenyl, carboxy, C1_,-alkoxycarbonyl, aminocarbonyl, Cl_3-alkylaminocarbonyl or di- (Cl_3-alkyl) -aminocarbonyl group, a straight-chain or branched C2_3-alkoxy-carbonyl group which is terminally substituted in the alkyl moiety by a hydroxy, Cl_3-alkoxy, amino, Cl_3-alkylamino or di- (Cl_3-alkyl) -amino group, an aminocarbonyl or methylaminocarbonyl group, an ethylaminocarbonyl group optionally substituted in the 2 position of the ethyl group by a hydroxy or C1_3-alkoxy group or, if R4 does not denote an aminosulphonyl-phenyl or N- (C1_5-alkyl) -Cl_3-alkylaminocarbonyl-phenyl group, it may also denote a di- (Cl_2-alkyl) -aminocarbonyl group, R3 denotes a C1_4-alkyl group or a phenyl group which may be substituted by a fluorine, chlorine or bromine atom, by a trifluoromethyl, C1_3-alkyl, hydroxy or C1_3-alkoxy group, R4 denotes a C5_6-cycloalkyl group, wherein the methylene group in position 4 of the cyclohexyl group may be substituted by an amino, Cl_3-alkylamino or di- (Cl_3-alkyl) -amino group or replaced by an -NH or -N(C1_3-alkyl) group, a phenyl group, a phenyl group disubstituted by C1_3-alkyl, C1_3-alkoxy or nitro groups, wherein the substituents may be identical or different, or a phenyl group substituted by the group R6+ which may additionally be substituted by a fluorine, chlorine or bromine atom or by an amino or nitro group, wherein R6 denotes a fluorine, chlorine or bromine atom, a C1_3-alkyl, Cl_3-alkoxy, nitro, amino or C5_6-cycloalkyl group, a pyrrolyl, pyrazolyl, imidazolyl, triazolyl or tetrazolyl group bound via a carbon atom, wherein the abovementioned heteroaromatic groups in the carbon skeleton may be substituted by a C1_3-alkyl group or a hydrogen atom bound to a nitrogen atom may be replaced by a C1_3-alkyl or phenyl-C1_3-alkyl group, the group of formula O

NH
CH
N O
H

a carboxy, C1_4-alkoxycarbonyl, phenyl-C1_3-alkylamino-carbonyl or C5_7-cycloalkyl-carbonyl group, a 5 or 6-membered cycloalkyleneimino group, wherein the methylene group in position 4 of the piperidino group may be replaced by an oxygen or sulphur atom, by an -NH or -N(Cl_3-alkyl) group, an unbranched C1_3-alkyl group terminally substituted by the group Rõ wherein R7 denotes a CS_7-cycloalkyl group, wherein in a 5 or 6-membered cycloalkyl group a-(CHz)2 group may be replaced by a -CO-NH group, a -(CH2)3 group may be replaced by an -NH-CO-NH- or a-(CH2)4 group may be replaced by an -NH-CO-NH-CO group, whilst in each case a hydrogen atom bound to a nitrogen atom may be replaced by a C1_3-alkyl group, a phenyl or pyridinyl group or a pyrrolyl, pyrazolyl, imidazolyl or triazolyl group bound via a carbon or nitrogen atom, wherein the abovementioned heteroaromatic groups in the carbon skeleton may be substituted by a , CA 02387013 2002-03-19 C1_3-alkyl group or a hydrogen atom bound to a nitrogen atom may be replaced by a C1_3-alkyl group, a hydroxy or Cl_3-alkoxy group, an amino, Cl_6-alkylamino, di- (Cl_6-alkyl) -amino, phenylamino, N-phenyl-C1_3-alkylamino, phenyl-C1_3-alkylamino or N- (C1_3-alkyl) -phenyl-Cl_3-alkylamino group, a w-hydroxy-CZ_3-alkyl-amino, N- (Cl_3-alkyl) -w-hydroxy-CZ_3-alkylamino, di- (w-hydroxy-C2_3-alkyl) -amino or di- (co- (C1_3-alkoxy) -CZ_3-alkyl) -amino group, a Cl_,-alkylcarbonylamino-CZ_3-alkyl-amino or Cl_3-alkylcarbonylamino-C2_3-alkyl-N- (Cl_3-alkyl) -amino group, a C1_3-alkylsulphonylamino, N- (C,_3-alkyl) -C1_3-alkylsulphonylamino, C1_3-alkylsulphonylamino--C2_3-alkylamino or Cl_3-alkylsulphonylamino--C2_3-alkyl-N- (Cl_3-alkyl) -amino group, a hydroxycarbonyl-C1_3-alkylamino or N- (Cl_3-alkyl) -hydroxycarbonyl-Cl_3-alkyl-amino group, a guanidino group wherein a hydrogen atom may be replaced by a C1_3-alkyl group, a group of formula -N(R8)-CO-(CH2)n-Rg (II), wherein R. denotes a hydrogen atom or a Cl_3-alkyl group, n denotes one of the numbers 0, 1, 2 or 3 and R9 denotes an amino, Cl_3-alkylamino, di- (C1_3-alkyl) -amino or Cl_4-alkoxy group, a 5- or 6-membered cycloalkyleneimino group, wherein the methylene group in position 4 of the piperidino group may be replaced by an -NH, -N(Cl_3-alkyl) or -N(C1_3-alkyl-carbonyl) group, or, if n denotes one of the numbers 1, 2 or 3, R9 may also denote a hydrogen atom, a group of formula -N(R10) - (CH2) m- (CO)o-R11 (III), wherein Rlo denotes a hydrogen atom or a Cl_3-alkyl group, m denotes one of the numbers 1, 2 or 3, o denotes the number 1 or, if m is one of the numbers 2 or 3, o may also denote the number 0 and Rll denotes an amino, C1_3-alkylamino, di- (C1_3-alkyl) -amino, C1_4-alkoxy or methoxy-C1_3-alkoxy group or a 5- or 6-membered cycloalkyleneimino group, wherein the methylene group in position 4 of the piperidino group may be replaced by an -NH, -N(Cl_3-alkyl) or -N(C1_3-alkyl-carbonyl) group, an azetidino, pyrrolidino, piperidino, 2,6-dimethyl-piperidino, 3,5-dimethyl-piperidino or azepino group, wherein the methylene group in position 3 of the pyrrolidino group may be substituted by a hydroxy group, the methylene group in position 4 of the piperidino group may be substituted by a hydroxy, hydroxy-Cl_3-alkyl or Cl_3-alkoxy group or may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, -NH, -N(C1_3-alkyl) , -N(C1_3-alkyl-carbonyl), -N(benzoyl) or -N(phenyl-C1_3-alkyl-carbonyl) group, wherein a methylene group linked to an imino-nitrogen atom of the pyrrolidino, piperidino or piperazino group may be replaced by a carbonyl group, or R6 denotes a straight-chain C1_3-alkyl group which is terminally substituted by a carboxy or C1_3-alkoxy-carbonyl group, a group of formula -N(R12)-CO-(CH2)p-R13 (IV), wherein R12 denotes a hydrogen atom, a C1_3-alkyl or phenyl-Cl_3-alkyl group, p denotes one of the numbers 0, 1 or 2 and R13 denotes an amino, Cl_4-alkylamino, di- (Cl_4-alkyl) -amino, benzylamino, N-(C1_3-alkyl)-benzylamino, C1_3-alkoxy-Cl_3-alkylamino, N- (C1_3-alkyl) -C1_3-alkoxy-C1_3-alkylamino, di- (2-methoxy-ethyl) -amino, di-(w-hydroxy-CZ_3-alkyl)-amino or aminocarbonyl-methyl-N-(methyl)-amino group, a pyrrolyl, pyrazolyl or imidazolyl group bound via a nitrogen atom and optionally substituted by a C1_3-alkyl group, a pyrrolidino, piperidino, morpholino, thiomorpholino or a piperazino group optionally substituted in the 4 position by a Cl_3-alkyl, phenyl-Cl_3-alkyl, Cl_3-alkylcarbonyl or C1_4-alkoxycarbonyl group or, if n denotes the number 1 or 2, it may also denote a hydrogen atom, a group of formula -N(R14) - (CH2) q- (CO) r-R15 (V) , wherein R14 denotes a hydrogen atom, a Cl_4-alkyl, C1_3-alkyl-carbonyl, phenylcarbonyl, phenyl-C1_3-alkylcarbonyl, furyl-carbonyl, pyridinyl-carbonyl, furyl-C1_3-alkylcarbonyl, pyridinyl-C1_3-alkylcarbonyl, C1_4-alkylsulphonyl, phenylsulphonyl or phenyl-C1_3-alkylsulphonyl group, q denotes one of the numbers 1, 2 or 3, r denotes the number 1 or, if q is one of the numbers 2 or 3, it may also denote the number 0 and Rls denotes an amino, Cl_4-alkylamino, di- (C1_4-alkyl) -amino, phenylamino, N-(C1_4-alkyl)-phenylamino, benzylamino or N- (Cl_9-alkyl) -benzylamino group, or a group of formula -N(R16)-SO2-Rl7 (VI), wherein R16 denotes a hydrogen atom or a C1_3-alkyl group optionally terminally substituted by a cyano, trifluoromethyl-carbonylamino or N-(C1_3-alkyl)-trifluoromethyl-carbonyl-amino group and R17 denotes a Cl_3-alkyl group, wherein all the single-bonded or fused phenyl groups contained in the groups mentioned under R6 may be substituted by a fluorine, chlorine or bromine atom, by a methyl, trifluoromethyl, methoxy, nitro or cyano group and R5 denotes a hydrogen atom, wherein a hydrogen atom bound.to a nitrogen atom in the abovementioned groups may be replaced by an acetyl or tert.butoxycarbonyl group, the carboxy groups contained in the abovementioned groups may also be present in the form of the tert.butoxycarbonyl precursor group and the saturated alkyl and alkoxy moieties contained in the abovementioned groups, which contain more than 2 carbon atoms, may be straight-chain or branched, unless otherwise stated, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof.
One subgroup of particularly preferred compounds of general formula I deserving special mention comprises those wherein X, Rl, R3 and R5 are as hereinbefore defined, R2 denotes a straight-chain or branched C1_q,-alkoxycarbonyl group or a phenoxycarbonyl group, a straight-chain or branched C1_3-alkoxycarbonyl group, which is terminally substituted in the alkyl moiety by a phenyl-carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, Cl_3-alkylaminocarbonyl or di- (Cl_3-alkyl) -aminocarbonyl group, or a straight-chain or branched CZ_3-alkoxy-carbonyl group, which is terminally substituted in the alkyl moiety by a hydroxy, Cl_3-alkoxy, amino, Cl_3-alkylamino or di- (Cl_3-alkyl) -amino group, and R4 denotes an R,- (n-Cl_3-alkyl) -phenyl group, wherein R. denotes an amino, C1_6-alkylamino, di- (Cl_4-alkyl) -amino, cw-hydroxy-C2_3-alkyl-amino, N- (Cl_3-alkyl) -ou-hydroxy-C2_3-alkyl-amino, di- (w-hydroxy-C2_3-alkyl) -amino or di- ((0- (Cl_3-alkoxy) -C2_3-alkyl) -amino group, or a phenyl group substituted by the group of formula -N(R12)-CO-(CH2)p-R13 (IV), wherein R12, p and R13 are as hereinbefore defined, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof.

A second subgroup of particularly preferred compounds of general formula I deserving special mention comprises those wherein X, Rl, R3 and RS are as hereinbefore defined, R2 denotes an aminocarbonyl or methylaminocarbonyl group, an ethylaminocarbonyl group optionally substituted in the 2 position of the ethyl group by a hydroxy or C1_3-alkoxy group or, if R4 does not denote an aminosulphonyl-phenyl or N- (Cl_5-alkyl) -C1_3-alkylaminocarbonyl-phenyl group, R2 may also denote a di-(C1_2-alkyl)-aminocarbonyl group and R4 denotes a R,- (n-Cl_3-alkyl) -phenyl group, wherein R7 denotes an amino, C1_6-alkylamino, di- (Cl_4-alkyl) -amino, cw-hydroxy-C2_3-alkyl-amino, N- (Cl_3-alkyl) -w-hydroxy--C2_3-alkyl-amino, di- (w-hydroxy-CZ_3-alkyl) -amino or di- (co- (Cl_3-alkoxy) -C2_3-alkyl) -amino group, or a phenyl group substituted by the group of formula -N(R12)-CO-(CH2)p-R13 (IV), wherein R12, p and R13 are as hereinbefore defined, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof.

Most particularly preferred compounds of general formula I are those wherein X denotes an oxygen atom, R. and R. each denote a hydrogen atom, R. denotes a methoxycarbonyl, ethoxycarbonyl or aminocarbonyl group, R3 denotes a phenyl group and R4 denotes a phenyl group monosubstituted by the group R6, wherein R6 denotes an N-methyl-imidazol-2-yl group, an unbranched C1_3-alkyl group which is terminally substituted by a Cl_4-alkylamino, di- (Cl_4-alkyl) -amino, piperidino or 2,6-dimethyl-piperidino group, a group of formula -N(R12)-CO-(CH2)p-R13 (IV), wherein R12 denotes a Cl_3-alkyl group, p denotes one of the numbers 1 or 2 and R13 denotes a di- (Cl_3-alkyl) -amino group, or a group of formula -N(R14) - (CH2) q- (CO) r-R15 (V) , wherein R14 denotes a Cl_3-alkyl-carbonyl or Cl_3-alkylsulphonyl group, q denotes one of the numbers 1, 2 or 3, r denotes the number 1 or, if q is one of the numbers 2 or 3, r may also denote the number 0 and Rls denotes a di- (Cl_3-alkyl) -amino group, wherein the saturated alkyl moieties contained in the abovementioned groups which contain more than 2 carbon atoms may be straight-chain or branched, unless otherwise stated, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof.

A subgroup of most particularly preferred compounds of general formula I deserving special mention comprises those wherein X, Rl, R3 and R. are as hereinbefore defined, RZ denotes a methoxycarbonyl or ethoxycarbonyl group and R4 denotes a di- (Cl_3-alkyl) -amino-Cl_3-alkylphenyl group or a phenyl group substituted by the group of formula -N(R12)-CO-(CH2)p-R13 (IV), wherein R12, p and R13 are as hereinbefore defined, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof.
The following are mentioned as examples of particularly preferred compounds:

(a) 3-Z- [1- (4- (piperidin-l-yl-methyl) -anilino) -1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, (b) 3-Z-[(1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone, (c)' 3-Z- [1- (4- (piperidin-l-yl-methyl) -anilino) -1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, (d) 3-Z-[1-(4-(dimethylaminomethyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, (e) 3-Z- [1- (4- ( (2, 6-dimethyl-piperidin-l-yl) -methyl) -anilino) -1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, (f) 3-Z- [1- (4- (N- (2-dimethylamino-ethyl) -N-acetyl-amino) -ani-lino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, (g) 3-Z-[1-(4-(N-(3-dimethylamino-propyl)-N-acetyl-amino)-ani-lino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, (h) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, (i) 3-Z-[1-(4-(dimethylaminomethyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, (j) 3-Z-[1-(4-(N-acetyl-N-dimethylaminocarbonylmethyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, (k) 3-Z-[1-(4-ethylaminomethyl-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, (1) 3-Z- [l- (4- (1-methyl-imidazol-2-yl) -anilino) -1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, (m) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-arnino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, (n) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, (o) 3-Z-[1-(4-(N-(3-dimethylamino-propyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, (p) 3-Z-[1-(4-(N-dimethylaminocarbonylmethyl-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, (q) 3-Z-[1-(4-(N-((2-dimethylamino-ethyl)-carbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, (r) 3-Z-[l-(4-(N-(2-dimethylamino-ethyl)-N-acetyl-amino)-ani-lino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone and (s) 3-Z-[1-(4-methylaminomethyl-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone the tautomers, the mixtures and the salts thereof.

Another subgroup of compounds of general formula I comprises those wherein X denotes an oxygen or sulphur atom, R1 denotes a hydrogen atom or a prodrug group such as a Cl_4-alkoxycarbonyl or C2_4-alkanoyl group, R. denotes a carboxy group, a straight-chain or branched C1_6-alkoxycarbonyl group, a C5_7-cycloalkoxycarbonyl or phenyl-C1_3-alkoxycarbonyl group, an aminocarbonyl or Cl_2-alkylaminocarbonyl group or, if R. does not denote an aminosulphonyl-phenyl or N-(C1_5-alkyl)-C1_3-alkylaminocarbonyl-phenyl group, a di-(C1_2-alkyl)-aminocarbonyl group, R3 denotes a hydrogen atom, a C1_6-alkyl, C3_7-cycloalkyl, trifluoromethyl or heteroaryl group, a phenyl or naphthyl group, a phenyl or naphthyl group mono-or disubstituted by a fluorine, chlorine, bromine or iodine atom, by a trifluoromethyl, C1_3-alkyl or C1_3-alkoxy group, whilst in the event of disubstitution the substituents may be identical or different and wherein the abovementioned unsubstituted as well as the mono- and disubstituted phenyl and naphthyl groups may additionally be substituted by a hydroxy, hydroxy-Cl_3-alkyl or Cl_3-alkoxy-Cl_3-alkyl group, by a cyano, carboxy, carboxy-C1_3-alkyl, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylamino-carbonyl or di- (Cl_3-alkyl) -aminocarbonyl group, by a nitro group, by an amino, Cl_3-alkylamino, di- (C1_3-alkyl) -amino or amino-Cl_3-alkyl group, by a C1_3-alkylcarbonylamino, N- (C1_3-alkyl) -C1_3-alkyl-carbonylamino, C1_3-alkylcarbonylamino-C1_3-alkyl, N- (C1_3-alkyl) -C1_3-alkylcarbonylamino-C1_3-alkyl, Cl_3-alkyl-sulphonylamino, C1_3-alkylsulphonylamino-C1_3-alkyl, N- (C1_3-alkyl) -Cl_3-alkylsulphonylamino-C1_3-alkyl or aryl-C1_3-alkylsulphonylamino group, by a cycloalkylamino, cycloalkyleneimino, cyclo-alkyleneiminocarbonyl, cycloalkyleneimino-C1_3-alkyl, cycloalkyleneiminocarbonyl-C1_3-alkyl or cycloalkyleneiminosulphonyl-C1_3-alkyl group having 4 to 7 ring members in each case, whilst in each case the methylene group in position 4 of a 6- or 7-membered cycloalkyleneimino group may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, -NH or -N(Cl_3-alkyl) group, or by a heteroaryl or heteroaryl-C1_3-alkyl group, R4 denotes a C3_7-cycloalkyl group, whilst the methylene group in the 4 position of a 6- or 7-membered cycloalkyl group may be substituted by an amino, Cl_3-alkylamino or di- (Cl_3-alkyl) -amino group or replaced by an -NH or -N(C1_3-alkyl) group, or a phenyl group substituted by the group R6, which may additionally be substituted by a fluorine, chlorine, bromine or iodine atom, by a Cl_5-alkyl, trifluoromethyl, Cl_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, aminosulphonyl, nitro or cyano group, wherein R6 denotes a hydrogen, fluorine, chlorine, bromine or iodine atom, a cyano, nitro, C1_5-alkyl, C3_7-cycloalkyl, trifluoromethyl, phenyl, tetrazolyl or heteroaryl group, a C1_3-alkoxy group optionally sunstituted by 1 to 3 fluorine atoms, a Cl_3-alkoxy-C1_3-alkoxy, phenyl-Cl_3-alkoxy, amino-C2_3-alkoxy, Cl_3-alkylamino-Cz_3-alkoxy, di- (C1_3-alkyl) -amino-Cz_3-alkoxy, phenyl-Cl_3-alkylamino-C2_3-alkoxy, N- (C1_3-alkyl) -phenyl-Cl_3-alkylamino-C2_3-alkoxy, C5_7-cycloalkyleneimino-C2_3-alkoxy or Cl_3-alkylmercapto group, a carboxy, C1_4-alkoxycarbonyl, aminocarbonyl, C1_3-alkyl-amino-carbonyl, N- (Cl_5-alkyl) -Cl_3-alkylaminocarbonyl, phenyl-C1_3-alkylamino-carbonyl, N- (C1_3-alkyl) -phenyl-Cl_3-alkylamino-carbonyl, piperazinocarbonyl or N-(C1_3-alkyl)-piperazinocarbonyl group, a C1_3-alkylaminocarbonyl or N- (Cl_5-alkyl) -C1_3-alkylaminocarbonyl group wherein an alkyl moiety is substituted by a carboxy or C1_3-alkoxycarbonyl group or is substituted in the 2 or 3 position by a di-(C1_3-alkyl)-amino, piperazino, N-(C1_3-alkyl)-piperazino or a 4- to 7-membered cycloalkyleneimino group, a 4- to 7-membered cycloalkyleneimino group, wherein a methylene group linked to the imino group may be replaced by a carbonyl or sulphonyl group or the cycloalkylene moiety may be fused to a phenyl ring or one or two hydrogen atoms may each be replaced by a C1_3-alkyl group and/or in each case the methylene group in the 4 position of a 6-or 7-membered cycloalkyleneimino group may be substituted by a carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylaminocarbonyl, di- (C1_3-alkyl) -aminocarbonyl, phenyl-C1_3-alkylamino or N- (Cl_3-alkyl) -phenyl-C1_3-alkylamino group or may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, -NH, -N(C1_3-alkyl) , -N(phenyl) , -N (C1_3-alkyl-carbonyl) or -N(benzoyl) group, a C1_4-alkyl group which may be substituted by a hydroxy or Cl_3-alkoxy group, by an amino, Cl_,-alkylamino, di- (Cl_,-alkyl) -amino, di-N- (Cl_3-alkyl) -amino-Cz_3-alkylamino, tri-N, N, N' - (Cl_3-alkyl) -amino-C2_3-alkylamino, phenylamino, N-phenyl-C1_3-alkyl-amino, phenyl-C1_3-alkylamino, N- (Cl_3-alkyl) -phenyl-C1_3-alkylamino or di-(phenyl-Cl_3-alkyl) -amino group, by a C1_3-alkylcarbonylamino, N- (C1_3-alkyl) -C1_3-alkylcarbonylamino, C1_3-alkoxycarbonyl-C1_3-alkylamino or N- (C1_3-alkyl) -Cl_3-alkoxycarbonyl-Cl_3-alkylamino group, by a C4_,-cycloalkylamino, C4_,-cycloalkyl-C1_3-alkylamino or C4_,-cycloalkenylamino group wherein position 1 of the ring is not involved in the double bond and wherein the abovementioned groups may each additionally be substituted at the amino-nitrogen atom by a C1_3-alkyl group wherein some or all of the hydrogen atoms are replaced by fluorine atoms, by a CS_,-cycloalkyl, CZ_,-alkenyl or C1_4-alkyl group, by a 4- to 7-membered cycloalkyleneimino group, wherein a methylene group linked to the imino group may be replaced by a carbonyl or sulphonyl group or the cycloalkylene moiety may be fused to a phenyl group or to an oxazolo, imidazolo, thiazolo, pyridino, pyrazino or pyrimidino group optionally substituted by a fluorine, chlorine, bromine or iodine atom, by a nitro, C1_3-alkyl, Cl_3-alkoxy or amino group or one or two hydrogen atoms may each be replaced by a Cl_3-alkyl, CS_7-cycloalkyl or phenyl group and/or in each case the methylene group in the 4 position of a 6- or 7-membered cycloalkyleneimino group may be substituted by a hydroxy, carboxy, C1_4-alkoxycarbonyl, aminocarbonyl, C1_3-alkylaminocarbonyl, di- (Cl_3-alkyl) -aminocarbonyl, phenyl-C1_3-alkylamino or N- (Cl_3-alkyl) -phenyl-Cl_3-alkylamino group or may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, -NH, -N ( C1_3 -alkyl ) , -N (phenyl ) , -N(C1_3-alkyl-carbonyl) or -N(benzoyl) group, by a carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylaminocarbonyl or di- (C1_3-alkyl) -aminocarbonyl group or by a 4- to 7-membered cycloalkyleneiminocarbonyl group, an amino, pyrrolidino, piperidino, morpholino, benzoylamino or N- (C,_3-alkyl) -benzoylamino group, an N- (C1_3-alkyl) -C2_4-alkanoylamino group which is additionally substituted in the alkyl moiety by a carboxy or C1_3-alkoxycarbonyl group, a group of formula -N(Rg) -CO- (CH2)n-Rg (II), wherein Re denotes a hydrogen atom or a C1_3-alkyl group, n denotes one of the numbers 0, 1, 2 or 3 and R9 denotes an amino, C1_4-alkylamino, phenylamino, N-(C1_4-alkyl)-phenylamino, benzylamino, N- (C1_4-alkyl) -benzylamino or di- (C1_4-alkyl) -amino group, a 4- to 7-membered cycloalkyleneimino group, whilst in each case the methylene group in the 4 position of a 6- or 7-membered cycloalkyleneimino group may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, -NH, -N (C1_3-alkyl) , -N (phenyl) , -N (C1_3-alkyl-carbonyl) or -N(benzoyl) group, or, if n denotes one of the numbers 1, 2 or 3, it may also denote a hydrogen atom, a group of formula -N(R10) - (CH2)m- (CO)o-R11 (III), wherein Rlo denotes a hydrogen atom, a C1_3-alkyl group, a C,._3-alkylcarbonyl, arylcarbonyl, phenyl-C1_3-alkylcarbonyl, C1_3-alkylsulphonyl, arylsulphonyl or phenyl-C1_3-alkylsulphonyl group, m denotes one of the numbers 1, 2, 3 or 4, o denotes one of the numbers 0 or 1 and R11 denotes an amino, C1_4-alkylamino, phenylamino, N-(C1_4-alkyl)-phenylamino, benzylamino, N- (Cl_,-alkyl) -benzylamino or di- (Cl_4-alkyl) -amino group, a 4- to 7-membered cycloalkyleneimino group, wherein the cycloalkylene moiety may be fused to a phenyl ring or in each case the methylene group in the 4 position of a 6- or 7-membered cycloalkyleneimino group may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, -NH, -N(Cl_3-alkyl) , -N(phenyl), -N(C1_3-alkyl-carbonyl) or -N(benzoyl) group, a Cl_j-alkoxy group or a di- (Cl_4-alkyl) -amino-C1_3-alkylamino group optionally substituted in the 1 position by a C1_3-alkyl group, or an N- (C1_3-alkyl) -C1_5-alkylsulphonylamino or N-(C1_3-alkyl)-phenylsulphonylamino group wherein the alkyl moiety is additionally substituted by a cyano or carboxy group, wherein all the single-bonded or fused phenyl groups contained in the groups mentioned under R. may be mono- or disubstituted by fluorine, chlorine, bromine or iodine atoms, by Cl_5-alkyl, trifluoromethyl, Cl_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, aminosulphonyl, nitro or cyano groups, wherein the substituents may be identical or different, or two adjacent hydrogen atoms of the phenyl groups may be replaced by a methylenedioxy group, and R5 denotes a hydrogen atom or a C1_3-alkyl group, wherein by an aryl group is meant a phenyl or naphthyl group optionally mono- or disubstituted by a fluorine, chlorine, bromine or iodine atom, by a trifluoromethyl, C1_3-alkyl or C1_3-alkoxy group and by a heteroaryl group is meant a monocyclic 5- or 6-membered heteroaryl group optionally substituted by a C1_3-alkyl group, wherein the 6-membered heteroaryl group contains one, two or three nitrogen atoms and the 5-membered heteroaryl group contains an imino group optionally substituted by a C1_3-alkyl group, an oxygen or sulphur atom or an imino group optionally substituted by a C1_3-alkyl group and an oxygen or sulphur atom or one or two nitrogen atoms, and moreover a phenyl ring may be fused to the abovementioned monocyclic heterocyclic groups via two adjacent carbon atoms, the saturated alkyl and alkoxy moieties present in the groups defined above which contain more than 2 carbon atoms also include the branched isomers thereof such as, for example, the isopropyl, tert.butyl or isobutyl group, unless otherwise stated, and additionally any carboxy, amino or imino group present may be substituted by a group which can be cleaved in vivo, the isomers and the salts thereof.

According to the invention the new compounds are obtained, for example, by the following methods known in principle from the literature:

a. reacting a compound of general formula / I
X (VII) , ~ N
Rz' I

wherein X and R3 are as hereinbefore defined, R2' has the meanings given for R2 hereinbefore, R1B denotes a hydrogen atom or a protecting group for the nitrogen atom of the lactam group, wherein one of the groups RZ' and R18 may also denote a bond to a solid phase optionally formed via a spacer and the other one of the groups R2' and R18 has the abovementioned meanings, and Z1 denotes a halogen atom, a hydroxy, alkoxy or aryl-alkoxy group, e.g. a chlorine or bromine atom, a methoxy, ethoxy or benzyloxy group, with an amine of general formula RS
H - N/ (VIII) , \ R4 wherein R4 and R5 are as hereinbefore defined, and if necessary subsequently cleaving any protecting group used for the nitrogen atom of the lactam group or cleaving from a solid phase.

The protecting group for the nitrogen atom of the lactam group may be, for example, an acetyl, benzoyl, ethoxycarbonyl, tert.butyloxycarbonyl or benzyloxycarbonyl group and the solid phase may be a resin such as a 4-(2',4'-dimethoxyphenylaminomethyl)-phenoxy resin, the bond preferably being formed via the amino group, or a p-benzyloxybenzyl alcohol resin, wherein the bond is conveniently formed via an intermediate member such as a 2,5-dimethoxy-4-hydroxy-benzyl derivative.

The reaction is conveniently carried out in a solvent such as dimethylformamide, toluene, acetonitrile, tetrahydrofuran, dimethylsulphoxide, methylene chloride or mixtures thereof, optionally in the presence of an inert base such as triethylamine, N-ethyl-diisopropylamine or sodium hydrogen carbonate at temperatures between 20 and 175 C, whilst any protecting group used can be cleaved at the same time by transamidation.

if Z1 in a compound of general formula VII denotes a halogen atom, the reaction is preferably carried out in the presence of an inert base at temperatures of between 20 and 120 C.

If Z. in a compound of general formula VII denotes a hydroxy, alkoxy or arylalkoxy group, the reaction is preferably carried out at temperatures between 20 and 200 C.

If a protecting group used subsequently has to be cleaved, this is conveniently done either hydrolytically in an aqueous or alcoholic solvent, e.g. in methanol/water, ethanol/water, isopropanol/water, tetrahydrofuran/water, dioxan/water, dimethylformamide/water, methanol or ethanol in the presence of an alkali metal base such as lithium hydroxide, sodium hydroxide or potassium hydroxide at temperatures between 0 and 100 C, preferably at temperatures between 10 and 50 C, or advantageously by transamidation with an organic base such as ammonia, butylamine, dimethylamine or piperidine in a solvent such as methanol, ethanol, dimethylformamide and the mixtures thereof or in an excess of the amine used, at temperatures between 0 and 100 C, preferably at temperatures between 10 and 50 C.

Cleaving from any solid phase used is preferably carried out using trifluoroacetic acid and water at temperatures between 0 and 35 C, preferably at ambient temperature.

b. In order to prepare a compound of general formula I wherein R2 has the meanings given hereinbefore, with the exception of the carboxy group:

reacting a compound of general formula N

Rs (IX) , HOOC N
I
Rl wherein Rl and R3 to RS are as hereinbefore defined, or the reactive derivatives thereof, with a compound of general formula H - R19 (X) , wherein R19 denotes a Cl_6-alkanol, a C4_7-cycloalkanol or an aromatic alcohol, a C1_6-alkanol which is terminally substituted in the alkyl moiety by a phenyl, heteroaryl, carboxy, C1_3-alkoxy-carbonyl, aminocarbonyl, C1_3-alkylamino-carbonyl or di- (C1_3-alkyl) -aminocarbonyl group, a C2_6-alkanol which is terminally substituted in the alkyl moiety by a chlorine atom or a hydroxy, C1_3-alkoxy, amino, C1_3-alkylamino or di- (C1_3-alkyl) -amino group, an amino or methylamino group, an ethylamino group optionally substituted in the 2 position of the ethyl group by a hydroxy or C1_3-alkoxy group or a di- (C1_2-alkyl) -amino group.

The esterification or amidation is preferably carried out in a solvent such as methylene chloride, diethylether, tetrahydrofuran, toluene, dioxan, acetonitrile, dimethylsulphoxide or dimethylformamide, optionally in the presence of an inorganic or a tertiary organic base, preferably at temperatures between 20 C and the boiling temperature of the solvent used. The reaction with a corresponding acid is preferably carried out in the presence of a dehydrating agent, e.g. in the presence of isobutyl chloroformate, tetraethyl orthocarbonate, trimethyl orthoacetate, 2,2-dimethoxypropane, tetramethoxysilane, thionylchloride, trimethylchiorosilane, phosphorus trichloride, phosphorus pentoxide, N,N'-dicyclohexylcarbodiimide, N,N'-dicyclohexyl-carbodiimide/N-hydroxysuccinimide, N,N'-dicyclohexyl-carbodiimide/1-hydroxy-benzotriazole, 2-(1H-benzotriazol-l-yl)-1,1,3,3-tetramethyluronium-tetrafluoroborate, 2-(1H-benzotriazol-l-yl)-1,1,3,3-tetramethyluronium-tetrafluoroborate/1-hydroxy-benzotriazole, N,N'-carbonyldiimidazole or triphenylphosphine/carbon tetrachloride, and optionally with the addition of a base such as pyridine, 4-dimethylaminopyridine, N-methyl-morpholine or triethylamine, conveniently at temperatures between 0 and 150 C, preferably at temperatures between 0 and 100 C, and the acylation with a corresponding reactive compound such as an anhydride, ester, imidazolide or halide thereof, is optionally carried out in the presence of a tertiary organic base such as triethylamine, N-ethyl-diisopropylamine or N-methyl-morpholine at temperatures between 0 and 150 C, preferably at temperatures between 50 and 100 C.

c. In order to prepare a compound of general formula I, wherein R4 denotes a C1_,,-alkyl group substituted by the group Rõ wherein R7 denotes an amino, Cl_7-alkylamino, di- (Cl_7-alkyl) -amino, phenylamino, N-phenyl-C1_3-alkyl-amino, phenyl-C1_3-alkyl-amino, N- (Cl_3-alkyl) -phenyl-C1_3-alkylamino or di- (phenyl-C1_3-alkyl) -amino group, aco-hydroxy - C2 _ 3- a l kyl - ami no , N- (Cl_3-alkyl ) -w-hydroxy-C2_3-alkyl-amino, di- (co-hydroxy-C2_3-alkyl) -amino, di- (co- (Cl_3-alkoxy) -C2_3-alkyl) -amino or N-(dioxolan-2-yl)-C1_3-alkyl-amino group, a Cl_3-alkylcarbonylamino-C2_3-alkyl-amino or Cl_3-alkylcarbonylamino-Cz_3-alkyl-N- (C1_3-alkyl) -amino group, a C1_3-alkylsulphonylamino, N- (Cl_3-alkyl) -C1_3-alkylsulphonylamino, Cl_3-alkylsulphonylamino-C2_3-alkyl-amino or C1_3-alkylsulphonylamino-C2_3-alkyl-N- (Cl_3-alkyl) -amino group, a group of formula -N(R10) - (CH2)m- (CO)o-R11 (III), wherein Rlo denotes a hydrogen atom, a Cl_3-alkyl group, a C1_3-alkylcarbonyl, arylcarbonyl, phenyl-C1_3-alkyl-carbonyl, C1_3-alkylsulphonyl, arylsulphonyl or phenyl-C1_3-alkylsulphonyl group, m denotes one of the numbers 1, 2, 3 or 4, o denotes the number 1 and Rll denotes an amino, Cl_4-alkylamino, di- (Cl_4-alkyl) -amino, phenylamino, N-(C1_4-alkyl)-phenylamino, benzylamino, N- (Cl_4-alkyl) -benzylamino, C1_4-alkoxy or . CA 02387013 2002-03-19 C1_3-alkoxy-Cl_3-alkoxy group, a di- (C1_4-alkyl) -amino-Cl_3-alkylamino group optionally substituted in the 1 position by a C1_3-alkyl group, or a 4- to 7-membered cycloalkyleneimino group, wherein the cycloalkylene moiety may be fused to a phenyl ring or in each case the methylene group in the 4 position of a 6- or 7-membered cycloalkyleneimino group may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, -NH, -N(C1_3-alkyl) , -N(phenyl) , -N(Cl_3-alkyl-carbonyl) or -N(benzoyl) group, a C4_,-cycloalkylamino, C4_7 -cycloalkyl-Cl_3-alkylamino or C4_7-cycloalkenylamino group wherein position 1 of the ring is not involved in the double bond and wherein the abovementioned groups may each additionally be substituted at the amino-nitrogen atom by a CS_7-cycloalkyl, C2_4-alkenyl or Cl_,,-alkyl group, or a 4- to 7-membered cycloalkyleneimino group, wherein the cycloalkylene moiety may be fused to a phenyl group or to an oxazolo, imidazolo, thiazolo, pyridino, pyrazino or pyrimidino group optionally substituted by a fluorine, chlorine, bromine or iodine atom, by a nitro, Cl_3-alkyl, C1_3-alkoxy or amino group, and/or one or two hydrogen atoms may each be replaced by a C1_3-alkyl, CS_,-cycloalkyl or phenyl group and/or the methylene group in the 3 position of a 5-membered cycloalkyleneimino group may be substituted by a hydroxy, hydroxy-Cl_3-alkyl, Cl_3-alkoxy or Cl_3-alkoxy-C1_3-alkyl group, in each case the methylene group in the 3 or 4 position of a 6- or 7-membered cycloalkyleneimino group may be substituted by a hydroxy, hydroxy-C1_3-alkyl, Cl_3-alkoxy, C1_3-alkoxy-Cl_3-alkyl, Cl_4-alkoxycarbonyl, aminocarbonyl, C1_3-alkylaminocarbonyl, di- (C1_3-alkyl) -aminocarbonyl, phenyl-C1_3-alkylamino or N- (Cl_3-alkyl) -phenyl-Cl_3-alkylamino group or may be replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, -NH, -N(C1_3-alkyl-), -N(phenyl), -N(phenyl-C1_3-alkyl-) , -N(Cl_3-alkyl-carbonyl-) , -N(Cl_4-alkoxy-carbonyl-) , -N(benzoyl-) or -N(phenyl-C1_3-alkyl-carbonyl-) group, wherein a methylene group linked to an imino-nitrogen atom of the cycloalkyleneimino group may be replaced by a carbonyl or sulphonyl group or in a 5-to 7-membered monocyclic cycloalkyleneimino group or a cycloalkyleneimino group fused to a phenyl group the two methylene groups linked to the imino-nitrogen atom may each be replaced by a carbonyl group:

reacting a compound of general formula R3 Rs I -A Za -N \ /

X (XI), N
R
z' Ria wherein R3, R5 and X are as hereinbefore defined, Rz' has the meanings given for R2 hereinbefore, R18 denotes a hydrogen atom or a protecting group for the nitrogen atom of the lactam group, wherein one of the groups R2' and R18 may also denote a bond to a solid phase optionally formed via a spacer and the other one of the groups RZ' and R18 has the abovementioned meanings, A denotes a C1_4-alkyl group and Z. denotes a leaving group, for example an alkyl or arylsulphonyloxy group such as the methylsulphonyloxy, ethylsulphonyloxy, p-toluenesulphonyloxy or trifluoromethanesulphonyloxy group, with an amine of general formula H-R7, (XII ) , wherein R7, has the meanings given for R7 hereinbefore, and subsequently, if necessary, cleaving any protecting group used for the nitrogen atom of the lactam group, or cleaving from a solid phase.

The reaction is conveniently carried out in a solvent such as methylene chloride, tetrahydrofuran, 1,4-dioxan, toluene, acetonitrile, dimethylsulphoxide, dimethylformamide, dimethyl-acetamide, N-methylpyrrolidone or the mixtures thereof, optionally with the addition of water as a co-solvent and/or with the addition of an inert auxiliary base, e.g. sodium hydrogen carbonate, pyridine, 2,4,6-trimethylpyridine, quinoline, triethylamine, N-ethyldiisopropylamine, N-ethyl-dicyclohexylamine, 1,4-diazabicyclo[2,2,2]octane or 1,8-diazabicyclo[5,4,0]undec-7-ene, at temperatures between -50 C
and +100 C, preferably between -10 C and +50 C, while any protecting group used may be cleaved at the same time by transamidation.

If any protecting group used for the nitrogen atom of the lactam group has to be removed or if the compound has to be cleaved from a solid phase this is carried out as described under method (a) above.

If according to the invention a compound of general formula I
is obtained which contains an alkoxycarbonyl group, this may be converted by hydrolysis into a corresponding carboxy compound, or if a compound of general formula I is obtained which contains an amino or alkylamino group, this may be converted by reductive alkylation into a corresponding alkylamino or dialkylamino compound, or if a compound of general formula I is obtained which contains an amino or alkylamino group, this may be converted by acylation or sulphonation into a corresponding acyl or sulphonyl compound, or if a compound of general formula I is obtained which contains a carboxy group, this may be converted by esterification or amidation into a corresponding ester or aminocarbonyl compound, or if a compound of general formula I is obtained which contains a cycloalkyleneimino group wherein a methylene group is replaced by a sulphur atom, this may be converted by oxidation into a corresponding sulphinyl or sulphonyl compound, or if a compound of general formula I is obtained which contains a nitro group, this may be converted by reduction into a corresponding amino compound, or if a compound of general formula I is obtained wherein R4 denotes a phenyl group substituted by an amino, alkylamino, aminoalkyl or N-alkyl-amino group, this may subsequently be converted, by reaction with a corresponding cyanate, iso-cyanate or carbamoyl halide, into a corresponding urea compound of general formula I, or if a compound of general formula I is obtained wherein R4 denotes a phenyl group substituted by an amino, alkylamino, aminoalkyl or N-alkyl-amino group, this may subsequently be converted, by reaction with a corresponding compound which transfers the amidino group or by reaction with a corresponding nitrile, into a corresponding guanidino compound of general formula I.

The subsequent hydrolysis is preferably carried out in an aqueous solvent, e.g. in water, methanol/water, ethanol/water, isopropanol/water, tetrahydrofuran/water or dioxan/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or in the presence of an alkali metal base such as lithium hydroxide, sodium hydroxide or potassium hydroxide at temperatures between 0 and 100 C, preferably at temperatures between 10 and 50 C.

The subsequent reductive alkylation is preferably carried out in a suitable solvent such as methanol, methanol/water, methanol/water/ammonia, ethanol, ether, tetrahydrofuran, dioxan or dimethylformamide, optionally with the addition of an acid such as hydrochloric acid in the presence of catalytically activated hydrogen, e.g. hydrogen in the presence of Raney nickel, platinum or palladium/charcoal, or in the presence of a metal hydride such as sodium borohydride, lithium borohydride, sodium cyanoborohydride or lithium aluminium hydride at temperatures between 0 and 100 C, preferably at temperatures between 20 and 80 C.

The subsequent acylation or sulphonylation is preferably carried out with the corresponding free acid or a corresponding reactive compound such as the anhydride, ester, imidazolide or halide thereof, preferably in a solvent such as methylene chloride, diethylether, tetrahydrofuran, toluene, dioxan, acetonitrile, dimethylsulphoxide or dimethylforrnamide, optionally in the presence of an inorganic or tertiary organic base at temperatures between -20 and 200 C, preferably at temperatures between 20 C and boiling temperature of the solvent used. The reaction with the free acid may optionally be carried out in the presence of an acid-activating agent or a dehydrating agent, e.g. in the presence of isobutyl chloroformate, tetraethyl orthocarbonate, trimethyl orthoacetate, 2,2-dimethoxypropane, tetramethoxysilane, thionyl chloride, trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide, N,N'-dicyclohexyl-carbodiimide, N,N'-dicyclohexylcarbodiimide/N-hydroxysuccinimide, N,N'-dicyclohexylcarbodiimide/1-hydroxy-benzotriazole, 2-(1H-benzotriazol-l-yl)-1,1,3,3-tetramethyluronium-tetrafluoroborate, 2-(1H-benzotriazol-i-yl)-1,1,3,3-tetramethyluronium-tetrafluoroborate/1-hydroxy-benzotriazole, N,N'-carbonyldiimidazole or triphenylphosphine/carbon tetrachloride, and optionally with the addition of a base such as pyridine, 4-dimethylamino-pyridine, N-methyl-morpholine or triethylamine, conveniently at temperatures between 0 and 150 C, preferably at temperatures between 0 and 100 C. The reaction with a corresponding reactive compound may optionally be carried out in the presence of a tertiary organic base such as triethylamine, N-ethyl-diisopropylamine, N-methyl-morpholine or pyridine or by using an anhydride in the presence of the corresponding acid at temperatures between 0 and 150 C, preferably at temperatures between 50 and 100 C.
The subsequent esterification or amidation is conveniently carried out by reacting a corresponding reactive carboxylic acid derivative with a corresponding alcohol or amine as described hereinbefore.
The subsequent oxidation of the sulphur atom is preferably carried out in a solvent or mixture of solvents, e.g. in water, water/pyridine, acetone, methylene chloride, acetic acid, acetic acid/acetic anhydride, dilute sulphuric acid or trifluoroacetic acid, usefully at temperatures of between -80 and 100 C depending on the oxidising agent used.

In order to prepare a corresponding sulphinyl compound of general formula I the oxidation is expediently carried out with one equivalent of the oxidising agent used, e.g. with hydrogen peroxide in glacial acetic acid, trifluoroacetic acid or formic acid at 0 to 20 C or in acetone at 0 to 60 C, with a peracid such as performic acid in glacial acetic acid or trifluoroacetic acid at 0 to 50 C or with m-chloroperbenzoic acid in methylene chloride, chloroform or dioxan at -20 to 80 C, with sodium metaperiodate in aqueous methanol or ethanol at -15 to 25 C, with bromine in glacial acetic acid or aqueous acetic acid optionally in the presence of a weak base such as sodium acetate, with N-bromosuccinimide in ethanol, with tert.butyl hypochlorite in methanol at -80 to -30 C, with iodobenzodichloride in aqueous pyridine at 0 to 50 C, with nitric acid in glacial acetic acid at 0 to 20 C, with chromic acid in glacial acetic acid or in acetone at 0 to 20 C and with sulphuryl chloride in methylene chloride at -70 C, the resulting thioether-chlorine complex is expediently hydrolysed with aqueous ethanol.

In order to prepare a sulphonyl compound of general formula I
the oxidation is expediently carried out starting from a corresponding sulphinyl compound with one or more equivalents of the oxidising agent used or starting from a corresponding mercapto compound, expediently with two or more equivalents of the oxidising agent used, e.g. with hydrogen peroxide in glacial acetic acid/acetic anhydride, trifluoroacetic acid or in formic acid at 20 to 100 C or in acetone at 0 to 60 C, with a peracid such as performic acid or m-chloroperbenzoic acid in glacial acetic acid, trifluoroacetic acid, methylene chloride or chloroform at temperatures between 0 and 60 C, with nitric acid in glacial acetic acid at 0 to 20 C, with chromic acid, sodium periodate or potassium permanganate in acetic acid, water/sulphuric acid or in acetone at 0 to 20 C.

The subsequent reduction of a nitro group is preferably carried out by hydrogenolysis, e.g. with hydrogen in the presence of a catalyst such as palladium/charcoal or Raney nickel in a solvent such as methanol, ethanol, ethyl acetate, dimethylformamide, dimethylformamide/acetone or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid or glacial acetic acid at temperatures of between 0 and 50 C, but preferably at ambient temperature, and at a hydrogen pressure of 1 to 7 bar, but preferably 3 to 5 bar.

The subsequent preparation of a corresponding urea compound of general formula I is conveniently carried out with an inorganic cyanate or a corresponding isocyanate or carbamoylchloride, preferably in a solvent such as dimethylformamide and optionally in the presence of a tertiary organic base such as triethylamine at temperatures between 0 and 50 C, preferably at ambient.

The subsequent preparation of a corresponding guanidino compound of general formula I is conveniently carried out by reacting with a compound which transfers the amidino group such as 3,5-dimethylpyrazole-l-carboxylic acid amidine, preferably in a solvent such as dimethylformamide and optionally in the presence of a tertiary organic base such as triethylamine at temperatures of between 0 and 50 C, preferably at ambient temperature.
In the reactions described hereinbefore, any reactive groups present such as carboxy, hydroxy, amino, alkylamino or imino groups may be protected during the reaction by conventional protecting groups which are cleaved again after the reaction.
For example, a protecting group for a carboxyl group may be a trimethylsilyl, methyl, ethyl, tert.butyl, benzyl or tetrahydropyranyl group and protecting groups for a hydroxy, amino, alkylamino or imino group may be an acetyl, trifluoroacetyl, benzoyl, ethoxycarbonyl, tert.butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-dimethoxybenzyl group and additionally, for the amino group, a phthalyl group.

Any protecting group used is optionally subsequently cleaved for example by hydrolysis in an aqueous solvent, e.g. in water, isopropanol/water, tetrahydrofuran/water or dioxan/water, in the presence of a acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or in the presence of an alkali metal base such as lithium hydroxide, sodium hydroxide or potassium hydroxide, at temperatures between 0 and 100 C, preferably at temperatures between 10 and 50 C.

However, a benzyl, methoxybenzyl or benzyloxycarbonyl group is cleaved, for example, hydrogenolytically, e.g. with hydrogen in the presence of a catalyst such as palladium/charcoal in a solvent such as methanol, ethanol, ethyl acetate, dimethylformamide, dimethylformamide/acetone or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid or glacial acetic acid at temperatures between 0 and 50 C, but preferably at ambient temperature, and at a hydrogen pressure of 1 to 7 bar, but preferably 3 to 5 bar.
A methoxybenzyl group may also be cleaved in the presence of an oxidising agent such as cerium(IV)ammonium nitrate in a solvent such as methylene chloride, acetonitrile or acetonitrile/water at temperatures of between 0 and 50 C, but preferably at ambient temperature.

A 2,4-dimethoxybenzyl group, however, is preferably cleaved in trifluoroacetic acid in the presence of anisole.

A tert.butyl or tert.butyloxycarbonyl group is preferably cleaved by treating with an acid such as trifluoroacetic acid or hydrochloric acid, optionally using a solvent such as methylene chloride, dioxan, ethyl acetate or ether.

A phthalyl group is preferably cleaved in the presence of hydrazine or a primary amine such as methylamine, ethylamine or n-butylamine in a solvent such as methanol, ethanol, isopropanol, toluene/water or dioxan at temperatures between 20 and 50 C.

Moreover, chiral compounds of general formula I obtained may be resolved into their enantiomers and/or diastereomers.

Thus, for example, the compounds of general formula I obtained which occur as racemates may be separated by methods known per se (cf. Allinger N. L. and Eliel E. L. in "Topics in Stereochemistry", Vol. 6,,,,Wiley Interscience, 1971) into their optical antipodes and compounds of general formula I with at least 2 asymmetric carbon atoms may be resolved into their diastereomers on the basis of their physical-chemical differences using methods known per se, e.g. by chromatography and/or fractional crystallisation, and, if these compounds are obtained in racemic form, they may subsequently be resolved into the enantiomers as mentioned above.
The enantiomers are preferably separated by column separation on chiral phases or by recrystallisation from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives such as e.g. esters or amides with the racemic compound, particularly acids and the activated derivatives or alcohols thereof, and separating the mixture of diastereomeric salts or derivatives thus obtained, e.g. on the basis of their differences in solubility, whilst the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents. Optically active acids in common use are e.g.
the D- and L-forms of tartaric acid or dibenzoyltartaric acid, di-o-tolyltartaric acid, malic acid, mandelic acid, camphorsulphonic acid, glutamic acid, N-acetylglutamic acid, aspartic acid, N-acetylaspartic acid or quinic acid. An optically active alcohol may be for example (+)- or (-)-menthol and an optically active acyl group in amides, for example, may be a(+)- or (-)-menthyloxycarbonyl group.
Furthermore, the compounds of formula I obtained may be converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts with inorganic or organic acids. Acids which may be used for this purpose include for example hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, maleic acid or methanesulphonic acid.

Moreover, if the new compounds of formula I thus obtained contain a carboxy group, they may subsequently, if desired, be converted into the salts thereof with inorganic or organic bases, particularly for pharmaceutical use into the physiologically acceptable salts thereof. Suitable bases for this purpose include for example sodium hydroxide, potassium hydroxide, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.
The compounds of general formulae VII to XII used as starting materials are known from the literature in some cases or may be obtained by methods known from the literature or may be obtained by the methods described hereinbefore and in the Examples. For example, the compounds of general formula VI
are described in German Patent Application 198 24 922.5.
Moreover, the compounds of general formula XI may be obtained from the compounds of general formula I wherein R4 denotes a C1_4-alkyl-phenyl group substituted in the alkyl moiety by a hydroxy group, for example, by reacting with alkyl- or arylsulphonyl chlorides.

As already mentioned, the new compounds of general formula I
wherein R1 denotes a hydrogen atom or a prodrug group have valuable pharmacological properties, particularly inhibitory effects on various kinases, especially on receptor-tyrosine kinases such as VEGFR2, PDGFRa, PDGFR(3, FGFR1, FGFR3, EGFR, HER2, IGF1R and HGFR, as well as on complexes of CDK's (Cyclin Dependent Kinases) such as CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9 with their specific cyclins (A, Bl, B2, C, Dl, D2, D3, E, F, G1, G2, H, I and K) and on viral cyclin, on the proliferation of cultivated human cells, particularly endothelial cells, e.g. in angiogenesis, but also on the proliferation of other cells, particularly tumour cells.

The biological properties of the new compounds were tested by the following standard procedure, as follows:

Human umbilical endothelial cells (HUVEC) were cultivated in IMDM (Gibco BRL), supplemented with 10 % foetal calf serum (FBS) (Sigma), 50 M of 9-mercaptoethanol (Fluka), standard antibiotics, 15 g/ml of endothelial cell growth factor (ECGS, Collaborative Biomedical Products) and 100 g/ml of heparin (Sigma) on gelatine-coated culture dishes (0.2 % gelatine, Sigma) at 37 C, under 5 % CO2 in a water-saturated atmosphere.
In order to investigate the inhibitory activity of the compounds according to the invention the cells were starved for 16 hours, i.e. kept in culture medium without growth factors (ECGS + heparin). The cells were detached from the culture dishes using trypsin/EDTA and washed once in serum-containing medium. Then they were seeded out in amounts of 2.5 x 103 cells per well.

The proliferation of the cells was stimulated with 5 ng/ml of VEGF165 (vascular endothelial growth factor; H. Weich, GBF
Braunschweig) and 10 g/ml of heparin. As a control, 6 wells in each dish were not stimulated.

The compounds according to the invention were dissolved in 100% dimethylsulphoxide and added to the cultures in various dilutions in triplicate, the maximum dimethyl sulphoxide concentration being 0.3 %.

The cells were incubated for 76 hours at 37 C, then for a further 16 hours 3H-thymidine (0.1 Ci/well, Amersham) was added in order to determine the DNA synthesis. Then the radioactively labelled cells were immobilised on filter mats and the radioactivity incorporated was measured in a i3-counter. In order to determine the inhibitory activity of the compounds according to the invention the mean value of the non-stimulated cells was subtracted from the mean value of the factor-stimulated cells (in the presence or absence of the compounds according to the invention).

The relative cell proliferation was calculated as a percentage of the control (HUVEC without inhibitor) and the concentration of active substance which inhibits the proliferation of the cells by 50 s (IC50) was determined.

The test results of the following compounds (a) to (s) of general formula I are given by way of example:

(a) 3-Z-[1-(4-(piperidin-l-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, (b) 3-Z-[(1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone, (c) 3-Z-[1-(4-(piperidin-l-yl-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, (d) 3-Z-[1-(4-(dimethylaminomethyl)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, (e) 3-Z-[1-(4-((2,6-dimethyl-piperidin-l-yl)-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, (f) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-acetyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, (g) 3-Z- [1- (4- (N- (3-dimethylamino-propyl) -N-acetyl-amino) -anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, (h) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, (i) 3-Z-[1-(4-(dimethylaminomethyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, (j) 3-Z-[1-(4-(N-acetyl-N-dimethylaminocarbonylmethyl-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, (k) 3-Z-[1-(4-ethylaminomethyl-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, (1) 3-Z- [1- (4- (1-methyl-imidazol-2-yl) -anilino) -1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, (m) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-arnino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, (n) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, (o) 3-Z- [1- (4- (N- (3-dimethylamino-propyl) -N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, (p) 3-Z-[1-(4-(N-dimethylaminocarbonylmethyl-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, (q) 3-Z-[1-(4-(N-((2-dimethylamino-ethyl)-carbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, (r) 3-Z- [1- (4- (N- (2-dimethylamino-ethyl) -N-acetyl-amino) -anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone and (s) 3-Z-[1-(4-methylaminomethyl-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone.
The following Table contains the results found:
Compound IC50 [ m]
(a) 0.04 (b) 0.35 (c) 0.01 (d) 0.02 (e) 0.05 (f) 0.01 (g) 0.003 (h) 0.01 (i) 0.03 (j) 0.02 (k) 0.03 (1) 0.1 (m) 0.02 (n) 0.02 (o) 0.01 (p) 0.02 (q) 0.02 (r) 0.01 (s) 0.04 In view of their inhibitory effect on the proliferation of cells, particularly endothelial cells and tumour cells, the compounds of general formula I are suitable for treating diseases in which the proliferation of cells, particularly endothelial cells, plays a part.

Thus, for example, the proliferation of endothelial cells and the concomitant neovascularisation constitute a crucial stage in tumour progression (Folkman J. et al., Nature 3-aa, 58-61, (1989); Hanahan D. and Folkman J., Cell $fi, 353-365, (1996)).
Furthermore, the proliferation of endothelial cells is also important in haemangiomas, in metastasisation, rheumatoid arthritis, psoriasis and ocular neovascularisation (Folkman J., Nature Med. 1, 27-31, (1995)). The therapeutic usefulness of inhibitors of endothelial cell proliferation was demonstrated in the animal model for example by O'Reilly et al. and Parangi et al. (O'Reilly M.S. et al., Cell $$, 277-285, (1997); Parangi S. et al., Proc Natl Acad Sci USA .43., 2002-2007, (1996)).

The compounds of general formula I, their tautomers, their stereoisomers or the physiologically acceptable salts thereof are thus suitable, for example, for treating tumours (e.g.
plate epithelial carcinoma, astrocytoma, Kaposi's sarcoma, glioblastoma, lung cancer, bladder cancer, carcinoma of the neck, melanoma, ovarian cancer, prostate cancer, breast cancer, small-cell lung cancer, glioma, colorectal carcinoma, urogenital cancer and gastrointestinal carcinoma as well as haematological cancers, such as multiple myeloma), psoriasis, arthritis (e.g. rheumatoid arthritis), haemangioma, angiofibroma, eye diseases (e.g. diabetic retinopathy), neovascular glaucoma, kidney diseases (e.g.
glomerulonephritis), diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy, fibrotic diseases (e.g. cirrhosis of the liver), mesangial cell proliferative diseases, arteriosclerosis and damage to the nerve tissue and also for inhibiting the reocclusion of blood vessels after treatment with a balloon catheter, in vascular prosthetics or after the insertion of mechanical devices for keeping blood vessels open (e.g. stents), or other diseases in which cell proliferation or angiogenesis are involved.

By reason of their biological properties the compounds according to the invention may be used on their own or in conjunction with other pharmacologically active compounds, for example in tumour therapy, in monotherapy or in conjunction with other anti-tumour therapeutic agents, for example in combination with topoisomerase inhibitors (e.g. etoposide), mitosis inhibitors (e.g. vinblastin, taxol), compounds which interact with nucleic acids (e.g. cis-platin, cyclophosphamide, adriamycin), hormone antagonists (e.g.
tamoxifen), inhibitors of metabolic processes (e.g. 5-FU
etc.), cytokines (e.g. interferons), kinase inhibitors, antibodies, or in conjunction with radiotherapy, etc. These combinations may be administered either simultaneously or sequentially.

For pharmaceutical use the compounds according to the invention are generally used for warm-blooded vertebrates, particularly humans, in doses of 0.01-100 mg/kg of body weight, preferably 0.1-20 mg/kg. For administration they are formulated with one or more conventional inert carriers and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene glycol, stearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof in conventional galenic preparations such as plain or coated tablets, capsules, powders, injectable solutions, ampoules, suspensions, solutions, sprays or suppositories.
The Examples which follow are intended to illustrate the invention:

Abbreviations used:

FMOC = 9-fluorenylmethoxycarbonyl HOBt = 1-hydroxy-lH-benzotriazole TBTU = O-benzotriazol-l-yl-N,N,N',N'-tetramethyluronium-tetrafluoroborate DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene Preparation of the starting compounds:

Gnl i d = hage Example T

2.0 g of Rink resin (MBHA resin, made by Messrs Novabiochem) are left to swell in 30 ml of dimethylformamide. Then 40 ml of 30% piperidine in dimethylformamide are added and the mixture is shaken for 7 minutes to cleave the FMOC protecting group.
The resin is then washed repeatedly with dimethylformamide.
Then 0.4 g of 2-indolinone-6-carboxylic acid (prepared analogously to Langenbeck et al., Justus Liebigs Ann. Chem.
499, 201-208 (1932)), 297 mg HOBt, 706 mg TBTU and 0.9 ml of N-ethyl-diisopropylamine in 30 ml of dimethylformamide are added and the mixture is shaken for 1 hour. Then the solution is suction filtered and the resin is washed five times with 30 ml of dimethylformamide and three times with 30 ml of methylene chloride. To dry it, nitrogen is blown through the resin.
Yield: 1.9 g of charged resin Snl i = haaP xam]a1 e TT

1.9 g of the resin obtained in Example I are stirred with 6 ml of acetic anhydride and 6 ml of triethyl orthobenzoate for 3 hours at 110 C. Then the mixture is left to cool and the resin is washed with dimethylformamide and subsequently with methylene chloride.
Yield: 1.9 g of moist resin The following charged resins are prepared analogously to Example II:

(1) resin charged with 3-Z-(1-ethoxy-methylene)-6-carbamoyl-2-indolinone Prepared by reacting the resin obtained according to Example I
with triethyl orthoformate (2) resin charged with 3-Z-(1-methoxy-l-methyl-methylene)-6-carbamoyl-2-indolinone Prepared by reacting the resin obtained according to Example I
with trimethyl orthoacetate (3) resin charged with 3-Z-(1-methoxy-i-ethyl-methylene)-6-carbamoyl-2-indolinone Prepared by reacting the resin obtained according to Example I
with trimethyl orthopropionate (4) resin charged with 3-Z-(1-methoxy-l-propyl-methylene)-6-carbamoyl-2-indolinone Prepared by reacting the product of Example I and trimethyl orthobutyrate F_xam= l e T T T

N- (4-ni _roz henyl) -N-methyl -m. _hanes 3lphonamide 3.0 g of N-methyl-4-nitroaniline are dissolved in 20 ml of pyridine and 2.4 g of inethanesulphonic acid chloride added dropwise at room temperature. The mixture is stirred for 12 hours at room temperature. After this time the mixture is poured onto water, the precipitate formed is filtered off and dried at 50 C in vacuo.
Yield: 4.0 g (87 t of theory), Rf value: 0.5 (silica gel, ethyl acetate/toluene = 7:3) Melting point: 107-108 C

E.xamz l e TV

N-( -di m hylamino-ethyl )-N-methy sulphonyl-4-ni roa i l i n_ 38.9 g of N-methylsulphonyl-4-nitroaniline are dissolved in 2.0 1 of acetone, 51.9 g of 1-chloro-2-dimethylamino-ethane, 77.4 g of potassium carbonate and 5.0 g of sodium iodide are added and the mixture is stirred for a total of 4 days at 50 C, while after 12 hours a further 25.9 g of 1-chloro-2-dimethylamino-ethane, 49.8 g of potassium carbonate and 5.0 g of sodium iodide in 500 ml of acetone are added and after 36 hours another 26.0 g of 1-chloro-2-dimethylamino-ethane, 50.0 g of potassium carbonate and 5.0 g of sodium iodide in 100 ml of acetone are added. After this time the mixture is filtered and the filtrate evaporated down. The residue is stirred with ether, suction filtered and dried at 40 C.
Yield: 25.3 g (49 0 of theory), Rf value: 0.5 (silica gel, methylene chloride/methanol/ammonia = 9:1:0.1) C11H17N30aS
ESI mass spectrum: m/z = 288 [M+H+]
The following compounds are prepared analogously to Example IV:

(1) 4-[N-(3-dimethylamino-propyl)-N-methylsulphonyl-amino]-nitrobenzene (2) N-carboxymethyl-N-methylsulphonyl-4-nitroaniline (3) N-cyanomethyl-N-methylsulphonyl-p-phenylenediamine (4) 4- [N- (2- (N-benzyl-N-methyl-amino) -ethyl) -N-methylsulphonyl-amino]-nitrobenzene (5) 4-[N-(3-phthalimido-2-yl-propyl)-N-methylsulphonyl-amino]-nitrobenzene (6) 4 - [N- ( 3 - (N-benzyl -N-methyl -amino ) -propyl ) -N-methylsulphonyl-amino]-nitrobenzene F'.xami 1 eV

N-(dimethylaminocarbonyl-methyl)-N-methylsulphonyl-4-nit-rnanilin 7.0 g of N-carboxymethyl-N-methylsulphonyl-4-nitroaniline, 2.5 g of dimethylamine hydrochloride, 8.1 g of TBTU and 3.9 g of HOBT are dissolved in 125 ml of dimethylformamide and at 0 C
17.6 ml of N-ethyl-diisopropylamine are added. The mixture is stirred for 4 hours at room temperature, diluted with 1 1 of water and the precipitate formed is suction filtered. After washing with water, ethanol and ether the residue is dried at 70 C in vacuo.
Yield: 5.3 g (69 % of theory), Rf value: 0.40 (silica gel, methylene chloride/methanol = 9:1) CiiHisNa0sS
ESI mass spectrum: m/z = 300 [M-H-]
The following compounds are prepared analogously to Example V:
(1) 4-[(N-dimethylaminocarbonylmethyl)-amino]-nitrobenzene prepared from 4-(N-carboxymethyl-amino)-nitrobenzene and dimethylamine hydrochloride (2) 4-(N-methylaminocarbonylmethyl-N-methylsulphonyl-amino)-nitrobenzene Prepared from N-carboxymethyl-N-methylsulphonyl-4-nitroaniline and methylamine hydrochloride (3) 4-[(N-(methylcarbamoyl-methyl)-N-methyl-amino)-methyl]-nitrobenzene Prepared from 4-[(N-carboxymethyl-N-methyl-amino)-methyl]-nitrobenzene and methylamine hydrochloride (4) 4-[(N-(dimethylcarbamoyl-methyl)-N-methyl-amino)-methyl]-nitrobenzene Prepared from 4-[(N-carboxymethyl-N-methyl-amino)-methyl]-nitrobenzene and dimethylamine hydrochloride Rxam= le V T

4- [N- (- im thyl amino-et-hyl) -N-ac-Pty1 - mi nol -ni rob n._ne 3.6 g of 4-(2-dimethylamino-ethylamino)-nitrobenzene (according to Gabbay et al., J. Am. Chem. Soc. 91, 5136 (1969)) are dissolved in 50 ml of methylene chloride and 5.0 ml of triethylamine are added. 1.3 ml of acetyl chloride are slowly added dropwise to this mixture at room'temperature and the mixture is stirred for 2 hours at room temperature. After this time another 5.0 ml of triethylamine and 1.3 ml of acetylchloride are added and the mixture is refluxed for another 2 hours. The solvent is removed, the residue is taken up in ethyl acetate and the organic phase is extracted twice with water. After drying over MgSO4 the solvent is removed and the residue dried in vacuo.

Yield: 2.0 g (45 's of theory), Rf value: 0.55 (silica gel, methylene chloride/methanol/ammonia = 9:1:0.1) Ci2Hi7N303 ESI mass spectrum: m/z = 252 [M+H`]

The following compounds are prepared analogously to Example VI:

(1) 4- [N- ( 3 -dimethylamino-propyl ) -N-acetyl -amino] -nitrobenzene Prepared from 4-(3-dimethylamino-propylamino)-nitrobenzene (according to Gabbay et al., J. Am. Chem. Soc. 21õ 5136 (1969) and acetyl chloride (2) 4-[N-(2-dimethylamino-ethyl)-N-propionyl-amino]-nitrobenzene Prepared from 4-(2-dimethylamino-ethylamino)-nitrobenzene and propionyl chloride (3) 4-[N-acetyl-N-(dimethylaminocarbonylmethyl)-amino]-nitrobenzene Prepared from 4-[N-(dimethylaminocarbonylmethyl)-amino]-nitrobenzene and acetyl chloride (4) 4-[N-(2-dimethylamino-ethyl)-N-butyryl-amino]-nitrobenzene Prepared from 4-(2-dimethylamirno-ethylamino)-nitrobenzene and butyryl chloride (5) 4-[N-(2-dimethylamino-ethyl)-N-isobutyryl-amino]-nitrobenzene Prepared from 4-(2-dimethylamino-ethylamino)-nitrobenzene and isobutyryl chloride (6) 4-[N-(2-dimethylamino-ethyl)-N-benzoyl-amino]-nitrobenzene Prepared from 4-(2-dimethylamino-ethylamino)-nitrobenzene and benzoyl chloride (7) 4-[N-(2-dimethylamino-ethyl)-N-acetyl-amino]-1,3-dinitrobenzene Prepared from 4-(2-dimethylamino-ethyl-amino)-1,3-dinitrobenzene and acetyl chloride (8) 4- [N- (2-dimethylamino-ethyl) -N- (furan-2-carbonyl) -amino] -nitrobenzene Prepared from 4-(2-dimethylamino-ethylamino)-nitrobenzene and furan-2-carbonyl chloride (9) 4-[N-(2-dimethylamino-ethyl)-N-(2-methoxy-benzoyl)-amino]-nitrobenzene Prepared from 4-(2-dimethylamino-ethylamino)-nitrobenzene and 2-methoxy-benzoyl chloride (10) 4-[N-(2-dimethylamino-ethyl)-N-(pyridine-3-carbonyl)-amino]-nitrobenzene Prepared from 4-(2-dimethylamino-ethylamino)-nitrobenzene and nicotinic acid chloride (11) 4- [N- (2-dimethylamino-ethyl) -N- (phenyl-acetyl) -amino] -nitrobenzene Prepared from 4-(2-dimethylamino-ethylamino)-nitrobenzene and phenylacetyl-chloride (12) 4-[N-(2-dimethylamino-ethyl)-N-acetyl-amino]-3-bromo-nitrobenzene Prepared from 4-[N-(2-dimethylamino-ethyl)-amino]-3-bromo-nitrobenzene and acetyl chloride (13) N-acryloyl-N-methyl-4-nitro-aniline Prepared from 4-methylamino-nitrobenzene and acrylic acid chloride (14) N-acryloyl-N-isopropyl-4-nitro-aniline Prepared from 4-isopropylamino-nitrobenzene and acrylic acid chloride (15) N-acryloyl-N-benzyl-4-nitro-aniline Prepared from 4-benzylamino-nitrobenzene and acrylic acid chloride (16) N-bromoacetyl-N-methyl-4-nitro-aniline Prepared from 4-methylamino-nitrobenzene and bromoacetyl chloride (17) N-bromoacetyl-N-isopropyl-4-nitro-aniline Prepared from 4-isopropylamino-nitrobenzene and bromoacetyl chloride (18) N-bromoacetyl-N-benzyl-4-nitro-aniline Prepared from 4-benzylamino-nitrobenzene and bromoacetyl chloride Examp1e VTT

r7- (i m thylaminomet-hyl rarhonyl) -N-met-.hyl -4-ni _ro-ani 1 i ne 1.8 g of dimethylamine hydrochloride and 5.5 g of potassium carbonate are placed in 80 ml of acetone and 4.2 g of N-bromoacetyl-N-methyl-4-nitroaniline are added in three batches at room temperature. The mixture is stirred for 12 hours at room temperature. After this time the mixture is filtered and the filtrate is evaporated down. The residue is dissolved in ethyl acetate, washed twice with water, dried over sodium sulphate and finally concentrated by rotary evaporation.
Yield: 2.8 g (79 % of theory), Rf value: 0.5 (silica gel, ethyl acetate/methanol = 7:3) Melting point: 121-122 C

The following compounds are prepared analogously to Example VII:

(1) N-(piperidin-1-yl-methylcarbonyl)-N-methyl-4-nitroaniline (2) N-(morpholin-4-yl-methylcarbonyl)-N-methyl-4-nitroaniline (3) N-[(4-benzyl-piperazin-1-yl)-methylcarbonyl]-N-methyl-4-nitroaniline .(4) N-(pyrrolidin-1-yl-methylcarbonyl)-N-methyl-4-nitroaniline (5) N-[(N-aminocarbonylmethyl-N-methyl-amino)-methylcarbonyl]-N-methyl-4-nitroaniline (6) N-[(N-benzyl-N-methyl-amino)-methylcarbonyl]-N-methyl-4-nitroaniline (7) N-[di-(2-methoxyethyl)-amino-methylcarbonyl]-N-methyl-4-nitroaniline (8) N-(dimethylaminomethylcarbonyl)-N-isopropyl-4-nitro-aniline (9) N-(piperidin-1-yl-methylcarbonyl)-N-isopropyl-4-nitro-aniline (10) N-[(4-tert.butoxycarbonyl-piperazin-1-yl)-methylcarbonyl]-N-isopropyl-4-nitro-aniline (11) N-[(N-benzyl-N-methyl-amino)-methylcarbonyl]-N-benzyl-4-nitro-aniline (12) N-(dimethylaminomethylcarbonyl)-N-benzyl-4-nitro-aniline (13) N-(piperidin-1-yl-methylcarbonyl)-N-benzyl-4-nitro-aniline (14) N-[di-(2-hydroxyethyl)-amino-methylcarbonyl]-N-methyl-4-nitroaniline (15) N-[(N-(2-methoxyethyl)-N-methyl-amino)-methylcarbonyl]-N-methyl-4-nitroaniline (16) N-[(N-(2-dimethylamino-ethyl)-N-methyl-amino)-methylcarbonyl]-N-methyl-4-nitroaniline (17) N-[(4-methyl-piperazin-1-yl)-methylcarbonyl]-N-methyl-4-nitroaniline (18) N-[(imidazol-l-yl)-methylcarbonyl]-N-methyl-4-nitroaniline (19) N-[(phthalimido-2-yl)-methylcarbonyl]-N-methyl-4-nitroaniline Fxamsla VITT

AT- r ( -di m hy] aminn- . hyl) -rar.banyl 1-N-benzyl -4-ni ro- n i l i n.
0.5 g of dimethylamine hydrochloride, 1.1 ml of triethylamine and 1.2 g of N-acryloyl-N-benzyl-4-nitro-aniline are dissolved in 50 ml of methanol and stirred for 24 hours at room temperature. After this time the mixture is evaporated down.
The residue is purified over an aluminium oxide column (activity 2-3) with methylene chloride/ethanol 50:1 as eluant.
Yield: 1.4 g (98 % of theory), Rf value: 0.8 (aluminium oxide, methylene chloride/ethanol =
20:1) Melting point: 73 C
The following compounds are prepared analogously to Example VIII:

(1) N-[(2-dimethylamino-ethyl)-carbonyl]-N-isopropyl-4-nitro-aniline Prepared from N-acryloyl-N-isopropyl-4-nitro-aniline and dimethylamine hydrochloride (2) N-[(2-dimethylamino-ethyl)-carbonyl]-N-methyl-4-nitro-aniline Prepared from N-acryloyl-N-methyl-4-nitro-aniline and dimethylamine hydrochloride (3) N-[(2-(4-tert.butoxycarbonyl-piperazin-1-yl)-ethyl)-carbonyl]-N-methyl-4-nitro-aniline Prepared from N-acryloyl-N-methyl-4-nitro-aniline and N-tert.butoxycarbonyl-piperazine (4) N-[(2-(piperidin-l-yl)-ethyl)-carbonyl]-N-methyl-4-nitro-aniline Prepared from N-acryloyl-N-methyl-4-nitro-aniline and piperidine (5) N-[(2-(N-benzyl-N-methyl-amino)-ethyl)-carbonyl]-N-methyl-4-nitro-aniline Prepared from N-acryloyl-N-methyl-4-nitro-aniline and N-benzyl-N-methyl-amine Fxam=le TX

4(4 methyl ~i_p razine ~-yl )-n; rc~benzene 31.5 g of 4-chloro-i-nitrobenzene and 44.4 ml of 1-methylpiperazine are combined and stirred for 18 hours at 90 C. Then the solution is poured onto ice water and the precipitate formed is suction filtered, washed with water and recrystallised from ethanol/water 1:1. The residue is dried in vacuo at 75 C.
Yield: 44.0 g (99 % of theory), Rf value: 0.5 (silica gel, methylene chloride/methanol = 10:1) Melting point: 108-112 C

The following compounds are prepared analogously to Example IX:

(1) N-(2-dimethylaminoethyl)-N-methyl-4-nitroaniline Prepared from 1-fluoro-4-nitrobenzene and 1-dimethylamino-2-methylamino-ethane (2) N-(3-dimethylaminopropyl)-N-methyl-4-nitroaniline Prepared from 1-fluoro-4-nitrobenzene and 1-dimethylamino-3-methylamino-propane (3) 4-(N-carboxymethyl-amino)-nitrobenzene Prepared from 1-fluoro-4-nitrobenzene and glycine (4) N-cyclohexyl-p-phenylenediamine Prepared from 1-fluoro-4-nitrobenzene and cyclohexylamine (5) 6-[N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino]-3-phthalimido-2-yl-nitrobenzene Prepared from 2-nitro-4-phthalimido-2-yl-fluorobenzene, N-(2-dimethylamino-ethyl)-methanesulphonamide and sodium hydride as base (6) 6-[N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino]-1,3-dinitrobenzene Prepared from 2,4-dinitro-chlorobenzene, N-(2-dimethylamino-ethyl)-methanesulphonamide and sodium hydride as base (7) 4-[N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino]-3-chloro-nitrobenzene Prepared from 2-fluoro-5-nitro-chlorobenzene, N-(2-dimethyl-amino-ethyl)-methanesulphonamide and sodium hydride as base (8) 4-(2-dimethylamino-ethyl-amino)-1,3-dinitrobenzene Prepared from 1-chloro-2,4-dinitro-benzene and N,N-dimethyl-ethylenediamine (9) 4- [N- (2-dimethylamino-ethyl) -N- (ethylsulphonyl) -amino] -nitrobenzene Prepared from 1-fluoro-4-nitro-benzene, N-(2-dimethylamino-ethyl)-ethanesulphonamide and sodium hydride as base (10) 4-[N-(2-dimethylamino-ethyl)-N-(propylsulphonyl)-amino]-nitrobenzene Prepared from 1-fluoro-4-nitro-benzene, N-(2-dimethylamino-ethyl)-propanesulphonamide and sodium hydride as base (11) 4-[N-(2-dimethylamino-ethyl)-N-(butylsulphonyl)-amino]-nitrobenzene Prepared from 1-fluoro-4-nitro-benzene, N-(2-dimethylamino-ethyl)-butanesulphonamide and sodium hydride as base (12) 4- [N- (2-dimethylamino-ethyl) -N- (benzylsulphonyl) -amino] -nitrobenzene Prepared from 1-fluoro-4-nitro-benzene, N-(2-dimethylamino-ethyl)-C-phenylmethanesulphonamide and sodium hydride as base (13) 4- [N- (2-dimethylamino-ethyl) -N- (phenylsulphonyl) -arnino] -nitrobenzene Prepared from 1-fluoro-4-nitro-benzene, N-(2-dimethylamino-ethyl)-benzenesulphonamide and sodium hydride as base (14) 4-[N-(2-dimethylamino-ethyl)-N-(isopropylsulphonyl)-amino]-nitrobenzene Prepared from 1-fluoro-4-nitro-benzene, N-(2-dimethylamino-ethyl)-isopropylsulphonamide and sodium hydride as base (15) 4-[N-(2-dimethylamino-ethyl)-amino]-3-bromo-nitrobenzene Prepared from 2-bromo-l-fluoro-4-nitro-benzene and N,N-dimethyl-ethylenediamine (16) 4-isopropylamino-nitrobenzene Prepared from 1-fluoro-4-nitrobenzene and isopropylamine (17) 4-benzylamino-nitrobenzene Prepared from 1-fluoro-4-nitrobenzene and benzylamine Fxami l_e X

4-(imidazol-4-yl)-ni_robenzene 9.5 g of 2-phenylimidazole are carefully dissolved in 50 ml of concentrated sulphuric acid and 5.8 g of ammonium nitrate are added to this solution at 0 C. After a further 60 minutes stirring at 0 C the mixture is poured onto ice water, made basic with ammonia water and the precipitate formed is suction filtered and recrystallised from ethanol.
Yield: 8.0 g (64 s of theory), Rf value: 0.6 (silica gel, ethyl acetate/ethanol = 10:1) Mass spectrum: m/z = 189 [M+]

The following compounds are prepared analogously to Example X:
(1) 4-(imidazol-2-yl)-nitrobenzene Prepared from 4-(imidazol-2-yl)-benzene (2) 4-(5-methyl-imidazol-4-yl)-nitrobenzene Prepared from 4-methyl-5-phenyl-imidazole (J. Heterocycl.
Chem. 1983, 20, 1277-1281) Fxa n? f- X T

4- (2- (imi(jazol-4-y1 ) -ethylene) -ni _roh _n . _n .
1.5 g of 4-nitrobenzaldehyde and 7.45 g of (N-trityl-imidazol-4-yl-methyl)-triphenylphosphonium chloride are dissolved in 75 ml of tetrahydrofuran and to this solution 3.0 ml of DBU are added dropwise at room temperature. After a further 120 minutes stirring at room temperature the mixture is poured onto water and the precipitate formed is suction filtered. The product is taken up in 25 ml of iN hydrochloric acid and refluxed for 4 hours. After this time it is neutralised with ammoniacal water, extracted with ethyl acetate and the organic phase is washed with water, dried over sodium sulphate and evaporated down. The residue is purified over a silica gel column with methylene chloride/methanol 10:1 as eluant.
Yield: 1.0 g of (47 s of theory), Rf value: 0.6 (silica gel, ethyl acetate/ethanol = 10:1) Melting point: 185-188 C

F=xatn= 1 e XT T

4- (lai = eridin-1 -yl-methyl) -ni troh _n .ene 40.0 g of 4-nitrobenzyl bromide are dissolved in 500 ml of methylene chloride, 51.5 ml of triethylamine are added and 18.3 ml of piperidine are carefully added dropwise. After the end of the exothermic reaction the mixture is refluxed for another 30 minutes. After cooling it is washed with water and the organic phase is dried over sodium sulphate. Finally, the organic phase is evaporated down.
Yield: 36.3 g of (89 % of theory), Rf value: 0.6 (silica gel, methylene chloride/methanol = 9:1) Ci2Hi6Nz0a Mass spectrum: m/z = 221 [M+) The following compounds are prepared analogously to Example XII:

(1) 4-[(2,6-dimethyl-piperidin-l-yl)-methyl]-nitrobenzene (2) 3-(N,N-dimethyl-aminomethyl)-nitrobenzene (3) 4-(N,N-dimethyl-aminomethyl)-nitrobenzene (4) 4-(2-dimethylamino-ethyl)-nitrobenzene (5) 4-(2-diethylamino-ethyl)-nitrobenzene (6) 4-(diethylamino-methyl)-nitrobenzene (7) 4-(N-benzyl-N-methyl-aminomethyl)-nitrobenzene (8) 4-(N-ethyl-N-methyl-aminomethyl)-nitrobenzene (9) 4-[N-(n-hexyl)-N-methyl-aminomethyl]-nitrobenzene (10) 4-(thiomorpholin-4-yl-methyl)-nitrobenzene (11) 4-[(4-methyl-piperazine-1-yl)-methyl]-nitrobenzene (12) 4-(imidazol-1-yl-methyl)-nitrobenzene (13) 4-[2-(4-hydroxy-piperidin-1-yl)-ethyl-amino]-nitrobenzene (14) 4-[(3-hydroxy-pyrrolidin-l-yl)-methyl]-nitrobenzene (15) 4-(1,2,4-triazol-l-yl-methyl)-nitrobenzene (16) 4-(1,2,3-triazol-2-yl-methyl)-nitrobenzene (17) 4-(1,2,3-triazol-l-yl-methyl)-nitrobenzene (18) 4-[(N-ethoxycarbonylmethyl-N-methyl-amino)-methyl]-nitrobenzene (19) 4-[(N-aminocarbonylmethyl-N-methyl-amino)-methyl]-nitrobenzene (20) 4-(azetidin-1-yl-methyl)-nitrobenzene (21) 4-[(di-(2-methoxy-ethyl)-amino)-methyl]-nitrobenzene (22) 4-[N-(N-tert.butoxycarbonyl-3-amino-propyl)-N-methyl-aminomethyl]-nitrobenzene (23) 4-[(N-propyl-N-methyl-amino)-methyl]-nitrobenzene (24) 4-[(N-(2-dimethylamino-ethyl)-N-methyl-amino)-methyl]-nitrobenzene (25) 4- [ (N- (3-dimethylamino-propyl) -N-methyl-amino) -methyl] -nitrobenzene (26) 4-[(N-(2-methoxy-ethyl)-N-methyl-amino)-methyl]-nitrobenzene (27) 4-[(N-(2-hydroxy-ethyl)-N-methyl-amino)-methyl]-nitrobenzene (28) 4-[(N-(dioxolan-2-yl-methyl)-N-methyl-amino)-methyl]-nitrobenzene (29) 4-(3-oxo-piperazine-1-yl-methyl)-nitrobenzene F.xa le XTTI

4- f (N-carboxymethyl-N-methyl -amino) -methyll -ni trob .nzene 7.33 g of 4-[(N-ethoxycarbonylmethyl-N-methyl-amino)-methyl]-nitrobenzene are dissolved in 140 ml of ethanol, 34.0 ml of iN
sodium hydroxide solution are added and the mixture is stirred for half an hour at room temperature. After this time the mixture is neutralised with 34 ml of 1N hydrochloric acid, the solvent removed, the residue taken up in methylene chloride and extracted with water. The aqueous phase is evaporated down and the residue is recrystallised from methylene chloride.
Yield: 5.43 g (84 % of theory), Rf value: 0.4 (silica gel, methylene chloride/methanol = 2:1) CioHiaN20a Mass spectrum: m/z = 223 [M+]
Fxamp1 e XTV

4- ( T-1~ e _lhyl -aminomethyl) -ni _robenzene 6.0 g of 4-nitrobenzyl bromide are dissolved in 25 ml of ethanol, combined with 25 ml of 10% ethanolic ethylamine solution and refluxed for 2 hours. Then the solution is concentrated by rotary evaporation, the residue is taken up with methylene chloride and washed with dilute sodium hydroxide solution. Finally the organic phase is evaporated down.
Yield: 2.3 g (46 % of theory), Rf value: 0.2 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 179 [M-H-]

The following compounds are prepared analogously to Example XIV:

(1) 4-[N-(4-chlorobenzyl)-aminomethyl]-nitrobenzene (2) 4-(N-cyclohexyl-aminomethyl)-nitrobenzene (3) 4-(N-isopropyl-aminomethyl)-nitrobenzene (4) 4-(N-propyl-aminomethyl)-nitrobenzene (5) 4-(N-methyl-aminomethyl)-nitrobenzene (6) 4-(N-butyl-aminomethyl)-nitrobenzene (7) 4-(N-methoxycarbonylmethyl-aminomethyl)-nitrobenzene (8) 4-(N-benzyl-aminomethyl)-nitrobenzene (9) 4-(aminomethyl)-nitrobenzene (10) 4-(pyrrolidin-1-yl-methyl)-nitrobenzene (11) 4-(morpholin-4-yl-methyl)-nitrobenzene (12) 4-(hexamethyleneiminomethyl)-nitrobenzene (13) 4-(4-hydroxy-piperidin-1-yl-methyl)-nitrobenzene (14) 4-(4-methoxy-piperidin-1-yl-methyl)-nitrobenzene (15) 4-(4-methyl-piperidin-1-yl-methyl)-nitrobenzene (16) 4-(4-ethyl-piperidin-1-yl-methyl)-nitrobenzene (17) 4-(4-isopropyl-piperidin-1-yl-methyl)-nitrobenzene (18) 4-(4-phenyl-piperidin-1-yl-methyl)-nitrobenzene (19) 4-(4-benzyl-piperidin-1-yl-methyl)-nitrobenzene (20) 4-(4-ethoxycarbonyl-piperidin-1-yl-methyl)-nitrobenzene (21) 4-(N,N-dipropyl-aminomethyl)-nitrobenzene (22) 4-(4-tert.butoxycarbonyl-piperazin-1-yl-methyl)-nitrobenzene (23) 4-(2-morpholin-4-yl-ethyl)-nitrobenzene (24) 4-(2-pyrrolidin-1-yl-ethyl)-nitrobenzene (25) 4-(2-piperidin-1-yl-ethyl)-nitrobenzene (26) 4-(N-ethyl-N-benzyl-aminomethyl)-nitrobenzene (27) 4-(N-propyl-N-benzyl-aminomethyl)-nitrobenzene (28) 4-[N-methyl-N-(4-chlorobenzyl)-aminomethyl]-nitrobenzene (29) 4-[N-methyl-N-(4-bromobenzyl)-aminomethyl]-nitrobenzene (30) 4- [N-methyl -N- ( 4 - f luorobenzyl ) -aminomethyl ] -nitrobenzene (31) 4-[N-methyl-N-(4-methylbenzyl)-aminomethyl]-nitrobenzene (32) 4-[N-methyl-N-(3-chlorobenzyl)-aminomethyl]-nitrobenzene (33) 4- [N-methyl -N- ( 3 , 4 -dimethoxybenzyl ) -aminomethyl ] -nitrobenzene (34) 4-[N-methyl-N-(4-methoxybenzyl)-aminomethyl]-nitrobenzene (35) 4-(N-2,2,2-trifluoroethyl-N-benzyl-aminomethyl)-nitrobenzene (36) 4-[N-2,2,2-trifluoroethyl-N-(4-chlorobenzyl)-aminomethyl]-nitrobenzene (37) 4-(thiomorpholin-4-yl-methyl)-nitrobenzene (38) 4-(azetidion-1-yl-methyl)-nitrobenzene (39) 4-(3,4-dihydropyrrolidin-1-yl-methyl)-nitrobenzene (40) 4-(3,4-dihydropiperidin-1-yl-methyl)-nitrobenzene (41) 4-(2-methoxycarbonyl-pyrrolidin-l-yl-methyl)-nitrobenzene (42) 4-(3,5-dimethyl-piperidin-1-yl-methyl)-nitrobenzene (43) 4-(4-phenyl-piperazin-1-yl-methyl)-nitrobenzene (44) 4-(4-phenyl-4-hydroxy-piperidin-1-yl-methyl)-nitrobenzene (45) 4-[N-(3,4,5-trimethoxybenzyl-N-methyl-aminomethyl)-nitrobenzene (46) 4-[N-(3,4-dimethoxybenzyl)-N-ethyl-aminomethyl]-nitrobenzene (47) 4- [N- ( 2 , 6 -dichlorobenzyl ) -N-methyl ) -aminomethyl ] -nitrobenzene (48) 4- [N- (4-trifluoromethylbenzyl) -N-methyl) -aminomethyl] -nitrobenzene (49) 4-(N-benzyl-N-isopropyl-aminomethyl)-nitrobenzene (50) 4-(N-benzyl-N-tert.butyl-aminomethyl)-nitrobenzene (51) 4-(N,N-diisopropyl-aminomethyl)-nitrobenzene (52) 4-(N,N-diisobutyl-aminomethyl)-nitrobenzene (53) 4-(2,3,4,5-tetrahydro-benzo(d)azepin-3-yl-methyl)-nitrobenzene (54) 4-(2,3-dihydro-isoindol-2-yl-methyl)-nitrobenzene (55) 4-(6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinolin-2-yl-methyl)-nitrobenzene (56) 4-(1,2,3,4-tetrahydro-isoquinolin-2-yl-methyl)-nitrobenzene (57) 4-[N-(2-hydroxyethyl)-N-benzyl-aminomethyl]-nitrobenzene (58) 4-[N-(1-ethyl-pentyl)-N-(pyridin-2-yl-methyl)-aminomethyl]-nitrobenzene (59) 4-(piperin-1-yl-methyl)-1,3-dinitrobenzene (60) 4-(N-phenethyl-N-methyl-aminomethyl)-nitrobenzene (61) 4-[N-(3,4-dihydroxy-phenethyl)-N-methyl-aminomethyl]-nitrobenzene (62) 4-[N-(3,4,5-trimethoxy-phenethyl)-N-methyl-aminomethyl]-nitrobenzene (63) 4-[N-(3,4-dimethoxy-phenethyl)-N-methyl-aminomethyl]-nitrobenzene (64) 4-[N-(3,4-dimethoxy-benzyl)-N-methyl-aminomethyl]-nitrobenzene (65) 4-[N-(4-chloro-benzyl)-N-methyl-aminomethyl]-nitrobenzene (66) 4-[N-(4-bromo-benzyl)-N-methyl-aminomethyl]-nitrobenzene (67) 4-[N-(4-fluoro-benzyl)-N-methyl-aminomethyl]-nitrobenzene (68) 4-[N-(4-methyl-benzyl)-N-methyl-aminomethyl]-nitrobenzene (69) 4-[N-(4-nitro-phenethyl)-N-methyl-aminomethyl]-nitrobenzene (70) 4-(N-phenethyl-N-benzyl-aminomethyl)-nitrobenzene (71) 4-(N-phenethyl-N-cyclohexyl-aminomethyl)-nitrobenzene (72) 4-[N-(2-(pyridin-2-yl)-ethyl)-N-methyl-aminomethyl]-nitrobenzene (73) 4-[N-(2-(pyridin-4-yl)-ethyl)-N-methyl-aminomethyl]-nitrobenzene (74) 4-[N-(pyridin-4-yl-methyl)-N-methyl-aminomethyl]-nitrobenzene (75) 4-(N,N-dibenzyl-aminomethyl)-nitrobenzene (76) 4- [N- (4-nitro-phenethyl) -N-propyl-aminomethyl] -nitrobenzene (77) 4-(N-benzyl-N-(3-cyano-propyl)-aminomethyl)-nitrobenzene (78) 4-(N-benzyl-N-allyl-aminomethyl)-nitrobenzene (79) 4- [N-benzyl-N- (2, 2, 2-trifluoroethyl) -aminomethyl] -nitrobenzene (80) 4-LN-(2-benzo(1,3)dioxol-5-yl-methyl)-N-methyl-aminomethyl]-nitrobenzene (81) 4-(7-chloro-2,3,4,5-tetrahydro-benzo(d)azepin-3-yl-methyl)-nitrobenzene (82) 4-(7,8-dichloro-2,3,4,5-tetrahydro-benzo(d)azepin-3-yl-methyl)-nitrobenzene (83) 4-(7-methoxy-2,3,4,5-tetrahydro-benzo(d)azepin-3-yl-methyl)-nitrobenzene (84) 4-(7-methyl-2,3,4,5-tetrahydro-benzo(d)azepin-3-yl-methyl)-nitrobenzene (85) 4-(7,8-dimethoxy-2,3,4,5-tetrahydro-benzo(d)azepin-3-yl-methyl)-nitrobenzene (86) 4-(6,7-dichloro-1,2,3,4-tetrahydro-isoquinolin-2-yl-methyl)-nitrobenzene (87) 4-(6,7-dimethyl-1,2,3,4-tetrahydro-isoquinolin-2-yl-methyl)-nitrobenzene (88) 4-(6-chloro-1,2,3,4-tetrahydro-isoquinolin-2-yl-methyl)-nitrobenzene (89) 4-(7-chloro-1,2,3,4-tetrahydro-isoquinolin-2-yl-methyl)-nitrobenzene (90) 4-(6-methoxy-1,2,3,4-tetrahydro-isoquinolin-2-yl-methyl)-nitrobenzene (91) 4-(7-methoxy-1,2,3,4-tetrahydro-isoquinolin-2-yl-methyl)-nitrobenzene (92) 4-[(2,3,4,5-tetrahydro-azepino(4,5-b)pyrazin-3-yl)-methyl]-nitrobenzene (93) 4-[(7-amino-2,3,4,5-tetrahydro-azepino(4,5-b)pyrazin-3-yl)-methyl]-nitrobenzene (94) 4-[(2-amino-5,6,7,8-tetrahydro-azepino(4,5-d)thiazol-6-yl)-methylJ-nitrobenzene (95) 4-[(5,6,7,8-tetrahydro-azepino(4,5-d)thiazol-6-yl)-methyll-nitrobenzene F'xamx 1 p XV

4- (1,i-di oxo-thi omor= holin-4-yl-methyl )-ni _rob .n ._ne 6.0 g of 4-(thiomorpholin-4-yl-methyl)-nitrobenzene are dissolved in 100 ml of methylene chloride and 10.3 g of meta-chloroperbenzoic acid are slowly added. After a further 3 hours stirring at room temperature the precipitate obtained is filtered off.
Yield: 6.2 g (91 % of theory) Rf value: 0.5 (silica gel, methylene chloride/methanol = 1:1) Mass spectrum: m/z = 270 [M+]

The following compound is prepared analogously to Example XV:
(1) 4-(1-oxo-thiomorpholin-4-yl-methyl)-nitrobenzene F.xampl P XVI

4 [N ('I-ami no-z _ropyl ) -N-methy1 qulnhon,yl -ami no1 -nitrobenzene 9.5 g of 4-[N-(3-phthalimido-2-yl-propyl)-N-methylsulphonyl-amino]-nitrobenzene are dissolved in 200 ml of ethanol, 11.5 ml of hydrazine hydrate are added and the mixture is stirred for 1.5 hours at 50 C. After cooling the residue is largely evaporated down, water is added and the solution is extracted with methylene chloride. The organic phase is dried, evaporated down and purified over a silica gel column with methylene chloride/methanol/ammonia 9:1:0.1.
Yield: 2.5 g (39 % of theory) Rf value: 0.2 (silica gel, methylene chloride/methanol = 9:1) CioHisN304S
ESI mass spectrum: m/z = 272 [M-H-]

The following compound is prepared analogously to Example XVI:
(1) 6-[N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino]-3-amino-nitrobenzene Prepared from 6-[N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino]-3-phthalimido-2-yl-nitrobenzene RxamnlP XVTT

4-(1 -mPthyl-imidazol-2-yl)-ni_trnhP_n!7.enP
7.5 g of 4-(imidazol-2-yl)-nitrobenzene are dissolved in 50 ml of dimethylsulphoxide and at 0 C 5.0 g of potassium tert.butoxide are added. After one hour of stirring at room temperature 2.6 ml of methyl iodide are added dropwise and the mixture is stirred for one hour at room temperature. After this time the residue is poured onto ice water and the precipitate formed is suction filtered, washed with water and dried.
Yield: 6.1 g (76 % of theory) Rf value: 0.6 (silica gel, methylene chloride/methanol = 10:1) Melting point: 186-187 C
The following compounds are prepared analogously to Example XVII:

(1) 4-(1-ethyl-imidazol-2-yl)-nitrobenzene Prepared from 4-(imidazol-2-yl)-nitrobenzene and ethyl iodide (2) 4-(i-benzyl-imidazol-2-yl)-nitrobenzene Prepared from 4-(imidazol-2-yl)-nitrobenzene and benzyl bromide Fxams 1 _ XVTTT

4- [ (N- (2- (2-methoxy-ethoxy) -ethyl) -N-methyl-amino) -methyl] -nitrob nzene 5.0 g of 4-methylaminomethyl-nitrobenzene are dissolved in 30 ml of dimethylformamide and 4.6 g of 2-(2-methoxy-ethoxy)-ethyl chloride are added. After six hours' stirring at 100 C
the solvent is removed and the residue is taken up in ethyl acetate. The organic phase is washed with water and dried over sodium sulphate. After the elimination of the solvent the residue is purified over an aluminium oxide column (activity 2-3) with toluene/ethyl acetate 5:1 as eluant.
Yield: 2.3 g (29 % of theory) Rf value: 0.5 (aluminium oxide, toluene/ethyl acetate = 5:1) Ci3H2oNz0a ESI mass spectrum: m/z = 267 [M-H"]
Fxa=1 p XLX

4- (N-~thyl-N- r butoxycarhonyl -aminomethyl) - i.rob .n . _n _ 2.2 g of 4-(ethylaminomethyl)-nitrobenzene are dissolved in 50 ml of ethyl acetate and stirred with 2.6 g of di-tert-butyl.
dicarbonate (tert.butoxycarbonyl-anhydride) for 30 minutes at room temperature. Then the solution is washed with water and evaporated down.
Yield: 3.4 g of theory Rf value: 0.3 (silica gel, methylene chloride/methanol =
50:1) Melting point: 85 C

The following compounds are prepared analogously to Example XIX:

(1) 4-[N-(4-chlorophenyl-methyl)-N-tert.butoxycarbonyl-aminomethyl]-nitrobenzene (2) 4-(N-tert.butoxycarbonyl-aminomethyl)-nitrobenzene (3) 4-(N-cyclohexyl-N-tert.butoxycarbonyl-aminomethyl)-nitrobenzene (4) 4-(N-isopropyl-N-tert.butoxycarbonyl-aminomethyl)-nitrobenzene (5) 4-(N-methyl-N-tert.butoxycarbonyl-aminomethyl)-nitrobenzene (6) 4-(N-propyl-N-tert.butoxycarbonyl-aminomethyl)-nitrobenzene (7) 4-(N-butyl-N-tert.butoxycarbonyl-aminomethyl)-nitrobenzene (8) 4-(N-methoxycarbonylmethyl-N-tert.butoxycarbonyl-aminomethyl)-nitrobenzene (9) 4-(N-benzyl-N-tert.butoxycarbonyl-aminomethyl)-nitrobenzene (10) 4-[N-(3-trifluoroacetylamino-propyl)-N-rnethylsulphonyl-amino]-nitrobenzene Prepared from 4-[N-(3-amino-propyl)-N-methylsulphonyl-amino]-nitrobenzene and trifluoroacetic acid anhydride (11) 4-[(4-tert.butoxycarbonyl-piperazin-l-yl)-methyl]-nitrobenzene F.xam= l e XX

4- (jain _ridin-l-yl -mPtt.hyl ) -ani l i ne 37.0 g of 4-(piperidin-l-yl-methyl)-nitrobenzene are dissolved in 300 ml of methanol, 8.0 g of Raney nickel are added and the mixture is hydrogenated for 85 minutes with 3 bars of hydrogen at room temperature. The catalyst is filtered off and the filtrate is evaporated down.
Yield: 24.0 g (75 % of theory), Rf value: 0.4 (silica gel, methylene chloride/methanol = 9:1) Ci2Hi8Nz ESI mass spectrum: m/z = 191 [M+H+]

The following compounds are prepared analogously to Example VIII:

(1) 4-[(2,6-dimethyl-piperidin-1-yl)-methyl]-aniline (2) N-(2-dimethylamino-ethyl)-N-methylsulphonyl-p-phenylenediamine (3) 3-(dimethylaminomethyl)-aniline (4) 4-(dimethylaminomethyl)-aniline (5) 4-(2-dimethylamino-ethyl)-aniline (6) 4-[N-(2-dimethylamino-ethyl)-N-acetyl-amino]-aniline (7) 4-[N-(3-dimethylamino-propyl)-N-acetyl-amino]-aniline (8) 4- [N- (2-dimethylamino-ethyl) -N-benzoyl-amino] -aniline (9) 4-[N-(2-dimethylamino-ethyl)-N-propionyl-amino]-aniline (10) 4-[N-(2-dimethylamino-ethyl)-N-butyryl-amino]-aniline (11) 4-[N-(2-dimethylamino-ethyl)-N-isobutyryl-amino]-aniline (12) 4-(N-tert.butoxycarbonyl-aminomethyl)-aniline (13) 4-(N-ethyl-N-tert.butoxycarbonyl-aminomethyl)-aniline (14) 4-[N-(4-chlorophenyl-methyl)-N-tert.butoxycarbonyl-aminomethyl]-aniline (15) 4-(N-cyclohexyl-N-tert.butoxycarbonyl-aminomethyl)-aniline (16) 4-(N-isopropyl-N-tert.butoxycarbonyl-aminomethyl)-aniline (17) 4-(N-propyl-N-tert.butoxycarbonyl-aminomethyl)-aniline (18) 4-(N-methyl-N-tert.butoxycarbonyl-aminomethyl)-aniline (19) 4-(N-butyl-N-tert.butoxycarbonyl-aminomethyl)-aniline (20) 4-(N-methoxycarbonyl-methyl-N-tert.butoxycarbonyl-aminomethyl)-aniline (21) 4-(N-benzyl-N-tert.butoxycarbonyl-aminomethyl)-aniline (22) 4-(pyrrolidin-1-yl-methyl)-aniline (23) 4-(morpholin-4-yl-methyl)-aniline (24) 4-(hexamethyleneiminomethyl)-aniline (25) 4-(4-hydroxy-piperidin-l-yl-methyl)-aniline (26) 4-(4-methoxy-piperidin-1-yl-methyl)-aniline (27) 4-(4-methyl-piperidin-l-yl-methyl)-aniline (28) 4-(4-ethyl-piperidin-1-yl-methyl)-aniline (29) 4-(4-isopropyl-piperidin-1-yl-methyl)-aniline (30) 4-(4-phenyl-piperidin-1-yl-methyl)-aniline (31) 4-(4-benzyl-piperidin-1-yl-methyl)-aniline (32) 4-(4-ethoxycarbonyl-piperidin-1-yl-methyl)-aniline (33) 4-(N,N-dipropyl-aminomethyl)-aniline (34) 4-(4-tert.butoxycarbonyl-piperazin-1-yl-methyl)-aniline (35) 4-(2-morpholin-4-yl-ethyl)-aniline (36) 4-(2-pyrrolidin-1-yl-ethyl)-aniline (37) 4-(2-piperidin-1-yl-ethyl)-aniline (38) 4-(N-propyl-N-benzyl-aminomethyl)-aniline (39) 4-[N-(n-hexyl)-N-methyl-aminomethyl]-aniline (40) 4-[N-methyl-N-(4-chlorobenzyl)-aminomethyl]-aniline (41) 4- [N-methyl -N- ( 4 -bromobenzyl ) - aminomethyl ] -aniline (42) 4-[N-methyl-N-(4-methylbenzyl)-aminomethyl]-aniline (43) 4- [N-methyl-N- (4-fluorobenzyl) -aminomethyl] -aniline (44) 4-[N-methyl-N-(3-chlorobenzyl)-aminomethyl]-aniline (45) 4-[N-methyl-N-(3,4-dimethoxybenzyl)-aminomethyl]-aniline (46) 4-[N-methyl-N-(4-methoxybenzyl)-aminomethyl]-aniline (47) 4-(N-2,2,2-trifluoroethyl-N-benzyl-aminomethyl)-aniline (48) 4- [N-2, 2, 2-trifluoroethyl-N- (4-chlorobenzyl) -aminomethyl]-aniline (49) 4-(thiomorpholin-4-yl-methyl)-aniline (50) 4-(1-oxo-thiomorpholin-4-yl-methyl)-aniline (51) 4-(1,1-dioxo-thiomorpholin-4-yl-methyl)-aniline (52) 4-(azetidion-1-yl-methyl)-aniline (53) 4-(3,4-dihydropyrrolidin-l-yl-methyl)-aniline (54) 4-(3,4-dihydropiperidin-l-yl-methyl)-aniline (55) 4-(2-methoxycarbonyl-pyrrolidin-l-yl-methyl)-aniline (56) 4-(3,5-dimethyl-piperidin-l-yl-methyl)-aniline (57) 4-(4-phenyl-piperazin-1-yl-methyl)-aniline (58) 4-(4-phenyl-4-hydroxy-piperidin-1-yl-methyl)-aniline (59) 4-[N-(3,4,5-trimethoxy-benzyl)-N-methyl-aminomethyl]-aniline (60) 4-[N-(3,4-dimethoxy-benzyl)-N-ethyl-aminomethyl]-aniline (61) 4-(N-benzyl-N-ethyl-aminomethyl)-aniline (62) 4-[N-(2,6-dichlorobenzyl)-N-methyl-aminomethyl]-aniline (63) 4-[N-(4-trifluoromethylbenzyl)-N-methyl-aminomethyl]-aniline (64) 4-(N-benzyl-N-isopropyl-aminomethyl)-aniline (65) 4-(N-benzyl-N-tert.butyl-aminomethyl)-aniline (66) 4-(diethylamino-methyl)-aniline (67) 4-(2-diethylamino-ethyl)-aniline (68) 4-(N,N-diisopropyl-aminomethyl)-aniline (69) 4-(N,N-diisobutyl-aminomethyl)-aniline (70) 4-(2,3,4,5-tetrahydro-benzo(d)azepin-3-yl-methyl)-aniline (71) 4-(2,3-dihydro-isoindol-2-yl-methyl)-aniline (72) 4-(6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinolin-2-yl-methyl)-aniline (73) 4-(1,2,3,4-tetrahydro-isoquinolin-2-yl-methyl)-aniline (74) 4-[N-(2-hydroxy-ethyl)-N-benzyl-aminomethyl]-aniline (75) 4-[N-(1-ethyl-pentyl)-N-(pyridin-2-yl-methyl)-aminomethyl]-aniline (76) 4-(piperidin-1-yl-methyl)-3-nitro-aniline (77) 4-(piperidin-1-yl-methyl)-3-amino-aniline (78) 4-(N-benzyl-N-methyl-aminomethyl)-aniline (79) 4-(N-ethyl-N-methyl-aminomethyl)-aniline (80) 4-(N-phenethyl-N-methyl-aminomethyl)-aniline (81) 4-[N-(3,4-dihydroxy-phenethyl)-N-methyl-aminomethyl]-aniline (82) 4-[N-(3,4,5-trimethoxy-phenethyl)-N-methyl-aminomethyl]-aniline (83) 4-[N-(3,4-dimethoxy-phenethyl)-N-methyl-aminomethyl]-aniline (84) 4-[N-(3,4-dimethoxy-benzyl)-N-methyl-aminomethyl]-aniline (85) 4-[N-(4-chloro-benzyl)-N-methyl-aminomethyl]-aniline (86) 4-[N-(4-bromo-benzyl)-N-methyl-aminomethyl]-aniline (87) 4- [N- (4-fluoro-benzyl) -N-methyl-aminomethyl] -aniline (88) 4-[N-(4-methyl-benzyl)-N-methyl-aminomethyl]-aniline (89) 4-[N-(4-nitro-phenethyl)-N-methyl-aminomethyl]-aniline (90) 4-(N-phenethyl-N-benzyl-aminomethyl)-aniline (91) 4-(N-phenethyl-N-cyclohexyl-aminomethyl)-aniline (92) 4- [N- (2- (pyridin-2-yl) -ethyl) -N-methyl-aminomethyl] -aniline (93) 4- [N- (2- (pyridin-4-yl) -ethyl) -N-methyl-aminomethyl] -aniline (94) 4-[N-(pyridin-4-yl-methyl)-N-methyl-aminomethyl]-aniline (95) 4-(N,N-dibenzylaminomethyl)-aniline (96) 4-[N-(4-nitro-benzyl)-N-propyl-aminomethyl]-aniline (97) 4-[N-benzyl-N-(3-cyano-propyl)-aminomethyl]-aniline (98) 4-(N-benzyl-N-allyl-aminomethyl)-aniline (99) 4-[N-benzyl-N-(2,2,2-trifluoroethyl)-aminomethyl]-aniline (100) 4-[(benzo(1,3)dioxol-5-yl-methyl)-methyl-aminomethyl]-aniline (101) 4-(7-chloro-2,3,4,5-tetrahydro-benzo(d)azepin-3-yl-methyl)-aniline (102) 4-(7,8-dichloro-2,3,4,5-tetrahydro-benzo(d)azepin-3-yl-methyl)-aniline (103) 4-(7-methoxy-2,3,4,5-tetrahydro-benzo(d)azepin-3-yl-methyl)-aniline (104) 4-(7-methyl-2,3,4,5-tetrahydro-benzo(d)azepin-3-yl-methyl)-aniline (105) 4-(7,8-dimethoxy-2,3,4,5-tetrahydro-benzo(d)azepin-3-yl-methyl)-aniline (106) 4-(6,7-dichloro-1,2,3,4-tetrahydro-isoquinolin-2-yl-methyl)-aniline (107) 4-(6,7-dimethyl-1,2,3,4-tetrahydro-isoquinolin-2-yl-methyl)-aniline (108) 4-(6-chloro-1,2,3,4-tetrahydro-isoquinolin-2-yl-methyl)-aniline (109) 4-(7-chloro-1,2,3,4-tetrahydro-isoquinolin-2-yl-methyl)-aniline (110) 4-(6-methoxy-1,2,3,4-tetrahydro-isoquinolin-2-yl-methyl)-aniline (111) 4-(7-methoxy-1,2,3,4-tetrahydro-isoquinolin-2-yl-methyl)-aniline (112) 4-(2,3,4,5-tetrahydro-azepino(4,5-b)pyrazin-3-yl-methyl)-aniline (113) 4-(7-amino-2,3,4,5-tetrahydro-azepino(4,5-b)pyrazin-3-yl-methyl)-aniline (114) 4-(2-amino-5,6,7,8-tetrahydro-azepino(4,5-d)thiazol-6-yl-methyl)-aniline (115) 4-(5,6,7,8-tetrahydro-azepino(4,5-d)thiazol-6-yl-methyl)-aniline (116) 4-(4-methyl-piperazin-1-yl)-aniline (117) 4-[N-(2-dimethylamino-ethyl)-N-methyl-amino]-aniline (118) 4-[N-(3-dimethylamino-propyl)-N-methyl-amino]-anil ine (119) N-(3-dimethylamino-propyl)-N-methylsulphonyl-p-phenylenediamine (120) 4-[(N-dimethylaminocarbonylmethyl-N-methylsulphonyl)-amino] -aniline (121) N-(4-aminophenyl)-N-methyl-methanesulphonamide (122) 4-(imidazol-4-yl)-aniline (123) 4-(tetrazol-5-yl)-aniline (124) 4-[N-(2-dimethylamino-ethyl)-N-propionyl-amino]-aniline (125) N-(dimethylaminomethylcarbonyl)-N-methyl-p-phenylenediamine (126) N-[(2-dimethylamino-ethyl)-carbonyl]-N-methyl-p-phenylenediamine (127) 4-(N-acetyl-N-dimethylaminocarbonylmethyl)-amino)-aniline (128) N-methylaminocarbonylmethyl-N-methylsulphonyl-p-phenylenediamine (129) N-aminocarbonylmethyl-N-methylsulphonyl-p-phenylenediamine (130) 4-(imidazolidin-2,4-dion-5-ylidene-methyl)-aniline (131) 4-(imidazolidin-2,4-dion-5-yl-methyl)-aniline (132) 4-(2-oxo-pyrrolidin-l-yl-methyl)-aniline (133) N-cyanomethyl-N-methylsulphonyl-p-phenylenediamine (134) 4-[2-(imidazol-4-yl)-ethyl]-aniline (135) 4-[(4-methyl-piperazin-1-yl)-methyl]-aniline (136) 4-[N-(2-(N-benzyl-N-methyl-amino)-ethyl)-N-methylsulphonyl-amino]-aniline (137) 4 - [N- ( 3 - (N-benzyl -N-methyl -amino) -propyl ) -N-methylsulphonyl-amino]-aniline (138) N-cyclohexyl-p-phenylenediamine (139) 4-(pyridin-4-yl-methyl)-aniline (140) 4-(imidazol-l-yl-methyl)-aniline (141) 4-benzyl-aniline (142) N-(3-trifluoroacetylamino-propyl)-N-methylsulphonyl-p-phenylenediamine (143) tert.butyl 4-amino-phenylacetate (144) 4-(imidazol-2-yl)-aniline (145) 4-(1-methyl-imidazol-2-yl)-aniline (146) 4-(1-ethyl-imidazol-2-yl)-aniline (147) 4-(1-benzyl-imidazol-2-yl)-aniline (148) 4-[N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino]-3-amino-aniline (149) 4-[N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino]-3-chloro-aniline (150) 4-[N-(2-dimethylamino-ethyl)-N-acetyl-amino]-3-amino-aniline (151) 4-[N-(2-dimethylamino-ethyl)-N-acetyl-amino]-3-bromo-aniline (152) 4-[2-(4-hydroxy-piperidin-1-yl)-ethyl-amino]-aniline (153) N-(2-dimethylamino-ethyl)-N-ethylsulphonyl-p-phenylenediamine (154) N-(2-dimethylamino-ethyl)-N-propylsulphonyl-p-phenylenediamine (155) N-(2-dimethylamino-ethyl)-N-isopropylsulphonyl-p-phenylenediamine (156) N-(2-dimethylamino-ethyl)-N-butylsulphonyl-p-phenylenediamine (157) N-(2-dimethylamino-ethyl)-N-benzylsulphonyl-p-phenylenediamine (158) N-(2-dimethylamino-ethyl)-N-phenylsulphonyl-p-phenylenediamine (159) 4-((3-hydroxy-pyrrolidin-1-yl)-methyl)-aniline (160) 4- [N- (2-dimethylamino-ethyl) -N- (furan-2-carbonyl) -amino] -aniline (161) 4-[N-(2-dimethylamino-ethyl)-N-(2-methoxy-benzoyl)-amino] -aniline (162) 4-[N-(2-dimethylamino-ethyl)-N-(pyridine-3-carbonyl)-amino] -aniline (163) 4-[N-(2-dimethylamino-ethyl)-N-(phenyl-acetyl)-amino]-aniline (164) N-(piperidin-1-yl-methylcarbonyl)-N-methyl-p-phenylenediamine (165) N-(morpholin-4-yl-methylcarbonyl)-N-methyl-p-phenylenediamine (166) N-[(4-benzyl-piperazin-l-yl)-methylcarbonyl]-N-methyl-p-phenylenediamine (167) N-(pyrrolidin-l-yl-methylcarbonyl)-N-methyl-p-phenylenediamine (168) 4-(5-methyl-imidazol-4-yl)-aniline (169) N-[(2-dimethylamino-ethyl)-carbonyl]-N-isopropyl-p-phenylenediamine (170) N-[(2-dimethylamino-ethyl)-carbonyl]-N-benzyl-p-phenylenediamine (171) N-(N-aminocarbonylmethyl-N-methyl-amino)-methylcarbonyl)-N-methyl-p-phenylenediamine (172) N-[(N-benzyl-N-methyl-amino)-methylcarbonyl]-N-methyl-p-phenylenediamine (173) N-[di-(2-methoxyethyl)-amino-methylcarbonyl]-N-methyl-p-phenylenediamine (174) N-[(2-(4-tert.butoxycarbonyl-piperazin-1-yl)-ethyl)-carbonyl]-N-methyl-p-phenylenediamine (175) N- [ (2- (piperidin-1-yl) -ethyl) -carbonyl] -N-methyl-p-phenylenediamine (176) N-[(2-(N-benzyl-N-methyl-amino)-ethyl)-carbonyl]-N-methyl-p-phenylenediamine (177) N-(dimethylaminomethylcarbonyl)-N-isopropyl-p-phenylenediamine (178) N-(piperidin-l-yl-methylcarbonyl)-N-isopropyl-p-phenylenediamine (179) N-[(4-tert.butoxycarbonyl-piperazin-1-yl)-methylcarbonyl]-N-isopropyl-p-phenylenediamine (180) N-[(N-benzyl-N-methyl-amino)-methylcarbonyl]-N-benzyl-p-phenylenediamine (181) N-(dimethylaminomethylcarbonyl)-N-benzyl-p-phenylenediamine (182) N-(piperidin-1-yl-methylcarbonyl)-N-benzyl-p-phenylenediamine (183) 4-(1,2,4-triazol-l-yl-methyl)-aniline (184) 4-(1,2,3-triazol-2-yl-methyl)-aniline (185) 4-(1,2,3-triazol-i-yl-methyl)-aniline (186) 4-[(N-ethoxycarbonylmethyl-N-methyl-amino)-methyl]-aniline (187) 4-[(N-aminocarbonylmethyl-N-methyl-amino)-methyl]-aniline (188) 4-(azetidin-l-yl-methyl)-aniline (189) 4-[(di-(2-methoxy-ethyl)-amino)-methyl]-aniline (190) 4-[(N-(2-(2-methoxy-ethoxy)-ethyl)-N-methyl-amino)-methyl]-aniline (191) 4-[N-(N-tert.butoxycarbonyl-3-amino-propyl)-N-methyl-aminomethyl]-aniline (192) 4-[(N-(methylcarbamoyl-methyl)-N-methyl-amino)-methyl]-aniline (193) 4-[(N-(dimethylcarbamoyl-methyl)-N-methyl-amino)-methyl]-aniline (194) 4-[(N-propyl-N-methyl-amino)-methyl]-aniline (195) 4-[(N-(2-dimethylamino-ethyl)-N-methyl-amino)-methyl]-aniline (196) 4-[(N-(3-dimethylamino-propyl)-N-methyl-amino)-methyl]-aniline (197) 4-[(N-(2-methoxy-ethyl)-N-methyl-amino)-methyl]-aniline (198) 4-[(N-(2-hydroxy-ethyl)-N-methyl-amino)-methyl]-aniline (199) 4-[(N-(dioxolan-2-yl-methyl)-N-methyl-amino)-methyl]-aniline (200) 4-(3-oxo-piperazin-1-yl-methyl)-aniline (201) N-[di-(2-hydroxyethyl)-amino-methylcarbonyl]-N-methyl-p-phenylenediamine (202) N-[(N-(2-methoxyethyl)-N-methyl-amino)-methylcarbonyl]-N-methyl-p-phenylenediamine (203) N-[(N-(2-dimethylamino-ethyl)-N-methyl-amino)-methylcarbonyl]-N-methyl-p-phenylenediamine (204) N-[(4-methyl-piperazin-l-yl)-methylcarbonyl]-N-methyl-p-phenylenediamine (205) N-[(imidazol-l-yl)-methylcarbonyl]-N-methyl-p-phenylenediamine (206) N-[(phthalimido-2-yl)-methylcarbonyl]-N-methyl-p-phenylenediamine FrxAms 1 e XXI

4- (4-hy roxymethyl-Kjip ri di n-1 -yl -mP hyl -ami no) -ani 1 i np-1.1 g of 4-(4-ethoxycarbonyl-piperidin-1-yl-methyl-amino)-aniline are suspended in 15 ml of tetrahydrofuran. 175 mg of lithium borohydride are added at room temperature, stirred for 24 h, another 175 mg of lithium borohydride are added and after a further 7.5 hours 15 ml of water are added and the mixture is stirred for 10 minutes. It is extracted three times with 15 ml of ethyl acetate. The combined organic phases are washed with water and saturated saline solution, dried over sodium sulphate and concentrated by rotary evaporation. The residue is purified over a silica gel column with methylene chloride/methanol/ammonia 4:1:0.01 as eluant.
Yield: 200 mg (27 % of theory) Rf value: 0.4 (silica gel, methylene chloride/methanol/ammonia 4:1:0.01) Melting point: 157 C
F.xampl p XXT T

mPt-hyl 4-m -hoxycarbonylmethyl--l-n i ro-b n .oa 54.3 g of methyl 3-nitro-benzoate and 29.0 g of methyl chloroacetate are dissolved in 100 ml of dimethylformamide and this solution is added dropwise at -10 C to a solution of 78.5 g of potassium-tert. butoxide in 500 ml of dimethylformamide.
The mixture is stirred for another 10 minutes at room temperature and after this time the solution is poured onto 350 ml of concentrated hydrochloric acid in 2 1 of ice water.
The solution is stirred for 0.5 hours, the precipitate obtained is suction filtered and washed with water. The product is recrystallised from 150 ml of methanol and dried at 40 C in vacuo.

Yield: 48.3 g of (51 %- of theory), contains about 20 0 of methyl 6-methoxycarbonylmethyl-3-nitro-benzoate Rf value: 0.7 (silica gel, petroleum ether/ethyl acetate =
1:1) Melting point: 65-73 C

The following compound is prepared analogously to Example XXII:

(1) ethyl 4-methoxycarbonylmethyl-3-nitro-benzoate Prepared from ethyl 4-thoxycarbonylmethyl-3-nitro-benzoate RxamIl1 e XXTTT

mPi- yl 2-i ndolinone-5-carboxy a_P
48.3 g of methyl 4-methoxycarbonylmethyl-3-nitro-benzoate are dissolved in 800 ml of concentrated acetic acid, 5.0 g of palladium on carbon (10%) are added and the solution is hydrogenated for 2.5 hours at room temperature and 50 psi. The catalyst is filtered off and the filtrate is evaporated down.
The residue is taken up in 150 ml of tert.-butylmethyl ether, filtered again and dried in vacuo at 100 C.

Yield: 28.6 g (98 % of theory), Rf value: 0.4 (silica gel, methylene chloride/methanol = 10:1) Melting point: 208-211 C

The following compound is prepared analogously to Example XXIII:

(1) ethyl 2-indolinone-6-carboxylate Prepared from ethyl 4-methoxycarbonylmethyl-3-nitro-benzoate Fxa 1P XXTV

1-acetyl-3-(i-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indalinone 15.0 g of ethyl 2-indolinone-6-carboxylate, 49.6 ml of triethyl orthobenzoate and 150 ml of acetic anhydride are stirred for 4 hours at 110 C. After this time the solvent is removed, the residue is recrystallised from petroleum ether and dried in vacuo at 50 C.
Yield: 16.9 g (61 % of theory), Rf value: 0.5 (silica gel, petroleum ether/methylene chloride/ethyl acetate = 5:4:1) Melting point: 98-100 C
C22H2iNOs The following compounds are prepared analogously to Example XXIV:

(1) 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone Prepared from methyl 2-indolinone-6-carboxylate, triethyl orthobenzoate and acetic anhydride (2) 1-acetyl-3-(1-ethoxy-l-ethyl-methylene)-6-ethoxycarbonyl-2-indolinone Prepared from ethyl 2-indolinone-6-carboxylate, triethyl orthopropionate and acetic anhydride Preparation of the final compounds:
R.xam l= A l 3-Z-[1-(4-(piperidin-l-yl-methyl)-anilino)-i-phenyl-mPtlyl PnPI -6- ar amoyl-2-i dol i non -trifl ioroa .._a _P
300 mg of resin obtained according to Example II are suspended in 3 ml of dimethylformamide and shaken with 0.2 g of 4-(piperidin-l-yl-methyl)-aniline for 22 hours at 70 C. Then it is filtered off and the resin is washed several times with methylene chloride, methanol and dimethylformamide. Then 1 ml of methanolic ammonia is added for 2 hours in order to eliminate the acetyl group. Then after further washing 4 ml of 10% trifluoroacetic acid in methylene chloride are added during another 60 minutes, the resin is separated off and the solution is evaporated down.
Yield: 69 mg Rf value: 0.1 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum: m/z = 452 (m+) The following compounds are prepared analogously to Example 1:
(1) 3-Z-(l-Anilino-l-phenyl-methylene)-6-carbamoyl-2-indolinone Prepared from the resin obtained according to Example II and aniline Mass spectrum: m/z = 355 (m+) (2) 3-Z-[1-(4-dimethylaminomethyl-anilino)-l-phenyl-methyleneJ-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example II and 4-dimethylaminomethyl-aniline Mass spectrum: m/z = 412 (m`) (3) 3-Z- [1- (4- (2-diethylamino-ethyl) -anilino) -i-phenyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example II and 4-(2-diethylamino-ethyl)-aniline Mass spectrum: m/z = 454 (m+) (4) 3-Z- [1- (4- (morpholin-4-yl-methyl) -anilino) -i-phenyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example II and 4-(morpholin-4-yl-methyl)-aniline R. value: 0.50 (silica gel, methylene chloride/methanol = 4:1) Mass spectrum: m/z = 454 (m') (5) 3-Z-[1-(4-(l-oxo-thiomorpholin-4-yl-methyl)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example II and 4-(1-oxo-thiomorpholin-4-yl-methyl)-aniline Rf value: 0.30 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum: m/z = 486 (m+) (6) 3-Z-[1-(4-(1,1-dioxo-thiomorpholin-4-yl-methyl)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example II and 4-(1,1-dioxo-thiomorpholin-4-yl-methyl)-aniline Rf value: 0.30 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum: m/z = 502 (m+) (7) 3-Z- [1- (4- (benzylaminomethyl) -anilino) -1-phenyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example II and 4-[N-(phenyl-methyl)-N-tert.butoxycarbonyl-aminomethyl]-aniline Rf value: 0.40 (silica gel, methylene chloride/methanol = 4:1) C30H26Na0z Mass spectrum: m/z = 474 (m') (8) 3-Z-[1-(4-(amino-methyl)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example II and 4-(N-tert.butoxycarbonyl-aminomethyl)-aniline R. value: 0.10 (silica gel, methylene chloride/methanol = 4:1) Mass spectrum: m/z = 384 (m+) (9) 3-Z- [1- (4- (2, 6-dimethylpiperidin-1-yl-methyl) -anilino) -1-phenyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example II and 4-(2,6-dimethylpiperidin-l-yl-methyl)-aniline Rf value: 0.45 (silica gel, methylene chloride/methanol = 4:1) Cs0H32Na0z Mass spectrum: m/z = 480 (m+) (10) 3-Z-[1-(4-(pyrrolidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example II and 4-(pyrrolidin-1-yl-methyl)-aniline Rf value: 0.15 (silica gel, methylene chloride/methanol = 4:1) Mass spectrum: m/z = 438 (m+) (11) 3-Z-[1-(3-(dimethylaminomethyl)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin.obtained according to Example II and 3-dimethylaminomethyl-aniline Rf value: 0.23 (silica gel, methylene chloride/methanol = 4:1) Mass spectrum: m/z = 412 (m+) (12) 3-Z-[1-(3-(N-methyl-N-ethyl-aminomethyl)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example II and 3-(N-methyl-N-ethyl-aminomethyl)-aniline Rf value: 0.23 (silica gel, methylene chloride/methanol = 4:1) Mass spectrum: m/z = 426 (m+) (13) 3-Z-[1-(3-(methylaminomethyl)-anilino)-i-phenyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example II and 4-(N-tert.butoxycarbonyl-N-methyl-aminomethyl)-aniline Rf value: 0.06 (silica gel, methylene chloride/methanol = 4:1) Mass spectrum: m/z = 399 (m+H+) (14) 3-Z-[1-(3-hydroxymethyl-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone Prepared from the resin obtained according to Example II and 3-amino-benzyl alcohol Rf value: 0.7 (silica gel, methylene chloride/methanol = 4:1) Mass spectrum: m/z = 385 (m+) (15) 3-Z-[1-(4-(methoxycarbonylmethyl-aminomethyl)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example II and 4-(N-methoxycarbonylmethyl-N-tert.butoxycarbonyl-aminomethyl)-aniline Rf value: 0.40 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum: m/z = 457 (m+H+) (16) 3-Z-[1-(4-(N-methylsulphonyl-N-(dimethylaminocarbonyl-methyl)-amino)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone Prepared from the resin obtained according to Example II and 4-(N-methylsulphonyl-N-(dimethylaminocarbonylmethyl)-amino)-aniline Rf value: 0.40 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum: m/z = 533 (m+) (17) 3-Z- [l- (4- (N-acetyl-aminomethyl) -anilino) -1-phenyl-methylene]-6-carbamoyl-2-indolinone Prepared from the resin obtained according to Example II and 4-(N-acetyl-aminomethyl)-aniline Rf value: 0.70 (silica gel, methylene chloride/methanol = 4:1) Mass spectrum: m/z = 426 (m') (18) 3-Z-[1-(3,4-dimethoxy-anilino)-i-phenyl-methylene]-6-carbamoyl-2-indolinone Prepared from the resin obtained according to Example II and 3,4-dimethoxy-aniline Rf value: 0.40 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum: m/z = 415 (m+) (19) 3-Z-[1-(4-(morpholin-4-yl)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example II and 4-morpholin-4-yl-aniline Rf value: 0.20 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum: m/z = 440 (m') (20) 3-Z-[1-(4-acetylamino-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone Prepared from the resin obtained according to Example II and 4-acetylamino-aniline Rf value: 0.25 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum: m/z = 412 (m+) (21) 3-Z- [1- (4-amino-anilino) -1-phenyl-methylene] -6-carbamoyl-2-indolinone Prepared from the resin obtained according to Example II and 4-amino-aniline Rf value: 0.40 (silica gel, methylene chloride/methanol = 9:1) C22HisN402 Mass spectrum: m/z = 370 (m+) (22) 3-Z-[1-(4-N-methyl-N-acetyl-amino-anilino)-i-phenyl-methylene]-6-carbamoyl-2-indolinone Prepared from the resin obtained according to Example II and 4-(N-methyl-N-acetyl-amino)-aniline Mass spectrum: m/z = 426 (m+) (23) 3-Z-[1-(4-ethoxycarbonyl-anilino)-i-phenyl-methylene]-6-carbamoyl-2-indolinone Prepared from the resin obtained according to Example II and ethyl 4-amino-benzoate Mass spectrum: m/z = 427 (m+) (24) 3-Z-[1-(4-carboxy-anilino)-i-phenyl-methylene]-6-carbamoyl-2-indolinone Prepared from the resin obtained according to Example II and 4-amino-benzoic acid R. value: 0.11 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum: m/z = 398 (m-H+) (25) 3-Z-[1-(4-benzylcarbamoyl-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone Prepared from the resin obtained according to Example II and 4-amino-benzoic acid-benzylamide Rf value: 0.21 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum: m/z = 488 (m+) (26) 3-Z-[1-(cyclohexyl-amino)-i-phenyl-methylene]-6-carbamoyl-2-indolinone Prepared from the resin obtained according to Example II and cyclohexylamine Rf value: 0.60 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum: m/z = 361 (m+) (27) 3-Z-[1-(4-amino-cyclohexyl-amino)-i-phenyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example II and 4-amino-cyclohexylamine Mass spectrum: m/z = 376 (m+) (28) 3-Z-[1-(N-methyl-piperidine-4-yl-amino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example II and 4-amino-i-methyl-piperidine Rf value: 0.15 (silica gel, methylene chloride/methanol = 4:1) Mass spectrum: m/z = 376 (m+) (29) 3-Z- [1- (4- (piperidin-1-yl-methyl) -anilino) -1-methyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example 11(2) and 4-(piperidin-1-yl-methyl)-aniline Rf value: 0.30 (silica gel, methylene chloride/methanol = 4:1) Mass spectrum: m/z = 390 (m+) (30) 3-Z-[1-(3-dimethylaminomethyl-anilino)-i-methyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example 11(2) and 3-dimethylaminomethyl-aniline Rf value: 0.51 (silica gel, methylene chloride/methanol = 4:1) Mass spectrum: m/z = 351 (m+H+) (31) 3-Z- [1- (4- (N-methyl-N-benzyl-aminomethyl) -anilino) -1-methyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example 11(2) and 4-(N-methyl-N-benzyl-aminomethyl)-aniline Rf value: 0.73 (silica gel, methylene chloride/methanol = 4:1) Mass spectrum: m/z = 426 (m+) (32) 3-Z-[1-(4-(N-methylsulphonyl-N-(2-dimethylamino-ethyl)-amino)-anilino)-1-methyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example 11(2) and 4-(N-methylsulphonyl-N-(2-dimethylamino-ethyl)-amino)-aniline Mass spectrum: m/z = 458 (m+H) (33) 3-Z-[1-(4-chloro-anilino)-1-methyl-methylene]-6-carbamoyl-2-indolinone Prepared from the resin obtained according to Example 11(2) and 4-chloro-aniline Rf value: 0.10 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum: m/z = 327/329 (m+) (34) 3-Z-[1-(3-chloro-anilino)-1-methyl-methylene]-6-carbamoyl-2-indolinone Prepared from the resin obtained according to Example 11(2) and 3-chloro-aniline Rf value: 0.11 (silica gel, methylene chloride/methanol = 9:1) C17H14ClN3O2 Mass spectrum: m/z = 327/329 (m`) (35) 3-Z-[1-(4-methoxycarbonyl-anilino)-1-methyl-methylene]-6-carbamoyl-2-indolinone Prepared from the resin obtained according to Example 11(2) and methyl 4-amino-benzoate Rf value: 0.11 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum: m/z = 351 (m+) (36) 3-Z- [1- (4-carboxy-anilino) -1-methyl-methylene] -6-carbamoyl-2-indolinone Prepared from the resin obtained according to Example 11(2) and 4-amino-benzoic acid Mass spectrum: m/z = 336 (m-H+) (37) 3-Z-[1-(4-methyl-3-nitro-anilino)-1-methyl-methylene]-6-carbamoyl-2-indolinone Prepared from the resin obtained according to Example 11(2) and 4-methyl-3-nitro-aniline Rf value: 0.82 (silica gel, methylene chloride/methanol = 4:1) Mass spectrum: m/z = 352 (m+) (38) 3-Z- [1- (4- (piperidin-1-yl-methyl) -anilino) -1-propyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example 11(4) and 4-(piperidin-1-yl-methyl)-aniline R. value: 0.37 (silica gel, methylene chloride/methanol = 4:1) Mass spectrum: m/z = 418 (m') (39) 3-Z-[1-(3-dimethylaminomethyl-anilino)-1-propyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example II(4) and 3-dimethylaminomethyl-aniline Rf value: 0.42 (silica gel, methylene chloride/methanol = 4:1) Mass spectrum: m/z = 378 (m+) (40) 3-Z-[1-(4-(N-methyl-N-benzyl-aminomethyl)-anilino)-1-pro-pyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example 11(4) and 4-(N-methyl-N-benzyl-aminomethyl)-aniline Rf value: 0.81 (silica gel, methylene chloride/methanol = 4:1) Mass spectrum: m/z = 454 (m+) (41) 3-Z-[1-(4-(N-methylsulphonyl-N-(2-dimethylamino-ethyl)-amino)-anilino)-1-propyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained.according to Example 11(4) and 4-(N-methylsulphonyl-N-(2-dimethylamino-ethyl)-amino)-aniline Rf value: 0.59 (silica gel, methylene chloride/methanol = 4:1) C24H31N504''S
Mass spectrum: m/z = 486 (m+H+) (42) 3-Z-[1-(4-chloro-anilino)-1-propyl-methylene]-6-carbamoyl-2-indolinone Prepared from the resin obtained according to Example 11(4) and 4-chloro-aniline Rf value: 0.17 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum: m/z = 355/357 (m+) (43) 3-Z-[1-(3-chloro-anilino)-1-propyl-methylene]-6-carbamoyl-2-indolinone Prepared from the resin obtained according to Example II(4) and 3-chloro-aniline R. value: 0.12 (silica gel, methylene chloride/methanol = 9:1) Mass spectrum: m/z = 355/357 (m+) (44) 3-Z-[1-(4-methoxycarbonyl-anilino)-1-propyl-methylene]-6-carbamoyl-2-indolinone Prepared from the resin obtained according to Example 11(4) and methyl 4-amino-benzoate R. value: 0.8 (silica gel, methylene chloride/methanol = 4:1) CaiHz iN309 Mass spectrum: m/z = 379 (m+) (45) 3-Z-[1-(4-carboxy-anilino)-1-propyl-methylene]-6-carbamoyl-2-indolinone Prepared from the resin obtained according to Example 11(4) and 4-amino-benzoic acid Cz0Hi9N30a Mass spectrum: m/z = 364 (m-H+) (46) 3-Z-[1-(4-methyl-3-nitro-anilino)-i-propyl-methylene]-6-carbamoyl-2-indolinone Prepared from the resin obtained according to Example 11(4) and 4-methyl-3-nitro-aniline R. value: 0.86 (silica gel, methylene chloride/methanol = 4:1) Mass spectrum: m/z = 380 (m+) Rxamile 2 3-Z-[1-(3-(piperidin-l-yl-methyl)-anilino)-1-phenyl-mei-hy1PnP1-6-carbamoyl-2-indolinone-triflLOroacetate 2.0 g of resin obtained according to Example II are reacted analogously to Example 1 with 2.0 g of 3-aminobenzyl alcohol in 20 ml of dimethylformamide for 22 hours at 70 C. Then the solvent is suction filtered and the resin is washed several times with dimethylformamide and methylene chloride. Then 200 mg of the moist charged resin are suspended in 2 ml of methylene chloride and left to stand with 0.2 ml of methanesulphonic acid chloride and 0.1 ml of triethylamine for 2 hours at room temperature. Then the resin is washed several times with methylene chloride, suspended in 2 ml of inethylene chloride and combined with 0.2 ml of piperidine. After 1 hour the resin is washed with methylene chloride and dimethylformamide and then treated with trifluoroacetic acid analogously to Example 1.
Yield: 15 mg Rf value: 0.30 (silica gel, methylene chloride/methanol = 4:1) C2eHzaNa02 Mass spectrum: m/z = 452 (m+) The following compounds are prepared analogously to Example 2:
(1) 3-Z-[1-(3-(diethylaminomethyl)-anilino)-i-phenyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example II and diethylamine Rf value: 0.80 (silica gel, methylene chloride/methanol = 4:1) Mass spectrum: m/z = 440 (m+) (2) 3-Z-[1-(3-(benzylaminomethyl)-anilino)-i-phenyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example II and benzylamine Rf value: 0.80 (silica gel, methylene chloride/methanol = 4:1) Mass spectrum: m/z = 474 (m+) (3) 3-Z-[1-(3-(N-methyl-N-benzyl-aminomethyl)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example II and N-methyl-benzylamine Rf value: 0.80 (silica gel, methylene chloride/methanol = 4:1) C3iH28N402 Mass spectrum: m/z = 488 (m+) (4) 3-Z- [1- (3- (butylaminomethyl) -anilino) -1-phenyl-methylene] -6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example II and butylamine Rf value: 0.40 (silica gel, methylene chloride/methanol = 4:1) Mass spectrum: m/z = 440 (m+) (5) 3-Z-[1-(3-(aminomethyl)-anilino)-i-phenyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example II and ammonia Mass spectrum: m/z = 385 (m+H+) (6) 3-Z- [1- (3- (N- (3-dimethylaminopropyl) -N-methyl-amino-methyl)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example II and 1-dimethylamino-3-methylaminopropane Rf value: 0.67 (silica gel, methylene chloride/methanol = 4:1) Mass spectrum: m/z = 484 (m+H+) (7) 3-Z-[1-(3-(N-(2-dimethylaminoethyl)-N-methyl-aminomethyl)-anilino)-i-phenyl-methylene]-6-carbamoyl-2-indolinone-trifluoroacetate Prepared from the resin obtained according to Example II and 1-dimethylamino-2-methylaminoethane Rf value: 0.40 (silica gel, methylene chloride/methanol = 4:1) Mass spectrum: m/z = 470 (m+H+) Fx m 1~-g-"~

3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylPne] -6-ethoxycarhonyl- .-;n ol;nonP
1.5 g of 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and 1.1 g of 4-(piperidin-l-yl-methyl)-aniline are dissolved in 15 ml of dimethylformamide and stirred for 45 minutes at 100 C. After cooling 5.0 ml of piperidine are added and the mixture is stirred for another 3 hours at room temperature. The solvent is removed and the residue purified over an aluminium oxide column (activity:
2-3) with methylene chloride/ethanol (100:3) as eluant.
Yield: 1.1 g(58% of theory), Rf value: 0.5 (aluminium oxide, methylene chloride/ethanol =
100:3) Mass spectrum: m/z = 481 [M+]

The following compounds are prepared analogously to Example 3:
(1) 3-Z-[1-(4-bromo-anilino)-i-phenyl-methylene]-6-ethoxy-carbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and 4-bromoaniline Rf value: 0.4 (silica gel, toluene/ethyl acetate = 5:1) C24H19BrN2O3 Mass spectrum: m/z = 462/464 [M+]

(2) 3-Z-[1-(3-(dimethylaminomethyl)-anilino)-1-phenyl-methylenel-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and 3-(dimethylaminomethyl)-aniline Rf value: 0.5 (aluminium oxide, methylene chloride/ethanol =
30:1) ESI mass spectrum: m/z = 442 [M+H']

(3) 3-Z-[1-(4-(dimethylaminomethyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and 4-(dimethylaminomethyl)-aniline Rf value: 0.7 (aluminium oxide, ethyl acetate/ethanol = 20:1) ESI mass spectrum: m/z = 442 [M+H+]

(4) 3-Z- [1- (4- [ (2, 6-dimethyl-piperidin-l-yl) -methyl] -anilino) -1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(l-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and 4- [(2,6-dimethyl-piperidin-l-yl) -methyl] -aniline Rf value: 0.6 (silica gel, methylene chloride/ethanol = 5:1) Mass spectrum: m/z = 509 [M+]

(5) 3-Z-[1-(4-(2-dimethylamino-ethyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from i-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and 4-(2-dimethylamino-ethyl)-aniline Rf value: 0.2 (silica gel, methylene chloride/ethanol = 5:1) Mass spectrum: m/z = 455 [M+]

(6) 3-Z- [1- (4- (N- (2-dimethylamino-ethyl) -N-acetyl-amino) -anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and 4-(N-(2-dimethylamino-ethyl)-N-acetyl-amino)-aniline R. value: 0.4 (aluminium oxide, methylene chloride/ethanol =
20:1) Mass spectrum: m/z = 512 [M+]

(7) 3-Z-[l-(4-tert.butyloxycarbonyl-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and 4-tert.butyloxycarbonyl-aniline Rf value: 0.4 (aluminium oxide, methylene chloride/ethanol =
40:1) Mass spectrum: m/z = 484 [M+]

(8) 3-Z- [1- (4- (N- (3-dimethylamino-propyl) -N-acetyl-amino) -anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and 4-(N-(3-dimethylamino-propyl)-N-acetyl-amino)-aniline Rf value: 0.2 (aluminium oxide, methylene chloride/ethanol =
40:1) Mass spectrum: m/z = 526 [M+]

(9) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(l-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and N-(2-dimethylamino-ethyl)-N-methylsulphonyl-p-phenylenediamine Rf value: 0.3 (aluminium oxide, methylene chloride/ethanol =
40:1) Mass spectrum: m/z = 548 [M+]

(10) 3-Z- [1- (4- (4-methyl-piperazin-1-yl) -anilino) -i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(l-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and 4-(4-methyl-piperazin-1-yl)-aniline Rf value: 0.3 (aluminium oxide, ethyl acetate) ESI mass spectrum: m/z = 483 [M+H`]

(11) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-methyl-amino)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and 4-(N-(2-dimethylamino-ethyl)-N-methyl-amino)-aniline Rf value: 0.5 (aluminium oxide, methylene chloride/ethanol =
20:1) ESI mass spectrum: m/z = 485 [M+H+]

(12) 3-Z-[1-(4-(N-(3-dimethylamino-propyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and 4-(N-(3-dimethylamino-propyl)-N-methyl-amino)-aniline Rf value: 0.5 (aluminium oxide, ethyl acetate) ESI mass spectrum: m/z = 499 [M+H+]

(13) 3-Z-[1-(4-(N-methyl-acetylamino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and 4-amino-N-methyl-acetanilide Rf value: 0.3 (silica gel, methylene chloride/ethanol = 15:1) Mass spectrum: m/z = 455 [M+]

(14) 3-Z-[l-(4-(N-methyl-methylsulphonylamino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and N-(4-aminophenyl)-N-methyl-methanesulphonamide R. value: 0.8 (aluminium oxide, ethyl acetate) Mass spectrum: m/z = 491 [M+]

(15) 3-Z-[1-(4-(N-(3-dimethllamino-propyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and N-(3-dimethylamino-propyl)-N-methylsulphonyl-p-phenylenediamine Rf value: 0.6 (silica gel, methylene chloride/ethanol/ammonia = 5:2:0.01) C30H34N405''S
ESI mass spectrum: m/z = 563 [M+H+]

(16) 3-Z-[1-(4-(N-dimethylaminocarbonylmethyl-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and 4-(N-dimethylaminocarbonylmethyl-N-methylsulphonyl)-amino)-aniline Rf value: 0.6 (silica gel, methylene chloride/ethanol = 10:1) C29H30N406''S ESI mass spectrum: m/z = 561 [M-H-]

(17) 3-Z-[1-(4-(imidazol-4-yl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(i-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and 4-(imidazol-4-yl)-aniline R. value: 0.5 (silica gel, methylene chloride/ethanol/ammonia = 10:1:0.01) Mass spectrum: m/z = 450 [M+]

(18) 3-Z- [1- (4- (tetrazol-5-yl) -anilino) -1-phenyl-methylene] -6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and 4-(tetrazol-5-yl)-aniline Rf value: 0.5 (silica gel, methylene chloride/ethanol = 5:1) C2sH2oN603 ESI mass spectrum: m/z = 451 [M-H-]

(19) 3-Z-[1-(4-(N-benzyl-N-methyl-aminomethyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and 4-(N-benzyl-N-methyl-aminomethyl)-aniline Rf value: 0.4 (silica gel, methylene chloride/ethanol = 10:1) ESI mass spectrum: m/z = 516 [M-H-]

(20) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-propionyl-amino)-aniline)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and 4-[N-(2-dimethylamino-ethyl)-N-propionyl-amino]-aniline Rf value: 0.2 (silica gel, methylene chloride/ethanol = 5:1) ESI mass spectrum: m/z = 525 [M-H-]

(21) 3-Z- [1- (4- (pyrrolidin-l-yl-methyl) -anilino) -1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and 4-(pyrrolidin-1-yl-methyl)-aniline Rf value: 0.1 (silica gel, methylene chloride/ethanol = 5:1) ESI mass spectrum: m/z = 466 [M-H-]

(22) 3-Z-[1-(4-(N-methyl-N-phenethyl-aminomethyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and 4-(N-phenethyl-N-methyl-aminomethyl)-aniline Rf value: 0.4 (silica gel, methylene chloride/ethanol = 10:1) ESI mass spectrum: m/z = 530 [M-H-]

(23) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and N-dimethylaminomethylcarbonyl-N-methyl-p-phenylenediamine Rf value: 0.1 (silica gel, methylene chloride/ethanol = 10:1) ESI mass spectrum: m/z = 497 [M-H-]

(24) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-ethylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and N-(2-dimethylamino-ethyl)-N-ethylsulphonyl-p-phenylenediamine Rf value: 0.6 (silica gel, methylene chloride/ethanol = 5:1) C30H34N4O5''S
ESI mass spectrum: m/z = 561 [M-H-]

(25) 3-Z-[1-(4-(N-tert.butoxycarbonyl-N-ethyl-aminomethyl)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(l-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and 4-(N-tert.butoxycarbonyl-N-ethyl-aminomethyl)-aniline R. value: 0.5 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 540 [M-H-]

(26) 3-Z-[1-(4-(piperidin-l-yl-methyl)-anilino)-1-ethyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-ethyl-methylene)-6-ethoxycarbonyl-2-indolinone and 4-(piperidin-1-yl-methyl)-aniline Rf value: 0.9 (silica gel, methylene chloride/ethanol = 5:1) ESI mass spectrum: m/z = 432 [M-H-]

(27) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino)-anilino)-i-ethyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-ethyl-methylene)-6-ethoxycarbonyl-2-indolinone and N-(2-dimethylamino-ethyl)-N-methylsulphonyl-p-phenylenediamine Rf value: 0.3 (silica gel, methylene chloride/ethanol = 5:1) ESI mass spectrum: m/z = 499 [M-H-]

(28) 3-Z-[1-(4-(dimethylaminomethyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(dimethylaminomethyl)-aniline Rf value: 0.6 (silica gel, methylene chloride/methanol = 5:1) ESI mass spectrum: m/z = 428 [M+H+]

(29) 3-Z-[1-(4-[(2,6-dimethyl-piperidin-1-yl)-methyl]-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(l-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4- [(2,6-dimethyl-piperidin-l-yl) -methyl] -aniline Rf value: 0.5 (RP 8, methanol/five percent saline solution =
4:1) ESI mass spectrum: m/z = 496 [M+H+]

(30) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-(2-dimethylamino-ethyl)-N-methylsulphonyl-p-phenylenediamine Rf value: 0.6 (silica gel, methylene chloride/methanol = 5:1) C28H30N4O5''S
ESI mass spectrum: m/z = 533 [M-H-]

(31) 3-Z-[1-(4-(N-(3-dimethylamino-propyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-(3-dimethylamino-propyl)-N-methylsulphonyl-p-phenylenediamine Rf value: 0.5 (aluminium oxide, methylene chloride/methanol =
30:1) ESI mass spectrum: m/z = 547 [M-H-]

(32) 3-Z-[1-(4-(N-dimethylaminocarbonylmethyl-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxy-carbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-dimethylaminocarbonyl-methyl-N-methylsulphonyl)-amino)-aniline Rf value: 0.5 (aluminium oxide, methylene chloride/methanol =
20:1) ESI mass spectrum: m/z = 547 [M-H-]

(33) 3-Z-[1-(4-(N-acetyl-N-dimethylaminocarbonylmethyl-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(i-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-acetyl-N-dimethylaminocarbonylmethyl)-amino)-aniline Rf value: 0.6 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 511 [M-H-]

(34) 3-Z-[1-(4-(N-dimethylaminocarbonylmethyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4- (N-dimethylaminocarbonyl-methyl) -amino) -aniline Rf value: 0.6 (aluminium oxide, methylene chloride/methanol =
30:1) ESI mass spectrum: m/z = 469 [M-H-]

(35) 3-Z- [1- (4- (N- (3-dimethylamino-propyl) -N-acetyl-amino) -anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-(3-dimethylamino-propyl)-N-acetyl-p-phenylenediamine Rf value: 0.5 (aluminium oxide, methylene chloride/methanol =
20:1) ESI mass spectrum: m/z = 511 [M-H-]

(36) 3-Z-[1-(4-(N-methylaminocarbonylmethyl-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-methylaminocarbonylmethyl-N-methylsulphonyl-p-phenylenediamine Rf value: 0.5 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 533 [M-H-]

(37) 3-Z-[1-(4-((imidazolidin-2,4-dion-5-ylidene)-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(i-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-((imidazolidin-2,4-dion-5-ylidene)-methyl)-aniline Rf value: 0.4 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 479 [M-H-]

(38) 3-Z-[1-(4-(N-((2-dimethylamino-ethyl)-carbonyl)-N-methyl-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-((2-dimethylamino-ethyl)-carbonyl)-N-methyl-p-phenylenediamine Rf value: 0.5 (aluminium oxide, methylene chloride/methanol =
20:1) ESI mass spectrum: m/z = 497 [M-H-]

(39) 3-Z-[1-(4-(N-tert.butoxycarbonyl-aminomethyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-tert.butoxycarbonyl-aminomethyl)-aniline Rf value: 0.3 (aluminium oxide, methylene chloride/methanol =
20:1) ESI mass spectrum: m/z = 498 [M-H-]

(40) 3-Z-[l-(4-(2-oxo-pyrrolidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(l-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(2-oxo-pyrrolidin-1-yl-methyl)-aniline Rf value: 0.3 (silica gel, methylene chloride/methanol = 20:1) C2aH2sN304 ESI mass spectrum: m/z = 466 [M-H-]

(41) 3-Z-[1-(4-(N-aminocarbonylmethyl-N-methylsulphonyl-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-aminocarbonylmethyl-N-methylsulphonyl-p-phenylenediamine Rf value: 0.7 (silica gel, methylene chloride/methanol = 5:1) Ca6H24N40eS
ESI mass spectrum: m/z = 519 [M-H-]

(42) 3-Z- [1- (4- (thiomorpholin-4-yl-methyl) -anilino) -1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(thiomorpholin-4-yl-methyl)-aniline Rf value: 0.4 (silica gel, methylene chloride/methanol = 15:1) ESI mass spectrum: m/z = 484 [M-H-]

(43) 3-Z-[1-(4-(1,1-dioxo-thiomorpholin-4-yl-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(1,1-dioxo-thiomorpholin-4-yl-methyl)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 516 [M-H-]

(44) 3-Z-[1-(4-(N-cyanomethyl-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-cyanomethyl-N-methyl-sulphonyl-p-phenylenediamine Rf value: 0.6 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 501 [M-H-]

(45) 3-Z-[1-(4-(N-tert.butoxycarbonyl-ethylaminomethyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-ethyl-N-tert.butoxycarbonyl-aminomethyl)-aniline Rf value: 0.6 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 526 [M-H-]

(46) 3-Z-[1-(4-(N-benzyl-N-methyl-aminomethyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-benzyl-N-methyl-aminomethyl)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 10:1) C3aHz9N303 ESI mass spectrum: m/z = 502 [M-H-1 (47) 3-Z-[1-(4-(1-oxo-thiomorpholin-4-yl-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(1-oxo-thiomorpholin-4-yl-methyl)-aniline Rf value: 0.7 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 500 [M-H-1 (48) 3-Z-[1-(4-(2-(imidazol-4-yl)-ethyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(i-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(2-(imidazol-4-yl)-ethyl)-aniline Rf value: 0.4 (silica gel, methylene chloride/methanol = 5:1) CzaHaeNa03 ESI mass spectrum: m/z = 463 [M-H-1 (49) 3-Z-[1-(4-(morpholin-4-yl-methyl)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(morpholin-4-yl-methyl)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 468 [M-H-1 (50) 3-Z- [1- (4- ( (4-methyl-piperazin-1-yl) -methyl) -anilino) -i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-((4-methyl-piperazin-1-yl)-methyl)-aniline Rf value: 0.4 (silica gel, methylene chloride/methanol 5:1) ESI mass spectrum: m/z = 481 [M-H-]

(51) 3-Z-[1-(4-((2-(N-benzyl-N-methyl-amino)-ethyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-(2-(N-benzyl-N-methyl-amino)-ethyl)-N-methylsulphonyl-amino)-aniline Rf value: 0.7 (silica gel, methylene chloride/methanol = 10:1) ESI =mass spectrum: m/z = 609 [M-H-]

(52) 3-Z-[1-(4-cyclohexylamino-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(l-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-cyclohexyl-p-phenylenediamine Rf value: 0.8 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 451 [M-H-]

(53) 3-Z-[1-(4-(pyridin-4-yl-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(pyridin-4-yl-methyl)-aniline Rf value: 0.6 (silica gel, methylene chloride/methanol/ammonia = 5:1:0.01) ESI mass spectrum: m/z = 460 [M-H-]

(54) 3-Z-[1-(4-(imidazol-l-yl-methyl)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(imidazol-l-yl-methyl)-aniline R. value: 0.4 (silica gel, methylene chloride/methanol/ammonia = 10:1:0.01) ESI mass spectrum: m/z = 449 [M-H-]

(55) 3-Z-[l-(4-(imidazol-l-yl-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(imidazol-1-yl-methyl)-aniline Rf value: 0.4 (silica gel, methylene chloride/methanol/ammonia = 10:1:0.01) ESI mass spectrum: m/z = 449 [M-H-]

(56) 3-Z-[1-(N-methyl-piperidine-4-yl-amino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(i-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-amino-l-methyl-piperidine Rf value: 0.3 (silica gel, methylene chloride/methanol = 5:1) ESI mass spectrum: m/z = 390 [M-H-]

(57) 3-Z-[1-(4-(imidazol-4-yl-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(imidazol-4-yl-methyl)-aniline Rf value: 0.2 (silica gel, methylene chloride/methanol = 5:1) ESI mass spectrum: m/z = 449 [M-H-]

(58) 3-Z- [1- (4- ( (4-hydroxy-piperidin-1-yl) -methyl) -anilino) -1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4- ((4-hydroxy-piperidin-l-yl) -methyl) -aniline R. value: 0.1 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 482 [M-H-]

(59) 3-Z-[1-(4-((4-methoxy-piperidin-1-yl)-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-((4-methoxy-piperidin-l-yl)-methyl)-aniline Rf value: 0.4 (silica gel, methylene chloride/methanol = 10:1) C30H3iN304 ESI mass spectrum: m/z = 496 [M-H-]

(60) 3-Z-[1-(4-benzyl-anilino)-1-phenyl-methylene]-6-methoxy-carbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-benzyl-aniline Rf value: 0.6 (silica gel, methylene chloride/methanol = 10:1) Melting point: 224 C

(61) 3-Z- [1- (4- (N- (3-trifluoroacetylamino-propyl) -N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-(3-trifluoroacetylamino-propyl)-N-methylsulphonyl-p-phenylenediamine Rf value: 0.5 (aluminium oxide, methylene chloride/methanol =
20:1) ESI mass spectrum: m/z = 615 [M-H-]

(62) 3-Z-[1-(4-tert.butoxycarbonylmethyl-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-ethoxycarbonyl-2-indolinone and tert.butyl 4-aminophenylacetate Rf value: 0.5 (aluminium oxide, ethyl acetate) ESI mass spectrum: m/z = 497 [M-H-]

(63) 3-Z-[1-(4-tert.butoxycarbonyl-anilino)-i-ethyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-ethylmethylen)-6-ethoxycarbonyl-2-indolinone and 4-tert.butoxycarbonyl-aniline Rf value: 0.4 (aluminium oxide, methylene chloride/ethanol =
20:1) ESI mass spectrum: m/z = 435 [M-H-]

(64) 3-Z-[1-(4-(4-tert.butoxycarbonyl-piperazin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(4-tert.butoxycarbonyl-piperazin-1-yl-methyl)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 567 [M-H-]

(65) 3-Z-[1-(4-(1-methyl-imidazol-2-yl)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(1-methyl-imidazol-2-yl)-aniline Rf value: 0.6 (silica gel, methylene chloride/methanol = 5:1) ESI mass spectrum: m/z = 449 [M-H-]

(66) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino)-3-nitro-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(l-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 6-(N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino)-3-amino-nitrobenzene Rf value: 0.6 (silica gel, methylene chloride/methanol = 5:1) ESI mass spectrum: m/z = 578 [M-H-]

(67) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino)-3-amino-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino)-3-amino-aniline Rf value: 0.5 (aluminium oxide, methylene chloride/methanol =
20:1) C28H3iN505S
ESI mass spectrum: m/z = 548 [M-H-]

(68) 3-Z-[1-(4-((3-(N-benzyl-N-methyl-amino)-propyl)-N-methyl-sulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-(3-(N-benzyl-N-methyl-amino)-propyl)-N-methylsulphonyl-amino)-aniline Rf value: 0.6 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 623 [M-H-]

(69) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino)-3-chloro-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(l-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino)-3-chloro-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 567/569 [M-H-]

(70) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-dimethylaminomethylcarbonyl-N-methyl-p-phenylenediamine Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 483 [M-H-]

(71) 3-Z- [1- (4- (N- (2-dimethylamino-ethyl) -N-acetyl-amino) -anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-(2-dimethylamino-ethyl)-N-acetyl-amino)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 497 [M-H-]

(72) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-propionyl-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(i-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-(2-dimethylamino-ethyl)-N-propionyl-amino)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 511 [M-H-]

(73) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-butyryl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-(2-dimethylamino-ethyl)-N-butyryl-amino)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 525 [M-H-]

(74) 3-Z-[l-(4-(N-(2-dimethylamino-ethyl)-N-isobutyryl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-(2-dimethylamino-ethyl)-N-isobutyryl-amino)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 525 [M-H-]

(75) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-benzoyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(l-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-(2-dimethylamino-ethyl)-N-benzoyl-amino)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 559 [M-H-]

(76) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-acetyl-amino)-3-amino-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-(2-dimethylamino-ethyl)-N-acetyl-amino)-3-amino-aniline Rf value: 0.5 (aluminium oxide, methylene chloride/methanol =
20:1) ESI mass spectrum: m/z = 512 [M-H-]

(77) 3-Z-[1-(4-(4-hydroxymethyl-piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(4-hydroxymethyl-piperidin-1-yl-methyl-amino)-aniline Rf value: 0.3 (silica gel, methylene chloride/methanol = 5:1) ESI mass spectrum: m/z = 496 [M-H-]

(78) 3-Z-[l-(4-(2-(4-hydroxy-piperidin-1-yl)-ethyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(2-(4-hydroxy-piperidin-l-yl)-ethyl-amino)-aniline Rf value: 0.3 (silica gel, methylene chloride/methanol = 5:1) ESI mass spectrum: m/z = 496 [M-H-]

(79) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-propylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-(2-dimethylamino-ethyl)-N-propylsulphonyl-p-phenylenediamine Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 561 [M-H-]

(80) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-butylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-(2-dimethylamino-ethyl)-N-butylsulphonyl-p-phenylenediamine Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) C31H36N4O5'S
ESI mass spectrum: m/z = 575 [M-H-]

(81) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-phenylsulphonyl-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-(2-dimethylamino-ethyl)-N-phenylsulphonyl-p-phenylenediamine R. value: 0.5 (silica gel, methylene chloride/methanol = 9:1) C33H32N405''S
ESI mass spectrum: m/z = 595 [M-H-]

(82) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-benzylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-(2-dimethylamino-ethyl)-N-benzylsulphonyl-p-phenylenediamine Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 609 [M-H-]

(83) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-ethylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-(2-dimethylamino-ethyl)-N-ethylsulphonyl-p-phenylenediamine Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) C29H32N405'S
ESI mass spectrum: m/z = 547 [M-H-]

(84) 3-Z-[1-(4-((imidazolidin-2,4-dion-5-yl)-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4- ((imidazolidin-2,4-dion-5-yl ) -methyl ) -aniline Rf value: 0.6 (silica gel, methylene chloride/methanol = 5:1) ESI mass spectrum: m/z = 481 [M-H-]

(85) 3-Z-[1-(4-((3-hydroxy-pyrrolidin-1-yl)-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-((3-hydroxy-pyrrolidin-l-yl)-methyl)-aniline Rf value: 0.1 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 468 [M-H-]

(86) 3-Z-[1-(4-(cyclohexylyl-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(cyclohexyl-methyl)-aniline (Eur. J. Med. Chem. Chim. Ther. 1992, 27, 537-544) Rf value: 0.6 (silica gel, methylene chloride/methanol = 10:1) C30H3aN203 ESI mass spectrum: m/z = 465 [M-H-]

(87) 3-Z-[1-(4-(cyclohexyl-carbonyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(cyclohexyl-carbonyl)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 479 [M-H-]

(88) 3-Z-[1-(4-diethylaminomethyl-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(diethylamino-methyl)-aniline Rf value: 0.4 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 454 [M-H-]

(89) 3-Z- [1- (4- (N- (n-hexyl) -N-methyl-aminomethyl) -anilino) -1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-(n-hexyl)-N-methyl-aminomethyl)-aniline Rf value: 0.6 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 496 [M-H-]

(90) 3-Z- [1- (4- (N- (2-dimethylamino-ethyl) -N- (furan-2-carbonyl)-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-(2-dimethylamino-ethyl)-N-(furan-2-carbonyl)-amino)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 549 [M-H-]

(91) 3-Z- [1- (4- (N- (2-dimethylamino-ethyl) -N- (2-methoxy-benzoyl)-amino)-anilino)-1-phenyl-methylene]-6-methoxy-carbonyl-2-indolinone Prepared from 1-acetyl-3-(i-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-(2-dimethylamino-ethyl)-N-(2-methoxy-benzoyl)-amino)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 589 [M-H"]

(92) 3-Z- [1- (4- (N- (2-dimethylamino-ethyl) -N- (pyridine-3-carbonyl)-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-(2-dimethylamino-ethyl)-N-(pyridine-3-carbonyl)-amino)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 560 [M-H-]

(93) 3-Z- [1- (4- (N- (2-dimethylamino-ethyl) -N- (phenyl-acetyl) -amino)-anilino)-1-phenyl-methylenel-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-(2-dimethylamino-ethyl)-N-(phenyl-acetyl)-amino)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 573 [M-H-]

(94) 3-Z- [1- (4- (N-ethyl-N-methyl-aminomethyl) -anilino) -1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-ethyl-N-methyl-aminomethyl)-aniline Rf value: 0.3 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 440 [M-H-]

(95) 3-Z-[1-(4-(imidazol-2-yl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(imidazol-2-yl)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 435 [M-H-1 (96) 3-Z-[1-(4-(i-ethyl-imidazol-2-yl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(1-ethyl-imidazol-2-yl)-aniline Rf value: 0.4 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 463 [M-H-1 (97) 3-Z-[1-(4-(1-benzyl-imidazol-2-yl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(1-benzyl-imidazol-2-yl)-aniline Rf value: 0.3 (silica gel, methylene chloride/methanol = 20:1) ESI mass spectrum: m/z = 525 [M-H-1 (98) 3-Z- [1- (4- (N- (2-dimethylamino-ethyl) -N-isopropylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-(2-dimethylamino-ethyl)-N-isopropylsulphonyl-p-phenylenediamine Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 561 [M-H-1 (99) 3-Z-[1-(4-(N-(piperidin-1-yl-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-(piperidin-1-yl-methylcarbonyl)-N-methyl-p-phenylenediamine Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 523 [M-H-]

(100) 3-Z-[1-(4-(N-(morpholin-4-yl-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylenel-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-(morpholin-4-yl-methylcarbonyl)-N-methyl-p-phenylenediamine Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 525 [M-H-]

(101) 3-Z-[1-(4-(N-((4-benzyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-((4-benzyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-p-phenylenediamine Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) C37H37Ns04 ESI mass spectrum: m/z = 614 [M-H-]

(102) 3-Z-[l-(4-(N-(pyrrolidin-1-yl-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylenel-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(i-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-(pyrrolidin-l-yl-methylcarbonyl)-N-methyl-p-phenylenediamine Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 509 [M-H-]

(103) 3-Z- [1- (4- (N- (2-dimethylamino-ethyl) -N-acetyl-amino) -3-bromo-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(i-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-(2-dimethylamino-ethyl)-N-acetyl-amino)-3-bromo-aniline Rf value: 0.6 (silica gel, methylene chloride/methanol = 5:1) C29H29BrN4O4 ESI mass spectrum: m/z = 575/577 [M-H-]

(104) 3-Z-[1-(4-(5-methyl-imidazol-4-yl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(l-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(5-methyl-imidazol-4-yl)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol/ammonia = 10:1:0.01) ESI mass spectrum: m/z = 449 [M-H-]

(105) 3-Z- [1- (4- (N- ( (2-dimethylamino-ethyl) -carbonyl) -N-isopropyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-((2-dimethylamino-ethyl)-carbonyl)-N-isopropyl-p-phenylenediamine Rf value: 0.1 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 525 [M-H"]

(106) 3-Z- [1- (4- (N- ( (2-dimethylamino-ethyl) -carbonyl) -N-benzyl-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-((2-dimethylamino-ethyl)-carbonyl)-N-benzyl-p-phenylenediamine Rf value: 0.1 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 525 [M-H-]

(107) 3-Z-[1-(4-(N-butyl-N-tert.butoxycarbonyl-aminomethyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-butyl-N-tert.butoxycarbonyl-aminomethyl)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 554 [M-H-]

(108) 3-Z- [1- (4- (N- ( (N-aminocarbonylmethyl-N-methyl-amino) -methylcarbonyl)-N-methyl-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(i-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-(N-aminocarbonylmethyl-N-methyl-amino)-methylcarbonyl)-N-methyl-p-phenylenediamine Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) C29H29N50s ESI mass spectrum: m/z = 526 [M-H-]

(109) 3-Z-[1-(4-(N-((N-benzyl-N-methyl-amino)-methylcarbonyl)-N-methyl-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(l-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-((N-benzyl-N-methyl-amino)-methylcarbonyl)-N-methyl-p-phenylenediamine Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 559 [M-H-]

(110) 3-Z-[1-(4-(N-(di-(2-methoxyethyl)-amino-methylcarbonyl)-N-methyl-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(l-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-(di-(2-methoxyethyl)-amino-methylcarbonyl)-N-methyl-p-phenylenediamine Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 571 [M-H-]

(111) 3-Z- [1- (4- (N- ( (2- (4-tert.butoxycarbonyl-piperazin-1-yl) -ethyl)-carbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-((2-(4-tert.butoxycarbonyl-piperazin-1-yl)-ethyl)-carbonyl)-N-methyl-p-phenylenediamine Rf value: 0.8 (silica gel, methylene chloride/methanol = 5:1) ESI mass spectrum: m/z = 638 [M-H-]

(112) 3-Z- [1- (4- (N- ( (2- (piperidin-l-yl) -ethyl) -carbonyl) -N-methyl-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-((2-(piperidin-1-yl)-ethyl)-carbonyl)-N-methyl-p-phenylenediamine Rf value: 0.5 (silica gel, methylene chloride/methanol = 5:1) ESI mass spectrum: m/z = 537 [M-H-]

(113) 3-Z- [1- (4- (N- ( (2- (N-benzyl-N-methyl-amino) -ethyl) -carbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-((2-(N-benzyl-N-methyl-amino)-ethyl)-carbonyl)-N-methyl-p-phenylenediamine = CA 02387013 2002-03-19 Rf value: 0.4 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 573 [M-H-]

(114) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-isopropyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-(dimethylaminomethylcarbonyl)-N-isopropyl-p-phenylenediamine Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 511 [M-H-]

(115) 3-Z- [1- (4- (N- (piperidin-1-yl-methylcarbonyl) -N-isopropyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-(piperidin-1-yl-methylcarbonyl)-N-isopropyl-p-phenylenediamine R. value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 551 [M-H-]

(116) 3-Z-[l-(4-(N-((4-tert.butoxycarbonyl-piperazin-l-yl)-methylcarbonyl)-N-isopropyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-((4-tert.butoxycarbonyl-piperazin-1-yl)-methylcarbonyl)-N-isopropyl-p-phenylenediamine Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 652 [M-H-]

(117) 3-Z- [1- (4- (N- ( (N-benzyl-N-methyl-amino) -methylcarbonyl) -N-benzyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-((N-benzyl-N-methyl-amino)-methylcarbonyl)-N-benzyl-p-phenylenediamine Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 635 [M-H-]

(118) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-benzyl-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and N-(dimethylaminomethyl-carbonyl)-N-benzyl-p-phenylenediamine R. value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 559 [M-H-]

(119) 3-Z-[1-(4-(N-(piperidin-1-yl-methylcarbonyl)-N-benzyl-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(5-methyl-imidazol-4-yl)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 559 [M-H-]

(120) 3-Z-[1-(4-(1,2,4-triazol-2-yl-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(i-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(1,2,4-triazol-1-yl-methyl)-aniline R. value: 0.5 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 450 [M-H-]

(121) 3-Z-[1-(4-(1,2,3-triazol-2-yl-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(1,2,3-triazol-2-yl-methyl)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 20:1) ESI mass spectrum: m/z = 450 [M-H-]

(122) 3-Z-[1-(4-(1,2,3-triazol-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(1,2,3-triazol-1-yl-methyl)-aniline Rf value: 0.4 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 450 [M-H-]

(123) 3-Z-[1-(4-((N-aminocarbonylmethyl-N-methyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-((N-aminocarbonylmethyl-N-methyl-amino)-methyl)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 469 [M-H-]

(124) 3-Z- [1- (4- ( (di- (2-methoxy-ethyl) -amino) -methyl) -anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-((di-(2-methoxy-ethyl)-amino)-methyl)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 514 [M-H-]

(125) 3-Z-[1-(4-(pyrrolidin-l-yl-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(l-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(pyrrolidin-1-yl-methyl)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 452 [M-H-]

(126) 3-Z- [1- (4- ( (di- (2-hydroxy-ethyl) -amino) -methyl) -anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(l-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4- ((di-(2-hydroxy-ethyl)-amino) -methyl) -aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 486 [M-H-]

(127) 3-Z-[1-(4-((N-ethoxycarbonylmethyl-N-methyl-amino)-methyl)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-((N-ethoxycarbonylmethyl-N-methyl-amino)-methyl)-aniline Rf value: 0.5 (aluminium oxide, methylene chloride/ethanol =
40:1) ESI mass spectrum: m/z = 498 [M-H-]

(128) 3-Z-[1-(4-(azetidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(azetidin-1-yl-methyl)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol/ammonia = 9:1:0.5) ESI mass spectrum: m/z = 438 [M-H"]

(129) 3-Z-[1-(4-(N-propyl-N-tert.butoxycarbonyl-aminomethyl)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-propyl-N-tert.butoxycarbonyl-aminomethyl)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 540 [M-H-]

(130) 3-Z- [l- (4 ( (N- (2- (2-methoxy-ethoxy) -ethyl) -N-methyl-amino)-methyl)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-((N-(2-(2-methoxy-ethoxy)-ethyl)-N-methyl-amino)-methyl)-aniline R. value: 0.4 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 514 [M-H"]

(131) 3-Z-[1-(4-((N-(tert.butoxycarbonyl-3-amino-propyl)-N-methyl-amino)-methyl)-anilino)-i-phenyl-methylene]-6-methoxy-carbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(N-(N-tert.butoxycarbonyl-3-amino-propyl)-N-methyl-aminomethyl)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 571 [M+H+]

(132) 3-Z-[1-(4-((N-(methylcarbamoyl-methyl)-N-methyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-((N-(methylcarbamoyl-methyl)-N-methyl-amino)-methyl)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 483 [M-H-]

(133) 3-Z-[1-(4-((N-(dimethylcarbamoyl-methyl)-N-methyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-((N-(dimethylcarbamoyl-methyl)-N-methyl-amino)-methyl)-aniline Rf value: 0.3 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 497 [M-H-]

(134) 3-Z-[1-(4-methyl-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-methyl-aniline Rf value: 0.4 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 383 [M-H-]

(135) 3-Z-[1-(4-((N-propyl-N-methyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-((N-propyl-N-methyl-amino)-methyl)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 454 [M-H-]

(136) 3-Z- [1- (4- ( (N- (2-hydroxy-ethyl) -N-methyl-amino) -methyl) -anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-((N-(2-hydroxy-ethyl)-N-methyl-amino)-methyl)-aniline Rf value: 0.5 (aluminium oxide, methylene chloride/ethanol =
40:1) ESI mass spectrum: m/z = 456 [M-H-]

(137) 3-Z-[1-(4-((N-(2-dimethylamino-ethyl)-N-methyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-((N-(2-dimethylamino-ethyl)-N-methyl-amino)-methyl)-aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 483 [M-H-]

(138) 3-Z-[1-(4-((N-(3-dimethylamino-propyl)-N-methyl-arnino)-methyl)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(l-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-((N-(3-dimethylamino-propyl)-N-methyl-amino)-methyl)-aniline aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) C30H3aNa03 ESI mass spectrum: m/z = 497 [M-H-]

(139) 3-Z-[1-(4-(3-oxo-piperazin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 1-acetyl-3-(1-ethoxy-l-phenylmethylene)-6-methoxycarbonyl-2-indolinone and 4-(3-oxo-piperazin-1-yl-methyl)-aniline aniline Rf value: 0.46 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 481 [M-H-]
Exam l 3-Z-[1-(4-carboxy-anilino)-i-phenyl-methylene]-6-ethoxy-canconyl - 2 - i ndol inone 485 mg of 3-Z-[1-(4-tert.butoxycarbonyl-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone are dissolved in 15 ml of methylene chloride and 6.0 ml of trifluoroacetic acid are added. The mixture is stirred for 2 hours at room temperature. Then the solvent is removed and the residue recrystallised from ether.
Yield: 375 mg (87 %~ of theory), Rf value: 0.3 (silica gel, methylene chloride/methanol = 10:1) C2sH2oN20s Mass spectrum: m/z = 428 [M+]

The following compounds are prepared analogously to Example 4:
(1) 3-Z-[1-(4-aminomethyl-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 3-Z-[1-(4-(N-tert.butoxycarbonyl-aminomethyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Rf value: 0.5 (silica gel, methylene chloride/methanol/ammonia = 5:1:0.01) ESI mass spectrum: m/z = 398 [M-H-]

(2) 3-Z-[1-(4-ethylaminomethyl-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 3-Z-[1-(4-(N-tert.butoxycarbonyl-ethylamino-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Rf value: 0.4 (silica gel, methylene chloride/methanol/ammonia = 10:1:0.01) C26H2sN303 ESI mass spectrum: m/z = 426 [M-H-]

(3) 3-Z-[1-(4-carboxymethyl-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 3-Z-[1-(4-tert.butoxycarbonylmethyl-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Rf value: 0.1 (aluminium oxide, methylene chloride/ethanol/ammonia = 5:1:0.01) ESI mass spectrum: m/z = 441 [M-H-]

(4) 3-Z-[1-(4-carboxy-anilino)-1-ethyl-methylene]-6-ethoxy-carbonyl-2-indolinone Prepared from 3-Z-[1-(4-tert.butoxycarbonyl-anilino)-i-ethyl-methylene]-6-ethoxycarbonyl-2-indolinone Rf value: 0.1 (aluminium oxide, methylene chloride/ethanol =
20:1) C2iH2oN20s ESI mass spectrum: m/z = 379 [M-H-]

(5) 3-Z- [1- (4- (piperazin-1-yl-methyl) -anilino) -1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 3-Z-[1-(4-(4-tert.butoxycarbonyl-piperazin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Rf value: 0.1 (silica gel, methylene chloride/methanol/ammonia = 10:1:0.01) ESI mass spectrum: m/z = 469 [M+H+]

(6) 3-Z-[1-(4-butylaminomethyl-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 3-Z-[l-(4-(N-butyl-N-tert.butoxycarbonyl-aminomethyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 454 [M-H-]

(7) 3-Z-[1-(4-ethylaminomethyl-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Prepared from 3-Z-[1-(4-(N-tert.butoxycarbonyl-N-ethyl-aminomethyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Rf value: 0.3 (silica gel, methylene chloride/methanol/ammonia = 10:1:0.01) C27H2'7N303 ESI mass spectrum: m/z = 442 [M+H']

(8) 3-Z-[1-(4-ethylaminomethyl-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone Prepared from 3-Z-[1-(4-(N-tert.butoxycarbonyl-ethylamino-methyl)-anilino)-i-phenyl-methylene]-6-carbamoyl-2-indolinone Rf value: 0.2 (silica gel, methylene chloride/methanol/ammonia = 5:1:0.01) ESI mass spectrum: m/z = 411 [M-H-]

(9) 3-Z-[1-(4-(N-(piperazin-1-yl-methylcarbonyl)-N-isopropyl-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 3-Z-[1-(4-(N-((4-tert.butoxycarbonyl-piperazin-1-yl)-methylcarbonyl)-N-isopropyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Rf value: 0.35 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 552 [M-H-]

(10) 3-Z- [1- (4- (N- ( (2- (piperazin-l-yl) -ethyl) -carbonyl) -N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 3-Z-[1-(4-(N-((2-(4-tert.butoxycarbonyl-piperazin-1-yl)-ethyl)-carbonyl)-N-methyl-amino)-anilino)-i-phenyl-methyleneJ-6-methoxycarbonyl-2-indolinone Rf value: 0.4 (silica gel, methylene chloride/methanol/ammonia = 5:1:0.01) ESI mass spectrum: m/z = 540 [M+H+]

(11) 3-Z-[1-(4-(N-propyl-aminomethyl)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 3-Z-[1-(4-(N-propyl-N-tert.butoxycarbonyl-aminomethyl)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Rf value: 0.35 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 440 [M-H-]

(12) 3-Z-[1-(4-((N-(3-amino-propyl)-N-methyl-amino)-methyl)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 3-Z-[1-(4-((N-(tert.butoxycarbonyl-3-amino-propyl)-N-methyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Rf value: 0.35 (silica gel, methylene chloride/methanol = 9:1) C2eH3 oN403 ESI mass spectrum: m/z = 471 [M+H+]

Example 5 3-Z-[1-(4-methylaminomethyl-anilino)-1-phenyl-methylene]-6-P-hoxycarbonyyl-2-indolinone 100 mg of 3-Z-[1-(4-(N-benzyl-N-methyl-aminomethyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone are dissolved in 20 ml of ethanol, 0.2 ml of 1N hydrochloric acid are added and the mixture is hydrogenated for 70 minutes at room temperature and 50 psi hydrogen pressure. The reaction solution is filtered and the filtrate concentrated by rotary evaporation. The residue is dried in vacuo at 100 C.

Yield: 50 mg (53 % of theory), Rf value: 0.3 (silica gel, methylene chloride/ethanol/ammonia = 5:1:0.01) ESI mass spectrum: m/z = 426 [M-H-]

The following compounds are prepared analogously to Example 5:
(1) 3-Z-[1-(4-methylaminomethyl-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 3-Z-[1-(4-(N-benzyl-N-methyl-aminomethyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Rf value: 0.2 (silica gel, methylene chloride/methanol/ammonia = 10:1:0.01) ESI mass spectrum: m/z = 412 [M-H"]

(2) 3-Z- [1- (4- (N- (2-methylamino-ethyl) -N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 3-Z-[1-(4-((2-(N-benzyl-N-methyl-amino)-ethyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Rf value: 0.3 (silica gel, methylene chloride/methanol/ammonia = 10:1:0.01) ESI mass spectrum: m/z = 519 [M-H-1 (3) 3-Z- [1- (4- (N- (2-amino-ethyl) -N-methylsulphonyl-amino) -anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 3-Z-[1-(4-(N-cyanomethyl-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Rf value: 0.5 (silica gel, methylene chloride/methanol/ammonia = 5:1:0.01) C2eHz6N405S
ESI mass spectrum: m/z = 505 [M-H-1 (4) 3-Z- [1- (4- (N- (3-methylamino-propyl) -N-methylsulphonyl-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 3-Z-[1-(4-(N-(3-(N-benzyl-N-methyl-amino)-propyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Rf value: 0.3 (silica gel, methylene chloride/methanol/ammonia = 5:1:0.01) ESI mass spectrum: m/z = 533 [M-H-1 (5) 3-Z- [1- (4- (N- (piperazin-1-yl-methylcarbonyl) -N-methyl-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 3-Z-[1-(4-(N-((4-benzyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Rf value: 0.5 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 524 [M-H-1 (6) 3-Z- [1- (4- (N- (methylamino-methylcarbonyl) -N-methyl-amino) -anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 3-Z-[l-(4-(N-((N-benzyl-N-methyl-amino)-methylcarbbnyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Rf value: 0.3 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 469 [M-H-]

(7) 3-Z- [1- (4- (N- ( (2-methylamino-ethyl) -carbonyl) -N-methyl-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 3-Z-[1-(4-(N-((2-(N-benzyl-N-methyl-amino)-ethyl)-carbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Rf value: 0.3 (silica gel, methylene chloride/methanol/ammonia = 5:1:0.01) ESI mass spectrum: m/z = 483 [M-H-]
Exams l e 6 3-Z-[1-(4-ureidomethyl-anilino)-1-phenyl-methylene]-6-methoxy-carbonyl-2-indolinon_ 300 mg of 3-Z-[1-(4-aminomethyl-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone are dissolved in 15 ml of methanol and 200 ml of triethylamine are added. Then 400 mg of potassium cyanate in 5 ml of water are added. After 2 days of stirring at room temperature the reaction solution is concentrated by rotary evaporation, the residue taken up in methylene chloride and washed once with water and once with saturated sodium chloride solution. The organic phase is dried over sodium sulphate and concentrated by rotary evaporation. The residue is dried in vacuo at 100 C.
Yield: 100 mg of (21 % of theory), Rf value: 0.7 (silica gel, methylene chloride/methanol = 5:1) ESI mass spectrum: m/z = 441 [M-H-]
Fxamz l_ e 7 3-Z-[1-(4-guanidinomethyl-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone 300 mg of 3-Z-[1-(4-aminomethyl-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone are dissolved in 5 ml of dimethylformamide and 300 ml of triethylamine are added. Then 700 mg of 3,5-dimethylpyrazol-i-carboxylic acid amidine in 5 ml of dimethylformamide are added. After one day of stirring at room temperature the reaction solution is concentrated by rotary evaporation. The residue is dried at 100 C in vacuo.
Yield: 200 mg (87 % of theory), Rf value: 0.1 (Reversed phase RP 8, methanol/five percent saline solution = 6:4) Mass spectrum: m/z = 441 [M+]
F=xaID ~~P 8 3-Z-[1-(4-acetylaminomethyl-anilino)-1-phenyl-methylene]-6-methoxycarbonyl - 2 - indol inone 100 mg of 3-Z-[1-(4-aminomethyl-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone are dissolved in 5 ml of glacial acetic acid, 0.1 ml of acetic anhydride is added and the mixture is stirred for 10 minutes at room temperature.
After this time the reaction solution is poured onto saturated soda solution and extracted four times with methylene chloride. The combined organic phases are washed with saturated saline solution, dried over sodium sulphate and concentrated by rotary evaporation. The residue is dried at 100 C in vacuo.

Yield: 20 mg (23 % of theory), Rf value: 0.4 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 440 [M-H-]

The following compounds are prepared analogously to Example 8:
(1) 3-Z- [1- (4- (N-methylsulphonyl-aminomethyl) -anilino) -1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 3-Z-[1-(4-aminomethyl-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone and methanesulphonyl chloride/triethylamine Rf value: 0.7 (silica gel, methylene chloride/methanol = 5:1) ESI mass spectrum: m/z = 476 [M-H-]

(2) 3-Z-[1-(4-(4-benzoyl-piperazin-1-yl-methyl)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 3-Z-[1-(4-(piperazin-i-yl-methyl)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone and benzoyl chloride Rf value: 0.7 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 571 [M-H-]

(3) 3-Z- [1- (4- ( (N- (3-acetylamino-propyl) -N-methyl-amino) -methyl)-anilino)-1-phenyl-methylenel-6-methoxycarbonyl-2-indolinone Prepared from 3-Z-[1-(4-((N-(3-amino-propyl)-N-methyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Rf value: 0.3 (silica gel, methylene chloride/methanol = 9:1) ESI mass spectrum: m/z = 511 [M-H-]

F, xam= 1 P 9 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-mPr ylene]-h-carboxy-2-indolinone 0.8 g of 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone are dissolved in 30 ml of ethanol, 8.3 ml of iN sodium hydroxide solution are added and the mixture is stirred for 1 hour at 80 C. After cooling, it is neutralised with 8.3 ml of iN hydrochloric acid. The precipitate formed is suction filtered, washed with water, ethanol and ether and dried in vacuo at 100 C.

Yield: 0.7 g of (89 % of theory), Rf value: 0.2 (silica gel, methylene chloride/methanol = 5:2) Mass spectrum: m/z = 453 [M+]

The following compounds are prepared analogously to Example 9:
(1) 3-Z-[1-(4-bromo-anilino)-i-phenyl-methylene]-6-carboxy-2-indolinone Prepared from 3-Z-[1-(4-bromo-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Rf value: 0.4 (silica gel, toluene/ethyl acetate = 5:1) C22HisBrN203 ESI mass spectrum: m/z = 435/437 [M+H+]

(2) 3-Z- [1- (3- (dimethylaminomethyl) -anilino) -i-phenyl-methylene]-6-carboxy-2-indolinone Prepared from 3-Z-[1-(3-(dimethylaminomethyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Rf value: 0.7 (Reversed phase RP 8, methanol/five percent saline solution = 4:1) ESI mass spectrum: m/z = 414 [M+H+]

(3) 3-Z-[1-(4-(dimethylaminomethyl)-anilino)-i-phenyl-methylene]-6-carboxy-2-indolinone Prepared from 3-Z-[1-(4-(dimethylaminomethyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Rf value: 0.7 (Reversed phase RP 8, methanol/five percent saline solution = 4:1) ESI mass spectrum: m/z = 412 [M-H-]

(4) 3-Z- [1- (4- [ (2,6-dimethyl-piperidin-1-yl) -methyl] -anilino) -1-phenyl-methylene]-6-carboxy-2-indolinone Prepared from 3-Z-[1-(4-[(2,6-dimethyl-piperidin-1-yl)-methyl]-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Rf value: 0.6 (Reversed phase RP 8, methanol/five percent saline solution = 4:1) ESI mass spectrum: m/z = 482 [M+H+]

(5) 3-Z-[1-(4-(1-methyl-imidazol-2-yl)-anilino)-i-phenyl-methylene]-6-carboxy-2-indolinone Prepared from 3-Z-[1-(4-(l-methyl-imidazol-2-yl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Rf value: 0.6 (Reversed phase RP 8, methanol/five percent saline solution = 4:1) ESI mass spectrum: m/z = 435 [M-H-]

(6) 3-Z-[1-(4-(N-acetyl-N-dimethylaminocarbonylmethyl-amino)-anilino)-i-phenyl-methylene]-6-carboxy-2-indolinone Prepared from 3-Z-[1-(4-(N-acetyl-N-dimethylaminocarbonylmethyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Rf value: 0.3 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 497 [M-H"]

(7) 3-Z-[1-(4-ethylaminomethyl-anilino)-1-phenyl-methylene]-6-carboxy-2-indolinone Prepared from 3-Z-[1-(4-ethylaminomethyl-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Rf value: 0.6 (Reversed phase RP 8, methanol/five percent saline solution = 4:1) ESI mass spectrum: m/z = 412 [M-H"]

(8) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-carboxy-2-indolinone Prepared from 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Rf value: 0.6 (Reversed phase RP 8, methanol/five percent saline solution = 4:1) ESI mass spectrum: m/z = 469 [M-H-]

(9) 3-Z-[1-(4-(N-tert.butoxycarbonyl-ethylaminomethyl)-anilino)-1-phenyl-methylene]-6-carboxy-2-indolinone Prepared from 3-Z-[1-(4-(N-tert.butoxycarbonyl-ethylamino-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone Rf value: 0.4 (silica gel, methylene chloride/methanol = 10:1) ESI mass spectrum: m/z = 512 [M-H-]

(10) 3-Z-[1-(4-((N-carboxymethyl-N-methyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone Prepared from 3-Z-[1-(4-((N-ethoxycarbonylmethyl-N-methyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl -2-indolinone Rf value: 0.4 (silica gel, methylene chloride/methanol = 6:1) ESI mass spectrum: m/z = 470 [M-H-]
Examsnl e 10 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene] -6-methoxycarbonyl -2-indol innnf-0.9 g of 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carboxy-2-indolinone are suspended in 35 ml of dimethylformamide and 0.4 g of carbonyldiimidazole are added.
The mixture is stirred for 14 hours at 80 C. After this time 20 ml of methanol are added and the mixture is stirred for another 3 hours at 50 C. The solvent is removed and the residue is purified over a silica gel column with methylene chloride/methanol (3:1) as eluant.
Yield: 0.5 g of (490 of theory), Rf value: 0.5 (aluminium oxide, methylene chloride/methanol =
30:1) ESI mass spectrum: m/z = 468 [M+H+]

The following compounds are prepared analogously to Example 10:

(1) 3-Z-[1-(4-(piperidin-l-yl-methyl)-anilino)-1-phenyl-methylene]-6-benzyloxycarbonyl-2-indolinone Prepared from 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carboxy-2-indolinone and benzyl alcohol Rf value: 0.6 (aluminium oxide, methylene chloride/methanol =
30:1) Mass spectrum: m/z = 543 [M+]

(2) 3-Z-[1-(4-(piperidin-l-yl-methyl)-anilino)-1-phenyl-methylene]-6-isopropyloxycarbonyl-2-indolinone Prepared from 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carboxy-2-indolinone and isopropanol Rf value: 0.4 (aluminium oxide, methylene chloride/isopropanol = 30:1) Mass spectrum: m/z = 495 [M']

(3) 3-Z- [1- (4- (piperidin-1-yl-methyl) -anilino) -1-phenyl-methylene]-6-propyloxycarbonyl-2-indolinone Prepared from 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carboxy-2-indolinone and n-propanol Rf value: 0.7 (silica gel, methylene chloride/methanol = 5:1) Mass spectrum: m/z = 495 [M+]

(4) 3-Z- [1- (4- (piperidin-l-yl-methyl) -anilino) -1-phenyl-methylene]-6-butyloxycarbonyl-2-indolinone Prepared from 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carboxy-2-indolinone and n-butanol Rf value: 0.5 (silica gel, methylene chloride/methanol = 10:1) Mass spectrum: m/z = 509 [M+]

(5) 3-Z-[1-(4-bromo-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone Prepared from 3-Z-[1-(4-bromo-anilino)-1-phenyl-methylene]-6-carboxy-2-indolinone and ammonia Rf value: 0.5 (silica gel, methylene chloride/methanol = 10:1) C22H16BrN2O3 Mass spectrum: m/z = 432/434 [M-H-]

(6) 3-Z- [1- (4- (piperidin-1-yl-methyl) -anilino) -1-phenyl-methylene]-6-ethylcarbamoyl-2-indolinone Prepared from 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carboxy-2-indolinone and ethylamine gas Rf value: 0.6 (silica gel, methylene chloride/methanol = 5:1) Mass spectrum: m/z = 480 [M+]

(7) 3-Z-[1-(4-(dimethylaminomethyl)-anilino)-1-phenyl-methylene]-6-[(2-methoxy-ethoxy)-carbonyl]-2-indolinone Prepared from 3-Z-[1-(4-(dimethylaminomethyl)-anilino)-1-phenyl-methylene]-6-carboxy-2-indolinone and methylglycol Rf value: 0.8 (silica gel, methylene chloride/methanol = 4:1) ESI mass spectrum: m/z = 470 [M-H-]

(8) 3-Z-[1-(4-(dimethylaminomethyl)-anilino)-i-phenyl-methylene]-6-[(2-dimethylamino-ethoxy)-carbonyl]-2-indolinone Prepared from 3-Z-[1-(4-(dimethylaminomethyl)-anilino)-1-phenyl-methylene]-6-carboxy-2-indolinone and 2-dimethylaminoethanol aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 5:2) ESI mass spectrum: m/z = 483 [M-H-]

(9) 3-Z-[1-(4-(dimethylaminomethyl)-anilino)-1-phenyl-methylene]-6-[(2-N-tert.butoxycarbonyl-amino-ethoxy)-carbonyl]-2-indolinone Prepared from 3-Z-[1-(4-(dimethylaminomethyl)-anilino)-1-phenyl-methylene]-6-carboxy-2-indolinone and 2-N-tert.butoxycarbonyl-amino-ethanol aniline Rf value: 0.8 (silica gel, methylene chloride/methanol = 5:2) ESI mass spectrum: m/z = 412 [M-H-]

(10) 3-Z-[1-(4-(dimethylaminomethyl)-anilino)-1-phenyl-methylene]-6-[(2,2,2-trifluoroethoxy)-carbonyl]-2-indolinone Prepared from 3-Z-[1-(4-(dimethylaminomethyl)-anilino)-1-phenyl-methylene]-6-carboxy-2-indolinone and 2,2,2-trifluoroethanol aniline Rf value: 0.5 (silica gel, methylene chloride/methanol = 5:1) C27H24F'3N303 ESI mass spectrum: m/z = 494 [M-H-]
F~mp1P ~~

3-Z-[1-(4-(piperidin-l-yl-methyl)-anilino)-1-phenyl-methylenp] - 6 - .arbamoyl - . - indol ; non .
0.9 g of 3-Z-[1-(4-(piperidin-l-yl-methyl)-anilino)-i-phenyl-methylene]-6-carboxy-2-indolinone, 0.8 g of TBTU and 0.4 g of HOBT are suspended in 25 ml of dimethylformamide and 1.0 ml of triethylamine are added. The mixture is stirred for 15 minutes at room temperature. After this time ammonia gas is introduced at 10-15 C over a period of 15 minutes and the mixture is stirred for 1.5 hours at room temperature. The precipitate formed is suction filtered, washed with water, ethanol and ether and dried at 100 C in vacuo.

Yield: 0.6 g (64 % of theory), Rf value: 0.4 (Reversed phase RP 8, methanol/five percent saline solution = 6:4) ESI mass spectrum: m/z = 453 [M+H+]

The following compounds are prepared analogously to Example 11:

(1) 3-Z- [1- (4- (piperidin-l-yl-methyl) -anilino) -1-phenyl-methylene]-6-dimethylcarbamoyl-2-indolinone Prepared from 3-Z- [1- (4- (piperidin-l-yl-methyl) -anilino) -1-phenyl-methylene]-6-carboxy-2-indolinone and dimethylamine hydrochloride/diisopropylethylamine Rf value: 0.5 (silica gel, methylene chloride/methanol = 5:1) ESI mass spectrum: m/z = 481 [M+H+]

(2) 3-Z- [1- (4- (piperidin-l-yl-methyl) -anilino) -1-phenyl-methylene]-6-(N-ethyl-N-methyl-carbamoyl)-2-indolinone Prepared from 3-Z-[1-(4-(piperidin-l-yl-methyl)-anilino)-1-phenyl-methylene]-6-carboxy-2-indolinone and N-ethyl-N-methyl-amine Rf value: 0.5 (aluminium oxide, methylene chloride/ethanol =
20:1) ESI mass spectrum: m/z = 495 [M+H+]

(3) 3-Z-[l-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-methylcarbamoyl-2-indolinone Prepared from 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carboxy-2-indolinone and methylamine hydrochloride/diisopropylethylamine Rf value: 0.3 (aluminium oxide, methylene chloride/ethanol =
20:1) ESI mass spectrum: m/z = 467 [M+H+]

(4) 3-Z-[1-(3-(dimethylaminomethyl)-anilino)-1-phenyl-methylene]-6-methylcarbamoyl-2-indolinone Prepared from 3-Z-[1-(3-(dimethylaminomethyl)-anilino)-i-phenyl-methylene]-6-carboxyl-2-indolinone and methylamine hydrochloride/triethylamine Rf value: 0.3 (silica gel, methylene chloride/ethanol = 2:1) Mass spectrum: m/z = 426 [M+]

(5) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-(2-hydroxyethyl-carbamoyl)-2-indolinone Prepared from 3-Z-[1-(4-(piperidin-l-yl-methyl)-anilino)-1-phenyl-methylene]-6-carboxy-2-indolinone and ethanolamine/diisopropylethylamine Rf value: 0.5 (aluminium oxide, methylene chloride/methanol =
20:1) ESI mass spectrum: m/z = 495 [M-H-]

(6) 3-Z-[1-(4-(piperidin-l-yl-methyl)-anilino)-1-phenyl-methylene]-6-diethylcarbamoyl-2-indolinone Prepared from 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carboxy-2-indolinone and diethylamine hydrochloride/diisopropylethylamine Rf value: 0.8 (aluminium oxide, methylene chloride/methanol =
10:1) ESI mass spectrum: m/z = 509 [M+H+]

(7) 3-Z-[1-(4-(N-tert.butoxycarbonyl-ethylaminomethyl)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone Prepared from 3-Z-[1-(4-(N-tert.butoxycarbonyl-ethylaminomethyl)-anilino)-1-phenyl-methylene]-6-carboxy-2-indolinone Rf value: 0.3 (silica gel, toluene/ethyl acetate/ethanol =
4:2:1) ESI mass spectrum: m/z = 511 [M-H-]

(8) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone Prepared from 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-carboxy-2-indolinone Rf value: 0.5 (silica gel, methylene chloride/methanol/ammonia = 5:1:0.01) ESI mass spectrum: m/z = 468 [M-H-]
F'xam 1 P- 12 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone x r.itriG acid 3.25 g of citric acid monohydrate are placed in 50 ml of methanol and 5.0 g of 3-Z-[1-(4-(N-dimethylaminomethyl-carbonyl-N-methyl-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone are added at room temperature.
The solution formed is evaporated down, the residue is washed with ether and recrystallised from ethyl acetate.
Yield: 6.3 g (90 % of theory), Rf value: 0.6 (silica gel, methylene chloride/methanol/ammonia = 5:1:0.01) Melting point: 198 C
C2eH2sNa05 x C6HeO7 ESI mass spectrum: m/z = 483 [M-H-]
Elemental analysis: calc.: C 60.34 H 5.37 N 8.28 found: 59.98 5.25 8.13 The following compound is prepared analogously to Example 12:
(1) 3-Z- [1- (4- (dimethylaminomethyl) -anilino) -1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone x methanesulphonic acid Prepared from 3-Z-[1-(4-(dimethylaminomethyl)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone and methanesulphonic acid Rf value: 0.6 (silica gel, methylene chloride/methanol/ammonia = 5:1:0.01) Melting point: 275 C

ESI mass spectrum: m/z = 426 [M-H-]

Elemental analysis: calc.: C 61.92 H 5.59 N 8.03 S 6.12 found: 61.43 5.87 7.85 5.39 The following compounds may be prepared analogously to the foregoing Examples:

(1) 3-Z-(1-anilino-l-phenyl-methylene)-6-ethoxycarbonyl-2-indolinone (2) 3-Z-[1-(4-nitro-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (3) 3-Z- [1- (4-fluoro-anilino) -1-phenyl-methylene] -6-ethoxy-carbonyl-2-indolinone (4) 3-Z-[1-(4-chloro-anilino)-1-phenyl-methylene]-6-ethoxy-carbonyl-2-indolinone (5) 3-Z- [1- (4-iodo-anilino) -1-phenyl-methylene] -6-ethoxycarbonyl-2-indolinone (6) 3-Z-[1-(4-cyano-anilino)-1-phenyl-methylene]-6-ethoxy-carbonyl-2-indolinone (7) 3-Z-[1-(4-methoxy-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (8) 3-Z-[1-(4-ethoxy-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (9) 3-Z-[1-(4-trifluoromethyl-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (10) 3-Z-[1-(4-methyl-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (11) 3-Z-[1-(4-methylmercapto-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (12) 3-Z-[1-(4-aminomethyl-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (13) 3-Z-[1-(4-(isopropylaminomethyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (14) 3-Z- [1- (4- (anilinomethyl) -anilino) -1-phenyl-methylene] -6-ethoxycarbonyl-2-indolinone (15) 3-Z-[1-(4-(propylaminomethyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (16) 3-Z-[1-(4-(butylaminomethyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (17) 3-Z-[1-(4-(isobutylaminomethyl)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (18) 3-Z-[1-(4-(cyclohexylaminomethyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (19) 3-Z- [1- (4- (benzylaminomethyl) -anilino) -1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (20) 3-Z- [1- (4- ( (N-ethyl-N-methyl-amino) -methyl) -anilino) -1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (21) 3-Z- [1- (4- ( (N-methyl-N-propyl-amino) -methyl) -anilino) -1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (22) 3-Z-[1-(4-((N-isopropyl-N-methyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (23) 3-Z-[1-(4-((N-ethyl-N-propyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (24) 3-Z-[1-(4-((N-ethyl-N-isopropyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (25) 3-Z-[1-(4-(dipropylaminomethyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (26) 3-Z-[1-(4-(diisopropylaminomethyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (27) 3-Z-[1-(4-((N-benzyl-N-ethyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (28) 3-Z-[1-(4-(dibenzylaminomethyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (29) 3-Z-[1-(4-(3,6-dihydro-2H-pyridin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (30) 3-Z-[1-(4-(3,5-dimethyl-piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (31) 3-Z-[1-(4-(azepan-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (32) 3-Z-[1-(4-(piperazin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (33) 3-Z-[1-(4-(morpholin-4-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (34) 3-Z-[1-(4-(thiomorpholin-4-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (35) 3-Z-[1-(4-(1-oxo-thiomorpholin-4-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (36) 3-Z- [1- (4- (1, 1-dioxo-thiomorpholin-4-yl-methyl) -anilino) -i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (37) 3-Z-[1-(4-(acetylamino-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (38) 3-Z- [1- (4- (2-amino-ethyl) -anilino) -1-phenyl-methylene] -6-ethoxycarbonyl-2-indolinone (39) 3-Z- [1- (4- (2-methylamino-ethyl) -anilino) -i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (40) 3-Z- [1- (4- (2-ethylamino-ethyl) -anilino) -i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (41) 3-Z- [1- (4- (2-diethylamino-ethyl) -anilino) -1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (42) 3-Z- [1- (4- (2-piperidin-1-yl-ethyl) -anilino) -i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (43) 3-Z-[1-(4-(2-acetylamino-ethyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (44) 3-Z- [1- (4- (3-amino-propyl) -anilino) -1-phenyl-methylene] -6-ethoxycarbonyl-2-indolinone (45) 3-Z-[1-(4-(3-dimethylamino-propyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (46) 3-Z-[1-(4-(N-aminomethylcarbonyl-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (47) 3-Z-[1-(4-(N-methylaminomethylcarbonyl-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (48) 3-Z-[1-(4-(N-ethylaminomethylcarbonyl-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (49) 3-Z-[1-(4-(N-diethylaminomethylcarbonyl-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (50) 3-Z-[1-(4-(N-(piperidin-1-yl-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (51) 3-Z-[1-(4-(N-(morpholin-4-yl-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (52) 3-Z-[1-(4-(N-(piperazin-1-yl-methylcarbonyl)-N-methyl-amino]-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (53) 3-Z-[1-(4-(N-(2-amino-ethylcarbonyl)-N-methyl-amino)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (54) 3-Z-[1-(4-(N-(2-methylamino-ethylcarbonyl)-N-methyl-amino)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (55) 3-Z-[1-(4-(N-(2-diethylamino-ethylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (56) 3-Z- [1- (4- (N-acetyl-N- (2-aminoethyl) -amino) -anilino) -1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (57) 3-Z-[1-(4-(N-acetyl-N-(2-methylamino-ethyl)-amino)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (58) 3-Z-[1-(4-(N-acetyl-N-(2-methylamino-propyl)-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (59) 3-Z- [1- (4- (N-acetyl-N- (2-piperidin-1-yl-ethyl) -amino) -anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (60) 3-Z-[1-(4-(N-acetyl-N-(aminocarbonylmethyl)-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (61) 3-Z- [1- (4- (N-acetyl-N- (dimethylaminocarbonylmethyl) -amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (62) 3-Z-[1-(4-(N-acetyl-N-(piperidin-1-yl-carbonylmethyl)-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (63) 3-Z-[1-(4-(N-methyl-N-(aminocarbonyl)-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (64) 3-Z-[1-(4-(N-methyl-N-(methylaminocarbonyl)-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (65) 3-Z-[1-(4-(N-methyl-N-(dimethylaminocarbonyl)-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (66) 3-Z-[1-(4-(N-methyl-N-(piperidin-l-yl-carbonyl)-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (67) 3-Z-[1-(4-(N-(2-aminoethyl)-N-methylsulphonyl-amino)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (68) 3-Z-[1-(4-(N-(2-methylamino-ethyl)-N-methylsulphonyl-amino)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (69) 3-Z-[1-(4-(N-(2-ethylamino-ethyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (70) 3-Z- [1- (4- (N- (2-diethylamino-ethyl) -N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (71) 3-Z-[1-(4-(N-(2-pyrrolidin-1-yl-ethyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (72) 3-Z-[1-(4-(N-(2-piperidin-1-yl-ethyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl=methylene]-6-ethoxycarbonyl-2-indolinone (73) 3-Z-[1-(4-(N-(2-piperazin-1-yl-ethyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (74) 3-Z-[1-(4-(N-(2-(morpholin-4-yl)-ethyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (75) 3-Z-[1-(4-(N-(aminocarbonylmethyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (76) 3-Z-[1-(4-(N-(methylaminocarbonylmethyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (77) 3-Z-[1-(4-(N-(ethylaminocarbonylmethyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (78) 3-Z- [1- (4- (N- (N- (2-dimethylamino-ethyl) -N-methyl-amino) -carbonylmethyl)-N-methylsulphonyl-amino)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (79) 3-Z-[1-(4-(N-(diethylaminocarbonylmethyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (80) 3-Z-[1-(4-(N-(pyrrolidin-1-yl-carbonylmethyl)-N-methyl-sulphonyl-amino)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (81) 3-Z-[1-(4-(N-(piperidin-1-yl-carbonylmethyl)-N-methylsulphonyl-amino)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (82) 3-Z-[1-(4-(N-(piperazin-1-yl-carbonylmethyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (83) 3-Z-[1-(4-(N-((morpholin-4-yl)-carbonylmethyl)-N-methyl-sulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (84) 3-Z-[1-(4-(2-dimethylamino-ethoxy)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (85) 3-Z-[1-(4-(3-dimethylamino-propoxy)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (86) 3-Z-[1-(4-(aminocarbonylmethyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (87) 3-Z- [1- (4- (2-aminocarbonyl-ethyl) -anilino) -1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (88) 3-Z- [1- (4- (pyridin-2-yl) -anilino) -1-phenyl-methylene] -6-ethoxycarbonyl-2-indolinone (89) 3-Z-[1-(4-(pyridine-3-yl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (90) 3-Z-[1-(4-(pyridin-4-yl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (91) 3-Z-[1-(4-(N-acetyl-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (92) 3-Z-[1-(4-(N-ethylcarbonyl-N-(dimethylaminocarbonyl-methyl)-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (93) 3-Z-[1-(carbamoylmethyl-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (94) 3-Z-[1-(4-dimethylcarbamoylmethyl-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (95) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-methylene]-6-ethoxycarbonyl-2-indolinone (96) 3-Z- [1- (4- (piperidin-l-yl-methyl) -anilino) -propylidene] -6-ethoxycarbonyl-2-indolinone (97) 3-Z- [1- (4- (piperidin-l-yl-methyl) -anilino) -butylidene] -6-ethoxycarbonyl-2-indolinone (98) 3-Z-[1-(4-(N-(3-dimethylamino-propyl)-N-acetyl-amino)-anilino)-methylene]-6-ethoxycarbonyl-2-indolinone (99) 3-Z-[1-(4-(N-(3-dimethylamino-propyl)-N-acetyl-amino)-anilino)-ethylidene]-6-ethoxycarbonyl-2-indolinone (100) 3-Z- [1- (4- (N- (3-dimethylamino-propyl) -N-acetyl-amino) -anilino)-propylidene]-6-ethoxycarbonyl-2-indolinone (101) 3-Z- [1- (4- (N- (3-dimethylamino-propyl) -N-acetyl-amino) -anilino)-butylidene]-6-ethoxycarbonyl-2-indolinone (102) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino)-anilino)-methylene]-6-ethoxycarbonyl-2-indolinone (103) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino)-anilino)-propylidene]-6-ethoxycarbonyl-2-indolinone (104) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino)-anilino)-butylidene]-6-ethoxycarbonyl-2-indolinone (105) 3-Z-[1-(4-tetrazol-5-yl-anilino)-methylene]-6-ethoxycarbonyl-2-indolinone (106) 3-Z- [1- (4-tetrazol-5-yl-anilino) -ethylidene] -6-ethoxy-carbonyl-2-indolinone (107) 3-Z-[1-(4-tetrazol-5-yl-anilino)-propylidene]-6-ethoxy-carbonyl-2-indolinone (108) 3-Z-[1-(4-tetrazol-5-yl-anilino)-butylidene]-6-ethoxycarbonyl-2-indolinone (109) 3-Z-[1-(4-carboxy-anilino)-methylene]-6-ethoxycarbonyl-2-indolinone (110) 3-Z- [1- (4-carboxy-anilino) -propylidene] -6-ethoxycarbonyl-2-indolinone (111) 3-Z-[1-(4-carboxy-anilino)-butylidene]-6-ethoxycarbonyl-2-indolinone (112) 3-Z- [1- (4- (N- (3-dimethylamino-propionyl) -N-dimethylaminocarbonylmethyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (113) 3-Z- [1- (4- (N- (4-dimethylamino-butyryl) -N-dimethylaminocarbonylmethyl-amino)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (114) 3-Z-[1-(4-(N-dimethylaminocarbonylmethyl-N-(2-dimethylamino-ethylsulphonyl)-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (115) 3-Z- [1- (4- (N-dimethylaminocarbonylmethyl-N- (3-dimethylamino-propylsulphonyl)-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (116) 3-Z-[1-(4-((2-hydroxy-ethyl)-amino-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (117) 3-Z-[1-(4-((2-methoxy-ethyl)-amino-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (118) 3-Z- [1- (4- ( (2-dimethylamino-ethyl) -amino-methyl) -anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (119) 3-Z- [1- (4- ( (3-dimethylamino-propyl) -amino-methyl) -anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (120) 3-Z-[1-(4-((N-tert.butoxycarbonyl-2-amino-ethyl)-amino-methyl)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (121) 3-Z-[1-(4-((N-tert.butoxycarbonyl-3-amino-propyl)-amino-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (122) 3-Z- [1- (4- ( (2-amino-ethyl) -amino-methyl) -anilino) -1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (123) 3-Z-[l-(4-((3-amino-propyl)-amino-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (124) 3-Z-[l-(4-((2-acetylamino-ethyl)-amino-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (125) 3-Z- [1- (4- ( (3-acetylamino-propyl) -amino-methyl) -anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (126) 3-Z-[1-(4-((2-methylsulphonylamino-ethyl)-amino-methyl)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (127) 3-Z-[1-(4-((3-methylsulphonylamino-propyl)-amino-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (128) 3-Z-[l-(4-(N-(N-tert.butoxycarbonyl-2-amino-ethyl)-N-methyl-amino-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (129) 3-Z- [1- (4- (N- (2-amino-ethyl) -N-methyl-amino-methyl) -anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (130) 3-Z- [1- (4- (N- (2-acetylamino-ethyl) -N-methyl-amino-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (131) 3-Z-[1-(4-(N-(2-methylsulphonylamino-ethyl)-N-methyl-amino-methyl)-anilino)-1-phenyl-methylene]-6-ethoxyc.arbonyl-2-indolinone (132) 3-Z-[1-(4-(carboxymethyl-amino-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (133) 3-Z-[1-(4-(ethoxycarbonylmethyl-amino-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (134) 3-Z-[1-(4-(carbamoylmethyl-amino-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (135) 3-Z-[1-(4-(dimethylcarbamoyl-methyl-amino-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (136) 3-Z-[1-(4-(methylcarbamoyl-methyl-amino-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (137) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-3-amino-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (138) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-3-nitro-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (139) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-3-acetylamino-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone , ..

(140) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-3-methylsulphonylamino-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (141) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-3-cyano-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (142) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-3-hydroxy-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (143) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-3-methoxy-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (144) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-3-ethoxycarbonyl-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (145) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-3-carboxy-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (146) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-3-carbamoyl-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (147) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-3-chloro-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (148) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-3-fluoro-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (149) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-3-bromo-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (150) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-3-methyl-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (151) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-3-trifluoromethyl-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (152) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-3,5-dibromo-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (153) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-3,5-dichloro-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (154) 3-Z- [1- (4- (dimethylaminomethyl) -3-amino-anilino) -1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (155) 3-Z-[1-(4-(dimethylaminomethyl)-3-nitro-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (156) 3-Z-[1-(4-(dimethylaminomethyl)-3-acetylamino-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (157) 3-Z-[1-(4-(dimethylaminomethyl)-3-(methylsulphonylamino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (158) 3-Z-[1-(4-(dimethylaminomethyl)-3-cyano-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (159) 3-Z-[1-(4-(dimethylaminomethyl)-3-hydroxy-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (160) 3-Z-[1-(4-(dimethylaminomethyl)-3-methoxy-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (161) 3-Z- [1- (4- (dimethylaminomethyl) -3- (ethoxycarbonyl) -anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (162) 3-Z-[1-(4-(dimethylaminomethyl)-3-carboxy-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (163) 3-Z-[1-(4-(dimethylaminomethyl)-3-carbamoyl-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (164) 3-Z- [1- (4- (dimethylaminomethyl) -3-chloro-anilino) -1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (165) 3-Z-[1-(4-(dimethylaminomethyl)-3-fluoro-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (166) 3-Z-[1-(4-(dimethylaminomethyl)-3-bromo-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (167) 3-Z- [1- (4- (dimethylaminomethyl) -3-methyl-anilino) -i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (168) 3-Z- [1- (4- (dimethylaminomethyl) -3-trifluoromethyl-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (169) 3-Z-[1-(4-(dimethylaminomethyl)-3,5-dibromo-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (170) 3-Z-[1-(4-(dimethylaminomethyl)-3,5-dichloro-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (171) 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (172) 3-Z-[1-(4-(N-(imidazo-i-yl-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (173) 3-Z-[1-(4-(N-(phthalimido-2-yl-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (174) 3-Z-[1-(4-(N-aminomethylcarbonyl-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (175) 3-Z-[1-(4-(N-acetylaminomethylcarbonyl-N-methyl-arnino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (176) 3-Z-[1-(4-(N-methylsulphonylaminomethylcarbonyl-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (177) 3-Z- [1- (4- (N- ( (N- (2-methoxyethyl) -N-methyl-amino) -methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (178) 3-Z- [1- (4- (N- ( (N- (2-dimethylaminoethyl) -N-methyl-amino) -methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (179) 3-Z- [1- (4- (N- ( (di- (2-hydroxyethyl) -amino) -methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (180) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-anilino)-methylene]-6-ethoxycarbonyl-2-indolinone (181) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-anilino)-ethylidene]-6-ethoxycarbonyl-2-indolinone (182) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-anilino)-propylidene]-6-ethoxycarbonyl-2-indolinone (183) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-anilino)-butylidene]-6-ethoxycarbonyl-2-indolinone (184) 3-Z-[1-(4-(dimethylaminomethyl)-anilino)-methylene]-6-ethoxycarbonyl-2-indolinone (185) 3-Z- [1- (4- (dimethylaminomethyl) -anilino) -ethylidene] -6-ethoxycarbonyl-2-indolinone (186) 3-Z- [1- (4- (dimethylaminomethyl) -anilino) -propylidene] -6-ethoxycarbonyl-2-indolinone (187) 3-Z- [1- (4- (dimethylaminomethyl) -anilino) -butylidene] -6-ethoxycarbonyl-2-indolinone (188) 3-Z-[1-(4-(N-dimethylaminocarbonylmethyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (189) 3-Z-[1-(4-(N-(3-dimethylamino-propyl)-N-acetyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (190) 3-Z-[1-(4-((imidazolidin-2,4-dion-5-ylidene)-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (191) 3-Z- [1- (4- (N- ( (2-dimethylamino-ethyl) -carbonyl) -N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (192) 3-Z-[1-(4-(N-tert.butoxycarbonyl-aminomethyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (193) 3-Z-[1-(4-(2-oxo-pyrrolidin-1-yl-methyl)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (194) 3-Z-[1-(4-(N-aminocarbonylmethyl-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (195) 3-Z-[1-(4-(N-cyanomethyl-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (196) 3-Z- [1- (4- (2- (imidazol-4-yl) -ethyl) -anilino) -1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (197) 3-Z- [1- (4- ( (2- (N-benzyl-N-methyl-amino) -ethyl) -N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (198) 3-Z-[1-(4-cyclohexylamino-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (199) 3-Z- [1- (4- (imidazol-i-yl-methyl) -anilino) -1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (200) 3-Z-[1-(4-(imidazol-i-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (201) 3-Z-[1-(N-methyl-piperidine-4-yl-amino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (202) 3-Z-[1-(4-(imidazol-4-yl-methyl)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (203) 3-Z-[1-(4-((4-hydroxy-piperidin-1-yl)-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (204) 3-Z-[1-(4-((4-methoxy-piperidin-1-yl)-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (205) 3-Z- [1- (4-benzyl-anilino) -1-phenyl-methylenel-6-ethoxycarbonyl-2-indolinone (206) 3-Z- [1- (4- (N- (3-trifluoroacetylamino-propyl) -N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (207) 3-Z-[1-(4-(4-tert.butoxycarbonyl-piperazin-l-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (208) 3-Z- [1- (4- (1-methyl-imidazol-2-yl) -anilino) -1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (209) 3-Z-[1-(4-(1-methyl-imidazol-2-yl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (210) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino)-3-amino-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (211) 3-Z- [1- (4- ( (3- (N-benzyl-N-methyl-amino) -propyl) -N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (212) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-acetyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (213) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-butyryl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (214) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-isobutyryl-amino)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (215) 3-Z- [1- (4- (N- (2-dimethylamino-ethyl) -N-benzoyl-amino) -anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (216) 3-Z- [1- (4- (N- (2-dimethylamino-ethyl) -N-acetyl-amino) -3-amino-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (217) 3-Z- [1- (4- (4-hydroxymethyl-piperidin-1-yl-methyl) -anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (218) 3-Z- [1- (4- (2- (4-hydroxy-piperidin-1-yl) -ethyl) -anilino) -1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (219) 3-Z- [1- (4- (N- (2-dimethylamino-ethyl) -N-propylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (220) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-butylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (221) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-phenylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (222) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-benzylsulphonyl-amino)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (223) 3-Z-[1-(4-((imidazolidin-2,4-dion-5-yl)-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (224) 3-Z- [1- (4- ( (3-hydroxy-pyrrolidin-1-yl) -methyl) -anilino) -1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (225) 3-Z- [1- (4- (cyclohexylyl-methyl) -anilino) -1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (226) 3-Z- [1- (4- (cyclohexyl-carbonyl) -anilino) -i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (227) 3-Z-[1-(4-diethylaminomethyl-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (228) 3-Z- [1- (4- (N- (n-hexyl) -N-methyl-aminomethyl) -anilino) -1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (229) 3-Z- [1- (4- (N- (2-dimethylamino-ethyl) -N- (furan-2-carbonyl)-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (230) 3-Z- [1- (4- (N- (2-dimethylamino-ethyl) -N- (2-methoxy-benzoyl)-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (231) 3-Z- [1- (4- (N- (2-dimethylamino-ethyl) -N- (pyridine-3-carbonyl)-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (232) 3-Z- [1- (4- (N- (2-dimethylamino-ethyl) -N- (phenyl-acetyl) -amino)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (233) 3-Z- [1- (4- (imidazol-2-yl) -anilino) -1-phenyl-methylene] -6-ethoxycarbonyl-2-indolinone (234) 3-Z-[1-(4-(1-ethyl-imidazol-2-yl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (235) 3-Z-[1-(4-(1-benzyl-imidazol-2-yl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (236) 3-Z- [1- (4- (N- (2-dimethylamino-ethyl) -N-isopropylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (237) 3-Z-[1-(4-(N-((4-benzyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (238) 3-Z-[1-(4-(N-(pyrrolidin-1-yl-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (239) 3-Z- [1- (4- (N- (2-dimethylamino-ethyl) -N-acetyl-amino) -3-bromo-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (240) 3-Z-[1-(4-(5-methyl-imidazol-4-yl)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (241) 3-Z- [1- (4- (N- ( (2-dimethylamino-ethyl) -carbonyl) -N-isopropyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (242) 3-Z- [1- (4- (N- ( (2-dimethylamino-ethyl) -carbonyl) -N-benzyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (243) 3-Z-[1-(4-(N-butyl-N-tert.butoxycarbonyl-aminomethyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (244) 3-Z-[1-(4-(N-((N-aminocarbonylmethyl-N-methyl-amino)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (245) 3-Z-[1-(4-(N-((N-benzyl-N-methyl-amino)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (246) 3-Z- [1- (4- (N- (di- (2-methoxyethyl) -amino-methylcarbonyl) -N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (247) 3-Z- [1- (4- (N- ( (2- (4-tert.butoxycarbonyl-piperazin-l-yl) -ethyl)-carbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (248) 3-Z- [1- (4- (N- ( (2- (piperidin-l-yl) -ethyl) -carbonyl) -N-methyl-amino)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (249) 3-Z- [1- (4- (N- ( (2- (N-benzyl-N-methyl-amino) -ethyl) -carbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (250) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-isopropyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (251) 3-Z- [1- (4- (N- (piperidin-1-yl-methylcarbonyl) -N-isopropyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (252) 3-Z-[1-(4-(N-((4-tert.butoxycarbonyl-piperazin-l-yl)-methylcarbonyl)-N-isopropyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (253) 3-Z-[1-(4-(N-((N-benzyl-N-methyl-amino)-methylcarbonyl)-N-benzyl-amino)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (254) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-benzyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (255) 3-Z-[1-(4-(N-(piperidin-1-yl-methylcarbonyl)-N-benzyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (256) 3-Z- [1- (4- (1, 2, 4-triazol-2-yl-methyl) -anilino) -i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (257) 3-Z-[1-(4-(1,2,3-triazol-2-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (258) 3-Z-[1-(4-(1,2,3-triazol-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (259) 3-Z-[1-(4-((N-aminocarbonylmethyl-N-methyl-amino)-methyl)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (260) 3-Z- [1- (4- ( (di- (2-methoxy-ethyl) -amino) -methyl) -anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (261) 3-Z- [1- (4- ( (di- (2-hydroxy-ethyl) -amino) -methyl) -anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (262) 3-Z-[1-(4-((N-ethoxycarbonylmethyl-N-methyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (263) 3-Z- [1- (4- (azetidin-1-yl-methyl) -anilino) -1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (264) 3-Z-[1-(4-(N-propyl-N-tert.butoxycarbonyl-aminomethyl)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (265) 3-Z- [l- (4- ( (N- (2- (2-methoxy-ethoxy) -ethyl) -N-methyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (266) 3-Z-[1-(4-((N-(tert.butoxycarbonyl-3-amino-propyl)-N-methyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (267) 3-Z-[1-(4-((N-(methylcarbamoyl-methyl)-N-methyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (268) 3-Z-[1-(4-((N-(dimethylcarbamoyl-methyl)-N-methyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (269) 3-Z-[1-(4-((N-propyl-N-methyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (270) 3-Z- [1- (4- ( (N- (2-dimethylamino-ethyl) -N-methyl-amino) -methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (271) 3-Z-[1-(4-((N-(3-dimethylamino-propyl)-N-methyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (272) 3-Z- [1- (4- ( (N- (2-methoxy-ethyl) -N-methyl-amino) -methyl) -anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (273) 3-Z- [l- (4- ( (N- (2-hydroxy-ethyl) -N-methyl-amino) -methyl) -anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (274) 3-Z-[1-(4-((N-(dioxolan-2-yl-methyl)-N-methyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (275) 3-Z-[1-(4-(3-oxo-piperazin-l-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (276) 3-Z-[1-(4-(N-(piperazin-1-yl-methylcarbonyl)-N-isopropyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (277) 3-Z- [1- (4- (N- ( (2- (piperazin-1-yl) -ethyl) -carbonyl) -N-methyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (278) 3-Z- [1- (4- ( (N- (3-amino-propyl) -N-methyl-amino) -methyl) -anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (279) 3-Z- [1- (4- (N- (3-methylamino-propyl) -N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (280) 3-Z-[l-(4-Ureidomethyl-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (281) 3-Z-[1-(4-guanidinomethyl-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (282) 3-Z-[1-(4-(N-methylsulphonyl-aminomethyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (283) 3-Z-[1-(4-(4-benzoyl-piperazin-1-yl-methyl)-anilino)-i-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (284) 3-Z- [1- (4- ( (N- (3-acetylamino-propyl) -N-methyl-amino) -methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (285) 3-Z-[1-(4-((N-(3-methylsulphonylamino-propyl)-N-methyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (286) 3-Z-[1-(4-((N-carboxymethyl-N-methyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone (287)3-Z-(1-anilino-l-phenyl-methylene)-6-methoxycarbonyl-2-indolinone (288) 3-Z-[1-(4-nitro-anilino)-1-phenyl-methylene]-6-methoxy-carbonyl-2-indolinone (289) 3-Z-[1-(4-fluoro-anilino)-1-phenyl-methylene]-6-methoxy-carbonyl-2-indolinone (290) 3-Z-[1-(4-chloro-anilino)-1-phenyl-methylene]-6-methoxy-carbonyl-2-indolinone (291) 3-Z-[1-(4-bromo-anilino)-1-phenyl-methylene]-6-methoxy-carbonyl-2-indolinone (292) 3-Z- [1- (4-iodo-anilino) -1-phenyl-methylene] -6-methoxycarbonyl-2-indolinone (293) 3-Z-[1-(4-cyano-anilino)-i-phenyl-methylene]-6-methoxy-carbonyl-2-indolinone (294) 3-Z-[1-(4-carboxy-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (295) 3-Z-[1-(4-methoxy-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (296) 3-Z-[1-(4-ethoxy-anilino)-1-phenyl-methylene]-6-methoxy-carbonyl-2-indolinone (297) 3-Z- [1- (4-trifluoromethyl-anilino) -i-phenyl-methylene] -6-methoxycarbonyl-2-indolinone (298) 3-Z-[1-(4-methylmercapto-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (299) 3-Z- [1- (4- (isopropylaminomethyl) -anilino) -i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (300) 3-Z- [1- (4- (anilinomethyl) -anilino) -1-phenyl-methylene] -6-methoxycarbonyl-2-indolinone (301) 3-Z-[1-(4-(isobutylaminomethyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (302) 3-Z-[1-(4-(cyclohexylaminomethyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (303) 3-Z-[1-(4-(benzylaminomethyl)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (304) 3-Z-[1-(4-((N-methyl-N-propyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (305) 3-Z-[1-(4-((N-isopropyl-N-methyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (306) 3-Z-[1-(4-((N-ethyl-N-propyl-amino)-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (307) 3-Z- [1- (4- ( (N-ethyl-N-isopropyl-amino) -methyl) -anilino) -1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (308) 3-Z-[1-(4-(dipropylaminomethyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (309) 3-Z-[1-(4-(diisopropylaminomethyl)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (310) 3-Z- [1- (4- ( (N-benzyl-N-ethyl-amino) -methyl) -anilino) -1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (311) 3-Z- [1- (4- (dibenzylaminomethyl) -anilino) -1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (312) 3-Z-[1-(4-(3,6-dihydro-2H-pyridin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (313) 3-Z-[1-(4-(3,5-dimethyl-piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (314) 3-Z-[1-(4-(azepan-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (315) 3-Z- [1- (4- (2-amino-ethyl) -anilino) -i-phenyl-methylene] -6-methoxycarbonyl-2-indolinone (316) 3-Z-[1-(4-(2-methylamino-ethyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (317) 3-Z-[1-(4-(2-ethylamino-ethyl)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (318) 3-Z-[1-(4-(2-dirnethylamino-ethyl)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (319) 3-Z-[1-(4-(2-diethylamino-ethyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (320) 3-Z- [1- (4- (2-piperidin-1-yl-ethyl) -anilino) -1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (321) 3-Z- [1- (4- (2-acetylamino-ethyl) -anilino) -1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (322) 3-Z- [1- (4- (3-amino-propyl) -anilino) -1-phenyl-methylene] -6-methoxycarbonyl-2-indolinone (323) 3-Z-[1-(4-(3-dimethylamino-propyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (324) 3-Z-[1-(4-(N-aminomethylcarbonyl-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (325) 3-Z-[1-(4-(N-ethylaminomethylcarbonyl-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (326) 3-Z-[1-(4-(N-diethylaminomethylcarbonyl-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (327) 3-Z-[1-(4-(N-dipropylaminomethylcarbonyl-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (328) 3-Z-[1-(4-(N-((N-ethyl-N-methyl-amino)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (329) 3-Z-[1-(4-(N-((N-ethyl-N-propyl-amino)-methylcarbonyl)-N-methyl-amirio) -anilino) -1-phenyl-methylene] -6-methoxycarbonyl-2-indolinone (330) 3-Z-[1-(4-(N-((N-methyl-N-propyl-amino)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (331) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-ethyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (332) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-propyl-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (333) 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-butyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (334) 3-Z- [1- (4.- (N- (2-amino-ethylcarbonyl) -N-methyl-amino) -anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (335) 3-Z-[1-(4-(N-(2-diethylamino-ethylcarbonyl)-N-methyl-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (336) 3-Z- [1- (4- (N-acetyl-N- (2-aminoethyl) -amino) -anilino) -1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (337) 3-Z- [1- (4- (N-acetyl-N- (2-methylamino-ethyl) -amino) -anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (338) 3-Z- [1- (4- (N-acetyl-N- (3-methylamino-propyl) -amino) -anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (339) 3-Z-[l-(4-(N-acetyl-N-(2-piperidin-1-yl-ethyl)-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (340) 3-Z- [1- (4- (N-acetyl-N- (aminocarbonylmethyl) -amino) -anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (341) 3-Z- [1- (4- (N-acetyl-N- (piperidin-1-yl-carbonylmethyl) -amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (342) 3-Z- [1- (4- (N-methyl-N- (aminocarbonyl) -amino) -anilino) -1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (343) 3-Z- [1- (4- (N-methyl-N- (methylaminocarbonyl) -amino) -anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (344) 3-Z-[1-(4-(N-methyl-N-(dimethylaminocarbonyl)-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (345) 3-Z-[1-(4-(N-methyl-N-(piperidin-1-yl-carbonyl)-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (346) 3-Z-[1-(4-(N-(2-ethylamino-ethyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (347) 3-Z-[1-(4-(N-(2-diethylamino-ethyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone l (348) 3-Z- [1- (4- (N- (2-pyrrolidin-1-yl-ethyl) -N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (349) 3-Z- [1- (4- (N- (2-piperidin-1-yl-ethyl) -N-methylsulphonyl-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (350) 3-Z-[1-(4-(N-(2-piperazin-1-yl-ethyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (351) 3-Z- [1- (4- (N- (2- (4-morpholin-1-yl) -ethyl) -N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (352) 3-Z-[1-(4-(N-(ethylaminocarbonylmethyl)-N-methylsulphonyl-amino)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (353) 3-Z-[1-(4-(N-(diethylaminocarbonylmethyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (354) 3-Z-[1-(4-(N-(pyrrolidin-1-yl-carbonylmethyl)-N-methyl-sulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (355) 3-Z-[1-(4-(N-(piperidin-1-yl-carbonylmethyl)-N-methyl-sulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (356) 3-Z-[1-(4-(N-(piperazin-1-yl-carbonylmethyl)-N-methyl-sulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (357) 3-Z-[1-(4-(N-((morpholin-4-yl)-carbonylmethyl)-N-methyl-sulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (358) 3-Z-[1-(4-(2-dimethylamino-ethoxy)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (359) 3-Z-[1-(4-(3-dimethylamino-propoxy)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (360) 3-Z-[1-(4-(aminocarbonylmethyl)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (361) 3-Z-[1-(4-(2-aminocarbonyl-ethyl)-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (362) 3-Z- [1- (4- (pyridin-2-yl) -anilino) -1-phenyl-methylene] -6-methoxycarbonyl-2-indolinone (363) 3-Z-[1-(4-(pyridine-3-yl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (364) 3-Z- [1- (4 ( (N-phenethyl-N-methyl-amino) -methyl) -anilino) -1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (365) 3-Z-[1-(4-(N-acetyl-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (366) 3-Z-[1-(4-(N-ethylcarbonyl-N-(dimethylaminocarbonyl-methyl)-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (367) 3-Z-[1-(4-(N-methyl-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (368) 3-Z-[1-(4-carboxymethyl-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (369) 3-Z-[1-(4-carbamoylmethyl-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (370) 3-Z-[1-(4-dimethylcarbamoylmethyl-anilino)-i-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (371) 3-Z-[1-(4-tetrazol-5-yl-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (372) 3-Z- [1- (4- (piperidin-1-yl-methyl) -anilino) -methylene] -6-methoxycarbonyl-2-indolinone (373) 3-Z- [1- (4- (piperidin-1-yl-methyl) -anilino) -ethylidene] -6-methoxycarbonyl-2-indolinone (374) 3-Z- [1- (4- (piperidin-1-yl-methyl) -anilino) -propylidene] -6-methoxycarbonyl-2-indolinone (375) 3-Z- [1- (4- (piperidin-1-yl-methyl) -anilino) -butylidene] -6-methoxycarbonyl-2-indolinone (376) 3-Z- [1- (4- (N- (3-dimethylamino-propyl) -N-acetyl-amino) -anilino)-methylene]-6-methoxycarbonyl-2-indolinone (377) 3-Z- [1- (4- (N- (3-dimethylamino-propyl) -N-acetyl-amino) -anilino)-ethylidene]-6-methoxycarbonyl-2-indolinone (378) 3-Z- [1- (4- (N- (3-dimethylamino-propyl) -N-acetyl-amino) -anilino)-propylidene]-6-methoxycarbonyl-2-indolinone (379) 3-Z-[1-(4-(N-(3-dimethylamino-propyl)-N-acetyl-amino)-anilino)-butylidene]-6-methoxycarbonyl-2-indolinone (380) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino)-anilino)-methylene]-6-methoxycarbonyl-2-indolinone (381) 3-Z- [1- (4- (N- (2-dimethylamino-ethyl) -N-methylsulphonyl-amino)-anilino)-ethylidene]-6-methoxycarbonyl-2-indolinone (382) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino)-anilino)-propylidene]-6-methoxycarbonyl-2-indolinone (383) 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino)-anilino)-butylidene]-6-methoxycarbonyl-2-indolinone (384) 3-Z-[1-(4-tetrazol-5-yl-anilino)-methylene]-6-methoxy-carbonyl-2-indolinone (385) 3-Z-[1-(4-tetrazol-5-yl-anilino)-ethylidene]-6-methoxy-carbonyl-2-indolinone (386) 3-Z-[1-(4-tetrazol-5-yl-anilino)-propylidene]-6-methoxy-carbonyl-2-indolinone (387) 3-Z-[1-(4-tetrazol-5-yl-anilino)-butylidene]-6-methoxy-carbonyl-2-indolinone (388) 3-Z-[1-(4-carboxy-anilino)-methylene]-6-methoxycarbonyl-2-indolinone (389) 3-Z- [1- (4-carboxy-anilino) -ethylidene] -6-methoxycarbonyl-2-indolinone (390) 3-Z-[1-(4-carboxy-anilino)-propylidene]-6-methoxy-carbonyl-2-indolinone (391) 3-Z- [1- (4-carboxy-anilino) -butylidene] -6-methoxycarbonyl-2-indolinone (392) 3-Z-[1-(4-(N-benzyl-N-methyl-aminomethyl)-anilino)-1-methyl-methylene]-6-methoxycarbonyl-2-indolinone (393) 3-Z-[1-(4-(2,3,4,5-tetrahydro-benzo(d)azepin-3-yl-methyl)-anilino)-1-methyl-methylene]-6-methoxycarbonyl-2-indolinone (394) 3-Z-[1-(4-((benzo(1,3)dioxol-5-yl-methyl)-methyl-amino-methyl)-anilino)-1-methyl-methylene]-6-methoxycarbonyl-2-indolinone (395) 3-Z-[1-(4-(N-phenethyl-N-methyl-aminomethyl)-anilino)-1-methyl-methylene]-6-methoxycarbonyl-2-indolinone , (396) 3-Z- [1- (4- (N- (3,4-dimethoxy-benzyl) -N-methyl-a-mino-methyl)-anilino)-1-methyl-methylene]-6-methoxycarbonyl-2-indolinone (397) 3-Z- [1- (4- (N- (4-Chloro-benzyl) -N-methyl-amino-methyl) -anilino)-i-methyl-methylene]-6-methoxycarbonyl-2-indolinone (398) 3-Z-[1-(4-(N-(4-methylbenzyl)-N-methyl-amino-methyl)-anilino)-1-methyl-methylene]-6-methoxycarbonyl-2-indolinone (399) 3-Z- [1- (4- (N- (4-fluoro-benzyl) -N-methyl-amino-methyl) -anilino)-1-methyl-methylene]-6-methoxycarbonyl-2-indolinone (400) 3-Z- [1- (4- (N- (4-bromo-benzyl) -N-methyl-amino-methyl) -anilino)-1-methyl-methylene]-6-methoxycarbonyl-2-indolinone (401) 3-Z- [1- (4- (N- (3-dimethylamino-propionyl) -N-dimethylaminocarbonylmethyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (402) 3-Z- [1- (4- (N- (4-dimethylamino-butyryl) -N-dimethylaminocarbonylmethyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (403) 3-Z-[1-(4-(N-dimethylaminocarbonylmethyl-N-(2-dimethylamino-ethylsulphonyl)-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (404) 3-Z-[1-(4-(N-dimethylaminocarbonylmethyl-N-(3-dimethylamino-propylsulphonyl)-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (405) 3-Z- [l- (4- ( (2-hydroxy-ethyl) -amino-methyl) -anilino) -1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (406) 3-Z-[1-(4-((2-methoxy-ethyl)-amino-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (407) 3-Z-[1-(4-((2-dimethylamino-ethyl)-amino-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (408) 3-Z-[1-(4-((3-dimethylamino-propyl)-amino-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (409) 3-Z-[1-(4-((N-tert.butoxycarbonyl-2-amino-ethyl)-amino-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (410) 3-Z-[1-(4-((N-tert.butoxycarbonyl-3-amino-propyl)-amino-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (411) 3-Z- [1- (4- ( (2-amino-ethyl) -amino-methyl) -anilino) -1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (412) 3-Z-[l-(4-((3-amino-propyl)-amino-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (413) 3-Z- [1- (4- ( (2-acetylamino-ethyl) -amino-methyl) -anilino) -1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (414) 3-Z-[1-(4-((3-acetylamino-propyl)-amino-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone (415) 3-Z-[1-(4-((2-methylsulphonylamino-ethyl)-amino-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.

NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.

JUMBO APPLICATIONS / PATENTS

THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.

NOTE: For additional volumes please contact the Canadian Patent Office.

Claims (54)

CLAIMS:
1. A compound of the formula I
wherein:

X denotes an oxygen or sulphur atom, R1 denotes a hydrogen atom or a C1-4-alkoxycarbonyl or C2-4-alkanoyl group, R2 denotes a carboxy group, a straight-chain or branched C1-6-alkoxy-carbonyl group, a C4-7-cycloalkoxy-carbonyl or an aryloxycarbonyl group;

a straight-chain or branched C1-6-alkoxy-carbonyl group, which is terminally substituted in the alkyl moiety by a phenyl, heteroaryl, carboxy, C1-3-alkoxy-carbonyl, aminocarbonyl, C1-3-alkylamino-carbonyl or di- (C1-3-alkyl) -aminocarbonyl group;

a straight-chain or branched C2-6-alkoxy-carbonyl group, which is terminally substituted in the alkyl moiety by a chlorine atom or a hydroxy, C1-3-alkoxy, amino, C1-3-alkylamino or di- (C1-3-alkyl) -amino group; or an aminocarbonyl or methylaminocarbonyl group or an ethylaminocarbonyl group optionally substituted in the 2 position of the ethyl group by a hydroxy or C1-3-alkoxy group;

R3 denotes a hydrogen atom, a C1-6-alkyl, C3-7-cycloalkyl, trifluoromethyl or heteroaryl group, a phenyl or naphthyl group or a phenyl or naphthyl group mono- or disubstituted by a fluorine, chlorine, bromine or iodine atom, by a trifluoromethyl, C1-3-alkyl or C1-3-alkoxy group, wherein, in the event of disubstitution, the substituents are identical or different and wherein the abovementioned unsubstituted as well as the mono- and disubstituted phenyl and naphthyl groups are optionally further substituted by a hydroxy, hydroxy-C1-3-alkyl or C1-3-alkoxy-C1-3-alkyl group;

by a cyano, carboxy, carboxy-C1-3-alkyl, C1-3-alkoxycarbonyl, aminocarbonyl, C1-3-alkylamino-carbonyl or di-(C1-3-alkyl)-aminocarbonyl group;

by a nitro group;

by an amino, C1-3-alkylamino, di-(C1-3-alkyl)-amino or amino-C1-3-alkyl group;

by a C1-3-alkylcarbonylamino, N-(C1-3-alkyl)-C1-3-alkyl-carbonylamino, C1-3-alkylcarbonylamino-C1-3-alkyl, N-(C1-3-alkyl)-C1-3-alkylcarbonylamino-C1-3-alkyl, C1-3-alkyl-sulphonylamino, C1-3-alkylsulphonylamino-C1-3-alkyl, N-(C1-3-alkyl)-C1-3-alkylsulphonylamino-C1-3-alkyl or aryl-C1-3-alkylsulphonylamino group;

by a cycloalkylamino, cycloalkyleneimino, cycloalkyleneiminocarbonyl, cycloalkyleneimino-C1-3-alkyl, cycloalkyleneiminocarbonyl-C1-3-alkyl or cycloalkyleneiminosulphonyl-C1-3-alkyl group having 4 to 7 ring members in each case, wherein in each case the methylene group in position 4 of a 6- or 7-membered cycloalkyleneimino group is optionally replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, -NH or -N(C1-3-alkyl) group;

or by a heteroaryl or heteroaryl-C1-3-alkyl group;
R4 denotes a C3-7-cycloalkyl group, wherein the methylene group in the 4 position of a 6- or 7-membered cycloalkyl group is optionally substituted by an amino, C1-3-alkylamino or di- (C1-3-alkyl) -amino group or is optionally replaced by an -NH or -N(C1-3-alkyl) group;

or a phenyl group substituted by the group R6, which is optionally further mono- or disubstituted by fluorine, chlorine, bromine or iodine atoms or by C1-5-alkyl, trifluoromethyl, hydroxy, C1-3-alkoxy, carboxy, C1-3-alkoxycarbonyl, amino, acetylamino, C1-3-alkyl-sulphonylamino, aminocarbonyl, C1-3-alkyl-aminocarbonyl, di- (C1-3-alkyl) -aminocarbonyl, aminosulphonyl, C1-3-alkyl-aminosulphonyl, di-(C1-3-alkyl)-aminosulphonyl, nitro or cyano groups, wherein the substituents are identical or different;

R6 denotes a hydrogen, fluorine, chlorine, bromine or iodine atom;

a cyano, nitro, amino, C1-5-alkyl, C3-7-cycloalkyl, trifluoromethyl, phenyl, tetrazolyl or heteroaryl group;
a group of formula wherein the hydrogen atoms bound to a nitrogen atom are optionally in each case replaced independently of one another by a C1-3-alkyl group;

a C1-3-alkoxy group, a C1-3-alkoxy-C1-3-alkoxy, phenyl-C1-3-alkoxy, amino-C2-3-alkoxy, C1-3-alkylamino-C2-3-alkoxy, di- (C1-3-alkyl) -amino-C2-3-alkoxy, phenyl-C1-3-alkylamino-C2-3-alkoxy, N- (C1-3-alkyl) -phenyl-C1-3-alkylamino-C2-3-alkoxy, C5-7-cycloalkyleneimino-C2-3-alkoxy or C1-3-alkylmercapto group;

a carboxy, C1-4-alkoxycarbonyl, aminocarbonyl, C1-3-alkylamino-carbonyl, N- (C1-5-alkyl) -C1-3-alkylaminocarbonyl, phenyl-C1-3-alkylamino-carbonyl, N- (C1-3-alkyl) -phenyl-C1-3-alkylamino-carbonyl, piperazinocarbonyl or N-(C1-3-alkyl)-piperazinocarbonyl group;

a C1-3-alkylaminocarbonyl or N- (C1-5-alkyl) -C1-3-alkylaminocarbonyl group wherein an alkyl moiety is substituted by a carboxy or C1-3-alkoxycarbonyl group or in the 2 or 3 position by a di-(C1-3-alkyl)-amino, piperazino, N- (C1-3-alkyl) -piperazino or a 4- to 7-membered cycloalkyleneimino group;

a C3-7-cycloalkyl-carbonyl group;

wherein the methylene group in the 4 position of the 6- or 7-membered cycloalkyl moiety is optionally substituted by an amino, C1-3-alkylamino or di-(C1-3-alkyl)-amino group or replaced by an -NH or -N(C1-3-alkyl) group;

a 4- to 7-membered cycloalkyleneimino group wherein a methylene group linked to the imino group is optionally replaced by a carbonyl or sulphonyl group or the cycloalkylene moiety is optionally fused to a phenyl ring or one or two hydrogen atoms are optionally each replaced by a C1-3-alkyl group and/or in each case the methylene group in the 4 position of a 6- or 7-membered cycloalkyleneimino group is optionally substituted by a carboxy, C1-3-alkoxycarbonyl, aminocarbonyl, C1-3-alkylaminocarbonyl, di- (C1-3-alkyl) -aminocarbonyl, phenyl-C1-3-alkylamino or N- (C1-3-alkyl) -phenyl-C1-3-alkylamino group or is optionally replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, -NH, -N(C1-3-alkyl), -N(phenyl), -N(C1-3-alkyl-carbonyl) or -N(benzoyl) group;
a C1-4-alkyl group substituted by the group R7, wherein R7 denotes a C3-7-cycloalkyl group, wherein the methylene group in the 4 position of the 6- or 7-membered cycloalkyl group is optionally substituted by an amino, C1-3-alkylamino or di- (C1-3-alkyl) -amino group or is optionally replaced by an -NH or -N(C1-3-alkyl) group or in a 5- to 7-membered cycloalkyl group a-(CH2)2 group is optionally replaced by a -CO-NH group, a -(CH2)3 group is optionally replaced by a -NH-CO-NH or -CO-NH-CO
group or a -(CH2)4 group is optionally replaced by a -NH-CO-NH-CO group, wherein in each case a hydrogen atom bound to a nitrogen atom is optionally replaced by a C1-3-alkyl group;

an aryl or heteroaryl group;

wherein, when the heteroaryl is a pyrrolyl, pyrazolyl or imidazolyl group bound via a nitrogen atom, the heteroaryl is optionally substituted by a C1-3-alkyl group, and when the heteroaryl is a pyrrolidine, piperidino, morpholino, thiomorpholino or piperazino group, the heteroaryl is optionally substituted in the 4 position by a C1-3-alkyl, phenyl-C1-3-alkyl, C1-3-alkylcarbonyl or C1-4-alkoxycarbonyl group or a hydrogen atom;

a hydroxy or C1-3-alkoxy group;

an amino, C1-,-alkylamino, di- (C1-,-alkyl) -amino, phenylamino, N-phenyl-C1-3-alkyl-amino, phenyl-C1-3-alkylamino, N- (C1-3-alkyl) -phenyl-C1-3-alkylamino or di- (phenyl-C1-3-alkyl ) -amino group;

an .omega.-hydroxy-C2-3-alkyl-amino, N- (C1-3-alkyl) -co-hydroxy-C2-3-alkyl-amino, di- (.omega.-hydroxy-C2-3-alkyl) -amino, di- (.omega.- (C1-3-alkoxy) -C2-3-alkyl) -amino or N- (dioxo-lan-2-yl) -C1-3-alkyl-amino group;

a C1-3-alkoxy-C1-3-alkylamino, N- (C1-3-alkyl) -C1-3-alkoxy-C1-3-alkylamino or di-(2-methoxy-ethyl)-amino group;

a C1-3-alkylcarbonylamino-C2-3-alkyl-amino or C1-3-alkylcarbonylamino-C2-3-alkyl-N- (C1-3-alkyl) -amino group;
a C1-3-alkylsulphonylamino, N- (C1-3-alkyl) -C1-3-alkylsulphonylamino, C1-3-alkylsulphonylamino-C2-3-alkyl-amino or C1-3-alkylsulphonylamino-C2-3-alkyl-N- (C1-3-alkyl) -amino group;

a hydroxycarbonyl-C1-3-alkylamino or N- (C1-3-alkyl) -hydroxycarbonyl-C1-3-alkyl-amino group;

a guanidino group wherein one or two hydrogen atoms are each optionally replaced by a C1-3-alkyl group;

a group of formula -N(R8) -CO- (CH2)n-R9 (II), wherein R8 denotes a hydrogen atom or a C1-3-alkyl group, n denotes 0, 1, 2 or 3 and R9 denotes an amino, C1-4-alkylamino, di- (C1-4-alkyl)-amino, phenylamino, N-(C1-4-alkyl)-phenylamino, benzylamino, N- (C1-4-alkyl) -benzylamino or C1-4-alkoxy group, or a 4- to 7-membered cycloalkyleneimino group, wherein in each case the methylene group in the 4 position of a 6- or 7-membered cycloalkyleneimino group is optionally replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, -NH, -N(C1-3-alkyl) , -N(phenyl), -N(C1-3-alkyl-carbonyl) or -N(benzoyl) group, or, if n denotes 1, 2 or 3, R9 is as defined herein or is a hydrogen atom;

a group of formula -N(R10) - (CH2) m- (CO)o-R11 (III) , wherein R10 denotes a hydrogen atom, a C1-3-alkyl group, a C1-3-alkylcarbonyl, arylcarbonyl, phenyl-C1-3-alkyl-carbonyl, C1-3-alkylsulphonyl, arylsulphonyl or phenyl-C1-3-alkylsulphonyl group;

m denotes 1, 2, 3 or 4;

o denotes 1 or, if m denotes 2, 3 or 4, o denotes 0 or 1; and R11 denotes an amino, CI-4-alkylamino, di- (C1-4-alkyl)-amino, phenylamino, N-(C1-4-alkyl)-phenylamino, benzylamino, N- (C1-4-alkyl) -benzylamino, C1-4-alkoxy or C1-3-alkoxy-C1-3-alkoxy group, a di- (C1-4-alkyl) -amino-C1-3-alkylamino group optionally substituted in the 1 position by a C1-3-alkyl group or a 4- to 7-membered cycloalkyleneimino group, wherein the cycloalkylene moiety is optionally fused to a phenyl ring or in each case the methylene group in the 4 position of the 6- or 7-membered cycloalkyleneimino group is optionally replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, -NH, -N(C1-3-alkyl) , -N(phenyl), -N(C1-3-alkyl-carbonyl) or -N(benzoyl) group;

a C4-7-cycloalkylamino, C4-7 -cycloalkyl-C1-3-alkylamino or C4-7-cycloalkenylamino group wherein position 1 of the ring is not involved in the double bond and wherein the abovementioned groups are each optionally further substituted at the amino-nitrogen atom by a C5-7-cycloalkyl, C2-4-alkenyl or C1-4-alkyl group;

or R7 is a 4- to 7-membered cycloalkyleneimino group, wherein the cycloalkylene moiety is optionally fused to a phenyl group or to an oxazolo, imidazolo, thiazolo, pyridino, pyrazino or pyrimidino group optionally substituted by a fluorine, chlorine, bromine or iodine atom or by a nitro, C1-3-alkyl, C1-3-alkoxy or amino group, and/or one or two hydrogen atoms are each optionally replaced by a C1-3-alkyl, C5-7-cycloalkyl or phenyl group;
and/or the methylene group in the 3 position of a 5-membered cycloalkyleneimino group is optionally substituted by a hydroxy, hydroxy-C1-3-alkyl, C1-3-alkoxy or C1-3-alkoxy-C1-3-alkyl group;

the methylene group in the 3 or 4 position of a 6-or 7-membered cycloalkyleneimino group is optionally in each case substituted by a hydroxy, hydroxy-C1-3-alkyl, C1-3-alkoxy, C1-3-alkoxy-C1-3-alkyl, carboxy, C1-4-alkoxycarbonyl, aminocarbonyl, C1-3-alkylaminocarbonyl, di- (C1-3-alkyl) -aminocarbonyl, phenyl-C1-3-alkylamino or N- (C1-3-alkyl) -phenyl-C1-3-alkyl-amino group or is optionally replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, -NH, -N(Cl-3-alkyl-), -N(phenyl), -N(phenyl-C1-3-alkyl-) , -N(C1-3-alkyl-carbonyl-) , -N(C1-4-hydroxy-carbonyl-) , -N(C1-4-alkoxy-carbonyl-) , -N(benzoyl-) or -N(phenyl-C1-j-alkyl-carbonyl-) group, wherein a methylene group linked to an imino-nitrogen atom of the cycloalkyleneimino group is optionally replaced by a carbonyl or sulphonyl group or in a 5- to 7-membered monocyclic cycloalkyleneimino group or a cycloalkyleneimino group fused to a phenyl group, the two methylene groups linked to the imino-nitrogen atom are each optionally replaced by a carbonyl group;

or R6 denotes a C1-4-alkyl group which is substituted by a carboxy, C1-3-alkoxycarbonyl, aminocarbonyl, C1-3-alkylaminocarbonyl or di-(C1-3-alkyl)-aminocarbonyl group or by a 4- to 7-membered cycloalkyleneiminocarbonyl group;

an N- (C1-3-alkyl) -C2-4-alkanoylamino group which is additionally substituted in the alkyl moiety by a carboxy or C1-3-alkoxycarbonyl group;

a group of formula -N (R12) -CO- (CH2) p-R13 (IV) wherein R12 denotes a hydrogen atom, a C1-6-alkyl or C3-7-cycloalkyl group or a C1-3-alkyl group terminally substituted by a phenyl, heteroaryl, trifluoromethyl, hydroxy, C1-3-alkoxy, aminocarbonyl, C1-4-alkylamino-carbonyl, di-(C1-4-alkyl)-amino-carbonyl, C1-3-alkyl-carbonyl, C1-3-alkyl-sulphonylamino, N- (C1-3-alkyl) -C1-3-alkyl-sulphonylamino, C1-3-alkyl-aminosulphonyl or di-((-1-3-alkyl)-aminosulphonyl group and p denotes 0, 1, 2 or 3 and R13 assumes the meanings of the abovementioned group R7, or, if p denotes 1, 2 or 3, R13 is as defined herein or R13 is a hydrogen atom;

a group of formula -N (R14) - (CH2) q- (CO) r-R15 (V), wherein R14 denotes a hydrogen atom, a C1-4-alkyl group or a C1-3-alkylcarbonyl, arylcarbonyl, phenyl-C1-3-alkylcarbonyl, heteroarylcarbonyl, heteroaryl-C1-3-alkylcarbonyl, C1-4-alkylsulphonyl, arylsulphonyl, phenyl-C1-3-alkylsulphonyl, heteroarylsulphonyl or heteroaryl-C1-3-alkyl-sulphonyl group, q denotes 1, 2, 3 or 4, r denotes the number 1 or, if q is 2, 3 and 4, r is 0 or 1, and R15 assumes the meanings of the abovementioned group R7; or a group of formula -N(R16) -SO2-R17 (VI), wherein R16 denotes a hydrogen atom or a C1-4-alkyl group optionally terminally substituted by a cyano, trifluoromethyl-carbonylamino or N-(C1-3-alkyl)-trifluoromethyl-carbonyl-amino group and R17 denotes a C1-3-alkyl group;

an amino group substituted by a di- (C1-3-alkyl) -amino-C1-3-alkyl-carbonyl or di- (C1-3-alkyl) -amino-C1-3-alkyl-sulphonyl group and a di- (C1-3-alkyl) -aminocarbonyl-C1-3-alkyl group;
or an N- (C1-3-alkyl) -C1-5-alkylsulphonylamino or N- (C1-3-alkyl)-phenylsulphonylamino group wherein the alkyl moiety is additionally substituted by a cyano or carboxy group;

wherein all the single-bonded or fused phenyl groups contained in the groups mentioned under R6 are optionally mono- or disubstituted by fluorine, chlorine, bromine or iodine atoms or by C1-5-alkyl, trifluoromethyl, hydroxy, C1-3-alkoxy, carboxy, C1-3-alkoxycarbonyl, aminocarbonyl, C1-4-alkylamino-carbonyl, di- (C1-4-alkyl) -amino-carbonyl, aminosulphonyl, C1-3-alkyl-aminosulphonyl, di- (C1-3-alkyl) -aminosulphonyl, C1-3-alkyl-sulphonylamino, nitro or cyano groups, wherein the substituents are identical or different, or two adjacent hydrogen atoms of the phenyl groups are optionally replaced by a methylenedioxy group;

and R5 denotes a hydrogen atom or a C1-3-alkyl group, wherein by an aryl group is meant a phenyl or naphthyl group optionally mono- or disubstituted by a fluorine, chlorine, bromine or iodine atom, by a cyano, trifluoromethyl, nitro, carboxy, aminocarbonyl, C1-3-alkyl or C1-3-alkoxy group and by a heteroaryl group is meant a monocyclic 5- or 6-membered heteroaryl group optionally substituted by a C1-3-alkyl group in the carbon skeleton, wherein the 6-membered heteroaryl group contains one, two or three nitrogen atoms and the 5-membered heteroaryl group contains an imino group optionally substituted by a C1-3-alkyl or phenyl-C1-3-alkyl group, an oxygen or sulphur atom or an imino group optionally substituted by a C1-3-alkyl or phenyl-C1-3-alkyl group or an oxygen or sulphur atom and additionally a nitrogen atom or an imino group optionally substituted by a C1-3-alkyl or phenyl-C1-3-alkyl group and two nitrogen atoms, and moreover a phenyl ring is optionally fused to the abovementioned monocyclic heterocyclic groups via two adjacent carbon atoms and the bonding takes place via a nitrogen atom or via a carbon atom of the heterocyclic moiety or a fused phenyl ring;

some or all of the hydrogen atoms in the abovementioned alkyl and alkoxy groups or in the alkyl moieties contained in the above-defined groups of formula I are optionally replaced by fluorine atoms;

and wherein any carboxy group contained in the abovementioned groups are optionally replaced by a tert.butoxycarbonyl group;

and wherein a hydrogen atom bound to a nitrogen atom is optionally each replaced by hydroxyl, benzoyl, pyridinoyl, formyl, acetyl, propionyl, butanoyl, pentanoyl, hexanoyl, allyloxycarbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert.butoxycarbonyl, pentoxycarbonyl, hexyloxycarbonyl, octyloxycarbonyl, nonyloxycarbonyl, decyloxycarbonyl, undecyloxycarbonyl, dodecyloxycarbonyl, hexadecyloxycarbonyl, benzyloxycarbonyl, phenylethoxycarbonyl, phenylpropoxycarbonyl, C1-3-alkylsulphonyl-C2-4-alkoxycarbonyl, C1-3-alkoxy-C2-4-alkoxy-C2-4-alkoxycarbonyl or an R e CO-O- (R f CR g) -O-CO group wherein R e denotes a C1-8-alkyl, C5-7-cycloalkyl, phenyl or phenyl-C1-3-alkyl group;

R f denotes a hydrogen atom, a C1-3-alkyl, C5-7-cycloalkyl or phenyl group and R g denotes a hydrogen atom or a C1-3-alkyl group;
or wherein an amino nitrogen optionally forms part of a phthalimido group, or a tautomer or pharmaceutically acceptable salt thereof.
2. A compound, tautomer or salt according to claim 1, wherein:

R1 and R3 are as defined in claim 1;
X denotes an oxygen atom;

R2 denotes a carboxy group, a straight-chain or branched C1-6-alkoxy-carbonyl group, a C5-7-cycloalkoxycarbonyl or a phenoxycarbonyl group;

a straight-chain or branched C1-3-alkoxy-carbonyl group, which is terminally substituted in the alkyl moiety by a phenyl, heteroaryl, carboxy, C1-3-alkoxycarbonyl, aminocarbonyl, C1-3-alkylaminocarbonyl or di- (C1-3-alkyl) -aminocarbonyl group;

a straight-chain or branched C2-3-alkoxy-carbonyl group, which is terminally substituted in the alkyl moiety by a chlorine atom or by a hydroxy, C1-3-alkoxy, amino, C1-3-alkylamino or di-(C1-3-alkyl)-amino group;

an aminocarbonyl or methylaminocarbonyl group or an ethylaminocarbonyl group optionally substituted in the 2 position of the ethyl group by a hydroxy or C1-3-alkoxy group;

R4 denotes a C3-7-cycloalkyl group, wherein the methylene group in the 4 position of the 6- or 7-membered cycloalkyl group is optionally substituted by an amino, C1-3-alkylamino or di- (C1-3-alkyl) -amino group or is optionally replaced by an -NH or -N(C1-3-alkyl) group;

or a phenyl group substituted by the group R6, which is optionally mono- or disubstituted by fluorine, chlorine or bromine atoms or by C1-3-alkyl, trifluoromethyl, hydroxy, C1-3-alkoxy, carboxy, C1-3-alkoxycarbonyl, amino, acetylamino, aminocarbonyl, C1-3-alkyl-aminocarbonyl, di- (C1-3-alkyl) -aminocarbonyl, nitro or cyano groups, wherein the substituents are identical or different;

R6 denotes a hydrogen, fluorine, chlorine, bromine or iodine atom, or a cyano, nitro, amino, C1-5-alkyl, C3-7-cycloalkyl, trifluoromethyl, phenyl, tetrazolyl or heteroaryl group;
a group of formula wherein a hydrogen atom bound to a nitrogen atom is optionally replaced by a C1-3-alkyl group, a C1-3-alkoxy group, an amino-C2-3-alkoxy, C1-3-alkylamino-C2-3-alkoxy, di- (C1-3-alkyl) -amino-C2-3-alkoxy, phenyl-C1-3-alkylamino-C2-3-alkoxy, N- (C1-3-alkyl) -phenyl-C1-3-alkylamino-C2-3-alkoxy, pyrrolidino-C2-3-alkoxy, piperidino-C2-3-alkoxy or C1-3-alkylmercapto group;

a carboxy, C1-4-alkoxycarbonyl, aminocarbonyl, C1-3-alkylamino-carbonyl, phenyl-C1-3-alkylamino-carbonyl or N- (C1-3-alkyl) -phenyl-C1-3-alkylamino-carbonyl group;

a C3-7-cycloalkyl-carbonyl group, wherein the methylene group in the 4 position of the 6- or 7-membered cycloalkyl moiety is optionally replaced by an -NH or -N(C1-3-alkyl) group;

a 4- to 7-membered cycloalkyleneimino group, wherein a methylene group linked to the imino group is optionally replaced by a carbonyl or sulphonyl group or one or two hydrogen atoms are each optionally replaced by a C1-3-alkyl group and/or in each case the methylene group in the 4 position of a 6- or 7-membered cycloalkyleneimino group is optionally substituted by a carboxy, C1-3-alkoxycarbonyl, aminocarbonyl, C1-3-alkylaminocarbonyl, di- (C1-3-alkyl) -aminocarbonyl, phenyl-C1-3-alkylamino or N- (C1-3-alkyl) -phenyl-C1-3-alkylamino group or is optionally replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, -NH or -N(C1-3-alkyl) group;

a C1-4-alkyl group terminally substituted by the group R7, wherein R7 denotes a C5-7-cycloalkyl group, wherein the methylene group in the 4 position of a 6- or 7-membered cycloalkyl group is optionally replaced by an -NH or -N(C1-3-alkyl) group or in a 5- to 7-membered cycloalkyl group a-(CH2)2 group is optionally replaced by a -CO-NH group, a-(CH2)3 group is optionally replaced by a -NH-CO-NH- or a -(CH2)4 group is optionally replaced by a -NH-CO-NH-CO group, wherein in each case a hydrogen atom bound to a nitrogen atom is optionally replaced by a C1-3-alkyl group;

a phenyl or heteroaryl group;
a hydroxy or C1-3-alkoxy group;

an amino, C1-6-alkylamino, di- (C1-6-alkyl) -amino, phenylamino, N-phenyl-C1-3-alkyl-amino, phenyl-C1-3-alkylamino, N- (C1-3-alkyl) -phenyl-C1-3-alkylamino or di- (phenyl-C1-3-alkyl) -amino group;

a w-hydroxy-C2-3-alkyl-amino, N- (C1-3-alkyl) -(o-hydroxy--C2-3-alkyl-amino, di- (.omega.-hydroxy-C2-3-alkyl) -amino, di- (.omega.- (C1-3-alkoxy) -C2-3-alkyl) -amino or N-(dioxolan-2-yl)-C1-3-alkyl-amino group;

a C1-3-alkylcarbonylamino-C2-3-alkyl-amino or C1-3-alkylcarbonylamino-C2-3-alkyl-N- (C1-3-alkyl) -amino group;
a C1-3-alkylsulphonylamino, N-(C1-3-alkyl) -C1-3-alkylsulphonylamino, C1-3-alkylsulphonylamino--C2-3-alkyl-amino or C1-3-alkylsulphonylamino-C2-3-alkyl--N- (C1-3-alkyl) -amino group;

a hydroxycarbonyl-C1-3-alkylamino or N- (C1-3-alkyl) -hydroxycarbonyl-C1-3-alkyl-amino group;

a guanidino group wherein a hydrogen atom is optionally replaced by a C1-3-alkyl group;

a group of formula - N(R8) - CO- (CH2)n-R9 (II), wherein R8 denotes a hydrogen atom or a C1-3-alkyl group;
n denotes 0, 1, 2 or 3 and R9 denotes an amino, C1-3-alkylamino, di-(C1-3-alkyl)-amino, phenylamino, benzylamino or C1-4-alkoxy group, or a 5- to 7-membered cycloalkyleneimino group, wherein the methylene group in position 4 of the cycloalkyleneimino group is optionally replaced by an oxygen or sulphur atom or by an -NH, -N(C1-3-alkyl),-N(phenyl) , -N(C1-3-alkyl-carbonyl) or -N(benzoyl) group, or, if n denotes 1, 2 and 3, R9 is as defined herein or denotes a hydrogen atom;

a group of formula -N(R10)-(CH2)m-(CO)o-R11 (III), wherein R10 denotes a hydrogen atom or a C1-3-alkyl, C1-3-alkylcarbonyl or C1-3-alkylsulphonyl group, m denotes 1, 2 or 3, o is 1 or, if m is 2 and 3, o is 0 or 1 and R11 denotes an amino, C1-3-alkylamino, di-(C1-3-alkyl)-amino, C1-4-alkoxy or C1-3-alkoxy-C1-3-alkoxy group or a 5- to 7-membered cycloalkyleneimino group, wherein the methylene group in position 4 of the cycloalkyleneimino group is optionally replaced by an oxygen or sulphur atom or by an -NH, -N(C1-3-alkyl) , -N(phenyl), -N(C1-3-alkyl-carbonyl) or -N(benzoyl) group;

a C4-7-cycloalkylamino or C4-7-cycloalkenylamino group wherein position 1 of the ring is not involved in the double bond;
or R7, is a 4- to 7-membered cycloalkyleneimino group, wherein the cycloalkylene moiety is optionally fused to a phenyl group or one or two hydrogen atoms is each optionally replaced by a C1-3-alkyl group and/or the methylene group in position 3 of the cycloalkyleneimino group is optionally substituted by a hydroxy or C1-3-alkoxy group, in each case the methylene group in the 4 position of a 6- or 7-membered cycloalkyleneimino group is optionally substituted by a hydroxy, hydroxy-C1-3-alkyl, C1-3-alkoxy, carboxy, C1-3-alkoxycarbonyl, aminocarbonyl, C1-3-alkylaminocarbonyl, di-(C1-3-alkyl)-aminocarbonyl, phenyl-C1-3-alkylamino or N-(C1-3-alkyl)-phenyl-C1-3-alkylamino group or is optionally replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, -NH, -N(C1-3-alkyl), -N(phenyl), -N(phenyl-C1-3-alkyl), -N(C1-3-alkyl-carbonyl) , -N(C1-4-alkoxy-carbonyl), -N(benzoyl) or -N(phenyl-C1-3-alkyl-carbonyl) group, wherein a methylene group linked to an imino-nitrogen atom of the cycloalkyleneimino group is optionally replaced by a carbonyl or sulphonyl group or in a 5- to 6-membered monocyclic cycloalkyleneimino group or a cycloalkyleneimino group fused to a phenyl group, the two methylene groups linked to the imino-nitrogen atom are each optionally replaced by a carbonyl group;

or R6 denotes a C1-4-alkyl group which is terminally substituted by a carboxy, C1-3-alkoxycarbonyl, aminocarbonyl, C1-3-alkylaminocarbonyl or di-(C1-3-alkyl)-aminocarbonyl group or by a 4- to 7-membered cycloalkyleneiminocarbonyl group;

a group of formula -N(R12)-CO-(CH2)p-R13 (IV) wherein R12 denotes a hydrogen atom or a C1-3-alkyl, C5-7-cycloalkyl, phenyl-C1-3-alkyl or heteroaryl-C1-3-alkyl group and p denotes 0, 1, 2 or 3 and R13 assumes the meanings of the abovementioned group R7, or, if p denotes one of the numbers 1, 2 and 3, R13 is as defined herein or denotes a hydrogen atom;

a group of formula -N(R14)-(CH2)q-(CO)r-R15 (V), wherein R14 denotes a hydrogen atom, a C1-4-alkyl group or a C1-3-alkylcarbonyl, phenylcarbonyl, phenyl-C1-3-alkylcarbonyl, heteroarylcarbonyl, heteroaryl-C1-3-alkylcarbonyl, C1-4-alkylsulphonyl, phenylsulphonyl, phenyl-C1-3-alkylsulphonyl, heteroarylsulphonyl or heteroaryl-C1-3-alkyl-sulphonyl group, q denotes 1, 2, 3 or 4, r is 1 or, if q is 2, 3 or 4, r is 0 or 1 and R15 assumes the meanings of the abovementioned group R7;

a group of formula -N(R16)-SO2-R17 (VI), wherein R16 denotes a hydrogen atom or a C1-4-alkyl group optionally terminally substituted by a cyano, trifluoromethyl-carbonylamino or N-(C1-3-alkyl)-trifluoromethyl-carbonyl-amino group and R17 denotes a C1-3-alkyl group; or an amino group substituted by a di-(C1-3-alkyl)-amino-C1-3-alkyl-carbonyl or di-(C1-3-alkyl)-amino-C1-3-alkyl-sulphonyl group and a di-(C1-3-alkyl)-aminocarbonyl-C1-3-alkyl group, wherein all the single-bonded or fused phenyl groups contained in the groups mentioned under R6 are optionally mono- or disubstituted by fluorine, chlorine or bromine atoms or by C1-3-alkyl, trifluoromethyl, hydroxy, C1-3-alkoxy, carboxy, C1-3-alkoxycarbonyl, aminocarbonyl, C1-3-alkyl-aminocarbonyl, aminosulphonyl, C1-3-alkyl-aminosulphonyl, nitro or cyano groups, wherein the substituents are identical or different, or two adjacent hydrogen atoms of the phenyl groups are optionally replaced by a methylenedioxy group; and R5 denotes a hydrogen atom or a C1-3-alkyl group;

wherein, by a heteroaryl group as mentioned above is meant a pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, furyl, thienyl, oxazolyl, thiazolyl, pyrazolyl, imidazolyl or triazolyl group optionally substituted in the carbon skeleton by a C1-3-alkyl group wherein a hydrogen atom bound to a nitrogen atom is optionally replaced by a C1-3-alkyl or phenyl-C1-3-alkyl group and wherein the 5-membered heteroaryl groups containing at least one imino group are bound via a carbon or nitrogen atom;

wherein a hydrogen atom bound to a nitrogen atom in the abovementioned groups is optionally replaced by hydroxyl, benzoyl, pyridinoyl, formyl, acetyl, propionyl, butanoyl, pentanoyl, hexanoyl, allyloxycarbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert.butoxycarbonyl, pentoxycarbonyl, hexyloxycarbonyl, octyloxycarbonyl, nonyloxycarbonyl, decyloxycarbonyl, undecyloxycarbonyl, dodecyloxycarbonyl, hexadecyloxycarbonyl, benzyloxycarbonyl, phenylethoxycarbonyl, phenylpropoxycarbonyl, C1-3-alkylsulphonyl-C2-4-alkoxycarbonyl, C1-3-alkoxy-C2-4-alkoxy-C2-4-alkoxycarbonyl or an R e CO-O-(R f CR g)-O-CO group wherein R e denotes a C1-8-alkyl, C5-7-cycloalkyl, phenyl or phenyl -C1-3-alkyl group, R f denotes a hydrogen atom or a C1-3-alkyl, C5-7-cycloalkyl or phenyl group and R g denotes a hydrogen atom or a C1-3-alkyl, or wherein an amino nitrogen optionally forms part of a phthalimido group;

and wherein any carboxy group contained in the abovementioned groups is optionally replaced by a tert.butoxycarbonyl group, and wherein some or all of the hydrogen atoms in the abovementioned alkyl and alkoxy groups or in the alkyl moieties contained in the above-defined groups of formula I
optionally replaced by fluorine atoms.
3. A compound, tautomer or salt according to claim 1, wherein:

X denotes an oxygen atom;
R1 denotes a hydrogen atom;

R2 denotes a carboxy group, a straight-chain or branched C1-4-alkoxycarbonyl group or a phenoxycarbonyl group;

a straight-chain or branched C1-3-alkoxy-carbonyl group, which is terminally substituted in the alkyl moiety by a phenyl, carboxy, C1-3-alkoxycarbonyl, aminocarbonyl, C1-3-alkylaminocarbonyl or di-(C1-3-alkyl)-aminocarbonyl group;

a straight-chain or branched C2-3-alkoxy-carbonyl group which is terminally substituted in the alkyl moiety by a hydroxy, C1-3-alkoxy, amino, C1-3-alkylamino or di-(C1-3-alkyl)-amino group; or an aminocarbonyl or methylaminocarbonyl group, or an ethylaminocarbonyl group optionally substituted in the 2 position of the ethyl group by a hydroxy or C1-3-alkoxy group or, if R4 denotes something other than an aminosulphonyl-phenyl or N-(C1-5-alkyl)-C1-3-alkylaminocarbonyl-phenyl group, the optional substituent further optionally denotes a di-(C1-2-alkyl)-aminocarbonyl group;

R3 denotes a C1-4-alkyl group or a phenyl group which is optionally substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C1-3-alkyl, hydroxy or C1-3-alkoxy group;

R4 denotes a C5-6-cycloalkyl group, wherein the methylene group in position 4 of the C5-C6 cycloalkyl group when the C5-C6 cycloalkyl group is a cyclohexyl group is optionally substituted by an amino, C1-3-alkylamino or di-(C1-3-alkyl)-amino group or is optionally replaced by an -NH or -N(C1-3-alkyl) group;

a phenyl group, a phenyl group disubstituted by C1-3-alkyl, C1-3-alkoxy or nitro groups, wherein the substituents are identical or different;

or a phenyl group substituted by the group R6, which is optionally further substituted by a fluorine, chlorine or bromine atom or by an amino or nitro group, wherein R6 denotes a fluorine, chlorine or bromine atom;
a C1-3-alkyl, C1-3-alkoxy, nitro, amino or C5-6-cycloalkyl group;

a pyrrolyl, pyrazolyl, imidazolyl, triazolyl or tetrazolyl group bound via a carbon atom, wherein the abovementioned heteroaromatic groups in the carbon skeleton are optionally substituted by a C1-3-alkyl group or a hydrogen atom bound to a nitrogen atom is optionally replaced by a C1-3-alkyl or phenyl-C1-3-alkyl group;

a group of formula a carboxy, C1-4-alkoxycarbonyl, phenyl-C1-3-alkylamino-carbonyl or C5-7-cycloalkyl-carbonyl group;

a 5 or 6-membered cycloalkyleneimino group, wherein the methylene group in position 4 of the cycloalkyleneimino group is optionally replaced by an oxygen or sulphur atom or by an -NH or -N(C1-3-alkyl) group;

an unbranched C1-3-alkyl group terminally substituted by the group R7, wherein R7 denotes a C5-7-cycloalkyl group;
wherein in a 5 or 6-membered cycloalkyl group a -(CH2)2 group is optionally replaced by a -CO-NH group, a -(CH2)3 group is optionally replaced by an -NH-CO-NH- or a -(CH2)4 group is optionally replaced by an -NH-CO-NH-CO
group, wherein in each case a hydrogen atom bound to a nitrogen atom is optionally replaced by a C1-3-alkyl group;

a phenyl or pyridinyl group or a pyrrolyl, pyrazolyl, imidazolyl or triazolyl group bound via a carbon or nitrogen atom, wherein the pyridinyl, pyrrolyl, pyrazolyl, imidazolyl and triazolyl groups in the carbon skeleton are optionally substituted by a C1-3-alkyl group or a hydrogen atom bound to a nitrogen atom is optionally replaced by a C1-3-alkyl group;
a hydroxy or C1-3-alkoxy group;

an amino, C1-6-alkylamino, di-(C1-6-alkyl)-amino, phenylamino, N-phenyl-C1-3-alkylamino, phenyl-C1-3-alkylamino or N-(C1-3-alkyl)-phenyl-C1-3-alkylamino group;

a .omega.-hydroxy-C2-3-alkyl-amino, N-(C1-3-alkyl)-.omega.-hydroxy-C2-3-alkylamino, di-(.omega.-hydroxy-C2-3-alkyl)-amino or di-(.omega.-(C1-3-alkoxy)-C2-3-alkyl)-amino group;
a C1-3-alkylcarbonylamino-C2-3-alkyl-amino or C1-3-alkylcarbonylamino-C2-3-alkyl-N-(C1-3-alkyl)-amino group;
a C1-3-alkylsulphonylamino, N-(C1-3-alkyl)-C1-3-alkylsulphonylamino, C1-3-alkylsulphonylamino-C2-3-alkylamino or C1-3-alkylsulphonylamino-C2-3-alkyl-N-(C1-3-alkyl)-amino group;

a hydroxycarbonyl-C1-3-alkylamino or N-(C1-3-alkyl)-hydroxycarbonyl-C1-3-alkyl-amino group;

a guanidino group wherein a hydrogen atom is optionally replaced by a C1-3-alkyl group;

a group of formula -N(R8)-CO-(CH2)n-R9 (II), wherein R8 denotes a hydrogen atom or a C1-3-alkyl group, n denotes 0, 1, 2 or 3 and R9 denotes an amino, C1-3-alkylamino, di- (C1-3-alkyl)-amino or C1-4-alkoxy group, a 5- or 6-membered cycloalkyleneimino group, wherein the methylene group in position 4 of the cycloalkyleneimino group is optionally replaced by an -NH, -N(C1-3-alkyl) or -N(C1-3-alkyl-carbonyl) group, or, if n denotes 1, 2 or 3, R9 is as defined herein or R9 denotes a hydrogen atom;

a group of formula -N(R10)-(CH2)m-(CO)o-R11 (III), wherein R10 denotes a hydrogen atom or a C1-3-alkyl group, m denotes 1, 2 or 3, o denotes 1 or, if m is 2 or 3, o denotes 0 or 1 and R11 denotes an amino, C1-3-alkylamino, di-(C1-3-alkyl)-amino, C1-4-alkoxy or methoxy-C1-3-alkoxy group or a 5-or 6-membered cycloalkyleneimino group, wherein the methylene group in position 4 of the cycloalkyleneimino group is optionally replaced by an -NH, -N(C1-3-alkyl) or -N(C1-3-alkyl-carbonyl) group;

or an azetidino, pyrrolidino, piperidino, 2,6-dimethyl-piperidino, 3,5-dimethyl-piperidino or azepino group, wherein the methylene group in position 3 of the pyrrolidino group is optionally substituted by a hydroxy group, the methylene group in position 4 of the piperidino group is optionally substituted by a hydroxy, hydroxy-C1-3-alkyl or C1-3-alkoxy group or is optionally replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, -NH, -N(C1-3-alkyl), -N(C1-3-alkyl-carbonyl), -N(benzoyl) or -N(phenyl-C1-3-alkyl-carbonyl) group, wherein a methylene group linked to an imino-nitrogen atom of the pyrrolidino, piperidino or azepino group is optionally replaced by a carbonyl group;

or R6 denotes a straight-chain C1-3-alkyl group which is terminally substituted by a carboxy or C1-3-alkoxy-carbonyl group;

a group of formula -N(R12)-CO-(CH2)p-R13 (IV), wherein R12 denotes a hydrogen atom, a C1-3-alkyl or phenyl-C1-3-alkyl group, p denotes 0, 1 or 2 and R13 denotes an amino, C1-4-alkylamino, di-(C1-4-alkyl)-amino, benzylamino, N-(C1-3-alkyl)-benzylamino, C1-3-alkoxy-C1-3-alkylamino, N-(C1-3-alkyl)-C1-3-alkoxy-C1-3-alkylamino, di-(2-methoxy-ethyl)-amino, di- (.omega.-hydroxy-C2-3-alkyl)-amino or aminocarbonyl-methyl-N-(methyl)-amino group, a pyrrolyl, pyrazolyl or imidazolyl group bound via a nitrogen atom and optionally substituted by a C1-3-alkyl group, or a pyrrolidino, piperidino, morpholino, thiomorpholino or a piperazino group optionally substituted in the 4 position by a C1-3-alkyl, phenyl-C1-3-alkyl, C1-3-alkylcarbonyl or C1-4-alkoxycarbonyl group or, if p denotes 1 or 2, R13 is as defined herein or denotes a hydrogen atom;

a group of formula -N(R14)-(CH2)q-(CO)r-R15 (V), wherein R14 denotes a hydrogen atom or a C1-4-alkyl, C1-3-alkyl-carbonyl, phenylcarbonyl, phenyl-C1-3-alkylcarbonyl, furyl-carbonyl, pyridinyl-carbonyl, furyl-C1-3-alkylcarbonyl, pyridinyl-C1-3-alkylcarbonyl, C1-4-alkylsulphonyl, phenylsulphonyl or phenyl-C1-3-alkylsulphonyl group, q denotes 1, 2 or 3, r denotes 1 or, if q is 2 or 3, r denotes 0 or 1 and R15 denotes an amino, C1-4-alkylamino, di-(C1-4-alkyl)-amino, phenylamino, N-(C1-4-alkyl)-phenylamino, benzylamino or N-(C1-4-alkyl)-benzylamino group;

or a group of formula -N(R16)-SO2-R17 (VI), wherein R16 denotes a hydrogen atom or a C1-3-alkyl group optionally terminally substituted by a cyano, trifluoromethyl-carbonylamino or N-(C1-3-alkyl)-trifluoromethyl-carbonyl-amino group and R17 denotes a C1-3-alkyl group, and R5 denotes a hydrogen atom, wherein a hydrogen atom bound to a nitrogen atom in the abovementioned groups is optionally replaced by an acetyl or tert.butoxycarbonyl group, and the carboxy groups contained in the abovementioned groups are optionally replaced with a tert.butoxycarbonyl group.
4. A compound, tautomer or salt according to claim 1, wherein:

X denotes an oxygen atom, R1 and R5 each denote a hydrogen atom, R2 denotes a methoxycarbonyl, ethoxycarbonyl or aminocarbonyl group, R3 denotes a phenyl group and R4 denotes a phenyl group monosubstituted by the group R6, wherein R6 denotes an N-methyl-imidazol-2-yl group, an unbranched C1-3-alkyl group which is terminally substituted by a C1-4-alkylamino, di-(C1-4-alkyl)-amino, piperidino or 2,6-dimethyl-piperidino group;

a group of formula -N(R12)-CO-(CH2)p-R13 (IV), wherein R12 denotes a C1-3-alkyl group, p denotes 1 or 2 and R13 denotes a di-(C1-3-alkyl)-amino group;
or a group of formula -N(R14)-(CH2)q-(CO)r-R15 (V), wherein R14 denotes a C1-3-alkyl-carbonyl or C1-3-alkylsulphonyl group, q denotes 1, 2 or 3, r denotes 1 or, if q is 2 or 3, r is 0 or 1 and R15 denotes a di-(C1-3-alkyl)-amino group.
5. 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, or a tautomer or pharmaceutically acceptable salt thereof.
6. 3-Z-[(1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone, or a tautomer or pharmaceutically acceptable salt thereof.
7. 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a tautomer or pharmaceutically acceptable salt thereof.
8. 3-Z-[1-(4-(dimethylaminomethyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, or a tautomer or pharmaceutically acceptable salt thereof.
9. 3-Z-[1-(4-((2,6-dimethyl-piperidin-1-yl)-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, or a tautomer or pharmaceutically acceptable salt thereof.
10. 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-acetyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, or a tautomer or pharmaceutically acceptable salt thereof.
11. 3-Z-[1-(4-(N-(3-dimethylamino-propyl)-N-acetyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, or a tautomer or pharmaceutically acceptable salt thereof.
12. 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, or a tautomer or pharmaceutically acceptable salt thereof.
13. 3-Z-[1-(4-(dimethylaminomethyl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a tautomer or pharmaceutically acceptable salt thereof.
14. 3-Z-[1-(4-(N-acetyl-N-dimethylaminocarbonylmethyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a tautomer or pharmaceutically acceptable salt thereof.
15. 3-Z-[1-(4-ethylaminomethyl-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a tautomer or pharmaceutically acceptable salt thereof.
16. 3-Z-[1-(4-(1-methyl-imidazol-2-yl)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a tautomer or pharmaceutically acceptable salt thereof.
17. 3-Z-[1-(4-(N-dimethylaminomethylcarbonyl-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a tautomer or pharmaceutically acceptable salt thereof.
18. 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a tautomer or pharmaceutically acceptable salt thereof.
19. 3-Z-[1-(4-(N-(3-dimethylamino-propyl)-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a tautomer or pharmaceutically acceptable salt thereof.
20. 3-Z-[1-(4-(N-dimethylaminocarbonylmethyl-N-methylsulphonyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a tautomer or pharmaceutically acceptable salt thereof.
21. 3-Z-[1-(4-(N-((2-dimethylamino-ethyl)-carbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a tautomer or pharmaceutically acceptable salt thereof.
22. 3-Z-[1-(4-(N-(2-dimethylamino-ethyl)-N-acetyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a tautomer or pharmaceutically acceptable salt thereof.
23. 3-Z-[1-(4-methylaminomethyl-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a tautomer or pharmaceutically acceptable salt thereof.
24. 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a tautomer or pharmaceutically acceptable salt thereof.
25. A pharmaceutical composition comprising a compound or salt according to any one of claims 1 to 24 and a pharmaceutically acceptable carrier or diluent.
26. A pharmaceutical composition according to claim 25 for treating excessive or anomalous cell proliferation.
27. Process for preparing a pharmaceutical composition according to claim 25 or 26, wherein a compound or salt according to any one of claims 1 to 24 is admixed with a pharmaceutically acceptable carrier or diluent.
28. Use of a compound or salt according to any one of claims 1 to 24 in manufacture of a medicament for treatment of excessive or anomalous cell proliferation.
29. Use of a compound or salt according to any one of claims 1 to 24 for treatment of excessive or anomalous cell proliferation.
30. A compound or salt according to any one of claims 1 to 24 for treatment of excessive or anomalous cell proliferation.
31. A process for preparing a compound according to claim 1, wherein:

a. a compound of general formula wherein X and R3 are defined as in claim 1, R2' has the meaning given for R2 in claim 1, R18 denotes a hydrogen atom or a protecting group for the nitrogen atom of the lactam group, wherein one of the groups R2' and R18 optionally denotes a bond to a solid phase optionally formed via a spacer and the other one of the groups R2' and R18 has the abovementioned meanings, and Z1 denotes a halogen atom, a hydroxy, alkoxy or aryl-alkoxy group, is reacted with an amine of general formula wherein R4 and R5 are defined as in claim 1, and subsequently, if a protecting group is present, any protecting group used for protecting the nitrogen atom of the lactam group is cleaved or a compound thus obtained is cleaved from a solid phase, or b. in order to prepare a compound of general formula I wherein R2 has the meanings given in claim 1, with the exception of the carboxy group, a compound of general formula wherein R1 and R3 to R5 are defined as in claim 1, is reacted with a compound of general formula H - R19 (X), wherein R19 denotes a C1-6-alkanol, a C4-7-cycloalkanol or an aromatic alcohol, a C1-6-alkanol which is terminally substituted in the alkyl moiety by a phenyl, heteroaryl, carboxy, C1-3-alkoxy-carbonyl, aminocarbonyl, C1-3-alkylamino-carbonyl or di-(C1-3-alkyl)-aminocarbonyl group, a C2-6-alkanol which is terminally substituted in the alkyl moiety by a chlorine atom or a hydroxy, C1-3-alkoxy, amino, C1-3-alkylamino or di-(C1-3-alkyl)-amino group, or an amino or methylamino group, or an ethylamino group optionally substituted in the 2 position of the ethyl group by a hydroxy or C1-3-alkoxy group or a di-(C1-2-alkyl)-amino group, or c. in order to prepare a compound of general formula I, wherein R6 denotes a C1-4-alkyl group substituted by the group R7, wherein R7 denotes an amino, C1-7-alkylamino, di-(C1-7-alkyl)-amino, phenylamino, N-phenyl-C1-3-alkyl-amino, phenyl-C1-3-alkylamino, N-(C1-3-alkyl)-phenyl-C1-3-alkylamino or di-(phenyl-C1-3-alkyl)-amino group;

a .omega.-hydroxy-C2-3-alkyl-amino, N-(C1-3-alkyl)-.omega.-hydroxy-C2-3-alkyl-amino, di-(.omega.-hydroxy-C2-3-alkyl)-amino, di-(.omega.-(C1-3-alkoxy)-C2-3-alkyl)-amino or N- (dioxolan-2-yl)-C1-3-alkyl-amino group;

a C1-3-alkylcarbonylamino-C2-3-alkyl-amino or C1-3-alkylcarbonylamino-C2-3-alkyl-N-(C1-3-alkyl)-amino group;
a C1-3-alkylsulphonylamino, N-(C1-3-alkyl)-C1-3-alkylsulphonylamino, C1-3-alkylsulphonylamino-C2-3-alkyl-amino or C1-3-alkylsulphonylamino-C2-3-alkyl-N-(C1-3-alkyl)-amino group;

a group of formula -N(R10)-(CH2)m-(CO)o-R11 (III), wherein R10 denotes a hydrogen atom, a C1-3-alkyl group, a C1-3-alkylcarbonyl, arylcarbonyl, phenyl-C1-3-alkylcarbonyl, C1-3-alkylsulphonyl, arylsulphonyl or phenyl-C1-3-alkylsulphonyl group, m denotes 1, 2, 3 or 4, o denotes 1 and R11 denotes an amino, C1-4-alkylamino, di-(C1-4-alkyl)-amino, phenylamino, N-(C1-4-alkyl)-phenylamino, benzylamino, N-(C1-4-alkyl)-benzylamino, C1-4-alkoxy or C1-3-alkoxy-C1-3-alkoxy group, a di-(C1-4-alkyl)-amino-C1-3-alkylamino group optionally substituted in the 1 position by a C1-3-alkyl group, or a 4- to 7-membered cycloalkyleneimino group, wherein the cycloalkylene moiety is optionally fused to a phenyl ring or in each case the methylene group in the 4 position of a 6- or 7-membered cycloalkyleneimino group is optionally replaced by an oxygen or sulphur atom, by a sulphinyl, sulphonyl, -NH, -N(C1-3-alkyl), -N(phenyl), -N(C1-3-alkyl-carbonyl) or -N(benzoyl) group;

a C4-7-cycloalkylamino, C4-7-cycloalkyl-C1-3-alkylamino or C4-7-cycloalkenylamino group wherein position 1 of the ring is not involved in the double bond and wherein the abovementioned groups are each optionally additionally be substituted at the amino-nitrogen atom by a C5-7-cycloalkyl, C2-4-alkenyl or C1-4-alkyl group;

or a 4- to 7-membered cycloalkyleneimino group, wherein the cycloalkylene moiety is optionally fused to a phenyl group or to an oxazolo, imidazolo, thiazolo, pyridino, pyrazino or pyrimidino group optionally substituted by a fluorine, chlorine, bromine or iodine atom or by a nitro, C1-3-alkyl, C1-3-alkoxy or amino group, and/or one or two hydrogen atoms are each optionally replaced by a C1-3-alkyl, C5-7-cycloalkyl or phenyl group and/or the methylene group in the 3 position of a 5-membered cycloalkyleneimino group is optionally substituted by a hydroxy, hydroxy-C1-3-alkyl, C1-3-alkoxy or C1-3-alkoxy-C1-3-alkyl group, in each case the methylene group in the 3 or 4 position of a 6- or 7-membered cycloalkyleneimino group is optionally substituted by a hydroxy, hydroxy-C1-3-alkyl, C1-3-alkoxy, C1-3-alkoxy-C1-3-alkyl, C1-4-alkoxycarbonyl, aminocarbonyl, C1-3-alkylaminocarbonyl, di-(C1-3-alkyl)-aminocarbonyl, phenyl-C1-3-alkylamino or N-(C1-3-alkyl)-phenyl-C1-3-alkylamino group or is optionally replaced by an oxygen or sulphur atom or by a sulphinyl, sulphonyl, -NH, -N(C1-3-alkyl-), -N(phenyl), -N(phenyl-C1-3-alkyl-), -N(C1-3-alkyl-carbonyl-), -N(C1-4-alkoxy-carbonyl-), -N(benzoyl-) or -N(phenyl-C1-3-alkyl-carbonyl-) group, wherein a methylene group linked to an imino-nitrogen atom of the cycloalkyleneimino group is optionally replaced by a carbonyl or sulphonyl group or in a 5- to 7-membered monocyclic cycloalkyleneimino group or a cycloalkyleneimino group fused to a phenyl group the two methylene groups linked to the imino-nitrogen atom are optionally each replaced by a carbonyl group, a compound of general formula wherein R3, R5 and X are defined as in claim 1, R2' has the meaning given for R2 in claim 1, R18 denotes a hydrogen atom or a protecting group for the nitrogen atom of the lactam group, wherein one of the groups R2' and R18 also optionally denotes a bond to a solid phase optionally formed via a spacer and the other one of the groups R2' and R18 has the abovementioned meanings, A
denotes a C1-4-alkyl group and Z2 denotes a leaving group, is reacted with an amine of general formula H-R7, (XII) wherein R7, has the meaning given for R7 hereinbefore, and subsequently, if a protecting group is present, any protecting group used for protecting the nitrogen atom of the lactam group is cleaved, or a compound thus obtained is cleaved from a solid phase, and subsequently, optionally, a compound of general formula I
thus obtained which contains an alkoxycarbonyl group is converted by hydrolysis into a corresponding carboxy compound, or a compound of general formula I thus obtained which contains an amino or alkylamino group is converted by reductive alkylation into a corresponding alkylamino or dialkylamino compound, or a compound of general formula I thus obtained which contains an amino or alkylamino group is converted by acylation or sulphonation into a corresponding acyl or sulphonyl compound, or a compound of general formula I thus obtained which contains a carboxy group is converted by esterification or amidation into a corresponding ester or aminocarbonyl compound, or a compound of general formula I thus obtained which contains a cycloalkyleneimino group wherein a methylene group is replaced by a sulphur atom is converted by oxidation into a corresponding sulphinyl or sulphonyl compound, or a compound of general formula I thus obtained which contains a nitro group is converted by reduction into a corresponding amino compound, or a compound of general formula I thus obtained wherein R4 denotes a phenyl group substituted by an amino, alkylamino, aminoalkyl or N-alkyl-amino group is converted, by reaction with a corresponding cyanate, isocyanate or carbamoyl halide, into a corresponding urea compound of general formula I, or a compound of general formula I thus obtained wherein R4 denotes a phenyl group substituted by an amino, alkylamino, aminoalkyl or N-alkyl-amino group is converted, by reaction with a corresponding compound which transfers the amidino group or by reaction with a corresponding nitrile, into a corresponding guanidino compound of general formula I, and any protecting group used during the reactions to protect reactive groups is cleaved.
32. The compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone.
33. A pharmaceutically acceptable salt of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone.
34. A pharmaceutical composition comprising the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
35. A pharmaceutical composition comprising the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a pharmaceutically acceptable salt thereof, and a fatty substance.
36. The pharmaceutical composition according to claim 35, wherein the fatty substance is a hard fat.
37. The pharmaceutical composition according to claim 34, which is formulated as a tablet.
38. The pharmaceutical composition according to claim 34, which is formulated as a capsule.
39. The pharmaceutical composition according to claim 34, 35, 36, 37 or 38, which is for use in the treatment of excessive or anomalous cell proliferation.
40. The pharmaceutical composition according to claim 39, wherein the cell is a tumour cell.
41. The pharmaceutical composition according to claim 34, 35, 36, 37 or 38, which is for use in the treatment of lung cancer, ovarian cancer, prostate cancer, colorectal carcinoma, urogenital cancer or a fibrotic disease.
42. Use of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a pharmaceutically acceptable salt thereof, for the treatment of excessive or anomalous cell proliferation.
43. Use according to claim 42, wherein the cell is a tumour cell.
44. Use of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a pharmaceutically acceptable salt thereof, for the treatment of lung cancer.
45. Use of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a pharmaceutically acceptable salt thereof, for the treatment of ovarian cancer.
46. Use of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a pharmaceutically acceptable salt thereof, for the treatment of prostate cancer.
47. Use of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-l-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a pharmaceutically acceptable salt thereof, for the treatment of colorectal carcinoma.
48. Use of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a pharmaceutically acceptable salt thereof, for the treatment of urogenital cancer.
49. Use of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a pharmaceutically acceptable salt thereof, for the treatment of a fibrotic disease.
50. Use according to claim 42, 43, 44, 45, 46, 47, 48 or 49, wherein the treatment further comprises simultaneous or sequential use with another compound that is pharmacologically active.
51. Use according to claim 42, 43, 44, 45, 46, 47, 48 or 49, wherein the treatment further comprises simultaneous or sequential use with another compound which is an anti-tumour therapeutic agent, or with radiotherapy.
52. Use according to claim 51, wherein the anti-tumour therapeutic agent is a topoisomerase inhibitor, a mitosis inhibitor, a compound that interacts with a nucleic acid, a hormone antagonist, an inhibitor of a metabolic process, a cytokine, a kinase inhibitor or an antibody.
53. Use according to claim 51, wherein the anti-tumour therapeutic agent is etoposide, vinblastin, taxol, cis-platin, cyclophosphamide, adriamycin, tamoxifin, 5-FU or interferon.
54. Use of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of lung cancer, ovarian cancer, prostate cancer, colorectal carcinoma, urogenital cancer or a fibrotic disease.
CA002387013A 1999-10-13 2000-10-09 6-position substituted indolinones, the preparation thereof and their use as pharmaceutical compositions Expired - Lifetime CA2387013C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19949208.5 1999-10-13
DE19949208A DE19949208A1 (en) 1999-10-13 1999-10-13 New 3-(amino-methylene)-2-indolinone derivatives are kinase inhibitors and cell proliferation inhibitors useful e.g. for treating tumors, metastasis, rheumatoid arthritis or psoriasis
DE2000142696 DE10042696A1 (en) 2000-08-31 2000-08-31 New 3-(amino-methylene)-2-indolinone derivatives are kinase inhibitors and cell proliferation inhibitors useful e.g. for treating tumors, metastasis, rheumatoid arthritis or psoriasis
DE10042696.4 2000-08-31
PCT/EP2000/009867 WO2001027081A1 (en) 1999-10-13 2000-10-09 6-position substituted indoline, production and use thereof as a medicament

Publications (2)

Publication Number Publication Date
CA2387013A1 CA2387013A1 (en) 2001-04-19
CA2387013C true CA2387013C (en) 2009-12-29

Family

ID=26006858

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002387013A Expired - Lifetime CA2387013C (en) 1999-10-13 2000-10-09 6-position substituted indolinones, the preparation thereof and their use as pharmaceutical compositions

Country Status (42)

Country Link
EP (2) EP2157081A1 (en)
JP (2) JP4021664B2 (en)
KR (2) KR100835546B1 (en)
CN (1) CN100455568C (en)
AR (1) AR026036A1 (en)
AT (1) ATE439342T1 (en)
AU (1) AU781939B2 (en)
BE (1) BE2015C018I2 (en)
BG (1) BG65983B1 (en)
BR (1) BRPI0014735B8 (en)
CA (1) CA2387013C (en)
CO (1) CO5261488A1 (en)
CY (2) CY1110067T1 (en)
CZ (1) CZ301073B6 (en)
DE (1) DE50015711D1 (en)
DK (1) DK1224170T5 (en)
EA (1) EA006080B1 (en)
EE (1) EE05427B1 (en)
EG (1) EG25931A (en)
ES (1) ES2331459T3 (en)
FR (1) FR15C0024I2 (en)
HK (1) HK1052505B (en)
HR (1) HRP20020306B1 (en)
HU (2) HU230416B1 (en)
IL (2) IL148756A0 (en)
LU (1) LU92681I2 (en)
ME (1) MEP45408A (en)
MX (1) MXPA02002799A (en)
MY (1) MY127956A (en)
NL (1) NL300725I2 (en)
NO (3) NO322746B1 (en)
NZ (1) NZ518489A (en)
PE (1) PE20010671A1 (en)
PL (1) PL207445B1 (en)
PT (1) PT1224170E (en)
RS (1) RS51013B (en)
SA (1) SA01210704B1 (en)
SI (1) SI1224170T1 (en)
SK (1) SK287312B6 (en)
TW (1) TWI268922B (en)
UA (1) UA75054C2 (en)
WO (1) WO2001027081A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9040555B2 (en) 2012-01-26 2015-05-26 Angion Biomedica Corp. Antifibrotic compounds and uses thereof

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816624A1 (en) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Novel substituted indolinones, their preparation and their use as pharmaceuticals
ES2318649T3 (en) 2000-10-20 2009-05-01 EISAI R&D MANAGEMENT CO., LTD. PROCEDURE FOR PREPARATION OF DERIVATIVES OF 4-FENOXI QUINOLINAS.
US6638965B2 (en) 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
DE10117204A1 (en) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma Indolinones substituted in the 6-position, their preparation and their use as medicaments
JP2004537542A (en) 2001-06-29 2004-12-16 アブ サイエンス Use of a tyrosine kinase inhibitor for treating inflammatory bowel disease (IBD)
US20030091974A1 (en) * 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
JP2005500041A (en) 2001-06-29 2005-01-06 アブ サイエンス Potent, selective and non-toxic C-KIT inhibitor
EP1401413B1 (en) 2001-06-29 2006-11-22 AB Science Use of tyrosine kinase inhibitions for treating allergic diseases
DE60227709D1 (en) * 2001-06-29 2008-08-28 Ab Science THE USE OF C-CRITERIA FOR THE TREATMENT OF AUTOIMMUNE DISEASES
DE60212627T2 (en) 2001-06-29 2007-06-14 Ab Science Use of tyrosine kinase inhibitors for the treatment of inflammatory diseases
WO2003027102A1 (en) * 2001-09-27 2003-04-03 Allergan, Inc. 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2002360753B2 (en) 2001-12-27 2008-08-21 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
SE0302546D0 (en) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
ITBO20020198A1 (en) * 2002-04-12 2003-10-13 Univ Bologna DERIVATIVES 2, 5 BIS DIAMMINO 1, 4 BENZOCHENIONIC USEFUL FOR THE TREATMENT OF ALZHEIMER DISEASE, METHOD FOR THEIR PREPARATION AND
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
DE10233500A1 (en) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z- [1- (4- (N - ((4-methyl-piperazin-1-yl) -methylcarbonyl) -N-methyl-amino) -anilino) -1-phenyl-methylene] -6-methoxycarbonyl- 2-indolinone monoethanesulfonate and its use as a medicament
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (en) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Treating immunological (or related) diseases, e.g. inflammatory bowel disease, rheumatoid arthritis or psoriasis, comprises administration of 3-methylene-2-indolinone derivative or quinazoline compound
US7148249B2 (en) * 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
JP4879492B2 (en) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド Kinase inhibitors for the treatment of diseases
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
CN101337930B (en) 2003-11-11 2010-09-08 卫材R&D管理有限公司 Urea derivative preparation process
SE0401790D0 (en) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP2364699A1 (en) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
PE20060777A1 (en) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
WO2007015578A1 (en) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
WO2007057397A1 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
EP1870400A1 (en) * 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
KR101472600B1 (en) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 Antitumor agent for undifferentiated gastric cancer
CA2676796C (en) 2007-01-29 2016-02-23 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
WO2008152013A1 (en) * 2007-06-12 2008-12-18 Boehringer Ingelheim International Gmbh Indolinone derivatives and their use in treating disease-states such as cancer
ES2435454T3 (en) 2007-06-21 2013-12-19 Janssen Pharmaceutica, N.V. Indolin-2-one and aza-indolin-2-one
WO2009060945A1 (en) 2007-11-09 2009-05-14 Eisai R & D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
PE20091445A1 (en) * 2007-12-03 2009-10-19 Boehringer Ingelheim Int INDOLINONE DERIVATIVES AND PROCEDURE FOR ITS MANUFACTURE
WO2009071523A1 (en) 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Process for the manufacture of an indolinone derivative
DK2293795T3 (en) 2008-06-06 2015-10-19 Boehringer Ingelheim Int Pharmaceutical combination.
TW201011002A (en) 2008-07-29 2010-03-16 Boehringer Ingelheim Int New compounds
EP2387401A1 (en) 2009-01-14 2011-11-23 Boehringer Ingelheim International GmbH Method for treating colorectal cancer
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
US20120142703A1 (en) 2009-05-14 2012-06-07 Boehringer Ingelheim International Gmbh New combination therapy in treatment of oncological and fibrotic diseases
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
EP2586443B1 (en) 2010-06-25 2016-03-16 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
WO2012068441A2 (en) 2010-11-19 2012-05-24 Ratiopharm Gmbh Intedanib salts and solid state forms thereof
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
ES2705950T3 (en) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarkers to predict and assess the responsiveness of subjects with thyroid and kidney cancer to lenvatinib compounds
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
CA2890207A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
AU2013337264B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
US9642851B2 (en) 2012-12-06 2017-05-09 Kbp Biosciences Co., Ltd. Indolinone derivative as tyrosine kinase inhibitor
CN104755463A (en) 2012-12-21 2015-07-01 卫材R&D管理有限公司 Amorphous form of quinoline derivative, and method for producing same
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
MX368099B (en) 2013-05-14 2019-09-19 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds.
CN104003925B (en) * 2013-06-05 2016-03-30 四川大学 Oxindole compounds or derivatives thereof and uses thereof
WO2015009889A1 (en) * 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
JO3783B1 (en) 2014-08-28 2021-01-31 Eisai R&D Man Co Ltd Highly pure quinoline derivative and method for producing the same
CN104262232B (en) * 2014-09-09 2016-05-04 苏州明锐医药科技有限公司 The preparation method of Ni Taidani
DK3263106T3 (en) 2015-02-25 2024-01-08 Eisai R&D Man Co Ltd PROCESS FOR SUPPRESSING BITTERNESS OF QUINOLINE DERIVATIVES
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
WO2016178064A1 (en) 2015-05-06 2016-11-10 Suven Life Sciences Limited Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
CN104844499B (en) * 2015-06-05 2017-03-08 北京康立生医药技术开发有限公司 One kettle way prepares the synthetic method of Nintedanib
WO2016200688A1 (en) 2015-06-06 2016-12-15 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
CN107801379B (en) 2015-06-16 2021-05-25 卫材R&D管理有限公司 Anticancer agent
CN105126909B (en) * 2015-07-13 2018-01-23 淮海工学院 Application of the immobilized palladium catalyst in the synthesis of the nitrobenzene methyl of 4 phenylacetylene base 3
CZ308695B6 (en) 2015-07-29 2021-03-03 Zentiva, K.S. Process for preparing methyl (Z) -3 - [[4- [methyl [2- (4-methyl-1-piperazinyl) acetyl] amino] phenyl] amino] phenylmethylene) -oxindole-6-carboxylate (intedanib, nintedanib)
CN106467500A (en) * 2015-08-14 2017-03-01 廊坊百瑞化工有限公司 A kind of one pot synthesis synthesize the new method of Nintedanib key intermediate
KR20180128390A (en) 2015-12-24 2018-12-03 레스피버트 리미티드 Indolinone compounds and their use in the treatment of fibrotic diseases
CZ2016104A3 (en) 2016-02-24 2017-09-06 Zentiva, K.S. Crystalline modifications of methyl (3Z)-3- {[(4-{methyl[(4-methylpiperazin-1yl)acetyl]amino}phenyl)amino](phenyl)methylidene}-2oxo-2,3-dihydro-1H-indole-6-carboxylate and the methods of their preparation
CA3017308A1 (en) 2016-03-08 2017-09-14 Respivert Limited Indole derivatives and their use as protein kinase inhibitors
JP2019511547A (en) 2016-04-13 2019-04-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
EP3246029A1 (en) 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
EP3464240A1 (en) 2016-05-27 2019-04-10 Boehringer Ingelheim International GmbH Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
JP2019523225A (en) 2016-06-01 2019-08-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of ECM biomarkers to determine initiation of treatment with nintedanib and pirfenidone
WO2017210130A1 (en) 2016-06-02 2017-12-07 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for improving glaucoma surgery success
US10159660B2 (en) 2016-07-29 2018-12-25 Oncternal Therapeutics, Inc. Uses of indolinone compounds
CN106748961A (en) * 2016-11-30 2017-05-31 瑞阳制药有限公司 The impurity compound of Nintedanib, preparation method, using and its detection method
CN106748960A (en) * 2016-11-30 2017-05-31 瑞阳制药有限公司 The potential impurity compound of Nintedanib, preparation method, using and its detection method
JP2019536812A (en) 2016-12-12 2019-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Nintedanib for use in methods of treating interstitial lung disease by co-administration with olodaterol
CN110573161A (en) 2017-03-28 2019-12-13 勃林格殷格翰国际有限公司 Nintedanib for use in a method of treating muscular dystrophy
CA3079299A1 (en) 2017-10-23 2019-05-02 Boehringer Ingelheim International Gmbh New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
WO2019097112A1 (en) 2017-11-17 2019-05-23 Fermion Oy Synthesis of a 2-indolinone derivative known as intermediate for preparing nintedanib
JP7061310B2 (en) * 2018-04-05 2022-04-28 国立大学法人 大分大学 Pharmaceuticals for the prevention and treatment of chronic fatty diseases
CN108358827A (en) * 2018-05-07 2018-08-03 日照市普达医药科技有限公司 It is a kind of to treat psoriasic 2- oxo-indoles analog derivative and preparation method thereof
EP3860976A1 (en) * 2018-10-05 2021-08-11 Ichnos Sciences S.A. Indolinone compounds for use as map4k1 inhibitors
EP4125890A1 (en) 2020-04-01 2023-02-08 Boehringer Ingelheim International GmbH Use of biomarkers in the treatment of fibrotic conditions
CN111848490B (en) * 2020-08-24 2021-09-24 江西国药有限责任公司 Preparation method of high-purity ethanesulfonic acid nintedanib
CN112574094B (en) * 2020-12-14 2022-07-01 成都大学 Indolone derivatives and pharmaceutical use thereof
WO2022158956A1 (en) 2021-01-25 2022-07-28 주식회사 나이벡 Peptide for preventing and treating fibrosis
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
CN115703758B (en) * 2021-08-12 2024-03-26 中国医学科学院药物研究所 Compounds used as kinase inhibitors, preparation method and application thereof
WO2024037982A1 (en) 2022-08-16 2024-02-22 Boehringer Ingelheim International Gmbh Pharmaceutical formulations of nintedanib for intraocular use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL96047C (en) * 1956-06-08
AU684950B2 (en) * 1994-05-06 1998-01-08 Alcon Laboratories, Inc. Use of vitamin E tocopheryl derivatives in ophthalmic compositions
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
ES2201266T3 (en) * 1996-01-17 2004-03-16 Taiho Pharmaceutical Company Limited INHIBITORS OF THE THREAT OF THE INTIMATE LAYER.
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19815020A1 (en) * 1998-04-03 1999-10-07 Boehringer Ingelheim Pharma New substituted indolinones, their production and their use as medicines
DE19816624A1 (en) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Novel substituted indolinones, their preparation and their use as pharmaceuticals
DE19824922A1 (en) * 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Novel substituted indolinones, their preparation and their use as pharmaceuticals
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9040555B2 (en) 2012-01-26 2015-05-26 Angion Biomedica Corp. Antifibrotic compounds and uses thereof

Also Published As

Publication number Publication date
YU26602A (en) 2004-11-25
NO20021719L (en) 2002-04-11
KR100835546B1 (en) 2008-06-09
HUP0204587A2 (en) 2003-05-28
NO20021719D0 (en) 2002-04-11
PE20010671A1 (en) 2001-06-28
SI1224170T1 (en) 2009-12-31
IL148756A (en) 2007-10-31
FR15C0024I2 (en) 2016-08-26
NO2023033I1 (en) 2023-09-05
NO322746B1 (en) 2006-12-04
PL207445B1 (en) 2010-12-31
LU92681I2 (en) 2015-05-18
NO2015009I2 (en) 2015-03-18
EG25931A (en) 2012-10-24
FR15C0024I1 (en) 2015-04-17
CY1110067T1 (en) 2015-01-14
NL300725I2 (en) 2017-07-13
EA006080B1 (en) 2005-08-25
BRPI0014735A (en) 2002-07-16
AR026036A1 (en) 2002-12-26
DK1224170T3 (en) 2009-12-07
JP2007302697A (en) 2007-11-22
EP1224170A1 (en) 2002-07-24
BE2015C018I2 (en) 2019-10-23
DK1224170T5 (en) 2018-01-22
HK1052505A1 (en) 2003-09-19
EE05427B1 (en) 2011-06-15
SK6462002A3 (en) 2002-08-06
EP1224170B9 (en) 2017-11-22
PT1224170E (en) 2009-10-01
BRPI0014735B8 (en) 2021-07-06
UA75054C2 (en) 2006-03-15
HRP20020306A2 (en) 2003-10-31
KR20070095996A (en) 2007-10-01
CN1391557A (en) 2003-01-15
NZ518489A (en) 2005-05-27
SK287312B6 (en) 2010-06-07
MXPA02002799A (en) 2003-02-27
BG65983B1 (en) 2010-08-31
KR20020038949A (en) 2002-05-24
ES2331459T3 (en) 2010-01-05
SA01210704B1 (en) 2006-12-05
EP1224170B1 (en) 2009-08-12
HUP0204587A3 (en) 2004-07-28
CY2015009I2 (en) 2016-12-14
CA2387013A1 (en) 2001-04-19
JP4021664B2 (en) 2007-12-12
EP2157081A1 (en) 2010-02-24
TWI268922B (en) 2006-12-21
EE200200197A (en) 2003-06-16
CZ301073B6 (en) 2009-10-29
RS51013B (en) 2010-10-31
JP2003511441A (en) 2003-03-25
HUS1600022I1 (en) 2017-02-28
BRPI0014735B1 (en) 2012-07-10
CZ20021410A3 (en) 2002-07-17
EA200200380A1 (en) 2002-10-31
CN100455568C (en) 2009-01-28
HK1052505B (en) 2009-06-26
HRP20020306B1 (en) 2010-09-30
CO5261488A1 (en) 2003-03-31
AU781939B2 (en) 2005-06-23
IL148756A0 (en) 2002-09-12
LU92681I9 (en) 2019-01-03
WO2001027081A1 (en) 2001-04-19
PL355433A1 (en) 2004-04-19
DE50015711D1 (en) 2009-09-24
KR100857734B1 (en) 2008-09-10
MEP45408A (en) 2011-02-10
HU230416B1 (en) 2016-05-30
BG106587A (en) 2003-01-31
NO2015009I1 (en) 2015-03-30
ATE439342T1 (en) 2009-08-15
CY2015009I1 (en) 2016-12-14
AU1023301A (en) 2001-04-23
MY127956A (en) 2007-01-31

Similar Documents

Publication Publication Date Title
CA2387013C (en) 6-position substituted indolinones, the preparation thereof and their use as pharmaceutical compositions
US6762180B1 (en) Substituted indolines which inhibit receptor tyrosine kinases
EP1212318B1 (en) Substituted indolinones as tyrosine kinase inhibitors
US7148249B2 (en) Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
SK18222000A3 (en) SUBSTITUTED INDOLINONES, THE PRODUCTION THEREOF AND THEIR USE ASì (54) MEDICAMENTS
US6858641B2 (en) Substituted indolinones
JP2005537276A (en) 6-substituted indolinone derivatives, their preparation and use as pharmaceutical compositions
DE10042696A1 (en) New 3-(amino-methylene)-2-indolinone derivatives are kinase inhibitors and cell proliferation inhibitors useful e.g. for treating tumors, metastasis, rheumatoid arthritis or psoriasis
DE19940829A1 (en) New 3-(anilino-methylidene)-2-indolinone derivatives, are kinase inhibitors and cell proliferation inhibitors, useful e.g. for treating tumors, metastasis, rheumatoid arthritis or psoriasis
DE19949208A1 (en) New 3-(amino-methylene)-2-indolinone derivatives are kinase inhibitors and cell proliferation inhibitors useful e.g. for treating tumors, metastasis, rheumatoid arthritis or psoriasis

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20201009